{"36e380bc6ac38be48a6bf6d52b10e054e1aa86ad": [["Parasitic diseases generally develop chronically, and most patients experience non-specifi c symptoms and show unobvious physical signs.", [["Parasitic diseases", "DISEASE", 0, 18], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["Parasitic diseases", "PROBLEM", 0, 18], ["non-specifi c symptoms", "PROBLEM", 79, 101], ["unobvious physical signs", "PROBLEM", 111, 135], ["diseases", "OBSERVATION", 10, 18]]], ["Except medical history and physical examination, the diagnosis is mainly based on the laboratory tests.", [["physical examination", "TEST", 27, 47], ["the laboratory tests", "TEST", 82, 102]]], ["The commonly applied laboratory tests for the diagnosis of parasitic diseases include etiological examination, immunological assay and molecular biological examination.", [["parasitic diseases", "DISEASE", 59, 77], ["laboratory tests", "TEST", 21, 37], ["parasitic diseases", "PROBLEM", 59, 77], ["etiological examination", "TEST", 86, 109], ["immunological assay", "TEST", 111, 130], ["molecular biological examination", "TEST", 135, 167], ["parasitic diseases", "OBSERVATION", 59, 77]]]], "b1d998f9c2b7febe22f7329020d226a3cc9cfa7d": [["IntroductionInfluenza is a highly contagious respiratory illness that can be debilitating or cause complications leading to hospitalization and death.", [["respiratory", "ANATOMY", 45, 56], ["Influenza", "DISEASE", 12, 21], ["respiratory illness", "DISEASE", 45, 64], ["death", "DISEASE", 144, 149], ["IntroductionInfluenza", "PROBLEM", 0, 21], ["a highly contagious respiratory illness", "PROBLEM", 25, 64], ["complications", "PROBLEM", 99, 112], ["death", "PROBLEM", 144, 149]]], ["The disease's etiological agents, influenza viruses (orthomyxoviruses), are single-stranded, negative-sense RNA viruses (Palese and Shaw, 2007) .", [["influenza viruses", "DISEASE", 34, 51], ["influenza viruses", "ORGANISM", 34, 51], ["orthomyxoviruses", "CANCER", 53, 69], ["The disease's etiological agents", "PROBLEM", 0, 32], ["influenza viruses (orthomyxoviruses", "PROBLEM", 34, 69], ["disease", "OBSERVATION", 4, 11]]], ["Of the 3 types (influenza A, B, and C), only A and B cause epidemic human disease.", [["human disease", "DISEASE", 68, 81], ["B", "GENE_OR_GENE_PRODUCT", 29, 30], ["B", "GENE_OR_GENE_PRODUCT", 51, 52], ["human", "ORGANISM", 68, 73], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73], ["epidemic human disease", "PROBLEM", 59, 81]]], ["In addition, influenza A virus (IAV) is the precursor of all pandemic viruses and will be the focus of this review.", [["influenza A virus", "DISEASE", 13, 30], ["influenza A virus", "ORGANISM", 13, 30], ["IAV", "ORGANISM", 32, 35], ["influenza A virus", "SPECIES", 13, 30], ["influenza A virus", "SPECIES", 13, 30], ["IAV", "SPECIES", 32, 35], ["influenza A virus (IAV", "PROBLEM", 13, 35], ["all pandemic viruses", "PROBLEM", 57, 77]]], ["The genome of IAV consists of 8 separate segments, encoding 10-11 proteins covered by the nucleocapsid protein (NP) (McGeoch et al., 1976) .", [["IAV", "ORGANISM", 14, 17], ["nucleocapsid protein", "GENE_OR_GENE_PRODUCT", 90, 110], ["10-11 proteins", "PROTEIN", 60, 74], ["nucleocapsid protein", "PROTEIN", 90, 110], ["NP", "PROTEIN", 112, 114], ["IAV", "OBSERVATION", 14, 17], ["segments", "ANATOMY_MODIFIER", 41, 49]]], ["Virions are enveloped with two surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA), which are responsible for binding of the virus to host cell receptors and release of progeny virions from host cells, respectively, and are the target of host antibody response.", [["surface", "ANATOMY", 31, 38], ["cell", "ANATOMY", 152, 156], ["virions", "ANATOMY", 190, 197], ["cells", "ANATOMY", 208, 213], ["hemagglutinin (HA)", "GENE_OR_GENE_PRODUCT", 54, 72], ["neuraminidase (NA)", "GENE_OR_GENE_PRODUCT", 77, 95], ["host cell", "CELL", 147, 156], ["host cells", "CELL", 203, 213], ["surface glycoproteins", "PROTEIN", 31, 52], ["hemagglutinin", "PROTEIN", 54, 67], ["HA", "PROTEIN", 69, 71], ["neuraminidase", "PROTEIN", 77, 90], ["NA", "PROTEIN", 92, 94], ["host cell receptors", "PROTEIN", 147, 166], ["host cells", "CELL_TYPE", 203, 213], ["Virions", "PROBLEM", 0, 7], ["two surface glycoproteins", "TREATMENT", 27, 52], ["hemagglutinin (HA", "TREATMENT", 54, 71], ["neuraminidase (NA)", "PROBLEM", 77, 95], ["the virus", "PROBLEM", 134, 143], ["surface", "OBSERVATION_MODIFIER", 31, 38], ["glycoproteins", "OBSERVATION", 39, 52], ["host cells", "OBSERVATION", 203, 213], ["antibody response", "OBSERVATION", 256, 273]]], ["The active RNA-dependent RNA polymerase responsible for replication and transcription consists of three polymerase proteins (PB1, PB2, and PA), which together with each viral genome segment and NP form the eight viral Influenza Human Infection Influenza A virus Genes A B S T R A C T Influenza A is a serious respiratory illness that can be debilitating and may cause complications leading to hospitalization and death.", [["respiratory", "ANATOMY", 309, 320], ["Influenza", "DISEASE", 218, 227], ["Influenza A", "DISEASE", 244, 255], ["Influenza A", "DISEASE", 284, 295], ["respiratory illness", "DISEASE", 309, 328], ["death", "DISEASE", 413, 418], ["PB1", "GENE_OR_GENE_PRODUCT", 125, 128], ["PB2", "GENE_OR_GENE_PRODUCT", 130, 133], ["PA", "GENE_OR_GENE_PRODUCT", 139, 141], ["Influenza", "ORGANISM", 218, 227], ["Human Infection Influenza A virus", "ORGANISM", 228, 261], ["T R A C T Influenza A", "CANCER", 274, 295], ["RNA polymerase", "PROTEIN", 25, 39], ["polymerase proteins", "PROTEIN", 104, 123], ["PB1", "PROTEIN", 125, 128], ["PB2", "PROTEIN", 130, 133], ["PA", "PROTEIN", 139, 141], ["viral genome segment", "DNA", 169, 189], ["Human", "SPECIES", 228, 233], ["Influenza A virus", "SPECIES", 244, 261], ["C T Influenza", "SPECIES", 280, 293], ["Human Infection Influenza A virus", "SPECIES", 228, 261], ["A B S T R A C T Influenza A", "SPECIES", 268, 295], ["The active RNA-dependent RNA polymerase", "PROBLEM", 0, 39], ["three polymerase proteins", "TEST", 98, 123], ["PB1", "TEST", 125, 128], ["PB2", "TEST", 130, 133], ["each viral genome segment", "PROBLEM", 164, 189], ["NP", "TEST", 194, 196], ["the eight viral Influenza Human Infection", "PROBLEM", 202, 243], ["Influenza", "PROBLEM", 284, 293], ["a serious respiratory illness", "PROBLEM", 299, 328], ["complications", "PROBLEM", 368, 381], ["death", "PROBLEM", 413, 418], ["active", "OBSERVATION_MODIFIER", 4, 10], ["RNA", "OBSERVATION", 11, 14]]], ["The outcome of infection with the influenza A virus is determined by a complex interplay of viral and host factors.", [["infection", "DISEASE", 15, 24], ["influenza A virus", "DISEASE", 34, 51], ["influenza A virus", "ORGANISM", 34, 51], ["viral and host factors", "PROTEIN", 92, 114], ["influenza A virus", "SPECIES", 34, 51], ["influenza A virus", "SPECIES", 34, 51], ["infection", "PROBLEM", 15, 24], ["the influenza A virus", "PROBLEM", 30, 51], ["viral and host factors", "PROBLEM", 92, 114], ["infection", "OBSERVATION", 15, 24], ["viral", "OBSERVATION", 92, 97]]], ["With the ongoing threat of seasonal influenza and the potential emergence of new, more virulent strains of influenza viruses, we need to develop a better understanding of genetic variation in the human population and its association with severe outcomes from influenza infection.", [["influenza", "DISEASE", 36, 45], ["influenza viruses", "DISEASE", 107, 124], ["influenza infection", "DISEASE", 259, 278], ["influenza viruses", "ORGANISM", 107, 124], ["human", "ORGANISM", 196, 201], ["human", "SPECIES", 196, 201], ["human", "SPECIES", 196, 201], ["seasonal influenza", "PROBLEM", 27, 45], ["influenza viruses", "PROBLEM", 107, 124], ["genetic variation in the human population", "PROBLEM", 171, 212], ["influenza infection", "PROBLEM", 259, 278], ["seasonal influenza", "OBSERVATION", 27, 45], ["influenza viruses", "OBSERVATION", 107, 124], ["severe", "OBSERVATION_MODIFIER", 238, 244], ["influenza", "OBSERVATION_MODIFIER", 259, 268], ["infection", "OBSERVATION", 269, 278]]], ["We propose a list of approximately 100 systems-based candidate genes for future study of the genetic basis of influenza disease and immunity in humans, based on evidence in the published literature for their potential role in the pathogenesis of this infection: binding of the virus to receptors on the host cell surface; cleavability of HA by host proteases; virus replication in host cells; destruction of host cells by apoptosis; state of immunocompetence of the individual host; and viral infections predisposing to bacterial infection.IntroductionPublished by Elsevier B.V.Introductionribonucleoprotein (vRNP) complexes in each virion (Compans et al., 1974) .", [["cell surface", "ANATOMY", 308, 320], ["cells", "ANATOMY", 386, 391], ["cells", "ANATOMY", 413, 418], ["influenza disease", "DISEASE", 110, 127], ["infection", "DISEASE", 251, 260], ["viral infections", "DISEASE", 487, 503], ["bacterial infection", "DISEASE", 520, 539], ["humans", "ORGANISM", 144, 150], ["cell surface", "CELLULAR_COMPONENT", 308, 320], ["HA", "GENE_OR_GENE_PRODUCT", 338, 340], ["host cells", "CELL", 381, 391], ["host cells", "CELL", 408, 418], ["vRNP", "GENE_OR_GENE_PRODUCT", 609, 613], ["candidate genes", "DNA", 53, 68], ["host proteases", "PROTEIN", 344, 358], ["host cells", "CELL_TYPE", 381, 391], ["host cells", "CELL_TYPE", 408, 418], ["Elsevier B.V.Introductionribonucleoprotein (vRNP) complexes", "PROTEIN", 565, 624], ["humans", "SPECIES", 144, 150], ["humans", "SPECIES", 144, 150], ["future study", "TEST", 73, 85], ["influenza disease", "PROBLEM", 110, 127], ["this infection", "PROBLEM", 246, 260], ["the virus", "PROBLEM", 273, 282], ["HA", "PROBLEM", 338, 340], ["host proteases", "PROBLEM", 344, 358], ["virus replication in host cells", "PROBLEM", 360, 391], ["destruction of host cells", "PROBLEM", 393, 418], ["apoptosis", "PROBLEM", 422, 431], ["the individual host", "PROBLEM", 462, 481], ["viral infections", "PROBLEM", 487, 503], ["bacterial infection", "PROBLEM", 520, 539], ["influenza", "OBSERVATION", 110, 119], ["infection", "OBSERVATION", 251, 260], ["host cell", "OBSERVATION_MODIFIER", 303, 312], ["surface", "OBSERVATION_MODIFIER", 313, 320], ["host cells", "OBSERVATION", 381, 391], ["host cells", "OBSERVATION", 408, 418], ["viral infections", "OBSERVATION", 487, 503], ["bacterial", "OBSERVATION_MODIFIER", 520, 529], ["infection", "OBSERVATION", 530, 539]]], ["Matrix protein 1 (M1) is a structural protein encasing the viral genome just beneath the envelope, and matrix protein 2 (M2) acts as an ion channel pump that permits ions to enter the virion and undergo uncoating in the endosome (Fujiyoshi et al., 1994; Pinto and Lamb, 2006) .", [["virion", "ANATOMY", 184, 190], ["endosome", "ANATOMY", 220, 228], ["Matrix protein 1", "GENE_OR_GENE_PRODUCT", 0, 16], ["M1", "GENE_OR_GENE_PRODUCT", 18, 20], ["matrix protein 2", "GENE_OR_GENE_PRODUCT", 103, 119], ["M2", "GENE_OR_GENE_PRODUCT", 121, 123], ["virion", "CELLULAR_COMPONENT", 184, 190], ["endosome", "CELLULAR_COMPONENT", 220, 228], ["Matrix protein 1", "PROTEIN", 0, 16], ["M1", "PROTEIN", 18, 20], ["structural protein", "PROTEIN", 27, 45], ["viral genome", "DNA", 59, 71], ["matrix protein 2", "PROTEIN", 103, 119], ["M2", "PROTEIN", 121, 123], ["Matrix protein", "TEST", 0, 14], ["a structural protein", "PROBLEM", 25, 45], ["the viral genome", "PROBLEM", 55, 71], ["matrix protein", "TEST", 103, 117], ["an ion channel pump", "TREATMENT", 133, 152], ["viral genome", "OBSERVATION", 59, 71]]], ["The NS gene encodes NS1, which has multiple functions including obstruction of the host antiviral response (Garcia-Sastre, 2006; Krug et al., 2003) , and NS2, also known as nuclear export protein, which is important for nuclear export of viral ribonucleic acids (RNAs) (Inglis et al., 1979) .", [["nuclear", "ANATOMY", 173, 180], ["nuclear", "ANATOMY", 220, 227], ["ribonucleic acids", "CHEMICAL", 244, 261], ["NS1", "GENE_OR_GENE_PRODUCT", 20, 23], ["NS2", "GENE_OR_GENE_PRODUCT", 154, 157], ["nuclear", "CELLULAR_COMPONENT", 173, 180], ["nuclear", "CELLULAR_COMPONENT", 220, 227], ["NS gene", "DNA", 4, 11], ["NS1", "PROTEIN", 20, 23], ["NS2", "PROTEIN", 154, 157], ["nuclear export protein", "PROTEIN", 173, 195], ["viral ribonucleic acids", "RNA", 238, 261], ["The NS gene encodes NS1", "TREATMENT", 0, 23], ["obstruction of the host antiviral response", "PROBLEM", 64, 106], ["NS2", "TREATMENT", 154, 157], ["nuclear export protein", "TEST", 173, 195], ["viral ribonucleic acids", "PROBLEM", 238, 261], ["obstruction", "OBSERVATION", 64, 75], ["host antiviral", "OBSERVATION", 83, 97], ["viral ribonucleic acids", "OBSERVATION", 238, 261]]], ["By virtue of possessing a segmented genome, influenza virus can easily reassort by rearranging viral segments of two different influenza viruses infecting the same cell and thereby acquire radically different antigenic properties to produce a novel subtype, a phenomenon termed antigenic shift (Cox and Subbarao, 2000; Parrish and Kawaoka, 2005) .", [["cell", "ANATOMY", 164, 168], ["influenza virus", "ORGANISM", 44, 59], ["influenza viruses", "ORGANISM", 127, 144], ["cell", "CELL", 164, 168], ["influenza virus", "SPECIES", 44, 59], ["influenza virus", "SPECIES", 44, 59], ["a segmented genome", "PROBLEM", 24, 42], ["influenza virus", "PROBLEM", 44, 59], ["rearranging viral segments of two different influenza viruses", "PROBLEM", 83, 144], ["a novel subtype", "PROBLEM", 241, 256], ["viral segments", "OBSERVATION", 95, 109], ["influenza viruses", "OBSERVATION", 127, 144]]], ["Antigenic shift may also occur when an animal or avian IAV is transmitted without reassortment directly from an animal reservoir to humans.", [["avian IAV", "ORGANISM", 49, 58], ["humans", "ORGANISM", 132, 138], ["humans", "SPECIES", 132, 138], ["IAV", "SPECIES", 55, 58], ["humans", "SPECIES", 132, 138], ["Antigenic shift", "PROBLEM", 0, 15], ["an animal reservoir", "TREATMENT", 109, 128], ["IAV", "OBSERVATION", 55, 58]]], ["A pandemic can occur when a new IAV subtype emerges from the reassortment process with the ability to cause disease and spread efficiently in large geographic areas (more than one continent) among humans who have little or no immunity.", [["humans", "ORGANISM", 197, 203], ["humans", "SPECIES", 197, 203], ["humans", "SPECIES", 197, 203], ["A pandemic", "PROBLEM", 0, 10], ["a new IAV subtype", "TREATMENT", 26, 43], ["disease", "PROBLEM", 108, 115], ["large", "OBSERVATION_MODIFIER", 142, 147], ["geographic", "OBSERVATION_MODIFIER", 148, 158], ["areas", "OBSERVATION_MODIFIER", 159, 164]]], ["An example is the current 2009 pandemic swine-origin H1N1 influenza A virus (Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, 2009; Smith et al., 2009; Zarocostas, 2009) , which is slightly more pathogenic than seasonal influenza viruses but much less so than the 1918 pandemic or H5N1 avian IAV in ferret and/or mouse models (Maines et al., 2009; Munster et al., 2009) .", [["influenza A virus", "DISEASE", 58, 75], ["influenza viruses", "DISEASE", 235, 252], ["pandemic", "DISEASE", 284, 292], ["swine-origin H1N1 influenza A virus", "ORGANISM", 40, 75], ["Novel Swine-Origin Influenza A (H1N1) Virus", "ORGANISM", 77, 120], ["H5N1 avian IAV", "ORGANISM", 296, 310], ["ferret", "ORGANISM", 314, 320], ["mouse", "ORGANISM", 328, 333], ["swine", "SPECIES", 40, 45], ["H1N1 influenza A virus", "SPECIES", 53, 75], ["Swine", "SPECIES", 83, 88], ["Influenza A (H1N1", "SPECIES", 96, 113], ["H5N1 avian IAV", "SPECIES", 296, 310], ["ferret", "SPECIES", 314, 320], ["mouse", "SPECIES", 328, 333], ["swine-origin H1N1 influenza A virus", "SPECIES", 40, 75], ["Novel Swine-Origin Influenza A (H1N1) Virus", "SPECIES", 77, 120], ["H5N1 avian IAV", "SPECIES", 296, 310], ["ferret", "SPECIES", 314, 320], ["mouse", "SPECIES", 328, 333], ["H1N1 influenza A virus", "PROBLEM", 53, 75], ["Zarocostas", "TEST", 167, 177], ["slightly more pathogenic", "PROBLEM", 196, 220], ["seasonal influenza viruses", "PROBLEM", 226, 252], ["H5N1", "PROBLEM", 296, 300], ["slightly", "OBSERVATION_MODIFIER", 196, 204], ["more pathogenic", "OBSERVATION_MODIFIER", 205, 220]]], ["During entry into cells, the IAV particle binds to the host cell receptor, sialic acid (SA), through the viral HA (Weis et al., 1988) .", [["cells", "ANATOMY", 18, 23], ["cell", "ANATOMY", 60, 64], ["sialic acid", "CHEMICAL", 75, 86], ["sialic acid", "CHEMICAL", 75, 86], ["cells", "CELL", 18, 23], ["IAV", "ORGANISM", 29, 32], ["host cell receptor", "GENE_OR_GENE_PRODUCT", 55, 73], ["sialic acid", "SIMPLE_CHEMICAL", 75, 86], ["SA", "GENE_OR_GENE_PRODUCT", 88, 90], ["host cell receptor", "PROTEIN", 55, 73], ["the IAV particle binds", "TREATMENT", 25, 47], ["sialic acid", "TEST", 75, 86], ["the viral HA", "PROBLEM", 101, 113], ["host cell", "OBSERVATION", 55, 64]]], ["The virus is taken up into the cell by endocytosis.", [["cell", "ANATOMY", 31, 35], ["cell", "CELL", 31, 35], ["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9], ["endocytosis", "OBSERVATION", 39, 50]]], ["Acidification of the endocytic vesicle results in a conformational change of HA, leading to fusion of the viral envelope with the endosomal membrane and liberation of vRNPs into the cytoplasm of the host cell (Pinto et al., 1992) .", [["endocytic vesicle", "ANATOMY", 21, 38], ["endosomal membrane", "ANATOMY", 130, 148], ["cytoplasm", "ANATOMY", 182, 191], ["cell", "ANATOMY", 204, 208], ["endocytic vesicle", "CELLULAR_COMPONENT", 21, 38], ["HA", "GENE_OR_GENE_PRODUCT", 77, 79], ["endosomal membrane", "CELLULAR_COMPONENT", 130, 148], ["vRNPs", "GENE_OR_GENE_PRODUCT", 167, 172], ["cytoplasm", "ORGANISM_SUBSTANCE", 182, 191], ["host cell", "CELL", 199, 208], ["HA", "PROTEIN", 77, 79], ["vRNPs", "PROTEIN", 167, 172], ["Acidification of the endocytic vesicle", "PROBLEM", 0, 38], ["a conformational change of HA", "PROBLEM", 50, 79], ["fusion", "TREATMENT", 92, 98], ["the viral envelope", "PROBLEM", 102, 120], ["the endosomal membrane", "TREATMENT", 126, 148], ["endocytic vesicle", "OBSERVATION", 21, 38], ["fusion", "OBSERVATION", 92, 98], ["viral envelope", "OBSERVATION", 106, 120], ["endosomal membrane", "OBSERVATION", 130, 148], ["liberation", "OBSERVATION_MODIFIER", 153, 163], ["cytoplasm", "ANATOMY_MODIFIER", 182, 191], ["host cell", "OBSERVATION", 199, 208]]], ["The vRNPs are transported to the nucleus for transcription of viral mRNAs and replication of genomic RNA in a complex process, which is delicately regulated by viral and host cellular factors (Boulo et al., 2007; Nagata et al., 2008) .", [["nucleus", "ANATOMY", 33, 40], ["cellular", "ANATOMY", 175, 183], ["vRNPs", "GENE_OR_GENE_PRODUCT", 4, 9], ["nucleus", "CELLULAR_COMPONENT", 33, 40], ["cellular", "CELL", 175, 183], ["vRNPs", "PROTEIN", 4, 9], ["viral mRNAs", "RNA", 62, 73], ["genomic RNA", "RNA", 93, 104], ["viral mRNAs", "PROBLEM", 62, 73], ["genomic RNA", "PROBLEM", 93, 104], ["nucleus", "ANATOMY", 33, 40], ["viral mRNAs", "OBSERVATION", 62, 73], ["genomic RNA", "OBSERVATION", 93, 104]]], ["Upon translation of viral proteins and assembly of nucleocapsids harboring replicated genomic RNA, progeny virions bud from the cellular membrane, aided by the activity of the NA (Fig. 1) .IntroductionBased on the antigenicity and amino acid sequences of HA and NA, IAVs are subdivided into 16 HA (H1-H16) and 9 NA (N1-N9) Fig. 1 .", [["cellular membrane", "ANATOMY", 128, 145], ["amino acid", "CHEMICAL", 231, 241], ["amino acid", "CHEMICAL", 231, 241], ["nucleocapsids", "CELLULAR_COMPONENT", 51, 64], ["cellular membrane", "CELLULAR_COMPONENT", 128, 145], ["amino acid", "AMINO_ACID", 231, 241], ["viral proteins", "PROTEIN", 20, 34], ["genomic RNA", "RNA", 86, 97], ["H1", "PROTEIN", 298, 300], ["viral proteins", "PROBLEM", 20, 34], ["nucleocapsids harboring replicated genomic RNA", "PROBLEM", 51, 97], ["progeny virions bud", "PROBLEM", 99, 118], ["the antigenicity", "TEST", 210, 226], ["amino acid sequences", "TEST", 231, 251], ["HA", "PROBLEM", 255, 257], ["NA", "TEST", 262, 264], ["IAVs", "PROBLEM", 266, 270], ["NA", "TEST", 312, 314], ["viral proteins", "OBSERVATION", 20, 34], ["genomic RNA", "OBSERVATION", 86, 97], ["cellular membrane", "OBSERVATION", 128, 145]]], ["Candidate genes (in purple) involved in IAV replication cycle.", [["IAV", "ORGANISM", 40, 43], ["Candidate genes", "DNA", 0, 15], ["IAV", "SPECIES", 40, 43], ["IAV replication", "OBSERVATION", 40, 55]]], ["Candidate genes controlling virus replication that are discussed in this review are highlighted in purple.", [["virus replication", "TREATMENT", 28, 45]]], ["During entry into a cell, the IVA particle binds to the host cell receptor SA through its HA.", [["cell", "ANATOMY", 20, 24], ["cell", "ANATOMY", 61, 65], ["IVA", "CHEMICAL", 30, 33], ["cell", "CELL", 20, 24], ["host cell", "CELL", 56, 65], ["SA", "GENE_OR_GENE_PRODUCT", 75, 77], ["the IVA particle binds", "TREATMENT", 26, 48], ["host cell", "OBSERVATION", 56, 65]]], ["The virus is taken up by the cell by endocytosis.", [["cell", "ANATOMY", 29, 33], ["cell", "CELL", 29, 33], ["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9], ["endocytosis", "OBSERVATION", 37, 48]]], ["Acidification of the endocytic vesicle results in a conformational change of HA, leading to fusion of the viral envelope with the endosomal membrane and liberation of RNPs into the cytoplasm.", [["endocytic vesicle", "ANATOMY", 21, 38], ["endosomal membrane", "ANATOMY", 130, 148], ["RNPs", "ANATOMY", 167, 171], ["cytoplasm", "ANATOMY", 181, 190], ["endocytic vesicle", "CELLULAR_COMPONENT", 21, 38], ["HA", "GENE_OR_GENE_PRODUCT", 77, 79], ["endosomal membrane", "CELLULAR_COMPONENT", 130, 148], ["RNPs", "CELLULAR_COMPONENT", 167, 171], ["cytoplasm", "ORGANISM_SUBSTANCE", 181, 190], ["HA", "PROTEIN", 77, 79], ["RNPs", "PROTEIN", 167, 171], ["Acidification of the endocytic vesicle", "PROBLEM", 0, 38], ["a conformational change of HA", "PROBLEM", 50, 79], ["fusion", "TREATMENT", 92, 98], ["the viral envelope", "PROBLEM", 102, 120], ["the endosomal membrane", "TREATMENT", 126, 148], ["endocytic vesicle", "OBSERVATION", 21, 38], ["fusion", "OBSERVATION", 92, 98], ["viral envelope", "OBSERVATION", 106, 120], ["endosomal membrane", "OBSERVATION", 130, 148], ["liberation", "OBSERVATION_MODIFIER", 153, 163], ["cytoplasm", "OBSERVATION_MODIFIER", 181, 190]]], ["The RNPs are transported to the nucleus for transcription of viral mRNAs and replication of genomic RNA in a complex process which is delicately regulated by viral and host cellular factors.", [["RNPs", "ANATOMY", 4, 8], ["nucleus", "ANATOMY", 32, 39], ["cellular", "ANATOMY", 173, 181], ["RNPs", "CELLULAR_COMPONENT", 4, 8], ["nucleus", "CELLULAR_COMPONENT", 32, 39], ["cellular", "CELL", 173, 181], ["RNPs", "PROTEIN", 4, 8], ["viral mRNAs", "RNA", 61, 72], ["genomic RNA", "RNA", 92, 103], ["viral and host cellular factors", "PROTEIN", 158, 189], ["viral mRNAs", "PROBLEM", 61, 72], ["genomic RNA", "PROBLEM", 92, 103], ["a complex process", "PROBLEM", 107, 124], ["viral and host cellular factors", "PROBLEM", 158, 189], ["RNPs", "OBSERVATION", 4, 8], ["viral mRNAs", "OBSERVATION", 61, 72], ["genomic RNA", "OBSERVATION", 92, 103], ["host cellular factors", "OBSERVATION", 168, 189]]], ["Upon translation of viral proteins and assembly of nucleocapsids harboring replicated genomic RNA, progeny virions bud from the cellular membrane by the NA activity.", [["cellular membrane", "ANATOMY", 128, 145], ["nucleocapsids", "CELLULAR_COMPONENT", 51, 64], ["cellular membrane", "CELLULAR_COMPONENT", 128, 145], ["viral proteins", "PROTEIN", 20, 34], ["genomic RNA", "RNA", 86, 97], ["viral proteins", "PROBLEM", 20, 34], ["nucleocapsids harboring replicated genomic RNA", "PROBLEM", 51, 97], ["progeny virions bud", "PROBLEM", 99, 118], ["viral proteins", "OBSERVATION", 20, 34], ["genomic RNA", "OBSERVATION", 86, 97], ["cellular membrane", "OBSERVATION", 128, 145], ["NA activity", "OBSERVATION", 153, 164]]], ["Chem. subtypes (Fouchier et al., 2005; World Health Organization, 1980) .", [["Chem", "TEST", 0, 4]]], ["IAVs can infect people and many other animal species, but wild aquatic birds are the natural hosts for all known subtypes of IAVs.", [["IAVs", "ANATOMY", 125, 129], ["IAVs", "CHEMICAL", 0, 4], ["IAVs", "DISEASE", 125, 129], ["IAVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["people", "ORGANISM", 16, 22], ["wild aquatic birds", "ORGANISM", 58, 76], ["IAVs", "CANCER", 125, 129], ["people", "SPECIES", 16, 22], ["IAVs", "PROBLEM", 0, 4], ["many other animal species", "PROBLEM", 27, 52], ["IAVs", "OBSERVATION", 125, 129]]], ["Avian IAV strains are further classified as low pathogenic or highly pathogenic avian influenza (LPAI or HPAI, respectively) on the basis of their intravenous pathogenicity criteria (Swayne and Pantin-Jackwood, 2006; World Animal Health Organization, 2008) .", [["intravenous", "ANATOMY", 147, 158], ["avian influenza", "DISEASE", 80, 95], ["LPAI", "DISEASE", 97, 101], ["HPAI", "DISEASE", 105, 109], ["Avian IAV strains", "ORGANISM", 0, 17], ["avian influenza", "ORGANISM", 80, 95], ["LPAI", "ORGANISM", 97, 101], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 147, 158], ["Avian IAV", "SPECIES", 0, 9], ["avian influenza", "SPECIES", 80, 95], ["LPAI", "SPECIES", 97, 101], ["HPAI", "SPECIES", 105, 109], ["Avian IAV strains", "PROBLEM", 0, 17], ["low pathogenic", "PROBLEM", 44, 58], ["highly pathogenic avian influenza", "PROBLEM", 62, 95], ["HPAI", "PROBLEM", 105, 109], ["IAV strains", "OBSERVATION", 6, 17]]], ["HPAI viruses mostly occur among avian H5 and H7 subtypes.", [["HPAI", "DISEASE", 0, 4], ["HPAI viruses", "ORGANISM", 0, 12], ["avian H5", "ORGANISM", 32, 40], ["H7 subtypes", "ORGANISM", 45, 56], ["HPAI viruses", "SPECIES", 0, 12], ["HPAI viruses", "PROBLEM", 0, 12], ["viruses", "OBSERVATION", 5, 12]]], ["In recent years, rare infections among humans with HPAI H5N1 viruses in areas experiencing H5N1 epizootics have resulted in over 60% mortality in humans (World Health Organization, 2009; Uyeki, 2008) .", [["infections", "DISEASE", 22, 32], ["HPAI H5N1 viruses", "DISEASE", 51, 68], ["epizootics", "DISEASE", 96, 106], ["humans", "ORGANISM", 39, 45], ["HPAI H5N1 viruses", "ORGANISM", 51, 68], ["humans", "ORGANISM", 146, 152], ["humans", "SPECIES", 39, 45], ["HPAI H5N1 viruses", "SPECIES", 51, 68], ["humans", "SPECIES", 146, 152], ["humans", "SPECIES", 39, 45], ["HPAI H5N1 viruses", "SPECIES", 51, 68], ["humans", "SPECIES", 146, 152], ["rare infections", "PROBLEM", 17, 32], ["HPAI H5N1 viruses", "PROBLEM", 51, 68], ["H5N1 epizootics", "PROBLEM", 91, 106], ["rare", "OBSERVATION_MODIFIER", 17, 21], ["infections", "OBSERVATION", 22, 32]]], ["H5N1 is considered a significant pandemic threat because human populations lack immunity to it and ongoing genetic variation may allow it to acquire capacity for human-to-human transmission.", [["H5N1", "DISEASE", 0, 4], ["H5N1", "ORGANISM", 0, 4], ["human", "ORGANISM", 57, 62], ["human", "ORGANISM", 162, 167], ["human", "ORGANISM", 171, 176], ["H5N1", "SPECIES", 0, 4], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 162, 167], ["human", "SPECIES", 171, 176], ["H5N1", "SPECIES", 0, 4], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 162, 167], ["human", "SPECIES", 171, 176], ["H5N1", "PROBLEM", 0, 4]]], ["Avian H7 and H9 subtypes, which have also infected humans, are also considered potential pandemic threats (Werner and Harder, 2006) .IntroductionThe IAV is notorious for its unique ability to cause both recurrent epidemics and global pandemics.", [["Avian H7", "ORGANISM", 0, 8], ["H9 subtypes", "CELL", 13, 24], ["humans", "ORGANISM", 51, 57], ["IAV", "ORGANISM", 149, 152], ["Avian", "SPECIES", 0, 5], ["humans", "SPECIES", 51, 57], ["Avian H7", "SPECIES", 0, 8], ["humans", "SPECIES", 51, 57], ["IAV", "SPECIES", 149, 152], ["Avian H7 and H9 subtypes", "PROBLEM", 0, 24], ["The IAV", "TREATMENT", 145, 152], ["both recurrent epidemics", "PROBLEM", 198, 222], ["global pandemics", "PROBLEM", 227, 243], ["H9 subtypes", "OBSERVATION_MODIFIER", 13, 24], ["infected", "OBSERVATION", 42, 50], ["IAV", "OBSERVATION", 149, 152], ["recurrent", "OBSERVATION_MODIFIER", 203, 212], ["epidemics", "OBSERVATION", 213, 222], ["global", "OBSERVATION_MODIFIER", 227, 233], ["pandemics", "OBSERVATION", 234, 243]]], ["Annually, the global burden of influenza epidemics is believed to be 3-5 million cases of severe illness and 300,000-500,000 deaths.", [["influenza", "DISEASE", 31, 40], ["illness", "DISEASE", 97, 104], ["deaths", "DISEASE", 125, 131], ["influenza epidemics", "PROBLEM", 31, 50], ["severe illness", "PROBLEM", 90, 104], ["global", "OBSERVATION_MODIFIER", 14, 20], ["burden", "OBSERVATION_MODIFIER", 21, 27], ["influenza", "OBSERVATION", 31, 40], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["illness", "OBSERVATION", 97, 104]]], ["In the United States alone, an annual average of approximately 36,000 deaths was estimated for the 1991 through 1999 influenza seasons (Thompson et al., 2003) .", [["deaths", "DISEASE", 70, 76], ["influenza", "DISEASE", 117, 126]]], ["In the 20th-21st centuries, pandemics occurred in 1918, 1957, 1968, and 2009 .", [["pandemics", "PROBLEM", 28, 37]]], ["The 1918 pandemic was the most severe, with half of the world population infected, of which 20% developed severe disease; estimates of the number of deaths range from 20 to 100 million (Johnson and Mueller, 2002; Oxford, 2000) .", [["deaths", "DISEASE", 149, 155], ["severe disease", "PROBLEM", 106, 120], ["most severe", "OBSERVATION_MODIFIER", 26, 37], ["infected", "OBSERVATION", 73, 81], ["severe", "OBSERVATION_MODIFIER", 106, 112], ["disease", "OBSERVATION", 113, 120]]], ["Fatality after influenza is often caused by secondary bacterial pneumonia and acute respiratory distress syndrome (Grose and Chokephaibulkit, 2004; Muir and Wilson, 1919) , as a consequence of highly efficient viral replication, preferred tropism, and a dysfunctional host inflammatory response (Maines et al., 2008) .", [["respiratory", "ANATOMY", 84, 95], ["influenza", "DISEASE", 15, 24], ["pneumonia", "DISEASE", 64, 73], ["acute respiratory distress syndrome", "DISEASE", 78, 113], ["influenza", "PROBLEM", 15, 24], ["secondary bacterial pneumonia", "PROBLEM", 44, 73], ["acute respiratory distress syndrome", "PROBLEM", 78, 113], ["highly efficient viral replication", "PROBLEM", 193, 227], ["a dysfunctional host inflammatory response", "PROBLEM", 252, 294], ["secondary", "OBSERVATION_MODIFIER", 44, 53], ["bacterial", "OBSERVATION_MODIFIER", 54, 63], ["pneumonia", "OBSERVATION", 64, 73], ["acute", "OBSERVATION_MODIFIER", 78, 83], ["respiratory distress syndrome", "OBSERVATION", 84, 113], ["viral replication", "OBSERVATION", 210, 227], ["inflammatory", "OBSERVATION_MODIFIER", 273, 285]]], ["The risk of serious illness and death from influenza is highest in persons aged 65 years or older and in patients with medical conditions that place them at increased risk of developing complications.", [["illness", "DISEASE", 20, 27], ["death", "DISEASE", 32, 37], ["influenza", "DISEASE", 43, 52], ["persons", "ORGANISM", 67, 74], ["patients", "ORGANISM", 105, 113], ["persons", "SPECIES", 67, 74], ["patients", "SPECIES", 105, 113], ["serious illness", "PROBLEM", 12, 27], ["death", "PROBLEM", 32, 37], ["influenza", "PROBLEM", 43, 52], ["medical conditions", "PROBLEM", 119, 137], ["developing complications", "PROBLEM", 175, 199], ["risk of", "UNCERTAINTY", 4, 11], ["serious", "OBSERVATION_MODIFIER", 12, 19], ["complications", "OBSERVATION", 186, 199]]], ["Recently, a substantial impact of influenza has been recognized in pediatric populations, especially among children who are co-infected with IAV and bacteria; even children who appear to be healthy, infection can progress rapidly to severe illness (Bhat et al., 2005) .IntroductionMany factors are associated with protection against or increased risk of a fatal outcome caused by a given influenza strain (Behrens and Stoll, 2006) .", [["influenza", "DISEASE", 34, 43], ["infection", "DISEASE", 199, 208], ["illness", "DISEASE", 240, 247], ["influenza", "DISEASE", 388, 397], ["children", "ORGANISM", 107, 115], ["IAV", "ORGANISM", 141, 144], ["children", "ORGANISM", 164, 172], ["children", "SPECIES", 107, 115], ["children", "SPECIES", 164, 172], ["IAV", "SPECIES", 141, 144], ["influenza", "PROBLEM", 34, 43], ["IAV", "PROBLEM", 141, 144], ["bacteria", "PROBLEM", 149, 157], ["infection", "PROBLEM", 199, 208], ["severe illness", "PROBLEM", 233, 247], ["a fatal outcome", "PROBLEM", 354, 369], ["influenza strain", "PROBLEM", 388, 404], ["substantial", "OBSERVATION_MODIFIER", 12, 23], ["impact", "OBSERVATION_MODIFIER", 24, 30], ["influenza", "OBSERVATION", 34, 43], ["infection", "OBSERVATION", 199, 208]]], ["The virulence of IAV is determined by numerous interacting host and viral factors (Baigent and McCauley, 2003) .", [["IAV", "ORGANISM", 17, 20], ["viral factors", "PROTEIN", 68, 81], ["IAV", "SPECIES", 17, 20], ["IAV", "PROBLEM", 17, 20], ["IAV", "OBSERVATION", 17, 20], ["numerous", "OBSERVATION_MODIFIER", 38, 46], ["interacting host", "OBSERVATION", 47, 63]]], ["Although characteristics of the host such as age, comorbidity, degree of pre-existing immunity, immunosuppression, pregnancy, and smoking are recognized to influence the acquisition, progression, and resolution of influenza infections, host genetic factors remain a possibility (Nicholson et al., 2003) .", [["smoking", "CHEMICAL", 130, 137], ["influenza infections", "DISEASE", 214, 234], ["comorbidity", "PROBLEM", 50, 61], ["pre-existing immunity", "PROBLEM", 73, 94], ["immunosuppression", "TREATMENT", 96, 113], ["pregnancy", "PROBLEM", 115, 124], ["influenza infections", "PROBLEM", 214, 234]]], ["It has been suggested that individual genetic variation may lead to differential response of the host to IAV infection (Albright et al., 2008) .", [["IAV infection", "DISEASE", 105, 118], ["IAV", "ORGANISM", 105, 108], ["IAV", "SPECIES", 105, 108], ["individual genetic variation", "PROBLEM", 27, 55], ["IAV infection", "PROBLEM", 105, 118], ["IAV", "OBSERVATION_MODIFIER", 105, 108], ["infection", "OBSERVATION", 109, 118]]], ["For example, in some recent familial clusters of H5N1 infection, fatal cases curiously clustered among blood relatives (Kandun et al., 2006; Normile, 2007; Olsen et al., 2005) .IntroductionHost genetic factors determining differential susceptibility or resistance to major infectious diseases of humans (including malaria, HIV/AIDS, tuberculosis, and invasive pneumococcal disease) are well documented (Burgner et al., 2006; Hill, 2006) .", [["blood", "ANATOMY", 103, 108], ["H5N1 infection", "DISEASE", 49, 63], ["infectious diseases", "DISEASE", 273, 292], ["malaria", "DISEASE", 314, 321], ["HIV/AIDS", "DISEASE", 323, 331], ["tuberculosis", "DISEASE", 333, 345], ["invasive pneumococcal disease", "DISEASE", 351, 380], ["H5N1", "ORGANISM", 49, 53], ["blood", "ORGANISM_SUBSTANCE", 103, 108], ["humans", "ORGANISM", 296, 302], ["humans", "SPECIES", 296, 302], ["HIV", "SPECIES", 323, 326], ["humans", "SPECIES", 296, 302], ["HIV", "SPECIES", 323, 326], ["pneumococcal", "SPECIES", 360, 372], ["H5N1 infection", "PROBLEM", 49, 63], ["major infectious diseases of humans", "PROBLEM", 267, 302], ["malaria", "PROBLEM", 314, 321], ["HIV/AIDS", "PROBLEM", 323, 331], ["tuberculosis", "PROBLEM", 333, 345], ["invasive pneumococcal disease", "PROBLEM", 351, 380], ["familial", "OBSERVATION_MODIFIER", 28, 36], ["clusters", "OBSERVATION_MODIFIER", 37, 45], ["H5N1 infection", "OBSERVATION", 49, 63], ["major", "OBSERVATION_MODIFIER", 267, 272], ["infectious", "OBSERVATION", 273, 283], ["invasive", "OBSERVATION_MODIFIER", 351, 359], ["pneumococcal disease", "OBSERVATION", 360, 380]]], ["We carried out a thorough literature review using PubMed and the Human Genome Epidemiology Network Published Literature database (www.hugenavigator.net) (Yu et al., 2008) but could not identify any published epidemiologic or family studies that examined individual genetic variability in relation to susceptibility to IAV disease and its outcomes.", [["IAV disease", "DISEASE", 318, 329], ["Human", "SPECIES", 65, 70], ["IAV", "SPECIES", 318, 321], ["family studies", "TEST", 225, 239], ["IAV disease", "PROBLEM", 318, 329], ["IAV", "OBSERVATION", 318, 321]]], ["In the past decade, a great deal of understanding of the pathogenesis and immune evasion strategies of influenza virus has developed; this could help us propose candidate genes that may be responsible for severe illness.", [["influenza virus", "DISEASE", 103, 118], ["illness", "DISEASE", 212, 219], ["influenza virus", "ORGANISM", 103, 118], ["influenza virus", "SPECIES", 103, 118], ["influenza virus", "SPECIES", 103, 118], ["the pathogenesis", "PROBLEM", 53, 69], ["immune evasion strategies", "TREATMENT", 74, 99], ["influenza virus", "PROBLEM", 103, 118], ["severe illness", "PROBLEM", 205, 219], ["may be responsible for", "UNCERTAINTY", 182, 204]]], ["Recently, genome-wide association (GWA) studies have had considerable success in identifying candidate genes for several common, complex diseases; this exploratory and hypothesis-free approach has been applied only twice to the study of infectious disease (Fellay et al., 2007; Jallow et al., 2009) .", [["infectious disease", "DISEASE", 237, 255], ["several common, complex diseases", "PROBLEM", 113, 145], ["this exploratory", "TEST", 147, 163], ["free approach", "TREATMENT", 179, 192], ["infectious disease", "PROBLEM", 237, 255], ["complex", "OBSERVATION_MODIFIER", 129, 136], ["diseases", "OBSERVATION", 137, 145], ["infectious", "OBSERVATION", 237, 247]]], ["With the annual threat of seasonal influenza and the potential emergence of a novel IAV pandemic strain with an unknown level of virulence, we need to understand genetic variation in the human population and its association with severe outcomes from IAV infection.", [["influenza", "DISEASE", 35, 44], ["IAV infection", "DISEASE", 250, 263], ["human", "ORGANISM", 187, 192], ["IAV", "ORGANISM", 250, 253], ["human", "SPECIES", 187, 192], ["human", "SPECIES", 187, 192], ["IAV", "SPECIES", 250, 253], ["seasonal influenza", "PROBLEM", 26, 44], ["a novel IAV pandemic strain", "PROBLEM", 76, 103], ["IAV infection", "PROBLEM", 250, 263], ["seasonal influenza", "OBSERVATION", 26, 44], ["IAV", "OBSERVATION_MODIFIER", 250, 253], ["infection", "OBSERVATION", 254, 263]]], ["These efforts will be crucial to the development of tools for targeting interventions in populations (Fauci, 2006) .IntroductionTo identify potential genes for future targeted research, we take a systems-based approach to propose candidate genes that could influence the response of the host to influenza infection based on animal studies, such as global transcriptional profiles and knockout mice, clinical data, or simply biological plausibility.", [["influenza infection", "DISEASE", 295, 314], ["mice", "ORGANISM", 393, 397], ["mice", "SPECIES", 393, 397], ["mice", "SPECIES", 393, 397], ["targeting interventions", "TREATMENT", 62, 85], ["a systems", "TREATMENT", 194, 203], ["influenza infection", "PROBLEM", 295, 314], ["animal studies", "TEST", 324, 338], ["clinical data", "TEST", 399, 412]]], ["We propose candidate genes whose proteins are implicated in one or more stages in the viral replication cycle and induction of host innate responses, and thus in pathogenesis: binding of the virus to receptors on the host cell surface; cleavability of HA by host proteases; virus replication in host cells; destruction of host cells by apoptosis; state of immunocompetence of the individual host; and viral infections predisposing to bacterial infection.", [["cell surface", "ANATOMY", 222, 234], ["cells", "ANATOMY", 300, 305], ["cells", "ANATOMY", 327, 332], ["viral infections", "DISEASE", 401, 417], ["bacterial infection", "DISEASE", 434, 453], ["cell surface", "CELLULAR_COMPONENT", 222, 234], ["HA", "GENE_OR_GENE_PRODUCT", 252, 254], ["host cells", "CELL", 295, 305], ["host cells", "CELL", 322, 332], ["host proteases", "PROTEIN", 258, 272], ["host cells", "CELL_TYPE", 295, 305], ["host cells", "CELL_TYPE", 322, 332], ["the viral replication cycle", "TREATMENT", 82, 109], ["the virus", "PROBLEM", 187, 196], ["HA", "PROBLEM", 252, 254], ["host proteases", "PROBLEM", 258, 272], ["virus replication in host cells", "PROBLEM", 274, 305], ["destruction of host cells", "PROBLEM", 307, 332], ["apoptosis", "PROBLEM", 336, 345], ["the individual host", "PROBLEM", 376, 395], ["viral infections", "PROBLEM", 401, 417], ["bacterial infection", "PROBLEM", 434, 453], ["viral replication", "OBSERVATION", 86, 103], ["host cell", "OBSERVATION_MODIFIER", 217, 226], ["surface", "OBSERVATION_MODIFIER", 227, 234], ["host cells", "OBSERVATION", 295, 305], ["host cells", "OBSERVATION", 322, 332], ["viral infections", "OBSERVATION", 401, 417], ["bacterial", "OBSERVATION_MODIFIER", 434, 443], ["infection", "OBSERVATION", 444, 453]]], ["A systemsbased approach can provide more complete coverage of candidate genes within a suspected etiologic system, for example, in aberrant host innate immune and cell death responses, which have been suggested by global transcriptional profiling of the host response to IAV infection in mice (Ding et al., 2008; Kash et al., 2006b; Rosseau et al., 2007; Seki et al., 2009) , ferrets (Cameron et al., 2008) , and macaques (Kobasa et al., 2007) .", [["cell", "ANATOMY", 163, 167], ["IAV infection", "DISEASE", 271, 284], ["cell", "CELL", 163, 167], ["IAV", "ORGANISM", 271, 274], ["mice", "ORGANISM", 288, 292], ["ferrets", "ORGANISM", 376, 383], ["macaques", "ORGANISM", 413, 421], ["candidate genes", "DNA", 62, 77], ["mice", "SPECIES", 288, 292], ["ferrets", "SPECIES", 376, 383], ["macaques", "SPECIES", 413, 421], ["IAV", "SPECIES", 271, 274], ["mice", "SPECIES", 288, 292], ["A systemsbased approach", "TREATMENT", 0, 23], ["IAV infection", "PROBLEM", 271, 284], ["host innate", "OBSERVATION_MODIFIER", 140, 151], ["IAV", "OBSERVATION_MODIFIER", 271, 274], ["infection", "OBSERVATION", 275, 284]]], ["By broadening our proposed candidate genes to include multiple genes in an interconnected system, rather than simply focusing on a single putatively interesting gene, we hope to provide a more complete picture of the impact of the entire system or pathway as we discuss below.", [["candidate genes", "DNA", 27, 42]]], ["We suggest that a systems-based approach to the study of susceptibility to IAV is reasonable, despite the popularity of hypothesis-free GWA studies, which have uncovered ''new'' candidate genes for a variety of common human diseases; such studies need very large sample sizes and their findings require further replication (Manolio et al., 2008) .", [["IAV", "DISEASE", 75, 78], ["IAV", "ORGANISM", 75, 78], ["human", "ORGANISM", 218, 223], ["human", "SPECIES", 218, 223], ["human", "SPECIES", 218, 223], ["the study", "TEST", 44, 53], ["IAV", "PROBLEM", 75, 78], ["free GWA studies", "TEST", 131, 147], ["common human diseases", "PROBLEM", 211, 232], ["such studies", "TEST", 234, 246], ["very large sample sizes", "PROBLEM", 252, 275], ["further replication", "TREATMENT", 303, 322]]], ["A systems-based approach takes advantage of understanding the phenotype and biological pathways relating genes to disease; this approach has identified several genes that confer susceptibility to common infectious diseases, e.g. HIV infection (O'Brien and Nelson, 2004; Tabor et al., 2002) .", [["infectious diseases", "DISEASE", 203, 222], ["HIV infection", "DISEASE", 229, 242], ["HIV", "SPECIES", 229, 232], ["HIV", "SPECIES", 229, 232], ["the phenotype", "PROBLEM", 58, 71], ["disease", "PROBLEM", 114, 121], ["common infectious diseases", "PROBLEM", 196, 222], ["HIV infection", "PROBLEM", 229, 242]]], ["A systems-based approach can be successful only if we apply rigorous epidemiological principles to the choice and analysis of candidate genes in the disease studied.", [["candidate genes", "DNA", 126, 141]]], ["A detailed rationale for the selection of each candidate gene we reviewed is listed in Supplementary Table.Binding of the virus to receptors on the host cell surfaceThe first key step in infection, transmission, and virulence of IVAs is the binding of HA to the host receptor, SA-terminated glycan, on the surface of host cells.", [["cell surface", "ANATOMY", 153, 165], ["surface", "ANATOMY", 306, 313], ["cells", "ANATOMY", 322, 327], ["infection", "DISEASE", 187, 196], ["IVAs", "DISEASE", 229, 233], ["cell", "CELL", 153, 157], ["IVAs", "GENE_OR_GENE_PRODUCT", 229, 233], ["HA", "GENE_OR_GENE_PRODUCT", 252, 254], ["SA", "SIMPLE_CHEMICAL", 277, 279], ["surface", "CELLULAR_COMPONENT", 306, 313], ["host cells", "CELL", 317, 327], ["SA", "PROTEIN", 277, 279], ["host cells", "CELL_TYPE", 317, 327], ["the virus", "PROBLEM", 118, 127], ["infection", "PROBLEM", 187, 196], ["virulence of IVAs", "PROBLEM", 216, 233], ["HA", "PROBLEM", 252, 254], ["virus", "OBSERVATION", 122, 127], ["host cell", "OBSERVATION_MODIFIER", 148, 157], ["surface", "OBSERVATION_MODIFIER", 158, 165], ["infection", "OBSERVATION", 187, 196], ["host cells", "OBSERVATION", 317, 327]]], ["The presence, type, and location of the receptor determine both host susceptibility to infection with specific viruses and location of infection.", [["infection", "DISEASE", 87, 96], ["infection", "DISEASE", 135, 144], ["host susceptibility to infection", "PROBLEM", 64, 96], ["specific viruses", "PROBLEM", 102, 118], ["infection", "PROBLEM", 135, 144], ["infection", "OBSERVATION", 87, 96], ["infection", "OBSERVATION", 135, 144]]], ["Human IAVs preferentially bind SA in a-2,6 linkage with galactose (Gal), a major glycan of human upper airways; avian IAVs (e.g., H5N1) preferentially recognize a receptor with SAa-2,3Gal linkage, which is common in birds, but is also found in the epithelium of the human lower respiratory tract van Riel et al., 2006) and less commonly in the upper respiratory tract (Nicholls et al., 2007) .", [["IAVs", "ANATOMY", 6, 10], ["upper airways", "ANATOMY", 97, 110], ["IAVs", "ANATOMY", 118, 122], ["epithelium", "ANATOMY", 248, 258], ["upper respiratory tract", "ANATOMY", 344, 367], ["SA", "CHEMICAL", 31, 33], ["galactose", "CHEMICAL", 56, 65], ["galactose", "CHEMICAL", 56, 65], ["Gal", "CHEMICAL", 67, 70], ["Human", "ORGANISM", 0, 5], ["IAVs", "GENE_OR_GENE_PRODUCT", 6, 10], ["SA", "GENE_OR_GENE_PRODUCT", 31, 33], ["galactose", "SIMPLE_CHEMICAL", 56, 65], ["Gal", "GENE_OR_GENE_PRODUCT", 67, 70], ["human", "ORGANISM", 91, 96], ["upper airways", "ORGAN", 97, 110], ["avian IAVs", "ORGANISM", 112, 122], ["H5N1", "ORGANISM", 130, 134], ["SAa-2,3Gal", "GENE_OR_GENE_PRODUCT", 177, 187], ["birds", "ORGANISM", 216, 221], ["epithelium", "TISSUE", 248, 258], ["human", "ORGANISM", 266, 271], ["upper respiratory", "ORGANISM_SUBDIVISION", 344, 361], ["tract", "ORGANISM_SUBDIVISION", 362, 367], ["SAa", "PROTEIN", 177, 180], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 266, 271], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 266, 271], ["galactose (Gal", "TREATMENT", 56, 70], ["SAa", "TEST", 177, 180], ["upper", "ANATOMY_MODIFIER", 97, 102], ["airways", "ANATOMY", 103, 110], ["epithelium", "ANATOMY_MODIFIER", 248, 258], ["lower", "ANATOMY_MODIFIER", 272, 277], ["respiratory tract", "ANATOMY", 278, 295], ["upper", "ANATOMY_MODIFIER", 344, 349], ["respiratory tract", "ANATOMY", 350, 367]]], ["Recent evidence suggests that the avian H5N1 virus can infect human nasopharyngeal and oropharyngeal epithelia in ex vivo cultures despite of the paucity of SAa-2,3Gal receptors; this finding suggests other binding sites on the epithelium may exist, although the identity of the specific receptors is not yet known (Nicholls et al., 2007; Nicholls et al., 2008) .", [["nasopharyngeal", "ANATOMY", 68, 82], ["oropharyngeal epithelia", "ANATOMY", 87, 110], ["epithelium", "ANATOMY", 228, 238], ["avian H5N1 virus", "ORGANISM", 34, 50], ["human", "ORGANISM", 62, 67], ["nasopharyngeal", "CANCER", 68, 82], ["oropharyngeal epithelia", "TISSUE", 87, 110], ["SAa-2,3Gal receptors", "GENE_OR_GENE_PRODUCT", 157, 177], ["epithelium", "TISSUE", 228, 238], ["SAa", "PROTEIN", 157, 160], ["2,3Gal receptors", "PROTEIN", 161, 177], ["avian H5N1 virus", "SPECIES", 34, 50], ["human", "SPECIES", 62, 67], ["H5N1 virus", "SPECIES", 40, 50], ["human", "SPECIES", 62, 67], ["the avian H5N1 virus", "PROBLEM", 30, 50], ["human nasopharyngeal and oropharyngeal epithelia", "PROBLEM", 62, 110], ["ex vivo cultures", "TEST", 114, 130], ["SAa", "TEST", 157, 160], ["other binding sites", "PROBLEM", 201, 220], ["H5N1", "OBSERVATION", 40, 44], ["nasopharyngeal", "ANATOMY", 68, 82], ["oropharyngeal epithelia", "ANATOMY", 87, 110], ["binding sites", "OBSERVATION", 207, 220], ["epithelium", "ANATOMY_MODIFIER", 228, 238]]], ["A switch in recognition from avian-like SAa-2,3Gal to human-like SAa-2,6Gal is believed to be one of the changes that must occur before avian IAVs can transmit efficiently among humans and acquire the potential to cause a pandemic Stevens et al., 2006; van Riel et al., 2007) .", [["avian", "ORGANISM", 29, 34], ["SAa-2,3Gal", "GENE_OR_GENE_PRODUCT", 40, 50], ["human", "ORGANISM", 54, 59], ["SAa-2,6Gal", "GENE_OR_GENE_PRODUCT", 65, 75], ["IAVs", "GENE_OR_GENE_PRODUCT", 142, 146], ["humans", "ORGANISM", 178, 184], ["SAa", "PROTEIN", 40, 43], ["human-like SAa-2,6Gal", "DNA", 54, 75], ["human", "SPECIES", 54, 59], ["humans", "SPECIES", 178, 184], ["human", "SPECIES", 54, 59], ["humans", "SPECIES", 178, 184], ["avian", "TEST", 29, 34], ["SAa", "TEST", 40, 43], ["SAa", "TEST", 65, 68]]], ["This adaption correlates with point mutations changing certain amino acids in viral HA (Vines et al., 1998; Yamada et al., 2006) .", [["amino acids", "CHEMICAL", 63, 74], ["amino acids", "CHEMICAL", 63, 74], ["amino acids", "AMINO_ACID", 63, 74], ["point mutations", "PROBLEM", 30, 45], ["amino acids", "TREATMENT", 63, 74]]], ["Genes that control the expression and specificity of oligosaccharide structures on human tissues may contribute to the host's susceptibility and/or to the extent of influenza infection in the upper or lower airways.", [["tissues", "ANATOMY", 89, 96], ["lower airways", "ANATOMY", 201, 214], ["influenza infection", "DISEASE", 165, 184], ["human", "ORGANISM", 83, 88], ["tissues", "TISSUE", 89, 96], ["upper", "ORGANISM_SUBDIVISION", 192, 197], ["lower airways", "MULTI-TISSUE_STRUCTURE", 201, 214], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 83, 88], ["oligosaccharide structures on human tissues", "PROBLEM", 53, 96], ["the host's susceptibility", "PROBLEM", 115, 140], ["influenza infection in the upper or lower airways", "PROBLEM", 165, 214], ["influenza", "OBSERVATION", 165, 174], ["infection", "OBSERVATION", 175, 184], ["upper", "ANATOMY_MODIFIER", 192, 197], ["lower", "ANATOMY_MODIFIER", 201, 206], ["airways", "ANATOMY", 207, 214]]], ["The host enzyme ST3 beta-galactosamide alpha-2,3-sialyltranferase 1 (ST3GAL1) produces the SAa-2,3Gal structure (Kitagawa and Paulson, 1994) , while the SAa-2,6Gal linkage is primarily generated by ST6 betagalactoside alpha-2,6-sialyltransferase 1(ST6GAL1) (Gagneux et al., 2003; Martin et al., 2002; Weinstein et al., 1987) .", [["beta-galactosamide alpha-2,3-sialyltranferase", "CHEMICAL", 20, 65], ["SAa-2,3Gal", "CHEMICAL", 91, 101], ["SAa-2,6Gal", "CHEMICAL", 153, 163], ["ST3 beta-galactosamide alpha-2,3-sialyltranferase 1", "GENE_OR_GENE_PRODUCT", 16, 67], ["ST3GAL1", "GENE_OR_GENE_PRODUCT", 69, 76], ["SAa-2,6Gal", "GENE_OR_GENE_PRODUCT", 153, 163], ["alpha-2,6-sialyltransferase 1", "GENE_OR_GENE_PRODUCT", 218, 247], ["ST6GAL1", "GENE_OR_GENE_PRODUCT", 248, 255], ["ST3 beta", "PROTEIN", 16, 24], ["galactosamide alpha", "PROTEIN", 25, 44], ["2,3-sialyltranferase 1", "PROTEIN", 45, 67], ["ST3GAL1", "PROTEIN", 69, 76], ["SAa", "PROTEIN", 91, 94], ["2,3Gal structure", "PROTEIN", 95, 111], ["sialyltransferase 1", "PROTEIN", 228, 247], ["ST6GAL1", "PROTEIN", 248, 255], ["The host enzyme", "TEST", 0, 15], ["beta", "TEST", 20, 24], ["galactosamide alpha", "TEST", 25, 44], ["the SAa", "TEST", 87, 94], ["the SAa", "TEST", 149, 156], ["alpha", "TEST", 218, 223]]], ["It has been shown that MDCK cells over-expressing human ST6GAL1 have significantly augmented susceptibility to human influenza viruses and produce more viruses when compared with unmodified cells Oh et al., 2008) .Binding of the virus to receptors on the host cell surfaceThe host may prevent attachment of influenza virus by mucociliary clearance or production of mucoproteins that are able to bind to viral HA .", [["MDCK cells", "ANATOMY", 23, 33], ["cells", "ANATOMY", 190, 195], ["cell surface", "ANATOMY", 260, 272], ["mucociliary", "ANATOMY", 326, 337], ["influenza viruses", "DISEASE", 117, 134], ["influenza", "DISEASE", 307, 316], ["MDCK cells", "CELL", 23, 33], ["human", "ORGANISM", 50, 55], ["ST6GAL1", "GENE_OR_GENE_PRODUCT", 56, 63], ["human", "ORGANISM", 111, 116], ["influenza viruses", "ORGANISM", 117, 134], ["cells", "CELL", 190, 195], ["cell", "CELL", 260, 264], ["influenza virus", "ORGANISM", 307, 322], ["mucociliary", "ORGAN", 326, 337], ["mucoproteins", "GENE_OR_GENE_PRODUCT", 365, 377], ["MDCK cells", "CELL_LINE", 23, 33], ["human ST6GAL1", "PROTEIN", 50, 63], ["unmodified cells", "CELL_LINE", 179, 195], ["mucoproteins", "PROTEIN", 365, 377], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 111, 116], ["influenza virus", "SPECIES", 307, 322], ["human", "SPECIES", 50, 55], ["human influenza viruses", "SPECIES", 111, 134], ["influenza virus", "SPECIES", 307, 322], ["MDCK cells", "PROBLEM", 23, 33], ["human influenza viruses", "PROBLEM", 111, 134], ["the virus", "PROBLEM", 225, 234], ["The host", "TREATMENT", 272, 280], ["influenza virus", "PROBLEM", 307, 322], ["mucociliary clearance", "PROBLEM", 326, 347], ["production of mucoproteins", "PROBLEM", 351, 377], ["viral HA", "PROBLEM", 403, 411], ["MDCK cells", "OBSERVATION", 23, 33], ["virus", "OBSERVATION", 229, 234], ["host cell", "OBSERVATION_MODIFIER", 255, 264], ["surface", "OBSERVATION_MODIFIER", 265, 272], ["influenza", "OBSERVATION", 307, 316]]], ["Collectins bind to N-linked glycans on HA and NA and can neutralize the virus by steric hindrance of HA, virus aggregation, opsonisation, and activation of complement-dependent pathways.", [["NA", "CHEMICAL", 46, 48], ["N", "CHEMICAL", 19, 20], ["HA", "SIMPLE_CHEMICAL", 39, 41], ["NA", "SIMPLE_CHEMICAL", 46, 48], ["HA", "GENE_OR_GENE_PRODUCT", 101, 103], ["complement", "GENE_OR_GENE_PRODUCT", 156, 166], ["N-linked glycans", "PROTEIN", 19, 35], ["HA", "PROBLEM", 39, 41], ["NA", "TREATMENT", 46, 48], ["the virus", "PROBLEM", 68, 77], ["HA", "PROBLEM", 101, 103], ["virus aggregation", "PROBLEM", 105, 122], ["opsonisation", "TREATMENT", 124, 136], ["steric hindrance", "OBSERVATION", 81, 97], ["virus aggregation", "OBSERVATION", 105, 122]]], ["This group includes surfactant, pulmonary-associated protein A1 (SFTPA1) and D (SFTPD), together with serum mannose-binding lectin 2 (MBL2) (Hartshorn et al., 1993; Lahti et al., 2002; White et al., 2005) .", [["pulmonary", "ANATOMY", 32, 41], ["serum", "ANATOMY", 102, 107], ["mannose", "CHEMICAL", 108, 115], ["pulmonary", "ORGAN", 32, 41], ["protein A1", "GENE_OR_GENE_PRODUCT", 53, 63], ["SFTPA1", "GENE_OR_GENE_PRODUCT", 65, 71], ["D (SFTPD", "GENE_OR_GENE_PRODUCT", 77, 85], ["serum", "ORGANISM_SUBSTANCE", 102, 107], ["mannose-binding lectin 2", "GENE_OR_GENE_PRODUCT", 108, 132], ["MBL2", "GENE_OR_GENE_PRODUCT", 134, 138], ["pulmonary-associated protein A1", "PROTEIN", 32, 63], ["SFTPA1", "PROTEIN", 65, 71], ["D", "PROTEIN", 77, 78], ["SFTPD", "PROTEIN", 80, 85], ["serum mannose-binding lectin 2", "PROTEIN", 102, 132], ["MBL2", "PROTEIN", 134, 138], ["surfactant", "TREATMENT", 20, 30], ["SFTPA1", "TEST", 65, 71], ["D (SFTPD)", "PROBLEM", 77, 86], ["serum mannose", "TEST", 102, 115], ["surfactant", "OBSERVATION", 20, 30], ["pulmonary", "ANATOMY", 32, 41]]], ["The SA-containing glycoprotein or proteoglycans compete with cellular receptors for virus binding, including alpha-2macroglobulin (A2 M) (Pritchett and Paulson, 1989) , amyloid P component, serum (APCS) (Andersen et al., 1997) , deleted in malignant brain tumors 1 (DMBT1) (Hartshorn et al., 2006a) , and mucins, the major macromolecular component of respiratory mucus encoded by different MUC genes .", [["cellular", "ANATOMY", 61, 69], ["serum", "ANATOMY", 190, 195], ["malignant brain tumors", "ANATOMY", 240, 262], ["respiratory mucus", "ANATOMY", 351, 368], ["malignant brain tumors", "DISEASE", 240, 262], ["SA-containing glycoprotein", "GENE_OR_GENE_PRODUCT", 4, 30], ["proteoglycans", "GENE_OR_GENE_PRODUCT", 34, 47], ["cellular", "CELL", 61, 69], ["alpha-2macroglobulin", "GENE_OR_GENE_PRODUCT", 109, 129], ["amyloid P", "GENE_OR_GENE_PRODUCT", 169, 178], ["serum", "ORGANISM_SUBSTANCE", 190, 195], ["malignant brain tumors", "CANCER", 240, 262], ["DMBT1", "ORGANISM", 266, 271], ["mucins", "GENE_OR_GENE_PRODUCT", 305, 311], ["mucus", "ORGAN", 363, 368], ["MUC", "GENE_OR_GENE_PRODUCT", 390, 393], ["SA-containing glycoprotein or proteoglycans", "PROTEIN", 4, 47], ["cellular receptors", "PROTEIN", 61, 79], ["alpha-2macroglobulin", "PROTEIN", 109, 129], ["amyloid P component", "PROTEIN", 169, 188], ["MUC genes", "DNA", 390, 399], ["cellular receptors", "TREATMENT", 61, 79], ["virus binding", "PROBLEM", 84, 97], ["amyloid P component", "PROBLEM", 169, 188], ["deleted in malignant brain tumors", "PROBLEM", 229, 262], ["respiratory mucus", "PROBLEM", 351, 368], ["malignant", "OBSERVATION_MODIFIER", 240, 249], ["brain", "ANATOMY", 250, 255], ["tumors", "OBSERVATION", 256, 262], ["respiratory mucus", "OBSERVATION", 351, 368], ["MUC genes", "OBSERVATION", 390, 399]]], ["Genetic variations at -211 and codon 54 in the promoter region of and within the MBL2 gene have been associated with severe acute respiratory syndrome (SARS) (Ip et al., 2005; Zhang et al., 2005) .", [["acute respiratory syndrome", "DISEASE", 124, 150], ["SARS", "DISEASE", 152, 156], ["MBL2", "GENE_OR_GENE_PRODUCT", 81, 85], ["codon 54", "DNA", 31, 39], ["promoter region", "DNA", 47, 62], ["MBL2 gene", "DNA", 81, 90], ["Genetic variations", "TEST", 0, 18], ["codon", "TEST", 31, 36], ["severe acute respiratory syndrome", "PROBLEM", 117, 150], ["associated with", "UNCERTAINTY", 101, 116], ["severe", "OBSERVATION_MODIFIER", 117, 123], ["acute", "OBSERVATION_MODIFIER", 124, 129], ["respiratory syndrome", "OBSERVATION", 130, 150]]], ["The common allelic variants of SFTPA1 and SFTPD genes are associated with respiratory distress syndrome (Haataja et al., 2001; Thomas et al., 2007) , and respiratory syncytial virus bronchiolitis (Lahti et al., 2002; Lofgren et al., 2002) .Cleavability of HA by host proteasesHA-mediated fusion between the host endosomal membrane and the viral envelope requires the cleavage of HA precursor molecule HA 0 into HA 1 and HA 2 subunits by host proteases.", [["respiratory", "ANATOMY", 74, 85], ["endosomal membrane", "ANATOMY", 312, 330], ["respiratory distress syndrome", "DISEASE", 74, 103], ["respiratory syncytial virus bronchiolitis", "DISEASE", 154, 195], ["HA", "CHEMICAL", 256, 258], ["SFTPA1", "GENE_OR_GENE_PRODUCT", 31, 37], ["SFTPD", "GENE_OR_GENE_PRODUCT", 42, 47], ["respiratory syncytial virus", "ORGANISM", 154, 181], ["HA", "GENE_OR_GENE_PRODUCT", 256, 258], ["proteasesHA", "GENE_OR_GENE_PRODUCT", 267, 278], ["endosomal membrane", "CELLULAR_COMPONENT", 312, 330], ["HA precursor molecule HA 0 into HA 1", "GENE_OR_GENE_PRODUCT", 379, 415], ["HA 2 subunits", "GENE_OR_GENE_PRODUCT", 420, 433], ["SFTPA1 and SFTPD genes", "DNA", 31, 53], ["proteasesHA", "PROTEIN", 267, 278], ["HA precursor molecule", "PROTEIN", 379, 400], ["HA 0", "PROTEIN", 401, 405], ["HA 1 and HA 2 subunits", "PROTEIN", 411, 433], ["host proteases", "PROTEIN", 437, 451], ["respiratory syncytial virus", "SPECIES", 154, 181], ["SFTPA1 and SFTPD genes", "TREATMENT", 31, 53], ["respiratory distress syndrome", "PROBLEM", 74, 103], ["respiratory syncytial virus bronchiolitis", "PROBLEM", 154, 195], ["HA", "PROBLEM", 256, 258], ["mediated fusion", "TREATMENT", 279, 294], ["the host endosomal membrane", "TREATMENT", 303, 330], ["the viral envelope", "PROBLEM", 335, 353], ["HA precursor molecule HA", "PROBLEM", 379, 403], ["common", "OBSERVATION_MODIFIER", 4, 10], ["allelic variants", "OBSERVATION", 11, 27], ["SFTPD genes", "OBSERVATION", 42, 53], ["associated with", "UNCERTAINTY", 58, 73], ["respiratory distress", "OBSERVATION", 74, 94], ["respiratory", "ANATOMY", 154, 165], ["syncytial virus bronchiolitis", "OBSERVATION", 166, 195], ["fusion", "OBSERVATION", 288, 294], ["host", "ANATOMY_MODIFIER", 307, 311], ["endosomal membrane", "OBSERVATION", 312, 330], ["viral envelope", "OBSERVATION", 339, 353]]], ["Cleavage of HA is indispensable for infectivity and determines viral pathogenicity and tissue tropism (Steinhauer, 1999) .", [["tissue", "ANATOMY", 87, 93], ["HA", "GENE_OR_GENE_PRODUCT", 12, 14], ["tissue", "TISSUE", 87, 93], ["HA", "PROTEIN", 12, 14], ["HA", "PROBLEM", 12, 14], ["infectivity", "PROBLEM", 36, 47], ["viral pathogenicity", "PROBLEM", 63, 82], ["tissue tropism", "OBSERVATION", 87, 101]]], ["The HA 0 of human and LPAI has a consensus cleavage site motif and is cleaved by a typsin-like protease; infection is localized to the primary site of infection, such as the respiratory tract in humans or the gastrointestinal tract of aquatic birds, respectively.", [["site", "ANATOMY", 143, 147], ["respiratory tract", "ANATOMY", 174, 191], ["gastrointestinal tract", "ANATOMY", 209, 231], ["infection", "DISEASE", 105, 114], ["infection", "DISEASE", 151, 160], ["human", "ORGANISM", 12, 17], ["LPAI", "ORGANISM", 22, 26], ["typsin", "GENE_OR_GENE_PRODUCT", 83, 89], ["respiratory tract", "ORGANISM_SUBDIVISION", 174, 191], ["humans", "ORGANISM", 195, 201], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 209, 231], ["consensus cleavage site motif", "DNA", 33, 62], ["typsin-like protease", "PROTEIN", 83, 103], ["human", "SPECIES", 12, 17], ["humans", "SPECIES", 195, 201], ["human", "SPECIES", 12, 17], ["humans", "SPECIES", 195, 201], ["a consensus cleavage site motif", "PROBLEM", 31, 62], ["a typsin-like protease", "PROBLEM", 81, 103], ["infection", "PROBLEM", 105, 114], ["infection", "PROBLEM", 151, 160], ["the respiratory tract in humans", "PROBLEM", 170, 201], ["infection", "OBSERVATION", 105, 114], ["infection", "OBSERVATION", 151, 160], ["respiratory tract", "ANATOMY", 174, 191], ["gastrointestinal tract", "ANATOMY", 209, 231], ["aquatic birds", "OBSERVATION", 235, 248]]], ["Some secreted enzymes isolated from rat and swine lungs are shown to support replication of influenza viruses in vitro using mouse-adapted IAV (e.g., WSN strain), including tryptase Clara, mini-plasmin, and ectopic anionic trypsin from rat lungs, and tryptase TC30 from porcine lungs (Kido et al., 2008) ; however, only a few proteases are present in the human respiratory tract or tissue fluids, including transmembrane protease, serine 2 (TMPRSS2), 11D (TMPRSS11D) (Bottcher et al., 2006) , 4 (TMPRSS4) (Chaipan et al., 2009) , and plasmin (PLG).", [["lungs", "ANATOMY", 50, 55], ["lungs", "ANATOMY", 240, 245], ["lungs", "ANATOMY", 278, 283], ["respiratory tract", "ANATOMY", 361, 378], ["tissue fluids", "ANATOMY", 382, 395], ["influenza viruses", "DISEASE", 92, 109], ["serine", "CHEMICAL", 431, 437], ["rat", "ORGANISM", 36, 39], ["swine", "ORGANISM", 44, 49], ["lungs", "ORGAN", 50, 55], ["influenza viruses", "ORGANISM", 92, 109], ["mouse", "ORGANISM", 125, 130], ["IAV", "ORGANISM", 139, 142], ["WSN strain", "ORGANISM", 150, 160], ["tryptase", "GENE_OR_GENE_PRODUCT", 173, 181], ["mini-plasmin", "GENE_OR_GENE_PRODUCT", 189, 201], ["ectopic anionic trypsin", "GENE_OR_GENE_PRODUCT", 207, 230], ["rat", "ORGANISM", 236, 239], ["lungs", "ORGAN", 240, 245], ["tryptase TC30", "GENE_OR_GENE_PRODUCT", 251, 264], ["porcine", "ORGANISM", 270, 277], ["lungs", "ORGAN", 278, 283], ["human", "ORGANISM", 355, 360], ["respiratory tract", "ORGANISM_SUBDIVISION", 361, 378], ["tissue fluids", "TISSUE", 382, 395], ["transmembrane protease, serine 2", "GENE_OR_GENE_PRODUCT", 407, 439], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 441, 448], ["plasmin", "GENE_OR_GENE_PRODUCT", 534, 541], ["PLG", "GENE_OR_GENE_PRODUCT", 543, 546], ["secreted enzymes", "PROTEIN", 5, 21], ["tryptase", "PROTEIN", 173, 181], ["mini-plasmin", "PROTEIN", 189, 201], ["ectopic anionic trypsin", "PROTEIN", 207, 230], ["tryptase TC30", "PROTEIN", 251, 264], ["proteases", "PROTEIN", 326, 335], ["transmembrane protease", "PROTEIN", 407, 429], ["plasmin", "PROTEIN", 534, 541], ["PLG", "PROTEIN", 543, 546], ["rat", "SPECIES", 36, 39], ["swine", "SPECIES", 44, 49], ["mouse", "SPECIES", 125, 130], ["rat", "SPECIES", 236, 239], ["porcine", "SPECIES", 270, 277], ["human", "SPECIES", 355, 360], ["rat", "SPECIES", 36, 39], ["swine", "SPECIES", 44, 49], ["mouse", "SPECIES", 125, 130], ["IAV", "SPECIES", 139, 142], ["rat", "SPECIES", 236, 239], ["human", "SPECIES", 355, 360], ["Some secreted enzymes", "TEST", 0, 21], ["influenza viruses", "PROBLEM", 92, 109], ["WSN strain", "TREATMENT", 150, 160], ["tryptase Clara", "TREATMENT", 173, 187], ["mini-plasmin", "TREATMENT", 189, 201], ["ectopic anionic trypsin from rat lungs", "PROBLEM", 207, 245], ["a few proteases", "PROBLEM", 320, 335], ["tissue fluids", "TREATMENT", 382, 395], ["transmembrane protease", "TREATMENT", 407, 429], ["plasmin (PLG)", "TREATMENT", 534, 547], ["lungs", "ANATOMY", 50, 55], ["influenza viruses", "OBSERVATION", 92, 109], ["lungs", "ANATOMY", 240, 245], ["lungs", "ANATOMY", 278, 283], ["respiratory tract", "ANATOMY", 361, 378]]], ["These transmembrane serine proteases are identified by gene expression systems in MDCK cells; TMPRSS2 and TMPRSS4 are considered good candidate proteases for the 1918 influenza virus HA (Chaipan et al., 2009) .", [["transmembrane", "ANATOMY", 6, 19], ["MDCK cells", "ANATOMY", 82, 92], ["serine", "CHEMICAL", 20, 26], ["MDCK cells", "CELL", 82, 92], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 94, 101], ["TMPRSS4", "GENE_OR_GENE_PRODUCT", 106, 113], ["influenza virus HA", "ORGANISM", 167, 185], ["transmembrane serine proteases", "PROTEIN", 6, 36], ["MDCK cells", "CELL_LINE", 82, 92], ["TMPRSS2", "PROTEIN", 94, 101], ["TMPRSS4", "PROTEIN", 106, 113], ["influenza virus", "SPECIES", 167, 182], ["1918 influenza virus", "SPECIES", 162, 182], ["These transmembrane serine proteases", "TEST", 0, 36], ["gene expression systems", "PROBLEM", 55, 78], ["MDCK cells", "TEST", 82, 92], ["TMPRSS2", "TEST", 94, 101], ["TMPRSS4", "TEST", 106, 113], ["the 1918 influenza virus HA", "PROBLEM", 158, 185]]], ["Plasmin is converted from plasminogen into the circulation.", [["Plasmin", "GENE_OR_GENE_PRODUCT", 0, 7], ["plasminogen", "GENE_OR_GENE_PRODUCT", 26, 37], ["Plasmin", "PROTEIN", 0, 7], ["plasminogen", "PROTEIN", 26, 37], ["Plasmin", "TREATMENT", 0, 7], ["circulation", "OBSERVATION_MODIFIER", 47, 58]]], ["WSN NA can sequester plasminogen, leading to increased HA cleavage by plasmin in vitro (Goto et al., 2001) .", [["NA", "CHEMICAL", 4, 6], ["plasminogen", "GENE_OR_GENE_PRODUCT", 21, 32], ["plasmin", "GENE_OR_GENE_PRODUCT", 70, 77], ["plasminogen", "PROTEIN", 21, 32], ["plasmin", "PROTEIN", 70, 77], ["increased HA cleavage", "PROBLEM", 45, 66], ["increased", "OBSERVATION_MODIFIER", 45, 54], ["HA cleavage", "OBSERVATION", 55, 66]]], ["Conversely, the HA 0 of HPAI viruses contains genetic insertions at the cleavage site of HA and is cleaved by subtilisin-like proteases Furin (FURIN) (Walker et al., 1994) , proprotein convertase subtilisin/kexin type 5 (PCSK5) (Horimoto et al., 1994) , and recently identified TMPRSS13 (Kido et al., 2008) .", [["HPAI", "DISEASE", 24, 28], ["HPAI viruses", "ORGANISM", 24, 36], ["HA", "GENE_OR_GENE_PRODUCT", 89, 91], ["subtilisin-like proteases Furin", "GENE_OR_GENE_PRODUCT", 110, 141], ["proprotein convertase subtilisin/kexin type 5", "GENE_OR_GENE_PRODUCT", 174, 219], ["PCSK5", "GENE_OR_GENE_PRODUCT", 221, 226], ["HA", "PROTEIN", 89, 91], ["subtilisin-like proteases", "PROTEIN", 110, 135], ["Furin", "PROTEIN", 136, 141], ["FURIN", "PROTEIN", 143, 148], ["proprotein convertase subtilisin/kexin type 5", "PROTEIN", 174, 219], ["PCSK5", "PROTEIN", 221, 226], ["HPAI viruses", "SPECIES", 24, 36], ["HPAI viruses", "PROBLEM", 24, 36], ["genetic insertions", "TREATMENT", 46, 64], ["HA", "PROBLEM", 89, 91], ["Furin (FURIN)", "TREATMENT", 136, 149], ["proprotein convertase subtilisin/kexin type", "TREATMENT", 174, 217], ["viruses", "OBSERVATION", 29, 36], ["genetic insertions", "OBSERVATION", 46, 64]]], ["Cleavage by these more ubiquitous proteases allows the HPAI viruses to infect various cell types and cause systemic infection.", [["cell", "ANATOMY", 86, 90], ["systemic infection", "DISEASE", 107, 125], ["HPAI viruses", "ORGANISM", 55, 67], ["cell", "CELL", 86, 90], ["ubiquitous proteases", "PROTEIN", 23, 43], ["HPAI viruses", "SPECIES", 55, 67], ["Cleavage", "TREATMENT", 0, 8], ["the HPAI viruses", "PROBLEM", 51, 67], ["systemic infection", "PROBLEM", 107, 125], ["cell types", "OBSERVATION", 86, 96], ["systemic", "OBSERVATION_MODIFIER", 107, 115], ["infection", "OBSERVATION", 116, 125]]], ["In addition to host cellular proteases, microbial proteases also activate viral HA, which may play a role in synergism of co-infection by IAV and bacteria, as discussed later (Tashiro et al., 1987) .", [["cellular", "ANATOMY", 20, 28], ["co-infection", "DISEASE", 122, 134], ["cellular", "CELL", 20, 28], ["HA", "GENE_OR_GENE_PRODUCT", 80, 82], ["IAV", "ORGANISM", 138, 141], ["host cellular proteases", "PROTEIN", 15, 38], ["microbial proteases", "PROTEIN", 40, 59], ["IAV", "SPECIES", 138, 141], ["host cellular proteases", "TREATMENT", 15, 38], ["microbial proteases", "TREATMENT", 40, 59], ["viral HA", "PROBLEM", 74, 82], ["co-infection", "PROBLEM", 122, 134], ["IAV", "PROBLEM", 138, 141], ["bacteria", "PROBLEM", 146, 154], ["host cellular proteases", "OBSERVATION", 15, 38], ["co-infection", "OBSERVATION", 122, 134]]], ["Host protease activities can be suppressed by protease inhibitors such as human mucus secretory leukocyte peptidase inhibitor (SLPI) in the upper respiratory tract and SFTPA1 and SFTPD in the lower respiratory tract, which inhibit the interaction between the proteases and viral HA and NA (Kido et al., 2007)Replication of the virus in host cellsOnce the viral HA binds to SA receptors on the cell surface, the virus is internalized either by clathrin-mediated or a clarin-and caveolin-independent endocytic pathway Rust et al., 2004) .", [["upper respiratory tract", "ANATOMY", 140, 163], ["lower respiratory tract", "ANATOMY", 192, 215], ["cells", "ANATOMY", 341, 346], ["cell surface", "ANATOMY", 393, 405], ["human", "ORGANISM", 74, 79], ["mucus secretory leukocyte peptidase", "GENE_OR_GENE_PRODUCT", 80, 115], ["SLPI", "GENE_OR_GENE_PRODUCT", 127, 131], ["upper respiratory", "ORGANISM_SUBDIVISION", 140, 157], ["tract", "ORGANISM_SUBDIVISION", 158, 163], ["SFTPA1", "GENE_OR_GENE_PRODUCT", 168, 174], ["SFTPD", "GENE_OR_GENE_PRODUCT", 179, 184], ["lower", "ORGANISM_SUBDIVISION", 192, 197], ["respiratory tract", "ORGANISM_SUBDIVISION", 198, 215], ["host cells", "CELL", 336, 346], ["SA receptors", "GENE_OR_GENE_PRODUCT", 373, 385], ["cell surface", "CELLULAR_COMPONENT", 393, 405], ["clathrin", "GENE_OR_GENE_PRODUCT", 443, 451], ["clarin", "GENE_OR_GENE_PRODUCT", 466, 472], ["caveolin", "GENE_OR_GENE_PRODUCT", 477, 485], ["protease", "PROTEIN", 5, 13], ["human mucus secretory leukocyte peptidase inhibitor", "PROTEIN", 74, 125], ["SLPI", "PROTEIN", 127, 131], ["proteases", "PROTEIN", 259, 268], ["host cells", "CELL_TYPE", 336, 346], ["viral HA", "PROTEIN", 355, 363], ["SA receptors", "PROTEIN", 373, 385], ["clathrin", "PROTEIN", 443, 451], ["clarin", "PROTEIN", 466, 472], ["caveolin", "PROTEIN", 477, 485], ["human", "SPECIES", 74, 79], ["human", "SPECIES", 74, 79], ["Host protease activities", "TREATMENT", 0, 24], ["protease inhibitors", "TREATMENT", 46, 65], ["human mucus secretory leukocyte peptidase inhibitor", "TREATMENT", 74, 125], ["the upper respiratory tract", "PROBLEM", 136, 163], ["SFTPA1", "TREATMENT", 168, 174], ["SFTPD in the lower respiratory tract", "PROBLEM", 179, 215], ["the proteases", "PROBLEM", 255, 268], ["viral HA", "PROBLEM", 273, 281], ["the virus in host cells", "PROBLEM", 323, 346], ["the viral HA binds", "PROBLEM", 351, 369], ["the virus", "PROBLEM", 407, 416], ["upper", "ANATOMY_MODIFIER", 140, 145], ["respiratory tract", "ANATOMY", 146, 163], ["lower", "ANATOMY_MODIFIER", 192, 197], ["respiratory tract", "ANATOMY", 198, 215], ["host cells", "OBSERVATION", 336, 346]]], ["At low pH within endosome, the viral HA undergoes a conformational change that enables fusion of the viral and host endosomal membranes, allowing for the release of vRNPs into the cytoplasm (Pinto et al., 1992) .", [["endosome", "ANATOMY", 17, 25], ["endosomal membranes", "ANATOMY", 116, 135], ["cytoplasm", "ANATOMY", 180, 189], ["endosome", "CELLULAR_COMPONENT", 17, 25], ["endosomal membranes", "CELLULAR_COMPONENT", 116, 135], ["vRNPs", "GENE_OR_GENE_PRODUCT", 165, 170], ["cytoplasm", "ORGANISM_SUBSTANCE", 180, 189], ["viral HA", "PROTEIN", 31, 39], ["vRNPs", "PROTEIN", 165, 170], ["low pH within endosome", "PROBLEM", 3, 25], ["the viral HA", "PROBLEM", 27, 39], ["a conformational change", "PROBLEM", 50, 73], ["the viral and host endosomal membranes", "PROBLEM", 97, 135], ["low pH", "OBSERVATION_MODIFIER", 3, 9], ["viral", "OBSERVATION", 101, 106], ["endosomal membranes", "OBSERVATION", 116, 135]]], ["The acidification of endosomes is regulated by host cellular vacuolar H+ ATPases (Guinea and Carrasco, 1995) .", [["endosomes", "ANATOMY", 21, 30], ["cellular", "ANATOMY", 52, 60], ["H+", "CHEMICAL", 70, 72], ["endosomes", "CELLULAR_COMPONENT", 21, 30], ["cellular", "CELL", 52, 60], ["H+ ATPases", "GENE_OR_GENE_PRODUCT", 70, 80], ["vacuolar H+ ATPases", "PROTEIN", 61, 80], ["The acidification of endosomes", "PROBLEM", 0, 30], ["endosomes", "OBSERVATION", 21, 30]]], ["After transport of the viral genome into the nucleus, viral transcription is performed by the viral RNAdependent RNA polymerase to produce mRNAs that are exported from the nucleus and translated into viral proteins in the cytoplasm.", [["nucleus", "ANATOMY", 45, 52], ["nucleus", "ANATOMY", 172, 179], ["cytoplasm", "ANATOMY", 222, 231], ["nucleus", "CELLULAR_COMPONENT", 45, 52], ["nucleus", "CELLULAR_COMPONENT", 172, 179], ["cytoplasm", "ORGANISM_SUBSTANCE", 222, 231], ["viral genome", "DNA", 23, 35], ["viral RNAdependent RNA polymerase", "RNA", 94, 127], ["mRNAs", "RNA", 139, 144], ["viral proteins", "PROTEIN", 200, 214], ["viral transcription", "TREATMENT", 54, 73], ["the viral RNAdependent RNA polymerase", "PROBLEM", 90, 127], ["viral proteins in the cytoplasm", "PROBLEM", 200, 231], ["viral genome", "OBSERVATION", 23, 35], ["nucleus", "ANATOMY", 45, 52], ["viral transcription", "OBSERVATION", 54, 73], ["nucleus", "ANATOMY", 172, 179], ["viral proteins", "OBSERVATION", 200, 214], ["cytoplasm", "OBSERVATION_MODIFIER", 222, 231]]], ["Trafficking of viral genomic RNA into and out of the nucleus through the nuclear membrane is through interactions with host cell nuclear import and export machinery, including importin alpha and beta, exportin 1, and RAN (Boulo et al., 2007) .Replication of the virus in host cellsFor replication and transcription of the influenza virus genome, not only viral factors but also host-derived cellular factors are required.", [["nucleus", "ANATOMY", 53, 60], ["nuclear membrane", "ANATOMY", 73, 89], ["cell nuclear", "ANATOMY", 124, 136], ["cells", "ANATOMY", 276, 281], ["cellular", "ANATOMY", 391, 399], ["nucleus", "CELLULAR_COMPONENT", 53, 60], ["nuclear membrane", "CELLULAR_COMPONENT", 73, 89], ["host cell nuclear", "CELLULAR_COMPONENT", 119, 136], ["importin alpha", "GENE_OR_GENE_PRODUCT", 176, 190], ["beta, exportin 1", "GENE_OR_GENE_PRODUCT", 195, 211], ["RAN", "GENE_OR_GENE_PRODUCT", 217, 220], ["host cells", "CELL", 271, 281], ["influenza virus", "ORGANISM", 322, 337], ["cellular", "CELL", 391, 399], ["viral genomic RNA", "RNA", 15, 32], ["importin alpha and beta", "PROTEIN", 176, 199], ["exportin 1", "PROTEIN", 201, 211], ["RAN", "PROTEIN", 217, 220], ["host cells", "CELL_TYPE", 271, 281], ["influenza virus genome", "DNA", 322, 344], ["viral factors", "PROTEIN", 355, 368], ["cellular factors", "PROTEIN", 391, 407], ["influenza virus", "SPECIES", 322, 337], ["influenza virus", "SPECIES", 322, 337], ["viral genomic RNA", "PROBLEM", 15, 32], ["the virus in host cells", "PROBLEM", 258, 281], ["replication", "TREATMENT", 285, 296], ["transcription", "TREATMENT", 301, 314], ["the influenza virus genome", "PROBLEM", 318, 344], ["viral factors", "PROBLEM", 355, 368], ["viral genomic RNA", "OBSERVATION", 15, 32], ["nucleus", "ANATOMY_MODIFIER", 53, 60], ["nuclear membrane", "OBSERVATION", 73, 89], ["virus", "OBSERVATION", 262, 267], ["host cells", "OBSERVATION", 271, 281], ["influenza virus genome", "OBSERVATION", 322, 344], ["cellular factors", "OBSERVATION", 391, 407]]], ["Key among the functional interactions during influenza virus infection is the dependence of the virus on cellular RNA synthesis by DNA-dependent RNA polymerase II (Pol II), as the viral mRNA transcription is initiated by use of short 5 0 capped RNA fragments, derived from host cellular Pol II transcripts, as primers .", [["cellular", "ANATOMY", 105, 113], ["cellular", "ANATOMY", 278, 286], ["influenza virus infection", "DISEASE", 45, 70], ["influenza virus", "ORGANISM", 45, 60], ["cellular", "CELL", 105, 113], ["DNA", "CELLULAR_COMPONENT", 131, 134], ["-dependent RNA polymerase II", "GENE_OR_GENE_PRODUCT", 134, 162], ["Pol II", "GENE_OR_GENE_PRODUCT", 164, 170], ["cellular Pol II", "GENE_OR_GENE_PRODUCT", 278, 293], ["DNA-dependent RNA polymerase II", "PROTEIN", 131, 162], ["Pol II", "PROTEIN", 164, 170], ["viral mRNA", "RNA", 180, 190], ["5 0 capped RNA fragments", "RNA", 234, 258], ["host cellular Pol II transcripts", "RNA", 273, 305], ["influenza virus", "SPECIES", 45, 60], ["influenza virus", "SPECIES", 45, 60], ["influenza virus infection", "PROBLEM", 45, 70], ["the virus", "PROBLEM", 92, 101], ["cellular RNA synthesis", "TREATMENT", 105, 127], ["the viral mRNA transcription", "TREATMENT", 176, 204], ["short 5 0 capped RNA fragments", "TREATMENT", 228, 258], ["host cellular Pol II transcripts", "TREATMENT", 273, 305]]], ["The virus can alter the distribution of Pol II on cellular genes, leading to a reduction in Pol II elongation, thereby contributing to the well-known phenomenon of host cell shutoff, in which there is a dramatic decrease in the translation of cellular mRNAs while viral transcripts remain efficiently and selectively translated during influenza virus infection Engelhardt et al., 2005) .", [["cellular", "ANATOMY", 50, 58], ["cell", "ANATOMY", 169, 173], ["cellular", "ANATOMY", 243, 251], ["influenza virus infection", "DISEASE", 335, 360], ["Pol II", "GENE_OR_GENE_PRODUCT", 40, 46], ["cellular", "CELL", 50, 58], ["Pol II", "GENE_OR_GENE_PRODUCT", 92, 98], ["host cell", "CELL", 164, 173], ["cellular", "CELL", 243, 251], ["influenza virus", "ORGANISM", 335, 350], ["Pol II", "PROTEIN", 40, 46], ["cellular genes", "DNA", 50, 64], ["Pol II", "PROTEIN", 92, 98], ["cellular mRNAs", "RNA", 243, 257], ["viral transcripts", "RNA", 264, 281], ["influenza virus", "SPECIES", 335, 350], ["The virus", "PROBLEM", 0, 9], ["Pol II on cellular genes", "PROBLEM", 40, 64], ["a reduction in Pol II elongation", "PROBLEM", 77, 109], ["host cell shutoff", "PROBLEM", 164, 181], ["a dramatic decrease", "PROBLEM", 201, 220], ["cellular mRNAs", "PROBLEM", 243, 257], ["viral transcripts", "PROBLEM", 264, 281], ["influenza virus infection", "PROBLEM", 335, 360], ["virus", "OBSERVATION", 4, 9], ["Pol II", "OBSERVATION", 40, 46], ["reduction", "OBSERVATION_MODIFIER", 79, 88], ["Pol II", "OBSERVATION_MODIFIER", 92, 98], ["elongation", "OBSERVATION_MODIFIER", 99, 109], ["host cell shutoff", "OBSERVATION", 164, 181], ["dramatic", "OBSERVATION_MODIFIER", 203, 211], ["decrease", "OBSERVATION_MODIFIER", 212, 220]]], ["Recent functional assays and proteomics have suggested a panel of host cellular proteins may interact with the viral polymerase and vRNP complexes (for review, see Mayer et al., 2007; Nagata et al., 2008) .", [["cellular", "ANATOMY", 71, 79], ["cellular", "CELL", 71, 79], ["vRNP", "GENE_OR_GENE_PRODUCT", 132, 136], ["host cellular proteins", "PROTEIN", 66, 88], ["viral polymerase", "PROTEIN", 111, 127], ["vRNP complexes", "PROTEIN", 132, 146], ["Recent functional assays", "TEST", 0, 24], ["a panel", "TEST", 55, 62], ["host cellular proteins", "PROBLEM", 66, 88], ["the viral polymerase", "TEST", 107, 127]]], ["Viral NS1 is also a major player in shutting down host protein synthesis by interacting with host proteins to interfere with the host machinery, such as CPSF4 (cleavage and polyadenylation specific factor 4, 30kDa) and PABN1 (poly(A) binding protein, nuclear 1) (Chen et al., 1999) in polyadenylation; IVNS1ABP (influenza virus NS1A binding protein) (Wolff et al., 1998) in splicing; and BAT1(HLA-B associated transcript 1) (Momose et al., 2001) in nucleocytoplasmic transport of cellular mRNAs.", [["nucleocytoplasmic", "ANATOMY", 449, 466], ["cellular", "ANATOMY", 480, 488], ["Viral", "ORGANISM", 0, 5], ["NS1", "GENE_OR_GENE_PRODUCT", 6, 9], ["CPSF4", "GENE_OR_GENE_PRODUCT", 153, 158], ["polyadenylation specific factor 4", "GENE_OR_GENE_PRODUCT", 173, 206], ["30kDa", "GENE_OR_GENE_PRODUCT", 208, 213], ["PABN1", "GENE_OR_GENE_PRODUCT", 219, 224], ["poly(A) binding protein", "GENE_OR_GENE_PRODUCT", 226, 249], ["IVNS1ABP", "GENE_OR_GENE_PRODUCT", 302, 310], ["influenza virus NS1A binding protein", "GENE_OR_GENE_PRODUCT", 312, 348], ["BAT1", "GENE_OR_GENE_PRODUCT", 388, 392], ["HLA-B associated transcript 1", "GENE_OR_GENE_PRODUCT", 393, 422], ["cellular", "CELL", 480, 488], ["Viral NS1", "PROTEIN", 0, 9], ["host proteins", "PROTEIN", 93, 106], ["CPSF4", "PROTEIN", 153, 158], ["polyadenylation specific factor 4", "PROTEIN", 173, 206], ["30kDa", "PROTEIN", 208, 213], ["PABN1", "PROTEIN", 219, 224], ["poly(A) binding protein", "PROTEIN", 226, 249], ["nuclear 1", "PROTEIN", 251, 260], ["IVNS1ABP", "PROTEIN", 302, 310], ["influenza virus NS1A binding protein", "PROTEIN", 312, 348], ["BAT1", "PROTEIN", 388, 392], ["transcript 1", "PROTEIN", 410, 422], ["cellular mRNAs", "RNA", 480, 494], ["influenza virus", "SPECIES", 312, 327], ["Viral NS1", "PROBLEM", 0, 9], ["host proteins", "TREATMENT", 93, 106], ["the host machinery", "TREATMENT", 125, 143], ["CPSF4 (cleavage", "TREATMENT", 153, 168], ["polyadenylation specific factor", "TEST", 173, 204], ["polyadenylation", "TREATMENT", 285, 300], ["IVNS1ABP (influenza virus", "TREATMENT", 302, 327], ["HLA", "TEST", 393, 396], ["NS1", "OBSERVATION", 6, 9], ["cellular mRNAs", "OBSERVATION", 480, 494]]], ["NS1 also recruits the cellular initiation factor, EIF4G1 (eukaryotic translation initiation factor 4 gamma, 1), allowing for the preferential translation of the IAV messengers (Aragon et al., 2000) .", [["cellular", "ANATOMY", 22, 30], ["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["cellular", "CELL", 22, 30], ["EIF4G1", "GENE_OR_GENE_PRODUCT", 50, 56], ["eukaryotic translation initiation factor 4 gamma", "GENE_OR_GENE_PRODUCT", 58, 106], ["1", "GENE_OR_GENE_PRODUCT", 108, 109], ["NS1", "PROTEIN", 0, 3], ["cellular initiation factor", "PROTEIN", 22, 48], ["EIF4G1", "PROTEIN", 50, 56], ["eukaryotic translation initiation factor 4 gamma, 1", "PROTEIN", 58, 109], ["IAV messengers", "PROTEIN", 161, 175], ["NS1", "PROBLEM", 0, 3]]], ["Viral M1 can interact with VPS28 (vacuolar protein-sorting 28 homolog), a component of endosomal complexes required for transport, and CDC42 (cell division cycle 42), a small G protein, playing an important role in budding of the IAV (Hui et al., 2006) .", [["endosomal complexes", "ANATOMY", 87, 106], ["cell", "ANATOMY", 142, 146], ["Viral M1", "ORGANISM", 0, 8], ["VPS28", "GENE_OR_GENE_PRODUCT", 27, 32], ["vacuolar protein-sorting 28 homolog", "GENE_OR_GENE_PRODUCT", 34, 69], ["endosomal", "CELLULAR_COMPONENT", 87, 96], ["CDC42", "GENE_OR_GENE_PRODUCT", 135, 140], ["cell division cycle 42", "GENE_OR_GENE_PRODUCT", 142, 164], ["small G protein", "GENE_OR_GENE_PRODUCT", 169, 184], ["Viral M1", "PROTEIN", 0, 8], ["VPS28", "PROTEIN", 27, 32], ["vacuolar protein-sorting 28 homolog", "PROTEIN", 34, 69], ["endosomal complexes", "PROTEIN", 87, 106], ["CDC42", "PROTEIN", 135, 140], ["cell division cycle 42", "PROTEIN", 142, 164], ["small G protein", "PROTEIN", 169, 184], ["vacuolar protein", "TEST", 34, 50], ["endosomal complexes", "PROBLEM", 87, 106], ["CDC42 (cell division cycle", "TEST", 135, 161], ["a small G protein", "PROBLEM", 167, 184], ["M1", "ANATOMY_MODIFIER", 6, 8], ["endosomal complexes", "OBSERVATION", 87, 106]]], ["A variety of intracellular signaling pathways activated by IAV infection, such as the Raf/MEK/ERK mitogenic kinase cascade, are in part exploited by the virus to ensure efficient replication (Ludwig, 2007) .", [["intracellular", "ANATOMY", 13, 26], ["infection", "DISEASE", 63, 72], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 13, 26], ["IAV", "ORGANISM", 59, 62], ["Raf", "GENE_OR_GENE_PRODUCT", 86, 89], ["MEK", "GENE_OR_GENE_PRODUCT", 90, 93], ["ERK", "GENE_OR_GENE_PRODUCT", 94, 97], ["Raf", "PROTEIN", 86, 89], ["MEK", "PROTEIN", 90, 93], ["ERK", "PROTEIN", 94, 97], ["intracellular signaling pathways", "PROBLEM", 13, 45], ["IAV infection", "PROBLEM", 59, 72], ["the Raf/MEK/ERK mitogenic kinase cascade", "TEST", 82, 122], ["the virus", "PROBLEM", 149, 158], ["intracellular signaling", "OBSERVATION", 13, 36], ["IAV", "OBSERVATION_MODIFIER", 59, 62], ["infection", "OBSERVATION", 63, 72], ["mitogenic kinase cascade", "OBSERVATION", 98, 122]]], ["Specific blockade of the Raf/MEK/ERK pathway results in nuclear retention of viral RNPs complexes in late stages of the replication cycle, which significantly impairs growth of IAVs tested in cell culture and Raf-BxB transgenic mice (Olschlager et al., 2004; Pleschka et al., 2001) .", [["nuclear", "ANATOMY", 56, 63], ["IAVs", "ANATOMY", 177, 181], ["cell culture", "ANATOMY", 192, 204], ["Raf", "GENE_OR_GENE_PRODUCT", 25, 28], ["MEK", "GENE_OR_GENE_PRODUCT", 29, 32], ["ERK", "GENE_OR_GENE_PRODUCT", 33, 36], ["nuclear", "CELLULAR_COMPONENT", 56, 63], ["IAVs", "PATHOLOGICAL_FORMATION", 177, 181], ["cell culture", "CELL", 192, 204], ["Raf", "GENE_OR_GENE_PRODUCT", 209, 212], ["BxB", "GENE_OR_GENE_PRODUCT", 213, 216], ["Raf", "PROTEIN", 25, 28], ["MEK", "PROTEIN", 29, 32], ["ERK", "PROTEIN", 33, 36], ["viral RNPs complexes", "PROTEIN", 77, 97], ["Raf", "PROTEIN", 209, 212], ["BxB", "PROTEIN", 213, 216], ["mice", "SPECIES", 228, 232], ["mice", "SPECIES", 228, 232], ["the Raf/MEK/ERK pathway", "TEST", 21, 44], ["viral RNPs complexes", "PROBLEM", 77, 97], ["the replication cycle", "TREATMENT", 116, 137], ["IAVs", "PROBLEM", 177, 181], ["cell culture", "TEST", 192, 204], ["Raf", "TEST", 209, 212], ["viral RNPs", "OBSERVATION", 77, 87], ["late stages", "OBSERVATION_MODIFIER", 101, 112], ["growth", "OBSERVATION_MODIFIER", 167, 173]]], ["A number of host proteins, including lipids, microfilaments, G proteins, and some protein kinases, have been shown to be involved in the budding of influenza virus (for a review, see Nayak et al., 2004) .", [["microfilaments", "ANATOMY", 45, 59], ["influenza virus", "DISEASE", 148, 163], ["microfilaments", "CELLULAR_COMPONENT", 45, 59], ["G proteins", "GENE_OR_GENE_PRODUCT", 61, 71], ["influenza virus", "ORGANISM", 148, 163], ["host proteins", "PROTEIN", 12, 25], ["microfilaments", "PROTEIN", 45, 59], ["G proteins", "PROTEIN", 61, 71], ["protein kinases", "PROTEIN", 82, 97], ["influenza virus", "SPECIES", 148, 163], ["influenza virus", "SPECIES", 148, 163], ["host proteins", "TEST", 12, 25], ["lipids", "TEST", 37, 43], ["microfilaments, G proteins", "TEST", 45, 71], ["some protein kinases", "PROBLEM", 77, 97], ["influenza virus", "PROBLEM", 148, 163], ["host proteins", "OBSERVATION_MODIFIER", 12, 25]]], ["For example, casein kinase 2 (CK2) is found in influenza virus particles; increased CK2 activity correlates with the replication cycle of influenza virus and its inhibitors disrupt virus budding in MDCK cells (Hui and Nayak, 2002; Tucker et al., 1991) .Replication of the virus in host cellsIAV has also developed translational control strategies that use both viral and cellular proteins to ensure high levels of viral protein synthesis during infection (Kash et al., 2006a) .", [["MDCK cells", "ANATOMY", 198, 208], ["cellular", "ANATOMY", 371, 379], ["influenza", "DISEASE", 138, 147], ["infection", "DISEASE", 445, 454], ["casein kinase 2", "GENE_OR_GENE_PRODUCT", 13, 28], ["CK2", "GENE_OR_GENE_PRODUCT", 30, 33], ["influenza virus particles", "ORGANISM", 47, 72], ["CK2", "GENE_OR_GENE_PRODUCT", 84, 87], ["influenza virus", "ORGANISM", 138, 153], ["MDCK cells", "CELL", 198, 208], ["cellular", "CELL", 371, 379], ["casein kinase 2", "PROTEIN", 13, 28], ["CK2", "PROTEIN", 30, 33], ["CK2", "PROTEIN", 84, 87], ["MDCK cells", "CELL_LINE", 198, 208], ["viral and cellular proteins", "PROTEIN", 361, 388], ["viral protein", "PROTEIN", 414, 427], ["influenza virus", "SPECIES", 138, 153], ["influenza virus", "SPECIES", 138, 153], ["casein kinase", "TEST", 13, 26], ["CK2", "TEST", 30, 33], ["influenza virus particles", "PROBLEM", 47, 72], ["increased CK2 activity", "PROBLEM", 74, 96], ["influenza virus", "PROBLEM", 138, 153], ["its inhibitors", "TREATMENT", 158, 172], ["the virus", "PROBLEM", 268, 277], ["translational control strategies", "TREATMENT", 314, 346], ["both viral and cellular proteins", "TREATMENT", 356, 388], ["viral protein synthesis during infection", "PROBLEM", 414, 454], ["influenza virus particles", "OBSERVATION", 47, 72], ["increased", "OBSERVATION_MODIFIER", 74, 83], ["CK2 activity", "OBSERVATION", 84, 96], ["influenza virus", "OBSERVATION", 138, 153], ["virus", "OBSERVATION", 272, 277], ["viral protein", "OBSERVATION", 414, 427]]], ["The short 5 0 capped and highly conserved host cellular RNA sequence at the IAV mRNAs can bind with several host cellular proteins such as the RNAbinding protein GRSF1 (G-rich RNA sequence binding factor 1), which acts as a positive regulator of IAV protein synthesis by selectively recruiting viral and host cellular mRNAs containing 5 0 UTR binding sites to polyribosomes in vitro (Kash et al., 2002; Park et al., 1999) .Replication of the virus in host cellsRecent studies indicate that exogenously administered synthetic small interfering RNAs (siRNAs) can protect against replication of the influenza virus in infected mice, although the extent to which this occurs naturally upon influenza infection is not clear (Tompkins et al., 2004) .", [["cellular", "ANATOMY", 47, 55], ["cellular", "ANATOMY", 113, 121], ["cellular", "ANATOMY", 309, 317], ["polyribosomes", "ANATOMY", 360, 373], ["cells", "ANATOMY", 456, 461], ["influenza virus", "DISEASE", 596, 611], ["influenza infection", "DISEASE", 686, 705], ["cellular", "CELL", 47, 55], ["cellular", "CELL", 113, 121], ["GRSF1", "GENE_OR_GENE_PRODUCT", 162, 167], ["G-rich RNA sequence binding factor 1", "GENE_OR_GENE_PRODUCT", 169, 205], ["IAV", "ORGANISM", 246, 249], ["cellular", "CELL", 309, 317], ["polyribosomes", "CELLULAR_COMPONENT", 360, 373], ["host cells", "CELL", 451, 461], ["influenza virus", "ORGANISM", 596, 611], ["mice", "ORGANISM", 624, 628], ["short 5 0 capped and highly conserved host cellular RNA sequence", "RNA", 4, 68], ["IAV mRNAs", "RNA", 76, 85], ["cellular proteins", "PROTEIN", 113, 130], ["RNAbinding protein", "PROTEIN", 143, 161], ["GRSF1", "PROTEIN", 162, 167], ["G-rich RNA sequence binding factor 1", "PROTEIN", 169, 205], ["IAV protein", "PROTEIN", 246, 257], ["viral and host cellular mRNAs", "RNA", 294, 323], ["5 0 UTR binding sites", "DNA", 335, 356], ["host cells", "CELL_TYPE", 451, 461], ["synthetic small interfering RNAs", "RNA", 515, 547], ["influenza virus", "SPECIES", 596, 611], ["mice", "SPECIES", 624, 628], ["IAV", "SPECIES", 246, 249], ["influenza virus", "SPECIES", 596, 611], ["mice", "SPECIES", 624, 628], ["several host cellular proteins", "PROBLEM", 100, 130], ["the RNAbinding protein GRSF1", "TEST", 139, 167], ["G-rich RNA sequence binding factor", "TEST", 169, 203], ["IAV protein synthesis", "TREATMENT", 246, 267], ["selectively recruiting viral and host cellular mRNAs", "TREATMENT", 271, 323], ["UTR binding sites", "TREATMENT", 339, 356], ["the virus in host cells", "PROBLEM", 438, 461], ["Recent studies", "TEST", 461, 475], ["synthetic small interfering RNAs (siRNAs)", "TREATMENT", 515, 556], ["the influenza virus", "PROBLEM", 592, 611], ["influenza infection", "PROBLEM", 686, 705], ["host cellular RNA", "OBSERVATION", 42, 59], ["IAV protein", "OBSERVATION", 246, 257], ["host cellular mRNAs", "OBSERVATION", 304, 323], ["virus", "OBSERVATION", 442, 447], ["host cells", "OBSERVATION", 451, 461], ["influenza virus", "OBSERVATION", 596, 611]]], ["RNA interference (RNAi) is a natural host cellular process that inhibits gene expression by causing the degradation of specific RNA molecules or by hindering the transcription of specific genes.", [["cellular", "ANATOMY", 42, 50], ["cellular", "CELL", 42, 50], ["RNA molecules", "PROTEIN", 128, 141], ["RNA interference (RNAi", "PROBLEM", 0, 22], ["a natural host cellular process", "PROBLEM", 27, 58], ["the degradation of specific RNA molecules", "PROBLEM", 100, 141], ["natural host", "OBSERVATION_MODIFIER", 29, 41], ["cellular process", "OBSERVATION", 42, 58], ["gene expression", "OBSERVATION", 73, 88], ["RNA molecules", "OBSERVATION", 128, 141]]], ["The RNAi pathway is initiated by the host cellular endonuclease Dicer1, which cleaves viral long, double-stranded RNA (dsRNA) molecules into short pieces siRNAs.", [["cellular", "ANATOMY", 42, 50], ["cellular", "CELL", 42, 50], ["Dicer1", "GENE_OR_GENE_PRODUCT", 64, 70], ["host cellular endonuclease", "PROTEIN", 37, 63], ["Dicer1", "PROTEIN", 64, 70], ["viral long, double-stranded RNA", "RNA", 86, 117], ["(dsRNA) molecules", "PROTEIN", 118, 135], ["the host cellular endonuclease Dicer1", "TREATMENT", 33, 70], ["double-stranded RNA (dsRNA)", "TREATMENT", 98, 125], ["short pieces siRNAs", "PROBLEM", 141, 160], ["endonuclease Dicer1", "OBSERVATION", 51, 70], ["stranded RNA", "OBSERVATION_MODIFIER", 105, 117], ["short pieces", "OBSERVATION_MODIFIER", 141, 153]]], ["The slicer, eukaryotic translation initiation factor 2C, 2 (EIF2C2), cuts the siRNA strand that is subsequently degraded and prevents viral replication (Rand et al., 2005) .Replication of the virus in host cellsReducing the nucleotide supply for synthesis of viral RNA can also inhibit replication of the influenza virus.", [["cells", "ANATOMY", 206, 211], ["nucleotide", "CHEMICAL", 224, 234], ["influenza", "DISEASE", 305, 314], ["nucleotide", "CHEMICAL", 224, 234], ["eukaryotic translation initiation factor 2C", "GENE_OR_GENE_PRODUCT", 12, 55], ["2", "GENE_OR_GENE_PRODUCT", 57, 58], ["EIF2C2", "GENE_OR_GENE_PRODUCT", 60, 66], ["host cells", "CELL", 201, 211], ["influenza virus", "ORGANISM", 305, 320], ["eukaryotic translation initiation factor 2C, 2 (EIF2C2)", "PROTEIN", 12, 67], ["siRNA strand", "DNA", 78, 90], ["host cells", "CELL_TYPE", 201, 211], ["viral RNA", "RNA", 259, 268], ["influenza virus", "SPECIES", 305, 320], ["influenza virus", "SPECIES", 305, 320], ["cuts the siRNA strand", "TREATMENT", 69, 90], ["the virus in host cells", "PROBLEM", 188, 211], ["the nucleotide supply", "TREATMENT", 220, 241], ["synthesis of viral RNA", "TREATMENT", 246, 268], ["the influenza virus", "PROBLEM", 301, 320], ["siRNA strand", "OBSERVATION", 78, 90], ["virus", "OBSERVATION", 192, 197], ["host cells", "OBSERVATION", 201, 211], ["influenza virus", "OBSERVATION", 305, 320]]], ["IMP dehydrogenase 1 (IMPDH1) is a key cellular enzyme involved in the biosynthesis of guanine nucleotides and viral RNA synthesis, which is the main target of antiviral action of Ribavirin, an anti-viral drug against both human and avian (H5N1) influenza viruses (De Clercq, 2006) .Destruction of host cells by apoptosisIAV infection can induce apoptosis, or programmed cell death, which has been postulated to be a host defense mechanism to limit the replication and spread of virus.", [["cellular", "ANATOMY", 38, 46], ["cells", "ANATOMY", 302, 307], ["cell", "ANATOMY", 370, 374], ["IMP", "CHEMICAL", 0, 3], ["guanine", "CHEMICAL", 86, 93], ["Ribavirin", "CHEMICAL", 179, 188], ["human and avian (H5N1) influenza viruses", "DISEASE", 222, 262], ["infection", "DISEASE", 324, 333], ["IMP", "CHEMICAL", 0, 3], ["guanine nucleotides", "CHEMICAL", 86, 105], ["Ribavirin", "CHEMICAL", 179, 188], ["IMP dehydrogenase 1", "GENE_OR_GENE_PRODUCT", 0, 19], ["IMPDH1", "GENE_OR_GENE_PRODUCT", 21, 27], ["cellular", "CELL", 38, 46], ["guanine", "SIMPLE_CHEMICAL", 86, 93], ["Ribavirin", "SIMPLE_CHEMICAL", 179, 188], ["human", "ORGANISM", 222, 227], ["avian (H5N1) influenza viruses", "ORGANISM", 232, 262], ["host cells", "CELL", 297, 307], ["apoptosisIAV", "GENE_OR_GENE_PRODUCT", 311, 323], ["cell", "CELL", 370, 374], ["IMP dehydrogenase 1", "PROTEIN", 0, 19], ["IMPDH1", "PROTEIN", 21, 27], ["host cells", "CELL_TYPE", 297, 307], ["human", "SPECIES", 222, 227], ["avian (H5N1", "SPECIES", 232, 243], ["human", "SPECIES", 222, 227], ["IMP dehydrogenase 1 (IMPDH1)", "PROBLEM", 0, 28], ["a key cellular enzyme", "PROBLEM", 32, 53], ["guanine nucleotides", "TREATMENT", 86, 105], ["viral RNA synthesis", "PROBLEM", 110, 129], ["antiviral action", "TREATMENT", 159, 175], ["Ribavirin", "TREATMENT", 179, 188], ["an anti-viral drug", "TREATMENT", 190, 208], ["influenza viruses", "PROBLEM", 245, 262], ["Destruction of host cells", "PROBLEM", 282, 307], ["apoptosisIAV infection", "PROBLEM", 311, 333], ["apoptosis", "PROBLEM", 345, 354], ["programmed cell death", "PROBLEM", 359, 380], ["virus", "PROBLEM", 478, 483], ["guanine nucleotides", "OBSERVATION", 86, 105], ["viral RNA synthesis", "OBSERVATION", 110, 129], ["host cells", "OBSERVATION", 297, 307], ["infection", "OBSERVATION", 324, 333], ["cell death", "OBSERVATION", 370, 380]]], ["The precise mechanism of virus-induced apoptosis is unclear.", [["virus", "PROBLEM", 25, 30], ["induced apoptosis", "PROBLEM", 31, 48], ["virus", "OBSERVATION", 25, 30], ["apoptosis", "OBSERVATION", 39, 48]]], ["Many pathways can be activated, and the initiation of one pathway can induce multiple signal transduction cascades through feedback loops.", [["transduction cascades", "OBSERVATION", 93, 114]]], ["Such pathways, at the least, include those mediated by Fas (TNF receptor superfamily, member 6), eukaryotic translation initiation factor 2alpha kinase 2 (EIF2AK2, also known as PKR), or transforming growth factor, beta 1 (TGFB1) (Brydon et al., 2005) .", [["Fas", "GENE_OR_GENE_PRODUCT", 55, 58], ["TNF receptor superfamily, member 6", "GENE_OR_GENE_PRODUCT", 60, 94], ["eukaryotic translation initiation factor 2alpha kinase 2", "GENE_OR_GENE_PRODUCT", 97, 153], ["EIF2AK2", "GENE_OR_GENE_PRODUCT", 155, 162], ["PKR", "GENE_OR_GENE_PRODUCT", 178, 181], ["transforming growth factor, beta 1", "GENE_OR_GENE_PRODUCT", 187, 221], ["TGFB1", "GENE_OR_GENE_PRODUCT", 223, 228], ["Fas", "PROTEIN", 55, 58], ["TNF receptor superfamily", "PROTEIN", 60, 84], ["member 6", "PROTEIN", 86, 94], ["eukaryotic translation initiation factor 2alpha kinase 2", "PROTEIN", 97, 153], ["EIF2AK2", "PROTEIN", 155, 162], ["PKR", "PROTEIN", 178, 181], ["transforming growth factor", "PROTEIN", 187, 213], ["beta 1", "PROTEIN", 215, 221], ["TGFB1", "PROTEIN", 223, 228], ["factor 2alpha kinase", "TEST", 131, 151], ["transforming growth factor", "PROBLEM", 187, 213]]], ["PKR is a key regulator in influenza virus-induced apoptosis.", [["PKR", "GENE_OR_GENE_PRODUCT", 0, 3], ["influenza virus", "ORGANISM", 26, 41], ["PKR", "PROTEIN", 0, 3], ["influenza virus", "SPECIES", 26, 41], ["PKR", "TEST", 0, 3], ["influenza virus", "PROBLEM", 26, 41], ["apoptosis", "PROBLEM", 50, 59], ["influenza virus", "OBSERVATION", 26, 41]]], ["Activation of PKR by IAV dsRNA leads to several sequential downstream events, including the activation of EIF2A, BAX, BCL2, and NFKB1.", [["PKR", "GENE_OR_GENE_PRODUCT", 14, 17], ["IAV dsRNA", "ORGANISM", 21, 30], ["EIF2A", "GENE_OR_GENE_PRODUCT", 106, 111], ["BAX", "GENE_OR_GENE_PRODUCT", 113, 116], ["BCL2", "GENE_OR_GENE_PRODUCT", 118, 122], ["NFKB1", "GENE_OR_GENE_PRODUCT", 128, 133], ["PKR", "PROTEIN", 14, 17], ["EIF2A", "PROTEIN", 106, 111], ["BAX", "PROTEIN", 113, 116], ["BCL2", "PROTEIN", 118, 122], ["NFKB1", "PROTEIN", 128, 133], ["PKR", "TREATMENT", 14, 17], ["IAV dsRNA leads", "TREATMENT", 21, 36], ["BCL2", "TREATMENT", 118, 122], ["NFKB1", "TREATMENT", 128, 133], ["PKR", "OBSERVATION", 14, 17], ["NFKB1", "ANATOMY", 128, 133]]], ["The latter leads to transcriptional induction of many pro-apoptotic genes, including those encoding Fas, TP53, and JUN.", [["Fas", "GENE_OR_GENE_PRODUCT", 100, 103], ["TP53", "GENE_OR_GENE_PRODUCT", 105, 109], ["JUN", "GENE_OR_GENE_PRODUCT", 115, 118], ["pro-apoptotic genes", "DNA", 54, 73], ["Fas", "PROTEIN", 100, 103], ["TP53", "PROTEIN", 105, 109], ["JUN", "PROTEIN", 115, 118], ["transcriptional induction", "TREATMENT", 20, 45], ["many pro-apoptotic genes", "PROBLEM", 49, 73], ["TP53", "TEST", 105, 109], ["pro-apoptotic genes", "OBSERVATION", 54, 73]]], ["PKR can initiate CASP8, a predominant apoptotic pathway in human bronchiolar cells during IAV infection, leading to a caspase cascade (Zhirnov et al., 2002) .Destruction of host cells by apoptosisSeveral influenza viral proteins are involved in induction of apoptosis.", [["bronchiolar cells", "ANATOMY", 65, 82], ["cells", "ANATOMY", 178, 183], ["infection", "DISEASE", 94, 103], ["PKR", "GENE_OR_GENE_PRODUCT", 0, 3], ["CASP8", "GENE_OR_GENE_PRODUCT", 17, 22], ["human", "ORGANISM", 59, 64], ["bronchiolar cells", "CELL", 65, 82], ["IAV", "ORGANISM", 90, 93], ["caspase", "GENE_OR_GENE_PRODUCT", 118, 125], ["host cells", "CELL", 173, 183], ["apoptosisSeveral influenza viral", "ORGANISM", 187, 219], ["PKR", "PROTEIN", 0, 3], ["CASP8", "PROTEIN", 17, 22], ["human bronchiolar cells", "CELL_TYPE", 59, 82], ["host cells", "CELL_TYPE", 173, 183], ["apoptosisSeveral influenza viral proteins", "PROTEIN", 187, 228], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64], ["IAV", "SPECIES", 90, 93], ["PKR", "PROBLEM", 0, 3], ["CASP8", "TEST", 17, 22], ["a predominant apoptotic pathway", "PROBLEM", 24, 55], ["human bronchiolar cells", "PROBLEM", 59, 82], ["IAV infection", "PROBLEM", 90, 103], ["a caspase cascade", "TREATMENT", 116, 133], ["Destruction of host cells", "PROBLEM", 158, 183], ["apoptosisSeveral influenza viral proteins", "PROBLEM", 187, 228], ["apoptosis", "PROBLEM", 258, 267], ["predominant", "OBSERVATION_MODIFIER", 26, 37], ["apoptotic pathway", "OBSERVATION", 38, 55], ["human", "OBSERVATION_MODIFIER", 59, 64], ["bronchiolar cells", "OBSERVATION", 65, 82], ["IAV", "OBSERVATION_MODIFIER", 90, 93], ["infection", "OBSERVATION", 94, 103], ["host cells", "OBSERVATION", 173, 183], ["apoptosis", "OBSERVATION", 258, 267]]], ["NA can activate latent TGFB1 on the cell surface to its active form.", [["cell surface", "ANATOMY", 36, 48], ["NA", "CHEMICAL", 0, 2], ["NA", "SIMPLE_CHEMICAL", 0, 2], ["TGFB1", "GENE_OR_GENE_PRODUCT", 23, 28], ["cell surface", "CELLULAR_COMPONENT", 36, 48], ["latent TGFB1", "PROTEIN", 16, 28], ["latent TGFB1", "PROBLEM", 16, 28], ["latent", "OBSERVATION_MODIFIER", 16, 22], ["TGFB1", "OBSERVATION", 23, 28], ["active", "OBSERVATION_MODIFIER", 56, 62]]], ["TGFB1 initiates a signaling cascade, leading to the activation of the JNK or SAPK, which in turn results in the activation of transcription factors and upregulation of pro-apoptotic gene expression.", [["TGFB1", "GENE_OR_GENE_PRODUCT", 0, 5], ["JNK", "GENE_OR_GENE_PRODUCT", 70, 73], ["SAPK", "GENE_OR_GENE_PRODUCT", 77, 81], ["TGFB1", "PROTEIN", 0, 5], ["JNK", "PROTEIN", 70, 73], ["SAPK", "PROTEIN", 77, 81], ["transcription factors", "PROTEIN", 126, 147], ["a signaling cascade", "PROBLEM", 16, 35], ["transcription factors", "PROBLEM", 126, 147], ["pro-apoptotic gene expression", "PROBLEM", 168, 197], ["signaling cascade", "OBSERVATION", 18, 35], ["pro-apoptotic gene expression", "OBSERVATION", 168, 197]]], ["In virus-infected cells, IAV encodes a second nonstructural polypeptide, PB1-F2, which induces apoptosis through mitochondrial solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 6 (SLC25A6) and voltage-dependent anion channel 1 (VDAC1) (Zamarin et al., 2005) .Immunocompetence state of the individual hostInfluenza virus infection elicits a complex network of host immune responses.", [["cells", "ANATOMY", 18, 23], ["mitochondrial", "ANATOMY", 113, 126], ["mitochondrial", "ANATOMY", 153, 166], ["adenine", "CHEMICAL", 176, 183], ["Influenza virus infection", "DISEASE", 344, 369], ["adenine", "CHEMICAL", 176, 183], ["cells", "CELL", 18, 23], ["IAV", "ORGANISM", 25, 28], ["PB1-F2", "GENE_OR_GENE_PRODUCT", 73, 79], ["mitochondrial", "CELLULAR_COMPONENT", 113, 126], ["solute carrier family 25", "GENE_OR_GENE_PRODUCT", 127, 151], ["mitochondrial", "CELLULAR_COMPONENT", 153, 166], ["adenine nucleotide translocator), member 6", "GENE_OR_GENE_PRODUCT", 176, 218], ["SLC25A6", "GENE_OR_GENE_PRODUCT", 220, 227], ["voltage-dependent anion channel 1", "GENE_OR_GENE_PRODUCT", 233, 266], ["VDAC1", "GENE_OR_GENE_PRODUCT", 268, 273], ["Influenza virus", "ORGANISM", 344, 359], ["virus-infected cells", "CELL_TYPE", 3, 23], ["PB1", "PROTEIN", 73, 76], ["mitochondrial solute carrier family 25", "PROTEIN", 113, 151], ["mitochondrial carrier; adenine nucleotide translocator", "PROTEIN", 153, 207], ["member 6", "PROTEIN", 210, 218], ["SLC25A6", "PROTEIN", 220, 227], ["voltage-dependent anion channel 1", "PROTEIN", 233, 266], ["VDAC1", "PROTEIN", 268, 273], ["Influenza virus", "SPECIES", 344, 359], ["IAV", "SPECIES", 25, 28], ["Influenza virus", "SPECIES", 344, 359], ["infected cells", "PROBLEM", 9, 23], ["a second nonstructural polypeptide", "TREATMENT", 37, 71], ["adenine nucleotide translocator", "TREATMENT", 176, 207], ["voltage-dependent anion channel", "TREATMENT", 233, 264], ["Immunocompetence state", "PROBLEM", 299, 321], ["the individual hostInfluenza virus infection", "PROBLEM", 325, 369], ["virus", "OBSERVATION", 3, 8], ["infected cells", "OBSERVATION", 9, 23], ["Influenza virus", "OBSERVATION", 344, 359]]], ["Innate immunity represents the first barrier to limit initial viral replication and provides the signals required for the subsequent adaptive cellular and humoral immune responses to develop.", [["cellular", "ANATOMY", 142, 150], ["cellular", "CELL", 142, 150], ["initial viral replication", "TREATMENT", 54, 79], ["humoral immune responses", "TREATMENT", 155, 179]]], ["The adaptive immune response ultimately helps to reduce the viral burden, to eliminate the virus, and to trigger disease recovery (Behrens and Stoll, 2006) .", [["the viral burden", "PROBLEM", 56, 72], ["the virus", "PROBLEM", 87, 96], ["viral burden", "OBSERVATION", 60, 72]]], ["The immunocompetence of the individual host affects the course of the disease outcome.Innate antiviral responseThe interferon (IFN)-induced cellular antiviral response has a primary protective function in the early stages of influenza virus infection (Garcia-Sastre, 2006) .", [["cellular", "ANATOMY", 140, 148], ["influenza virus infection", "DISEASE", 225, 250], ["interferon", "GENE_OR_GENE_PRODUCT", 115, 125], ["IFN", "GENE_OR_GENE_PRODUCT", 127, 130], ["cellular", "CELL", 140, 148], ["influenza virus", "ORGANISM", 225, 240], ["interferon", "PROTEIN", 115, 125], ["IFN", "PROTEIN", 127, 130], ["influenza virus", "SPECIES", 225, 240], ["influenza virus", "SPECIES", 225, 240], ["the disease outcome", "PROBLEM", 66, 85], ["Innate antiviral response", "PROBLEM", 86, 111], ["The interferon (IFN)", "TREATMENT", 111, 131], ["cellular antiviral response", "PROBLEM", 140, 167], ["influenza virus infection", "PROBLEM", 225, 250], ["antiviral response", "OBSERVATION", 93, 111], ["antiviral response", "OBSERVATION", 149, 167], ["early stages", "OBSERVATION_MODIFIER", 209, 221], ["influenza virus", "OBSERVATION", 225, 240]]], ["Both single-strand (ss) and dsRNA, viral RNA products generated during infection, act like triggers for the production of type I IFN, IFNA1 and IFNB1, which are recognized by two types of sensors, the transmembrane Toll-like receptors (TLR3, -7, and -8) and cytoplasmic RIG-I-like receptors (RIG-I, MDA5, and LGP2) (Garcia-Sastre and Biron, 2006) .", [["cytoplasmic", "ANATOMY", 258, 269], ["infection", "DISEASE", 71, 80], ["type I IFN", "GENE_OR_GENE_PRODUCT", 122, 132], ["IFNA1", "GENE_OR_GENE_PRODUCT", 134, 139], ["IFNB1", "GENE_OR_GENE_PRODUCT", 144, 149], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 215, 234], ["TLR3", "GENE_OR_GENE_PRODUCT", 236, 240], ["-7", "GENE_OR_GENE_PRODUCT", 242, 244], ["-8", "GENE_OR_GENE_PRODUCT", 250, 252], ["cytoplasmic", "ORGANISM_SUBSTANCE", 258, 269], ["RIG-I-like receptors", "GENE_OR_GENE_PRODUCT", 270, 290], ["RIG-I", "GENE_OR_GENE_PRODUCT", 292, 297], ["MDA5", "GENE_OR_GENE_PRODUCT", 299, 303], ["LGP2", "GENE_OR_GENE_PRODUCT", 309, 313], ["viral RNA products", "PROTEIN", 35, 53], ["type I IFN", "PROTEIN", 122, 132], ["IFNA1", "PROTEIN", 134, 139], ["IFNB1", "PROTEIN", 144, 149], ["transmembrane Toll-like receptors", "PROTEIN", 201, 234], ["TLR3, -7, and -8", "PROTEIN", 236, 252], ["cytoplasmic RIG-I-like receptors", "PROTEIN", 258, 290], ["RIG", "PROTEIN", 292, 295], ["I", "PROTEIN", 296, 297], ["MDA5", "PROTEIN", 299, 303], ["LGP2", "PROTEIN", 309, 313], ["single-strand (ss)", "TREATMENT", 5, 23], ["dsRNA", "TREATMENT", 28, 33], ["viral RNA products", "TREATMENT", 35, 53], ["infection", "PROBLEM", 71, 80], ["type I IFN", "PROBLEM", 122, 132], ["IFNA1", "TEST", 134, 139], ["IFNB1", "TEST", 144, 149], ["the transmembrane Toll", "TEST", 197, 219], ["TLR3", "TEST", 236, 240], ["cytoplasmic RIG", "TEST", 258, 273], ["RIG", "TEST", 292, 295], ["MDA5", "TEST", 299, 303], ["dsRNA", "ANATOMY", 28, 33], ["viral RNA", "OBSERVATION", 35, 44], ["infection", "OBSERVATION", 71, 80], ["MDA5", "ANATOMY", 299, 303]]], ["The Tolllike receptors signal via their adaptors either TRIF in the case of TLR3 or MyD88 in the case of TLR7 and -8 (Diebold et al., 2004; Guillot et al., 2005) .", [["Tolllike receptors", "GENE_OR_GENE_PRODUCT", 4, 22], ["TRIF", "GENE_OR_GENE_PRODUCT", 56, 60], ["TLR3", "GENE_OR_GENE_PRODUCT", 76, 80], ["MyD88", "GENE_OR_GENE_PRODUCT", 84, 89], ["TLR7", "GENE_OR_GENE_PRODUCT", 105, 109], ["-8", "GENE_OR_GENE_PRODUCT", 114, 116], ["Tolllike receptors", "PROTEIN", 4, 22], ["TRIF", "PROTEIN", 56, 60], ["TLR3", "PROTEIN", 76, 80], ["MyD88", "PROTEIN", 84, 89], ["TLR7", "PROTEIN", 105, 109]]], ["The RIG-I-like receptors signal via mitochondrial antiviral signaling protein (MASP), also known as IPS-1 (Yoneyama and Fujita, 2007) .", [["mitochondrial", "ANATOMY", 36, 49], ["RIG-I-like receptors", "GENE_OR_GENE_PRODUCT", 4, 24], ["mitochondrial", "CELLULAR_COMPONENT", 36, 49], ["MASP", "GENE_OR_GENE_PRODUCT", 79, 83], ["IPS-1", "GENE_OR_GENE_PRODUCT", 100, 105], ["RIG-I-like receptors", "PROTEIN", 4, 24], ["mitochondrial antiviral signaling protein", "PROTEIN", 36, 77], ["MASP", "PROTEIN", 79, 83], ["IPS", "PROTEIN", 100, 103], ["The RIG-I-like receptors signal", "TEST", 0, 31], ["mitochondrial antiviral signaling protein (MASP)", "PROBLEM", 36, 84], ["IPS", "TEST", 100, 103], ["mitochondrial antiviral signaling protein", "OBSERVATION", 36, 77]]], ["These interactions initiate signaling pathways that differ in their initial steps but converge in the activation of IRF3 and NFKB1, which induce transcription of IFNB1 and IFNB2.", [["IRF3", "GENE_OR_GENE_PRODUCT", 116, 120], ["NFKB1", "GENE_OR_GENE_PRODUCT", 125, 130], ["IFNB1", "GENE_OR_GENE_PRODUCT", 162, 167], ["IFNB2", "GENE_OR_GENE_PRODUCT", 172, 177], ["IRF3", "PROTEIN", 116, 120], ["NFKB1", "PROTEIN", 125, 130], ["IFNB1", "PROTEIN", 162, 167], ["IFNB2", "PROTEIN", 172, 177], ["IRF3 and NFKB1", "TREATMENT", 116, 130]]], ["Mice lacking both Myd88 and Masp genes fail to upregulate antiviral responses; Tlr7-and Myd88-deficient mice have no protection against IAV vaccination challenges (Koyama et al., 2007) .", [["Mice", "ORGANISM", 0, 4], ["Myd88", "GENE_OR_GENE_PRODUCT", 18, 23], ["Masp", "GENE_OR_GENE_PRODUCT", 28, 32], ["Tlr7", "GENE_OR_GENE_PRODUCT", 79, 83], ["Myd88", "GENE_OR_GENE_PRODUCT", 88, 93], ["mice", "ORGANISM", 104, 108], ["Myd88 and Masp genes", "DNA", 18, 38], ["Tlr7", "PROTEIN", 79, 83], ["Myd88", "PROTEIN", 88, 93], ["Mice", "SPECIES", 0, 4], ["mice", "SPECIES", 104, 108], ["mice", "SPECIES", 104, 108], ["IAV", "SPECIES", 136, 139], ["Mice lacking both Myd88", "TREATMENT", 0, 23], ["Masp genes", "TREATMENT", 28, 38], ["antiviral responses", "TREATMENT", 58, 77], ["Tlr7", "TEST", 79, 83], ["Myd88-deficient mice", "TREATMENT", 88, 108], ["IAV vaccination challenges", "TREATMENT", 136, 162]]], ["Tlr3 knockout mice show significantly reduced inflammatory mediators and better survival rates compared with wild-type mice after IAV infection, despite of a higher viral load in the lungs (Le Goffic et al., 2006) .", [["lungs", "ANATOMY", 183, 188], ["IAV infection", "DISEASE", 130, 143], ["Tlr3", "GENE_OR_GENE_PRODUCT", 0, 4], ["mice", "ORGANISM", 14, 18], ["wild-type", "ORGANISM", 109, 118], ["mice", "ORGANISM", 119, 123], ["IAV", "ORGANISM", 130, 133], ["lungs", "ORGAN", 183, 188], ["Tlr3", "PROTEIN", 0, 4], ["inflammatory mediators", "PROTEIN", 46, 68], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 119, 123], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 119, 123], ["IAV", "SPECIES", 130, 133], ["significantly reduced inflammatory mediators", "PROBLEM", 24, 68], ["IAV infection", "PROBLEM", 130, 143], ["a higher viral load in the lungs", "PROBLEM", 156, 188], ["significantly", "OBSERVATION_MODIFIER", 24, 37], ["reduced", "OBSERVATION_MODIFIER", 38, 45], ["inflammatory", "OBSERVATION_MODIFIER", 46, 58], ["infection", "OBSERVATION", 134, 143], ["higher", "OBSERVATION_MODIFIER", 158, 164], ["viral load", "OBSERVATION", 165, 175], ["lungs", "ANATOMY", 183, 188]]], ["A loss-of-function mutant in TLR3 (F303S) was identified in a patient with influenza-associated encephalopathy (Hidaka et al., 2006) .Innate antiviral responseVirus-infected cells synthesize IFN and secrete it into extracellular fluid, where it binds to type 1 IFN receptors, IFNAR1 and IFNAR2, on uninfected neighboring cells.", [["cells", "ANATOMY", 174, 179], ["extracellular fluid", "ANATOMY", 215, 234], ["cells", "ANATOMY", 321, 326], ["influenza", "DISEASE", 75, 84], ["encephalopathy", "DISEASE", 96, 110], ["TLR3", "GENE_OR_GENE_PRODUCT", 29, 33], ["patient", "ORGANISM", 62, 69], ["responseVirus", "GENE_OR_GENE_PRODUCT", 151, 164], ["cells", "CELL", 174, 179], ["IFN", "GENE_OR_GENE_PRODUCT", 191, 194], ["extracellular fluid", "ORGANISM_SUBSTANCE", 215, 234], ["type 1 IFN receptors", "GENE_OR_GENE_PRODUCT", 254, 274], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 276, 282], ["IFNAR2", "GENE_OR_GENE_PRODUCT", 287, 293], ["cells", "CELL", 321, 326], ["loss-of-function mutant", "PROTEIN", 2, 25], ["TLR3", "PROTEIN", 29, 33], ["F303S", "PROTEIN", 35, 40], ["Innate antiviral responseVirus-infected cells", "CELL_TYPE", 134, 179], ["IFN", "PROTEIN", 191, 194], ["type 1 IFN receptors", "PROTEIN", 254, 274], ["IFNAR1", "PROTEIN", 276, 282], ["IFNAR2", "PROTEIN", 287, 293], ["uninfected neighboring cells", "CELL_TYPE", 298, 326], ["patient", "SPECIES", 62, 69], ["A loss", "PROBLEM", 0, 6], ["influenza", "PROBLEM", 75, 84], ["associated encephalopathy", "PROBLEM", 85, 110], ["Innate antiviral responseVirus", "TREATMENT", 134, 164], ["infected cells synthesize IFN", "TREATMENT", 165, 194], ["extracellular fluid", "PROBLEM", 215, 234], ["type 1 IFN receptors", "PROBLEM", 254, 274], ["IFNAR1", "PROBLEM", 276, 282], ["IFNAR2", "PROBLEM", 287, 293], ["uninfected neighboring cells", "PROBLEM", 298, 326], ["loss", "OBSERVATION", 2, 6], ["encephalopathy", "OBSERVATION", 96, 110], ["infected cells", "OBSERVATION", 165, 179], ["fluid", "OBSERVATION", 229, 234], ["neighboring cells", "OBSERVATION", 309, 326]]], ["This binding, followed by activation of the Janus kinase (JAK) family and subsequent activation of signal transducers and activators of transcription (STAT) proteins (Murray, 2007) , results in the induction of a cellular antiviral response involving the transcriptional upregulation of more than 100 IFN-stimulated genes (such as CXCL10, MX1, PKR, OAS1, RNASEL, and PML), through several signaling pathways, including NFKB1, JUN, and MX1 (Garcia-Sastre and Biron, 2006).", [["cellular", "ANATOMY", 213, 221], ["Janus kinase", "GENE_OR_GENE_PRODUCT", 44, 56], ["JAK", "GENE_OR_GENE_PRODUCT", 58, 61], ["signal transducers and activators of transcription", "GENE_OR_GENE_PRODUCT", 99, 149], ["STAT", "GENE_OR_GENE_PRODUCT", 151, 155], ["cellular", "CELL", 213, 221], ["CXCL10", "GENE_OR_GENE_PRODUCT", 331, 337], ["MX1", "GENE_OR_GENE_PRODUCT", 339, 342], ["PKR", "GENE_OR_GENE_PRODUCT", 344, 347], ["OAS1", "GENE_OR_GENE_PRODUCT", 349, 353], ["RNASEL", "GENE_OR_GENE_PRODUCT", 355, 361], ["PML", "GENE_OR_GENE_PRODUCT", 367, 370], ["NFKB1", "GENE_OR_GENE_PRODUCT", 419, 424], ["JUN", "GENE_OR_GENE_PRODUCT", 426, 429], ["MX1", "GENE_OR_GENE_PRODUCT", 435, 438], ["Janus kinase (JAK) family", "PROTEIN", 44, 69], ["signal transducers and activators of transcription (STAT) proteins", "PROTEIN", 99, 165], ["IFN", "PROTEIN", 301, 304], ["CXCL10", "PROTEIN", 331, 337], ["MX1", "DNA", 339, 342], ["PKR", "DNA", 344, 347], ["OAS1", "DNA", 349, 353], ["RNASEL", "DNA", 355, 361], ["PML", "DNA", 367, 370], ["NFKB1", "DNA", 419, 424], ["JUN", "DNA", 426, 429], ["MX1", "DNA", 435, 438], ["a cellular antiviral response", "PROBLEM", 211, 240], ["CXCL10", "TEST", 331, 337], ["MX1", "TEST", 339, 342], ["PKR", "TEST", 344, 347], ["OAS1", "TEST", 349, 353], ["RNASEL", "TEST", 355, 361], ["PML", "PROBLEM", 367, 370], ["NFKB1", "TEST", 419, 424], ["JUN", "TEST", 426, 429], ["antiviral response", "OBSERVATION", 222, 240]]], ["IFN also stimulates the production of a form of inducible NOS2A and the MHC class I and II proteins, all of which play important roles in the immune response to infections.", [["IFN", "CHEMICAL", 0, 3], ["infections", "DISEASE", 161, 171], ["IFN", "GENE_OR_GENE_PRODUCT", 0, 3], ["NOS2A", "GENE_OR_GENE_PRODUCT", 58, 63], ["MHC class I", "GENE_OR_GENE_PRODUCT", 72, 83], ["II", "GENE_OR_GENE_PRODUCT", 88, 90], ["IFN", "PROTEIN", 0, 3], ["NOS2A", "PROTEIN", 58, 63], ["MHC class I and II proteins", "PROTEIN", 72, 99], ["inducible NOS2A", "PROBLEM", 48, 63], ["infections", "PROBLEM", 161, 171], ["infections", "OBSERVATION", 161, 171]]], ["The IFNG-induced genes are vigorously expressed in H5N1-infected ferret lungs, in particular, CXCL10, for which blockade of its cognate receptor, CXCR3, reduces the mortality associated with H5N1 infection in ferrets (Cameron et al., 2008) .", [["lungs", "ANATOMY", 72, 77], ["H5N1 infection", "DISEASE", 191, 205], ["IFNG", "GENE_OR_GENE_PRODUCT", 4, 8], ["H5N1", "ORGANISM", 51, 55], ["ferret", "ORGANISM", 65, 71], ["lungs", "ORGAN", 72, 77], ["CXCL10", "GENE_OR_GENE_PRODUCT", 94, 100], ["CXCR3", "GENE_OR_GENE_PRODUCT", 146, 151], ["H5N1", "ORGANISM", 191, 195], ["ferrets", "ORGANISM", 209, 216], ["IFNG-induced genes", "DNA", 4, 22], ["CXCL10", "PROTEIN", 94, 100], ["cognate receptor", "PROTEIN", 128, 144], ["CXCR3", "PROTEIN", 146, 151], ["ferret", "SPECIES", 65, 71], ["ferrets", "SPECIES", 209, 216], ["ferret", "SPECIES", 65, 71], ["H5N1", "SPECIES", 191, 195], ["ferrets", "SPECIES", 209, 216], ["H5N1", "PROBLEM", 51, 55], ["infected ferret lungs", "PROBLEM", 56, 77], ["CXCL10", "TEST", 94, 100], ["CXCR3", "TEST", 146, 151], ["H5N1 infection", "PROBLEM", 191, 205], ["infected", "OBSERVATION", 56, 64], ["lungs", "ANATOMY", 72, 77], ["H5N1", "OBSERVATION_MODIFIER", 191, 195], ["infection", "OBSERVATION", 196, 205]]], ["Susceptibility to the SARS coronavirus has been associated with genetic variants in human OAS1 and MX1 genes (Hamano et al., 2005; He et al., 2006) .", [["SARS coronavirus", "DISEASE", 22, 38], ["SARS coronavirus", "ORGANISM", 22, 38], ["human", "ORGANISM", 84, 89], ["OAS1", "GENE_OR_GENE_PRODUCT", 90, 94], ["MX1", "GENE_OR_GENE_PRODUCT", 99, 102], ["human OAS1 and MX1 genes", "DNA", 84, 108], ["human", "SPECIES", 84, 89], ["SARS coronavirus", "SPECIES", 22, 38], ["human", "SPECIES", 84, 89], ["the SARS coronavirus", "PROBLEM", 18, 38]]], ["Genetic susceptibility to human respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes (JUN, IFNA5, and NOS2A) (Janssen et al., 2007) .Innate antiviral responseTo establish a productive infection, influenza viruses must first overcome the IFN-induced blocks imposed on viral replication. dsRNA-activated PKR can restrict viral replication through its ability to phosphorylate the protein synthesis initiation factor EIF2A, resulting in a reduced ability of EIF2A to initiate translation.", [["respiratory syncytial virus", "DISEASE", 32, 59], ["bronchiolitis", "DISEASE", 60, 73], ["infection", "DISEASE", 226, 235], ["influenza viruses", "DISEASE", 237, 254], ["IFN", "CHEMICAL", 279, 282], ["human", "ORGANISM", 26, 31], ["respiratory syncytial virus", "ORGANISM", 32, 59], ["JUN", "GENE_OR_GENE_PRODUCT", 128, 131], ["IFNA5", "GENE_OR_GENE_PRODUCT", 133, 138], ["NOS2A", "GENE_OR_GENE_PRODUCT", 144, 149], ["influenza viruses", "ORGANISM", 237, 254], ["IFN", "GENE_OR_GENE_PRODUCT", 279, 282], ["PKR", "GENE_OR_GENE_PRODUCT", 344, 347], ["EIF2A", "GENE_OR_GENE_PRODUCT", 456, 461], ["EIF2A", "GENE_OR_GENE_PRODUCT", 497, 502], ["innate immune genes", "DNA", 107, 126], ["JUN", "DNA", 128, 131], ["IFNA5", "DNA", 133, 138], ["NOS2A", "DNA", 144, 149], ["IFN", "PROTEIN", 279, 282], ["PKR", "PROTEIN", 344, 347], ["protein synthesis initiation factor", "PROTEIN", 420, 455], ["EIF2A", "PROTEIN", 456, 461], ["EIF2A", "PROTEIN", 497, 502], ["human", "SPECIES", 26, 31], ["respiratory syncytial virus", "SPECIES", 32, 59], ["human respiratory syncytial virus", "SPECIES", 26, 59], ["Genetic susceptibility to human respiratory syncytial virus bronchiolitis", "PROBLEM", 0, 73], ["Innate antiviral responseTo", "TREATMENT", 175, 202], ["a productive infection", "PROBLEM", 213, 235], ["influenza viruses", "PROBLEM", 237, 254], ["the IFN", "TREATMENT", 275, 282], ["induced blocks", "PROBLEM", 283, 297], ["viral replication", "TREATMENT", 309, 326], ["dsRNA", "PROBLEM", 328, 333], ["activated PKR", "TREATMENT", 334, 347], ["viral replication", "TREATMENT", 361, 378], ["respiratory syncytial virus bronchiolitis", "OBSERVATION", 32, 73], ["productive", "OBSERVATION_MODIFIER", 215, 225], ["infection", "OBSERVATION", 226, 235], ["viral replication", "OBSERVATION", 309, 326]]], ["This prevents viral replication and inhibits normal cell ribosome function, killing both the virus and the host cell if the response is active for a sufficient time.", [["cell ribosome", "ANATOMY", 52, 65], ["cell", "ANATOMY", 112, 116], ["cell", "CELL", 52, 56], ["host cell", "CELL", 107, 116], ["viral replication", "PROBLEM", 14, 31], ["viral replication", "OBSERVATION", 14, 31], ["normal cell ribosome function", "OBSERVATION", 45, 74], ["host cell", "OBSERVATION", 107, 116], ["active", "OBSERVATION_MODIFIER", 136, 142]]], ["To evade the antiviral effects of PKR, IAV has evolved 2 strategies to block PKR activation or action: the virus activates a host cellular inhibitor of PKR, p58 IPK , and its NS1 protein blocks PKR activation (Kash et al., 2006a) .", [["cellular", "ANATOMY", 130, 138], ["PKR", "GENE_OR_GENE_PRODUCT", 34, 37], ["IAV", "ORGANISM", 39, 42], ["PKR", "GENE_OR_GENE_PRODUCT", 77, 80], ["cellular", "CELL", 130, 138], ["PKR", "GENE_OR_GENE_PRODUCT", 152, 155], ["p58", "GENE_OR_GENE_PRODUCT", 157, 160], ["IPK", "GENE_OR_GENE_PRODUCT", 161, 164], ["NS1", "GENE_OR_GENE_PRODUCT", 175, 178], ["PKR", "GENE_OR_GENE_PRODUCT", 194, 197], ["PKR", "PROTEIN", 34, 37], ["PKR", "PROTEIN", 77, 80], ["PKR", "PROTEIN", 152, 155], ["p58 IPK", "PROTEIN", 157, 164], ["NS1 protein", "PROTEIN", 175, 186], ["PKR", "PROTEIN", 194, 197], ["IAV", "SPECIES", 39, 42], ["PKR", "TREATMENT", 34, 37], ["IAV", "TREATMENT", 39, 42], ["block PKR activation", "TREATMENT", 71, 91], ["the virus", "PROBLEM", 103, 112], ["PKR", "TEST", 152, 155], ["IPK", "TEST", 161, 164], ["its NS1 protein blocks", "TREATMENT", 171, 193], ["antiviral", "OBSERVATION", 13, 22]]], ["IAV NS1 protein has been identified as a potent agonist of the innate antiviral signaling, both by interference with the RIG-I induction of IFNB (Guo et al., 2007; Mibayashi et al., 2007) , and at a later stage, by modulating processing of pre-mRNA .", [["IAV NS1", "ORGANISM", 0, 7], ["RIG-I", "GENE_OR_GENE_PRODUCT", 121, 126], ["IFNB", "GENE_OR_GENE_PRODUCT", 140, 144], ["IAV NS1 protein", "PROTEIN", 0, 15], ["RIG-I", "PROTEIN", 121, 126], ["pre-mRNA", "RNA", 240, 248], ["IAV", "SPECIES", 0, 3], ["IAV NS1 protein", "TREATMENT", 0, 15], ["NS1 protein", "OBSERVATION", 4, 15], ["antiviral signaling", "OBSERVATION", 70, 89], ["pre-mRNA", "OBSERVATION", 240, 248]]], ["A recent in vitro study has shown that IAVs not only suppress IFNB gene production but also inhibit type I IFN signaling via a NFKB1-dependent induction of the suppressor of cytokine signaling 3 (SOCS3) protein, a potent endogenous blocker of JAK/STAT signaling, which results in an impaired antiviral response (Pauli et al., 2008) .", [["IAVs", "SIMPLE_CHEMICAL", 39, 43], ["IFNB", "GENE_OR_GENE_PRODUCT", 62, 66], ["type I IFN", "GENE_OR_GENE_PRODUCT", 100, 110], ["NFKB1", "GENE_OR_GENE_PRODUCT", 127, 132], ["suppressor of cytokine signaling 3", "GENE_OR_GENE_PRODUCT", 160, 194], ["SOCS3", "GENE_OR_GENE_PRODUCT", 196, 201], ["JAK", "GENE_OR_GENE_PRODUCT", 243, 246], ["STAT", "GENE_OR_GENE_PRODUCT", 247, 251], ["IAVs", "PROTEIN", 39, 43], ["IFNB gene", "DNA", 62, 71], ["IFN", "PROTEIN", 107, 110], ["NFKB1", "PROTEIN", 127, 132], ["suppressor of cytokine signaling 3 (SOCS3) protein", "PROTEIN", 160, 210], ["JAK", "PROTEIN", 243, 246], ["STAT", "PROTEIN", 247, 251], ["A recent in vitro study", "TEST", 0, 23], ["IAVs", "PROBLEM", 39, 43], ["type I IFN signaling", "PROBLEM", 100, 120], ["a NFKB1-dependent induction", "TREATMENT", 125, 152], ["cytokine signaling", "TEST", 174, 192], ["STAT signaling", "PROBLEM", 247, 261], ["an impaired antiviral response", "PROBLEM", 280, 310], ["IAVs", "OBSERVATION", 39, 43], ["impaired", "OBSERVATION_MODIFIER", 283, 291], ["antiviral response", "OBSERVATION", 292, 310]]], ["Evidence from animal studies suggests that evasion of host innate immunity, including the type I interferon response, is a mechanism of virulence of avian H5N1 viruses in mammals including humans (Maines et al., 2008) .Innate antiviral responseWhile on the one hand the IAVs are capable of suppressing unwanted antiviral signaling events, there is accumulating evidence that the viruses have evolved strategies to benefit from the antiviral signaling activates to ensure efficient replication (Ludwig, 2007) .", [["IAVs", "ANATOMY", 270, 274], ["avian H5N1 viruses", "DISEASE", 149, 167], ["type I interferon", "GENE_OR_GENE_PRODUCT", 90, 107], ["avian H5N1 viruses", "ORGANISM", 149, 167], ["humans", "ORGANISM", 189, 195], ["IAVs", "GENE_OR_GENE_PRODUCT", 270, 274], ["type I interferon", "PROTEIN", 90, 107], ["avian H5N1", "SPECIES", 149, 159], ["humans", "SPECIES", 189, 195], ["humans", "SPECIES", 189, 195], ["animal studies", "TEST", 14, 28], ["the type I interferon response", "TREATMENT", 86, 116], ["suppressing unwanted antiviral signaling events", "PROBLEM", 290, 337], ["the viruses", "PROBLEM", 375, 386], ["the antiviral signaling", "TREATMENT", 427, 450], ["IAVs", "OBSERVATION", 270, 274], ["viruses", "OBSERVATION", 379, 386]]], ["For example, the IAVs appear to be able to switch the antiviral activity of NFKB1 into a virus supportive event (Ludwig and Planz, 2008) , as evidenced by two independent studies showing that influenza viruses replicated much better in human cells in vitro where NFKB1 was pre-activated (Nimmerjahn et al., 2004; Wurzer et al., 2004) .Innate antiviral responseThe respiratory tract secretes antimicrobial peptides such as the b-defensins and CAMP (Hartshorn et al., 2006b) . b-defensins (DEFA1, DEFA2, DEFB3, and DEFT1P) inhibit infectivity of IAV via interactions with SFTPD.", [["cells", "ANATOMY", 242, 247], ["respiratory tract", "ANATOMY", 364, 381], ["influenza viruses", "DISEASE", 192, 209], ["IAVs", "GENE_OR_GENE_PRODUCT", 17, 21], ["NFKB1", "GENE_OR_GENE_PRODUCT", 76, 81], ["influenza viruses", "ORGANISM", 192, 209], ["human", "ORGANISM", 236, 241], ["cells", "CELL", 242, 247], ["NFKB1", "GENE_OR_GENE_PRODUCT", 263, 268], ["respiratory tract", "ORGANISM_SUBDIVISION", 364, 381], ["b-defensins", "GENE_OR_GENE_PRODUCT", 426, 437], ["b-defensins", "GENE_OR_GENE_PRODUCT", 475, 486], ["DEFA1", "GENE_OR_GENE_PRODUCT", 488, 493], ["DEFA2", "GENE_OR_GENE_PRODUCT", 495, 500], ["DEFB3", "GENE_OR_GENE_PRODUCT", 502, 507], ["DEFT1P", "GENE_OR_GENE_PRODUCT", 513, 519], ["IAV", "ORGANISM", 544, 547], ["SFTPD", "GENE_OR_GENE_PRODUCT", 570, 575], ["NFKB1", "PROTEIN", 76, 81], ["human cells", "CELL_TYPE", 236, 247], ["NFKB1", "PROTEIN", 263, 268], ["CAMP", "PROTEIN", 442, 446], ["b-defensins", "PROTEIN", 475, 486], ["DEFA1", "PROTEIN", 488, 493], ["DEFA2", "PROTEIN", 495, 500], ["DEFB3", "PROTEIN", 502, 507], ["DEFT1P", "PROTEIN", 513, 519], ["SFTPD", "PROTEIN", 570, 575], ["human", "SPECIES", 236, 241], ["human", "SPECIES", 236, 241], ["IAV", "SPECIES", 544, 547], ["two independent studies", "TEST", 155, 178], ["influenza viruses", "PROBLEM", 192, 209], ["Innate antiviral response", "PROBLEM", 335, 360], ["The respiratory tract secretes antimicrobial peptides", "TREATMENT", 360, 413], ["b-defensins", "PROBLEM", 475, 486], ["DEFA1", "TEST", 488, 493], ["DEFA2", "TEST", 495, 500], ["SFTPD", "TREATMENT", 570, 575], ["influenza viruses", "OBSERVATION", 192, 209], ["antiviral response", "OBSERVATION", 342, 360], ["respiratory tract", "ANATOMY", 364, 381], ["antimicrobial peptides", "OBSERVATION", 391, 413], ["defensins", "OBSERVATION", 477, 486]]], ["Retrocyclin 2, a synthetic theta-defensin based on a human pseudogene, DEFT1P, and DEFB3 can block virus entry of influenza by blocking membrane fusion mediated by the viral HA (Leikina et al., 2005) .", [["membrane", "ANATOMY", 136, 144], ["Retrocyclin 2", "CHEMICAL", 0, 13], ["theta-defensin", "CHEMICAL", 27, 41], ["DEFB3", "CHEMICAL", 83, 88], ["influenza", "DISEASE", 114, 123], ["Retrocyclin 2", "CHEMICAL", 0, 13], ["theta-defensin", "CHEMICAL", 27, 41], ["Retrocyclin 2", "SIMPLE_CHEMICAL", 0, 13], ["theta-defensin", "GENE_OR_GENE_PRODUCT", 27, 41], ["human", "ORGANISM", 53, 58], ["DEFT1P", "GENE_OR_GENE_PRODUCT", 71, 77], ["DEFB3", "GENE_OR_GENE_PRODUCT", 83, 88], ["influenza", "ORGANISM", 114, 123], ["membrane", "CELLULAR_COMPONENT", 136, 144], ["human pseudogene", "DNA", 53, 69], ["DEFT1P", "DNA", 71, 77], ["DEFB3", "DNA", 83, 88], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 53, 58], ["Retrocyclin", "TREATMENT", 0, 11], ["a synthetic theta-defensin", "TREATMENT", 15, 41], ["a human pseudogene", "TREATMENT", 51, 69], ["DEFT1P", "TREATMENT", 71, 77], ["DEFB3", "TREATMENT", 83, 88], ["influenza", "PROBLEM", 114, 123], ["blocking membrane fusion", "TREATMENT", 127, 151], ["the viral HA", "PROBLEM", 164, 176]]], ["Numerous plasma acute phase proteins, including CRP, SAA1, and orosomucoid, increase dramatically in concentration in response to IAV infection (Barclay et al., 1969; Falsey et al., 2001) .Acute inflammatory reaction, cytokine release, and cytokine stormRapid replication and distribution of the IAV within the lungs causes local and systemic inflammation and production of chemokines and cytokines, such as CCL2, CCL5, CCR5, CX3CR1, CXCR3, CXCL10, and IL8 (see Supplementary Table for list of cytokine genes) .", [["plasma", "ANATOMY", 9, 15], ["lungs", "ANATOMY", 311, 316], ["infection", "DISEASE", 134, 143], ["inflammation", "DISEASE", 343, 355], ["plasma", "ORGANISM_SUBSTANCE", 9, 15], ["CRP", "GENE_OR_GENE_PRODUCT", 48, 51], ["SAA1", "GENE_OR_GENE_PRODUCT", 53, 57], ["orosomucoid", "GENE_OR_GENE_PRODUCT", 63, 74], ["IAV", "ORGANISM", 130, 133], ["IAV", "ORGANISM", 296, 299], ["lungs", "ORGAN", 311, 316], ["CCL2", "GENE_OR_GENE_PRODUCT", 408, 412], ["CCL5", "GENE_OR_GENE_PRODUCT", 414, 418], ["CCR5", "GENE_OR_GENE_PRODUCT", 420, 424], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 426, 432], ["CXCR3", "GENE_OR_GENE_PRODUCT", 434, 439], ["CXCL10", "GENE_OR_GENE_PRODUCT", 441, 447], ["IL8", "GENE_OR_GENE_PRODUCT", 453, 456], ["plasma acute phase proteins", "PROTEIN", 9, 36], ["CRP", "PROTEIN", 48, 51], ["SAA1", "PROTEIN", 53, 57], ["orosomucoid", "PROTEIN", 63, 74], ["cytokine", "PROTEIN", 218, 226], ["cytokine", "PROTEIN", 240, 248], ["chemokines", "PROTEIN", 374, 384], ["cytokines", "PROTEIN", 389, 398], ["CCL2", "PROTEIN", 408, 412], ["CCL5", "PROTEIN", 414, 418], ["CCR5", "PROTEIN", 420, 424], ["CX3CR1", "PROTEIN", 426, 432], ["CXCR3", "PROTEIN", 434, 439], ["CXCL10", "PROTEIN", 441, 447], ["IL8", "PROTEIN", 453, 456], ["cytokine genes", "DNA", 494, 508], ["IAV", "SPECIES", 130, 133], ["IAV", "SPECIES", 296, 299], ["Numerous plasma acute phase proteins", "PROBLEM", 0, 36], ["CRP", "TEST", 48, 51], ["SAA1", "TEST", 53, 57], ["orosomucoid", "PROBLEM", 63, 74], ["IAV infection", "PROBLEM", 130, 143], ["Acute inflammatory reaction", "PROBLEM", 189, 216], ["cytokine release", "TREATMENT", 218, 234], ["cytokine stormRapid replication", "TREATMENT", 240, 271], ["the IAV", "PROBLEM", 292, 299], ["local and systemic inflammation", "PROBLEM", 324, 355], ["chemokines and cytokines", "PROBLEM", 374, 398], ["CCL2", "TEST", 408, 412], ["CCL5", "TEST", 414, 418], ["CCR5", "TEST", 420, 424], ["CX3CR1", "TEST", 426, 432], ["CXCR3", "TEST", 434, 439], ["CXCL10", "TEST", 441, 447], ["IL8", "TEST", 453, 456], ["cytokine genes", "TREATMENT", 494, 508], ["plasma", "OBSERVATION_MODIFIER", 9, 15], ["acute", "OBSERVATION_MODIFIER", 16, 21], ["phase proteins", "OBSERVATION", 22, 36], ["increase", "OBSERVATION_MODIFIER", 76, 84], ["dramatically", "OBSERVATION_MODIFIER", 85, 97], ["IAV", "OBSERVATION_MODIFIER", 130, 133], ["infection", "OBSERVATION", 134, 143], ["inflammatory", "OBSERVATION", 195, 207], ["cytokine release", "OBSERVATION", 218, 234], ["distribution", "OBSERVATION_MODIFIER", 276, 288], ["IAV", "OBSERVATION", 296, 299], ["lungs", "ANATOMY", 311, 316], ["local", "OBSERVATION_MODIFIER", 324, 329], ["systemic", "OBSERVATION_MODIFIER", 334, 342], ["inflammation", "OBSERVATION", 343, 355], ["CCL2", "ANATOMY", 408, 412], ["CCL5", "ANATOMY", 414, 418], ["CCR5", "ANATOMY", 420, 424]]], ["Cytokines, components of the innate immune response, also affect the adaptive immune response and manifestation of the disease (Kaufmann et al., 2001) .", [["Cytokines", "PROTEIN", 0, 9], ["Cytokines", "PROBLEM", 0, 9], ["the disease", "PROBLEM", 115, 126]]], ["Cytokines can signal immune cells, including T-cells and macrophages, to travel to the site of infection.", [["immune cells", "ANATOMY", 21, 33], ["T-cells", "ANATOMY", 45, 52], ["macrophages", "ANATOMY", 57, 68], ["infection", "DISEASE", 95, 104], ["immune cells", "CELL", 21, 33], ["T-cells", "CELL", 45, 52], ["macrophages", "CELL", 57, 68], ["Cytokines", "PROTEIN", 0, 9], ["immune cells", "CELL_TYPE", 21, 33], ["T-cells", "CELL_TYPE", 45, 52], ["macrophages", "CELL_TYPE", 57, 68], ["Cytokines can signal immune cells", "PROBLEM", 0, 33], ["macrophages", "PROBLEM", 57, 68], ["infection", "PROBLEM", 95, 104], ["immune cells", "OBSERVATION", 21, 33], ["infection", "OBSERVATION", 95, 104]]], ["In addition, cytokines activate those cells, stimulating them to produce more cytokines.", [["cells", "ANATOMY", 38, 43], ["cells", "CELL", 38, 43], ["cytokines", "PROTEIN", 13, 22], ["cytokines", "PROTEIN", 78, 87], ["cytokines activate those cells", "TREATMENT", 13, 43]]], ["Normally this positive feedback loop is kept in check by negative regulatory elements, including other specific cytokines.", [["negative regulatory elements", "DNA", 57, 85], ["cytokines", "PROTEIN", 112, 121], ["feedback loop", "OBSERVATION", 23, 36]]], ["In some instances, however, an uncontrolled or excessive immune response to the IAV results in an outpouring of numerous chemokines and cytokines (Osterholm, 2005) .", [["IAV", "ORGANISM", 80, 83], ["chemokines", "PROTEIN", 121, 131], ["cytokines", "PROTEIN", 136, 145], ["an uncontrolled or excessive immune response", "PROBLEM", 28, 72]]], ["Both proinflammatory cytokines, such as TNF, IL1B, and IL6, and antiinflammatory cytokines, such as IL10 and IL1RN, are elevated in the serum.", [["serum", "ANATOMY", 136, 141], ["TNF", "GENE_OR_GENE_PRODUCT", 40, 43], ["IL1B", "GENE_OR_GENE_PRODUCT", 45, 49], ["IL6", "GENE_OR_GENE_PRODUCT", 55, 58], ["IL10", "GENE_OR_GENE_PRODUCT", 100, 104], ["IL1RN", "GENE_OR_GENE_PRODUCT", 109, 114], ["serum", "ORGANISM_SUBSTANCE", 136, 141], ["proinflammatory cytokines", "PROTEIN", 5, 30], ["TNF", "PROTEIN", 40, 43], ["IL1B", "PROTEIN", 45, 49], ["IL6", "PROTEIN", 55, 58], ["antiinflammatory cytokines", "PROTEIN", 64, 90], ["IL10", "PROTEIN", 100, 104], ["IL1RN", "PROTEIN", 109, 114], ["Both proinflammatory cytokines", "PROBLEM", 0, 30], ["TNF", "TREATMENT", 40, 43], ["IL1B", "TREATMENT", 45, 49], ["IL6", "TREATMENT", 55, 58], ["antiinflammatory cytokines", "TREATMENT", 64, 90], ["IL10 and IL1RN", "TREATMENT", 100, 114], ["elevated in the serum", "PROBLEM", 120, 141], ["proinflammatory cytokines", "OBSERVATION", 5, 30], ["antiinflammatory cytokines", "OBSERVATION", 64, 90], ["elevated", "OBSERVATION_MODIFIER", 120, 128]]], ["The fierce and often lethal interplay of these cytokines leading to the acute respiratory distress syndrome is referred to as a ''cytokine storm'', which has been suggested as an explanation, in addition to highly efficient viral replication, for the devastating nature of the 1918 pandemic flu, particularly in younger adults.", [["respiratory", "ANATOMY", 78, 89], ["respiratory distress syndrome", "DISEASE", 78, 107], ["flu", "DISEASE", 291, 294], ["cytokines", "PROTEIN", 47, 56], ["cytokine", "PROTEIN", 130, 138], ["these cytokines", "PROBLEM", 41, 56], ["the acute respiratory distress syndrome", "PROBLEM", 68, 107], ["acute", "OBSERVATION_MODIFIER", 72, 77], ["respiratory distress", "OBSERVATION", 78, 98], ["viral replication", "OBSERVATION", 224, 241]]], ["Evidence for this hypothesis comes from 1918-virus-infected mouse (Kash et al., 2006b ) and 1918 -virus-infected macaque (Kobasa et al., 2007 models and may help explain the high rate of severe and fatal disease outcomes in humans infected with highly pathogenic avian H5N1 influenza viruses (de Jong et al., 2006) .Adaptive immunityThe adaptive immune response requires some days to be effective in a na\u00efve but not a primed or immune individual, then works to contain the viral spread, to eradicate the virus, and finally to establish a memory response resulting in a long-lived resistance to reinfection with homologous infection.", [["avian H5N1 influenza viruses", "DISEASE", 263, 291], ["reinfection", "DISEASE", 594, 605], ["infection", "DISEASE", 622, 631], ["1918-virus", "ORGANISM", 40, 50], ["mouse", "ORGANISM", 60, 65], ["1918 -virus", "ORGANISM", 92, 103], ["macaque", "ORGANISM", 113, 120], ["humans", "ORGANISM", 224, 230], ["avian H5N1 influenza viruses", "ORGANISM", 263, 291], ["mouse", "SPECIES", 60, 65], ["macaque", "SPECIES", 113, 120], ["humans", "SPECIES", 224, 230], ["avian H5N1 influenza", "SPECIES", 263, 283], ["mouse", "SPECIES", 60, 65], ["humans", "SPECIES", 224, 230], ["this hypothesis", "PROBLEM", 13, 28], ["the high rate of severe and fatal disease outcomes", "PROBLEM", 170, 220], ["highly pathogenic avian H5N1 influenza viruses", "PROBLEM", 245, 291], ["Adaptive immunity", "TREATMENT", 316, 333], ["the viral spread", "PROBLEM", 469, 485], ["the virus", "PROBLEM", 500, 509], ["homologous infection", "PROBLEM", 611, 631], ["severe", "OBSERVATION_MODIFIER", 187, 193], ["fatal disease", "OBSERVATION", 198, 211], ["infection", "OBSERVATION", 622, 631]]], ["Mucosal or systematically produced antibodies to viral HA are the primary mediators of virus neutralization and the main objectives of immunization with vaccine.", [["Mucosal", "ANATOMY", 0, 7], ["Mucosal", "ORGAN", 0, 7], ["antibodies", "PROTEIN", 35, 45], ["Mucosal or systematically produced antibodies", "PROBLEM", 0, 45], ["viral HA", "PROBLEM", 49, 57], ["virus neutralization", "TREATMENT", 87, 107], ["immunization with vaccine", "TREATMENT", 135, 160]]], ["Like antibodies to NA, anti-HA antibodies can also reduce viral load by non-neutralizing mechanisms, which include lysis of the infected cell via a complement system or antibodydependent cellular cytotoxicity (ADCC).", [["cell", "ANATOMY", 137, 141], ["cellular", "ANATOMY", 187, 195], ["NA", "CHEMICAL", 19, 21], ["NA", "SIMPLE_CHEMICAL", 19, 21], ["anti-HA antibodies", "GENE_OR_GENE_PRODUCT", 23, 41], ["cell", "CELL", 137, 141], ["antibodydependent cellular", "CELL", 169, 195], ["ADCC", "CANCER", 210, 214], ["antibodies", "PROTEIN", 5, 15], ["anti-HA antibodies", "PROTEIN", 23, 41], ["infected cell", "CELL_TYPE", 128, 141], ["NA", "TEST", 19, 21], ["anti-HA antibodies", "TREATMENT", 23, 41], ["viral load", "PROBLEM", 58, 68], ["non-neutralizing mechanisms", "PROBLEM", 72, 99], ["lysis", "TREATMENT", 115, 120], ["the infected cell", "PROBLEM", 124, 141], ["a complement system", "PROBLEM", 146, 165], ["antibodydependent cellular cytotoxicity", "PROBLEM", 169, 208], ["infected cell", "OBSERVATION", 128, 141], ["cellular cytotoxicity", "OBSERVATION", 187, 208]]], ["Antibodies to the M1 and NP proteins are made following influenza infection but they play an unknown role in immunity against influenza.", [["influenza infection", "DISEASE", 56, 75], ["influenza", "DISEASE", 126, 135], ["M1", "GENE_OR_GENE_PRODUCT", 18, 20], ["NP", "GENE_OR_GENE_PRODUCT", 25, 27], ["M1 and NP proteins", "PROTEIN", 18, 36], ["Antibodies", "TEST", 0, 10], ["NP proteins", "TREATMENT", 25, 36], ["influenza infection", "PROBLEM", 56, 75], ["influenza", "PROBLEM", 126, 135], ["M1", "ANATOMY", 18, 20]]], ["Although antibodies to M2 can protect from severe disease and reduce viral load in experimental animal studies, evidence for a similar role in humans is lacking.", [["antibodies to M2", "GENE_OR_GENE_PRODUCT", 9, 25], ["humans", "ORGANISM", 143, 149], ["antibodies", "PROTEIN", 9, 19], ["M2", "PROTEIN", 23, 25], ["humans", "SPECIES", 143, 149], ["humans", "SPECIES", 143, 149], ["antibodies", "TREATMENT", 9, 19], ["severe disease", "PROBLEM", 43, 57], ["reduce viral load", "PROBLEM", 62, 79], ["experimental animal studies", "TEST", 83, 110], ["severe", "OBSERVATION_MODIFIER", 43, 49], ["disease", "OBSERVATION", 50, 57], ["viral load", "OBSERVATION", 69, 79]]], ["Antigen presentation via MHC class I and II molecules by dendritic cells lead to activation, proliferation, and differentiation of the antigen-specific T-cells, CD4 + and CD8 + .", [["dendritic cells", "ANATOMY", 57, 72], ["T-cells", "ANATOMY", 152, 159], ["CD4 +", "ANATOMY", 161, 166], ["MHC class I", "GENE_OR_GENE_PRODUCT", 25, 36], ["dendritic cells", "CELL", 57, 72], ["antigen", "GENE_OR_GENE_PRODUCT", 135, 142], ["T-cells", "CELL", 152, 159], ["CD4", "GENE_OR_GENE_PRODUCT", 161, 164], ["CD8", "GENE_OR_GENE_PRODUCT", 171, 174], ["MHC class I and II molecules", "PROTEIN", 25, 53], ["dendritic cells", "CELL_TYPE", 57, 72], ["antigen-specific T-cells", "CELL_TYPE", 135, 159], ["CD4", "PROTEIN", 161, 164], ["CD8", "PROTEIN", 171, 174], ["dendritic cells", "PROBLEM", 57, 72], ["activation, proliferation", "PROBLEM", 81, 106], ["the antigen", "TEST", 131, 142], ["CD4", "TEST", 161, 164], ["dendritic cells", "OBSERVATION", 57, 72]]], ["The influenza-specific CD4 + T helper cells are primarily responsible for promoting a high-quality antibody response.", [["CD4 + T helper cells", "ANATOMY", 23, 43], ["CD4", "GENE_OR_GENE_PRODUCT", 23, 26], ["influenza-specific CD4 + T helper cells", "CELL_TYPE", 4, 43], ["The influenza-specific CD4", "TEST", 0, 26]]], ["The CD8 + cytotoxic T lymphocytes (CTL) have the ability to recognize specific viral epitopes encoded by multiple viral genes on MHC class I molecules, but depending on an individual's HLA haplotype.", [["CD8 + cytotoxic T lymphocytes", "ANATOMY", 4, 33], ["CTL", "ANATOMY", 35, 38], ["CD8", "GENE_OR_GENE_PRODUCT", 4, 7], ["CD8", "PROTEIN", 4, 7], ["cytotoxic T lymphocytes", "CELL_TYPE", 10, 33], ["CTL", "CELL_TYPE", 35, 38], ["viral epitopes", "PROTEIN", 79, 93], ["viral genes", "DNA", 114, 125], ["MHC class I molecules", "PROTEIN", 129, 150], ["The CD8", "TEST", 0, 7], ["cytotoxic T lymphocytes", "PROBLEM", 10, 33], ["specific viral epitopes", "PROBLEM", 70, 93], ["cytotoxic T lymphocytes", "OBSERVATION", 10, 33], ["viral epitopes", "OBSERVATION", 79, 93]]], ["CD8 + T cells recognizing only one or a few viral epitopes will dominate the response, producing antiviral cytokines and lysing target cells that present viral determinants for which they bear a specific T-cell receptor.", [["CD8 + T cells", "ANATOMY", 0, 13], ["cells", "ANATOMY", 135, 140], ["T-cell", "ANATOMY", 204, 210], ["CD8", "GENE_OR_GENE_PRODUCT", 0, 3], ["cells", "CELL", 135, 140], ["T-cell receptor", "GENE_OR_GENE_PRODUCT", 204, 219], ["CD8", "PROTEIN", 0, 3], ["T cells", "CELL_TYPE", 6, 13], ["viral epitopes", "PROTEIN", 44, 58], ["antiviral cytokines", "PROTEIN", 97, 116], ["lysing target cells", "CELL_TYPE", 121, 140], ["T-cell receptor", "PROTEIN", 204, 219], ["T cells", "PROBLEM", 6, 13], ["a few viral epitopes", "PROBLEM", 38, 58], ["antiviral cytokines", "TREATMENT", 97, 116], ["lysing target cells", "PROBLEM", 121, 140]]], ["CD8 + and CD4 + effector T cells (T eff cells) can control lung inflammation during acute influenza virus infection by producing Il10 in mice.", [["CD8 +", "ANATOMY", 0, 5], ["CD4 + effector T cells", "ANATOMY", 10, 32], ["T eff cells", "ANATOMY", 34, 45], ["lung", "ANATOMY", 59, 63], ["lung inflammation", "DISEASE", 59, 76], ["influenza virus infection", "DISEASE", 90, 115], ["CD8", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD4", "GENE_OR_GENE_PRODUCT", 10, 13], ["lung", "ORGAN", 59, 63], ["acute influenza virus", "ORGANISM", 84, 105], ["Il10", "GENE_OR_GENE_PRODUCT", 129, 133], ["mice", "ORGANISM", 137, 141], ["CD8", "PROTEIN", 0, 3], ["CD4 + effector T cells", "CELL_TYPE", 10, 32], ["T eff cells", "CELL_TYPE", 34, 45], ["Il10", "PROTEIN", 129, 133], ["influenza virus", "SPECIES", 90, 105], ["mice", "SPECIES", 137, 141], ["mice", "SPECIES", 137, 141], ["CD8", "TEST", 0, 3], ["CD4", "TEST", 10, 13], ["T eff cells", "TEST", 34, 45], ["lung inflammation", "PROBLEM", 59, 76], ["acute influenza virus infection", "PROBLEM", 84, 115], ["lung", "ANATOMY", 59, 63], ["inflammation", "OBSERVATION", 64, 76], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["influenza", "OBSERVATION", 90, 99]]], ["Blocking the action of the T eff cell-derived Il10 results in increased pulmonary inflammation and lethal injury (Sun et al., 2009) .", [["T eff cell", "ANATOMY", 27, 37], ["pulmonary", "ANATOMY", 72, 81], ["pulmonary inflammation", "DISEASE", 72, 94], ["lethal injury", "DISEASE", 99, 112], ["T eff cell-derived Il10", "GENE_OR_GENE_PRODUCT", 27, 50], ["pulmonary", "ORGAN", 72, 81], ["T eff cell", "CELL_TYPE", 27, 37], ["Il10", "PROTEIN", 46, 50], ["the T eff cell", "TEST", 23, 37], ["increased pulmonary inflammation", "PROBLEM", 62, 94], ["lethal injury", "PROBLEM", 99, 112], ["increased", "OBSERVATION_MODIFIER", 62, 71], ["pulmonary", "ANATOMY", 72, 81], ["inflammation", "OBSERVATION", 82, 94], ["lethal", "OBSERVATION_MODIFIER", 99, 105]]], ["CD8 + CTLs clear IVA-infected epithelial cells mainly by CD69-mediated cytotoxicity or exocytosis granules containing perforin 1 and granzymes, such as granzyme B (Topham et al., 1997) .", [["CD8 + CTLs", "ANATOMY", 0, 10], ["epithelial cells", "ANATOMY", 30, 46], ["exocytosis granules", "ANATOMY", 87, 106], ["IVA", "CHEMICAL", 17, 20], ["CD8", "GENE_OR_GENE_PRODUCT", 0, 3], ["epithelial cells", "CELL", 30, 46], ["CD69", "GENE_OR_GENE_PRODUCT", 57, 61], ["granules", "CELLULAR_COMPONENT", 98, 106], ["perforin 1", "GENE_OR_GENE_PRODUCT", 118, 128], ["granzymes", "GENE_OR_GENE_PRODUCT", 133, 142], ["granzyme B", "GENE_OR_GENE_PRODUCT", 152, 162], ["CD8", "PROTEIN", 0, 3], ["CTLs", "CELL_TYPE", 6, 10], ["IVA-infected epithelial cells", "CELL_TYPE", 17, 46], ["CD69", "PROTEIN", 57, 61], ["perforin 1", "PROTEIN", 118, 128], ["granzymes", "PROTEIN", 133, 142], ["granzyme B", "PROTEIN", 152, 162], ["CD8", "TEST", 0, 3], ["infected epithelial cells", "PROBLEM", 21, 46], ["CD69", "TEST", 57, 61], ["mediated cytotoxicity", "PROBLEM", 62, 83], ["exocytosis granules", "PROBLEM", 87, 106], ["infected epithelial cells", "OBSERVATION", 21, 46]]], ["Natural killer (NK) cells have lectin-like 'nonspecific' receptors for virus-infected cells (Biassoni et al., 2001) .", [["Natural killer (NK) cells", "ANATOMY", 0, 25], ["cells", "ANATOMY", 86, 91], ["Natural killer (NK) cells", "CELL", 0, 25], ["lectin", "GENE_OR_GENE_PRODUCT", 31, 37], ["cells", "CELL", 86, 91], ["Natural killer (NK) cells", "CELL_TYPE", 0, 25], ["lectin", "PROTEIN", 31, 37], ["virus-infected cells", "CELL_TYPE", 71, 91], ["Natural killer (NK) cells", "TREATMENT", 0, 25], ["lectin", "TEST", 31, 37], ["virus", "PROBLEM", 71, 76], ["infected cells", "PROBLEM", 77, 91]]], ["The IAV HA protein can interact with two lysis receptors, NCR1 and NCR2 Mandelboim et al., 2001) .", [["IAV", "ORGANISM", 4, 7], ["NCR1", "GENE_OR_GENE_PRODUCT", 58, 62], ["IAV HA protein", "PROTEIN", 4, 18], ["lysis receptors", "PROTEIN", 41, 56], ["NCR1", "PROTEIN", 58, 62], ["The IAV HA protein", "TREATMENT", 0, 18], ["two lysis receptors", "TREATMENT", 37, 56], ["NCR1", "TREATMENT", 58, 62]]], ["Increased binding to influenza virus-infected cells is also observed in 2 inhibitory receptors, KIR2DL1 and LILRBI (Achdout et al., 2003) .", [["cells", "ANATOMY", 46, 51], ["influenza virus-infected", "DISEASE", 21, 45], ["influenza virus", "ORGANISM", 21, 36], ["cells", "CELL", 46, 51], ["KIR2DL1", "GENE_OR_GENE_PRODUCT", 96, 103], ["inhibitory receptors", "PROTEIN", 74, 94], ["KIR2DL1", "PROTEIN", 96, 103], ["influenza virus", "SPECIES", 21, 36], ["influenza virus", "SPECIES", 21, 36], ["Increased binding", "PROBLEM", 0, 17], ["influenza virus", "PROBLEM", 21, 36], ["infected cells", "PROBLEM", 37, 51], ["influenza virus", "OBSERVATION", 21, 36], ["infected cells", "OBSERVATION", 37, 51]]], ["NK cells can recognize antibody-coated virally infected cells through their Fcg receptors, FCGR3A and FCGR3B, and kill the targets by ADCC (Hashimoto et al., 1983) .", [["NK cells", "ANATOMY", 0, 8], ["cells", "ANATOMY", 56, 61], ["NK cells", "CELL", 0, 8], ["cells", "CELL", 56, 61], ["Fcg receptors", "GENE_OR_GENE_PRODUCT", 76, 89], ["FCGR3A", "GENE_OR_GENE_PRODUCT", 91, 97], ["FCGR3B", "GENE_OR_GENE_PRODUCT", 102, 108], ["NK cells", "CELL_TYPE", 0, 8], ["antibody-coated virally infected cells", "CELL_TYPE", 23, 61], ["Fcg receptors", "PROTEIN", 76, 89], ["FCGR3A", "PROTEIN", 91, 97], ["FCGR3B", "PROTEIN", 102, 108], ["NK cells", "PROBLEM", 0, 8], ["antibody", "TEST", 23, 31], ["coated virally infected cells", "PROBLEM", 32, 61], ["FCGR3A", "TEST", 91, 97], ["FCGR3B", "TEST", 102, 108]]], ["Various Fcg receptors, including Fcgr1a, Fcgr2b, Fcgr1 g, Fcgr3a, and Fcgr3b, are over-expressed in murine lungs after infection with IAV (Rosseau et al., 2007) .", [["lungs", "ANATOMY", 107, 112], ["infection", "DISEASE", 119, 128], ["Fcg receptors", "GENE_OR_GENE_PRODUCT", 8, 21], ["Fcgr1a", "GENE_OR_GENE_PRODUCT", 33, 39], ["Fcgr2b", "GENE_OR_GENE_PRODUCT", 41, 47], ["Fcgr1 g", "GENE_OR_GENE_PRODUCT", 49, 56], ["Fcgr3a", "GENE_OR_GENE_PRODUCT", 58, 64], ["Fcgr3b", "GENE_OR_GENE_PRODUCT", 70, 76], ["murine", "ORGANISM", 100, 106], ["lungs", "ORGAN", 107, 112], ["Fcg receptors", "PROTEIN", 8, 21], ["Fcgr1a", "PROTEIN", 33, 39], ["Fcgr2b", "PROTEIN", 41, 47], ["Fcgr1 g", "PROTEIN", 49, 56], ["Fcgr3a", "PROTEIN", 58, 64], ["Fcgr3b", "PROTEIN", 70, 76], ["murine", "SPECIES", 100, 106], ["IAV", "SPECIES", 134, 137], ["Fcgr1a", "TEST", 33, 39], ["Fcgr2b", "TEST", 41, 47], ["Fcgr3a", "TEST", 58, 64], ["Fcgr3b", "TEST", 70, 76], ["infection", "PROBLEM", 119, 128], ["IAV", "PROBLEM", 134, 137], ["lungs", "ANATOMY", 107, 112], ["infection", "OBSERVATION", 119, 128]]], ["The list of host genes involved in the adaptive immune response is extensive (Doherty et al., 2006) and is beyond the scope of this review.Viral infections predisposing to bacterial infectionIt has been appreciated for more than a century that influenza virus can predispose the host to bacterial infections that lead to disease complications.", [["Viral infections", "DISEASE", 139, 155], ["bacterial infection", "DISEASE", 172, 191], ["influenza virus", "DISEASE", 244, 259], ["bacterial infections", "DISEASE", 287, 307], ["influenza virus", "ORGANISM", 244, 259], ["host genes", "DNA", 12, 22], ["influenza virus", "SPECIES", 244, 259], ["Viral infections", "PROBLEM", 139, 155], ["bacterial infection", "PROBLEM", 172, 191], ["influenza virus", "PROBLEM", 244, 259], ["bacterial infections", "PROBLEM", 287, 307], ["disease complications", "PROBLEM", 321, 342], ["extensive", "OBSERVATION_MODIFIER", 67, 76], ["infections", "OBSERVATION", 145, 155], ["bacterial", "OBSERVATION_MODIFIER", 172, 181], ["infection", "OBSERVATION", 182, 191], ["bacterial", "OBSERVATION_MODIFIER", 287, 296], ["infections", "OBSERVATION", 297, 307]]], ["The influenza pandemic of 1918 claimed 40 to 50 million lives, many because of secondary bacterial pneumonia (Muir and Wilson, 1919) .", [["influenza pandemic", "DISEASE", 4, 22], ["pneumonia", "DISEASE", 99, 108], ["The influenza pandemic", "PROBLEM", 0, 22], ["secondary bacterial pneumonia", "PROBLEM", 79, 108], ["secondary", "OBSERVATION_MODIFIER", 79, 88], ["bacterial", "OBSERVATION_MODIFIER", 89, 98], ["pneumonia", "OBSERVATION", 99, 108]]], ["In recent years in the United States, numbers of influenza-associated pediatric deaths, in which both influenza and pneumonia or bacteremia due to Streptococus aureus coinfection were identified, have increased.", [["influenza", "DISEASE", 49, 58], ["deaths", "DISEASE", 80, 86], ["influenza", "DISEASE", 102, 111], ["pneumonia", "DISEASE", 116, 125], ["bacteremia", "DISEASE", 129, 139], ["Streptococus aureus coinfection", "DISEASE", 147, 178], ["Streptococus aureus", "ORGANISM", 147, 166], ["Streptococus aureus", "SPECIES", 147, 166], ["Streptococus aureus", "SPECIES", 147, 166], ["influenza-associated pediatric deaths", "PROBLEM", 49, 86], ["influenza", "PROBLEM", 102, 111], ["pneumonia", "PROBLEM", 116, 125], ["bacteremia", "PROBLEM", 129, 139], ["Streptococus aureus coinfection", "PROBLEM", 147, 178], ["influenza", "OBSERVATION", 102, 111], ["pneumonia", "OBSERVATION", 116, 125], ["bacteremia", "OBSERVATION", 129, 139], ["aureus", "OBSERVATION_MODIFIER", 160, 166], ["coinfection", "OBSERVATION", 167, 178], ["increased", "OBSERVATION_MODIFIER", 201, 210]]], ["Most of these young people were in good health before the onset of illness but progressed rapidly to severe illness (CDC, 2007) .Viral infections predisposing to bacterial infectionSeveral factors may explain the lethal synergism between influenza virus and bacteria (McCullers, 2006) .", [["illness", "DISEASE", 67, 74], ["illness", "DISEASE", 108, 115], ["Viral infections", "DISEASE", 129, 145], ["influenza virus and bacteria", "DISEASE", 238, 266], ["people", "ORGANISM", 20, 26], ["influenza virus", "ORGANISM", 238, 253], ["bacterial infectionSeveral factors", "PROTEIN", 162, 196], ["people", "SPECIES", 20, 26], ["influenza virus", "SPECIES", 238, 253], ["influenza virus", "SPECIES", 238, 253], ["illness", "PROBLEM", 67, 74], ["severe illness", "PROBLEM", 101, 115], ["Viral infections", "PROBLEM", 129, 145], ["bacterial infectionSeveral factors", "PROBLEM", 162, 196], ["the lethal synergism", "PROBLEM", 209, 229], ["influenza virus", "PROBLEM", 238, 253], ["bacteria", "PROBLEM", 258, 266], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["infections", "OBSERVATION", 135, 145], ["bacterial", "OBSERVATION_MODIFIER", 162, 171]]], ["Destruction of respiratory epithelium by the virus can promote bacterial adhesion.", [["respiratory epithelium", "ANATOMY", 15, 37], ["respiratory epithelium", "TISSUE", 15, 37], ["Destruction of respiratory epithelium", "PROBLEM", 0, 37], ["the virus", "PROBLEM", 41, 50], ["bacterial adhesion", "PROBLEM", 63, 81], ["respiratory epithelium", "OBSERVATION", 15, 37], ["virus", "OBSERVATION", 45, 50], ["bacterial adhesion", "OBSERVATION", 63, 81]]], ["In addition, several bacteria secrete proteases that activate infectivity of IAV by proteolytic cleavage of the viral HA (Tashiro et al., 1987) .", [["IAV", "ORGANISM", 77, 80], ["proteases", "PROTEIN", 38, 47], ["IAV", "SPECIES", 77, 80], ["several bacteria secrete proteases", "PROBLEM", 13, 47], ["IAV", "PROBLEM", 77, 80], ["the viral HA", "PROBLEM", 108, 120], ["several", "OBSERVATION_MODIFIER", 13, 20], ["bacteria", "OBSERVATION", 21, 29], ["infectivity", "OBSERVATION_MODIFIER", 62, 73], ["IAV", "OBSERVATION_MODIFIER", 77, 80], ["viral", "OBSERVATION_MODIFIER", 112, 117]]], ["Inflammatory response to viral infection may up-regulate expression of molecules such as PTAFR (plateletactivating factor receptor) that bacteria can use as receptors, as suggested by studies in mice (McCullers and Rehg, 2002) and Ptafrknockout mice (van der Sluijs et al., 2006) .", [["viral infection", "DISEASE", 25, 40], ["PTAFR", "GENE_OR_GENE_PRODUCT", 89, 94], ["plateletactivating factor receptor", "GENE_OR_GENE_PRODUCT", 96, 130], ["mice", "ORGANISM", 195, 199], ["Ptafrknockout mice", "ORGANISM", 231, 249], ["PTAFR", "PROTEIN", 89, 94], ["plateletactivating factor receptor", "PROTEIN", 96, 130], ["mice", "SPECIES", 195, 199], ["mice", "SPECIES", 245, 249], ["mice", "SPECIES", 195, 199], ["mice", "SPECIES", 245, 249], ["Inflammatory response", "PROBLEM", 0, 21], ["viral infection", "PROBLEM", 25, 40], ["PTAFR (plateletactivating factor receptor", "TREATMENT", 89, 130], ["bacteria", "PROBLEM", 137, 145], ["viral", "OBSERVATION_MODIFIER", 25, 30], ["infection", "OBSERVATION", 31, 40]]], ["Recently, a DNA microarray analysis has demonstrated that 15 platelet activating factor-related molecules were specifically induced in the murine lungs co-infected by IAV and Streptococus pneumoniae (Seki et al., 2009) .", [["lungs", "ANATOMY", 146, 151], ["DNA", "CELLULAR_COMPONENT", 12, 15], ["platelet activating factor-related molecules", "GENE_OR_GENE_PRODUCT", 61, 105], ["murine", "ORGANISM", 139, 145], ["lungs", "ORGAN", 146, 151], ["IAV", "ORGANISM", 167, 170], ["Streptococus pneumoniae", "ORGANISM", 175, 198], ["platelet activating factor-related molecules", "PROTEIN", 61, 105], ["murine", "SPECIES", 139, 145], ["Streptococus pneumoniae", "SPECIES", 175, 198], ["IAV", "SPECIES", 167, 170], ["Streptococus pneumoniae", "SPECIES", 175, 198], ["a DNA microarray analysis", "TEST", 10, 35], ["15 platelet activating factor", "PROBLEM", 58, 87], ["related molecules", "PROBLEM", 88, 105], ["IAV", "PROBLEM", 167, 170], ["Streptococus pneumoniae", "PROBLEM", 175, 198], ["lungs", "ANATOMY", 146, 151], ["co-infected", "OBSERVATION", 152, 163], ["Streptococus pneumoniae", "OBSERVATION", 175, 198]]], ["The virus infection can cause bacterial superinfections by impairing the ability of the host to mount a productive immune response against subsequent bacterial infection.", [["infection", "DISEASE", 10, 19], ["bacterial infection", "DISEASE", 150, 169], ["The virus infection", "PROBLEM", 0, 19], ["bacterial superinfections", "PROBLEM", 30, 55], ["a productive immune response", "PROBLEM", 102, 130], ["subsequent bacterial infection", "PROBLEM", 139, 169], ["virus", "OBSERVATION_MODIFIER", 4, 9], ["infection", "OBSERVATION", 10, 19], ["bacterial", "OBSERVATION_MODIFIER", 30, 39], ["superinfections", "OBSERVATION", 40, 55], ["bacterial", "OBSERVATION_MODIFIER", 150, 159], ["infection", "OBSERVATION", 160, 169]]], ["Host immunopathology may be increased through the overproduction of inflammatory cytokines, cytokine storm, and apoptosis (Kash et al., 2006b) .", [["inflammatory cytokines", "PROTEIN", 68, 90], ["cytokine", "PROTEIN", 92, 100], ["inflammatory cytokines", "PROBLEM", 68, 90], ["cytokine storm", "PROBLEM", 92, 106], ["apoptosis", "PROBLEM", 112, 121], ["may be", "UNCERTAINTY", 21, 27], ["increased", "OBSERVATION_MODIFIER", 28, 37], ["inflammatory", "OBSERVATION_MODIFIER", 68, 80]]], ["Rosseau and colleagues have reported inflammatory transcriptional signatures of 1300 genes from murine lungs after infection with either IAV or Streptococus pneumoniae.", [["lungs", "ANATOMY", 103, 108], ["infection", "DISEASE", 115, 124], ["murine", "ORGANISM", 96, 102], ["lungs", "ORGAN", 103, 108], ["Streptococus pneumoniae", "ORGANISM", 144, 167], ["1300 genes", "DNA", 80, 90], ["murine", "SPECIES", 96, 102], ["Streptococus pneumoniae", "SPECIES", 144, 167], ["IAV", "SPECIES", 137, 140], ["Streptococus pneumoniae", "SPECIES", 144, 167], ["inflammatory transcriptional signatures", "PROBLEM", 37, 76], ["infection", "PROBLEM", 115, 124], ["IAV", "PROBLEM", 137, 140], ["Streptococus pneumoniae", "PROBLEM", 144, 167], ["inflammatory", "OBSERVATION_MODIFIER", 37, 49], ["lungs", "ANATOMY", 103, 108], ["infection", "OBSERVATION", 115, 124], ["IAV", "OBSERVATION", 137, 140], ["Streptococus pneumoniae", "OBSERVATION", 144, 167]]], ["Of these, approximately 36% were specific for pneumococcus and 30% were specific for the virus; a differential response was observed on the cytokine and chemokine level, although common induction of type I and type II interferon, Tnf, and Il6 underlies both infections (Rosseau et al., 2007) .", [["pneumococcus", "DISEASE", 46, 58], ["infections", "DISEASE", 258, 268], ["pneumococcus", "CANCER", 46, 58], ["type I", "GENE_OR_GENE_PRODUCT", 199, 205], ["type II interferon", "GENE_OR_GENE_PRODUCT", 210, 228], ["Tnf", "GENE_OR_GENE_PRODUCT", 230, 233], ["Il6", "GENE_OR_GENE_PRODUCT", 239, 242], ["cytokine", "PROTEIN", 140, 148], ["chemokine", "PROTEIN", 153, 162], ["type I and type II interferon", "PROTEIN", 199, 228], ["Tnf", "PROTEIN", 230, 233], ["Il6", "PROTEIN", 239, 242], ["pneumococcus", "PROBLEM", 46, 58], ["the virus", "PROBLEM", 85, 94], ["the cytokine", "TEST", 136, 148], ["chemokine level", "TEST", 153, 168], ["type I", "PROBLEM", 199, 205], ["type II interferon", "TREATMENT", 210, 228], ["Tnf", "PROBLEM", 230, 233], ["Il6", "PROBLEM", 239, 242], ["both infections", "PROBLEM", 253, 268], ["both", "OBSERVATION_MODIFIER", 253, 257], ["infections", "OBSERVATION", 258, 268]]], ["OX40-immunogolubulin, an effective immunosuppressive agent that targets the co-stimulatory molecule TNFRSF4, formerly OX40, allows sufficient activation of the host immune response to clear an IAV infection, but it suppresses the response enough to prevent severe immunopathology in lungs of infected mice (Humphreys et al., 2003) .ConclusionAnnual epidemics of influenza and the threat of another influenza pandemic present a unique challenge to public health and biomedical research worldwide.", [["lungs", "ANATOMY", 283, 288], ["OX40-immunogolubulin", "CHEMICAL", 0, 20], ["infection", "DISEASE", 197, 206], ["immunopathology in lungs of infected", "DISEASE", 264, 300], ["influenza", "DISEASE", 362, 371], ["influenza pandemic", "DISEASE", 398, 416], ["OX40", "GENE_OR_GENE_PRODUCT", 0, 4], ["immunogolubulin", "GENE_OR_GENE_PRODUCT", 5, 20], ["TNFRSF4", "GENE_OR_GENE_PRODUCT", 100, 107], ["OX40", "GENE_OR_GENE_PRODUCT", 118, 122], ["lungs", "ORGAN", 283, 288], ["mice", "ORGANISM", 301, 305], ["OX40", "PROTEIN", 0, 4], ["co-stimulatory molecule", "PROTEIN", 76, 99], ["TNFRSF4", "PROTEIN", 100, 107], ["OX40", "PROTEIN", 118, 122], ["mice", "SPECIES", 301, 305], ["IAV", "SPECIES", 193, 196], ["mice", "SPECIES", 301, 305], ["OX40", "TREATMENT", 0, 4], ["immunogolubulin", "TREATMENT", 5, 20], ["an effective immunosuppressive agent", "TREATMENT", 22, 58], ["an IAV infection", "PROBLEM", 190, 206], ["severe immunopathology in lungs", "PROBLEM", 257, 288], ["ConclusionAnnual epidemics", "PROBLEM", 332, 358], ["influenza", "PROBLEM", 362, 371], ["another influenza pandemic", "PROBLEM", 390, 416], ["IAV", "OBSERVATION_MODIFIER", 193, 196], ["infection", "OBSERVATION", 197, 206], ["severe", "OBSERVATION_MODIFIER", 257, 263], ["immunopathology", "OBSERVATION", 264, 279], ["lungs", "ANATOMY", 283, 288], ["influenza", "OBSERVATION", 362, 371]]], ["Recent developments in large-scale complete-genome sequencing, antigenic mapping, and epidemiological modeling promise to provide a more comprehensive picture of the evolution of influenza viruses and of their pattern of transmission through human and animal populations (Nelson and Holmes, 2007) .", [["influenza viruses", "DISEASE", 179, 196], ["influenza viruses", "ORGANISM", 179, 196], ["human", "ORGANISM", 242, 247], ["human", "SPECIES", 242, 247], ["human", "SPECIES", 242, 247], ["antigenic mapping", "TEST", 63, 80], ["influenza viruses", "PROBLEM", 179, 196], ["large", "OBSERVATION_MODIFIER", 23, 28], ["influenza", "OBSERVATION", 179, 188]]], ["Completion of the human genome project, validation of millions of human genetic variants in HapMap (International HapMap Consortium, 2005) and rapid advances in genotyping technologies create a great opportunity to advance human genomic studies of influenza infection in areas such as susceptibility and disease severity.", [["influenza infection", "DISEASE", 248, 267], ["human", "ORGANISM", 18, 23], ["human", "ORGANISM", 66, 71], ["human", "ORGANISM", 223, 228], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 223, 228], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 223, 228], ["the human genome project", "TREATMENT", 14, 38], ["rapid advances in genotyping technologies", "TREATMENT", 143, 184], ["influenza infection", "PROBLEM", 248, 267], ["susceptibility and disease severity", "PROBLEM", 285, 320], ["influenza", "OBSERVATION_MODIFIER", 248, 257], ["infection", "OBSERVATION", 258, 267]]], ["By leveraging biological knowledge to propose an extended selection of candidate genes across different systems or pathways in the pathogenesis of influenza virus infection, we hope to provide a more complete picture of the impact of the entire system, for which the list of candidate genes should not be limited only to those highlighted here.", [["influenza virus infection", "DISEASE", 147, 172], ["influenza virus", "ORGANISM", 147, 162], ["candidate genes", "DNA", 71, 86], ["candidate genes", "DNA", 275, 290], ["influenza virus", "SPECIES", 147, 162], ["influenza virus", "SPECIES", 147, 162], ["influenza virus infection", "PROBLEM", 147, 172], ["influenza virus", "OBSERVATION", 147, 162]]], ["Studies of candidate genes in human host response to IAV infection are an important starting point for understanding the constantly evolving interaction between virus and host, for identifying prognostic indicators, and for developing tools for targeting interventions in populations and novel antiviral therapies (Fauci, 2006) .", [["IAV infection", "DISEASE", 53, 66], ["human", "ORGANISM", 30, 35], ["IAV", "ORGANISM", 53, 56], ["candidate genes", "DNA", 11, 26], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 30, 35], ["IAV", "SPECIES", 53, 56], ["IAV infection", "PROBLEM", 53, 66], ["targeting interventions", "TREATMENT", 245, 268], ["novel antiviral therapies", "TREATMENT", 288, 313], ["IAV", "OBSERVATION_MODIFIER", 53, 56], ["infection", "OBSERVATION", 57, 66]]], ["Establishing a DNA bank from patients with influenza infection for study of genetic variation in the human population and its association with the pathogenicity of influenza, its transmissibility, and the effectiveness of vaccines (and their side effects) will be a first step in this process.Conflict of interestNone of the authors hold any commercial association that might pose or create a conflict of interest with the information presented in the submitted manuscript, including consultancies, stock ownership, or other equity interests, patent-licensing arrangements, and payments for conducting or publicizing a study described in the manuscript.", [["influenza infection", "DISEASE", 43, 62], ["influenza", "DISEASE", 164, 173], ["DNA", "CELLULAR_COMPONENT", 15, 18], ["patients", "ORGANISM", 29, 37], ["human", "ORGANISM", 101, 106], ["patients", "SPECIES", 29, 37], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 101, 106], ["influenza infection", "PROBLEM", 43, 62], ["genetic variation", "PROBLEM", 76, 93], ["the human population", "PROBLEM", 97, 117], ["influenza", "PROBLEM", 164, 173], ["vaccines", "TREATMENT", 222, 230], ["a study", "TEST", 617, 624], ["influenza", "OBSERVATION", 164, 173], ["patent", "OBSERVATION", 543, 549]]]], "PMC7102867": [["OverviewFetal thrombotic vasculopathy (FTV) is a vascular thrombotic condition causing obstruction of arteries and veins in the fetal circulation of the placenta, resulting in ischemic changes in the villi peripheral to the obstruction.", [["vascular", "ANATOMY", 49, 57], ["arteries", "ANATOMY", 102, 110], ["veins", "ANATOMY", 115, 120], ["fetal", "ANATOMY", 128, 133], ["placenta", "ANATOMY", 153, 161], ["villi", "ANATOMY", 200, 205], ["thrombotic vasculopathy", "DISEASE", 14, 37], ["FTV", "DISEASE", 39, 42], ["vascular thrombotic condition", "DISEASE", 49, 78], ["obstruction of arteries and veins", "DISEASE", 87, 120], ["obstruction", "DISEASE", 224, 235], ["vascular", "MULTI-TISSUE_STRUCTURE", 49, 57], ["arteries", "MULTI-TISSUE_STRUCTURE", 102, 110], ["veins", "MULTI-TISSUE_STRUCTURE", 115, 120], ["fetal circulation", "MULTI-TISSUE_STRUCTURE", 128, 145], ["placenta", "ORGAN", 153, 161], ["villi peripheral", "TISSUE", 200, 216], ["FTV", "SPECIES", 39, 42], ["OverviewFetal thrombotic vasculopathy", "PROBLEM", 0, 37], ["a vascular thrombotic condition", "PROBLEM", 47, 78], ["obstruction of arteries and veins in the fetal circulation of the placenta", "PROBLEM", 87, 161], ["ischemic changes in the villi peripheral to the obstruction", "PROBLEM", 176, 235], ["thrombotic", "OBSERVATION_MODIFIER", 14, 24], ["vasculopathy", "OBSERVATION", 25, 37], ["vascular", "ANATOMY", 49, 57], ["thrombotic", "OBSERVATION", 58, 68], ["obstruction", "OBSERVATION", 87, 98], ["arteries", "ANATOMY", 102, 110], ["veins", "ANATOMY", 115, 120], ["fetal", "ANATOMY_MODIFIER", 128, 133], ["circulation", "ANATOMY_MODIFIER", 134, 145], ["placenta", "ANATOMY", 153, 161], ["ischemic", "OBSERVATION", 176, 184], ["villi", "ANATOMY", 200, 205], ["peripheral", "ANATOMY_MODIFIER", 206, 216], ["obstruction", "OBSERVATION", 224, 235]]], ["When sufficiently extensive, FTV may cause a reduction in functional placental reserve or in other cases may be associated with additional thrombotic or thromboembolic events in the somatic vessels of the fetus itself.", [["placental", "ANATOMY", 69, 78], ["somatic vessels", "ANATOMY", 182, 197], ["fetus", "ANATOMY", 205, 210], ["thrombotic", "DISEASE", 139, 149], ["thromboembolic", "DISEASE", 153, 167], ["placental", "ORGAN", 69, 78], ["somatic vessels", "MULTI-TISSUE_STRUCTURE", 182, 197], ["fetus", "ORGAN", 205, 210], ["a reduction in functional placental reserve", "PROBLEM", 43, 86], ["additional thrombotic or thromboembolic events", "PROBLEM", 128, 174], ["may cause", "UNCERTAINTY", 33, 42], ["reduction", "OBSERVATION_MODIFIER", 45, 54], ["functional placental reserve", "OBSERVATION", 58, 86], ["may be associated with", "UNCERTAINTY", 105, 127], ["thrombotic", "OBSERVATION", 139, 149], ["thromboembolic", "OBSERVATION", 153, 167], ["somatic vessels", "OBSERVATION", 182, 197], ["fetus", "ANATOMY", 205, 210]]], ["When extensive, the former condition can lead to fetal growth restriction or stillbirth, whereas the latter may result in infarcts of various fetal structures, such as the brain, kidney, or, rarely, an extremity, such as an arm or leg.", [["fetal", "ANATOMY", 49, 54], ["fetal structures", "ANATOMY", 142, 158], ["brain", "ANATOMY", 172, 177], ["kidney", "ANATOMY", 179, 185], ["extremity", "ANATOMY", 202, 211], ["arm", "ANATOMY", 224, 227], ["leg", "ANATOMY", 231, 234], ["stillbirth", "DISEASE", 77, 87], ["infarcts", "DISEASE", 122, 130], ["fetal structures", "TISSUE", 142, 158], ["brain", "ORGAN", 172, 177], ["kidney", "ORGAN", 179, 185], ["extremity", "ORGANISM_SUBDIVISION", 202, 211], ["arm", "ORGANISM_SUBDIVISION", 224, 227], ["leg", "ORGANISM_SUBDIVISION", 231, 234], ["fetal growth restriction", "PROBLEM", 49, 73], ["stillbirth", "PROBLEM", 77, 87], ["infarcts of various fetal structures", "PROBLEM", 122, 158], ["infarcts", "OBSERVATION", 122, 130], ["various fetal structures", "OBSERVATION", 134, 158], ["brain", "ANATOMY", 172, 177], ["kidney", "ANATOMY", 179, 185], ["extremity", "ANATOMY", 202, 211], ["arm", "ANATOMY", 224, 227], ["leg", "ANATOMY", 231, 234]]], ["As with intravascular clotting in general, causal factors of FTV include a combination of the triad of stasis (by compression of cord or aberrant vessels); a thrombophilic state, both genetic (eg, protein S or factor V Leiden) and acquired (anticardiolipin antibody and so forth); and vascular injury (inflammatory and localized compression).", [["intravascular", "ANATOMY", 8, 21], ["cord", "ANATOMY", 129, 133], ["vessels", "ANATOMY", 146, 153], ["vascular", "ANATOMY", 285, 293], ["intravascular clotting", "DISEASE", 8, 30], ["FTV", "DISEASE", 61, 64], ["stasis", "DISEASE", 103, 109], ["vascular injury", "DISEASE", 285, 300], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 8, 21], ["cord", "ORGAN", 129, 133], ["vessels", "MULTI-TISSUE_STRUCTURE", 146, 153], ["protein S", "GENE_OR_GENE_PRODUCT", 197, 206], ["factor V Leiden", "GENE_OR_GENE_PRODUCT", 210, 225], ["anticardiolipin antibody", "GENE_OR_GENE_PRODUCT", 241, 265], ["vascular", "MULTI-TISSUE_STRUCTURE", 285, 293], ["protein S", "PROTEIN", 197, 206], ["factor V Leiden", "PROTEIN", 210, 225], ["anticardiolipin antibody", "PROTEIN", 241, 265], ["intravascular clotting", "PROBLEM", 8, 30], ["FTV", "PROBLEM", 61, 64], ["the triad of stasis", "PROBLEM", 90, 109], ["aberrant vessels)", "PROBLEM", 137, 154], ["a thrombophilic state", "PROBLEM", 156, 177], ["protein S", "TEST", 197, 206], ["factor V Leiden", "TEST", 210, 225], ["acquired (anticardiolipin antibody", "PROBLEM", 231, 265], ["vascular injury (inflammatory and localized compression)", "PROBLEM", 285, 341], ["intravascular", "OBSERVATION_MODIFIER", 8, 21], ["clotting", "OBSERVATION", 22, 30], ["stasis", "OBSERVATION", 103, 109], ["cord", "ANATOMY", 129, 133], ["vessels", "ANATOMY", 146, 153], ["thrombophilic", "OBSERVATION", 158, 171], ["vascular", "ANATOMY", 285, 293], ["injury", "OBSERVATION", 294, 300], ["inflammatory", "OBSERVATION_MODIFIER", 302, 314]]], ["The most serious outcomes include growth restriction, neurologic injury, and perinatal death.Key Features FTV: Potential Morphologic or Clinical Associations and SequelaeObstructive cord lesion or cord accident (common)Admit to neonatal ICU; normal at discharge (common)Neonatal encephalopathy (%)Cerebral palsy (rare); includes cerebral infarct, porencephalic cyst, hypoxic-ischemic encephalopathyStillbirth (uncommon)Intrauterine growth restriction (uncommon)OligohydramniosMaternal diabetes mellitus (common)Maternal autoimmune disease (lupus, anticardiolipin antibodies, and so forth) (uncommon)Severe acute respiratory syndrome (rare)Cytomegalovirus, Toxoplasma gondii (rare)Transverse limb reduction (rare)Maternal thrombophilic state (occurs equally in nonthrombophilic mothers)", [["neurologic", "ANATOMY", 54, 64], ["cord lesion", "ANATOMY", 182, 193], ["cord", "ANATOMY", 197, 201], ["Cerebral", "ANATOMY", 297, 305], ["cerebral", "ANATOMY", 329, 337], ["porencephalic cyst", "ANATOMY", 347, 365], ["limb", "ANATOMY", 691, 695], ["neurologic injury", "DISEASE", 54, 71], ["death", "DISEASE", 87, 92], ["cord lesion", "DISEASE", 182, 193], ["cord accident", "DISEASE", 197, 210], ["Neonatal encephalopathy", "DISEASE", 270, 293], ["Cerebral palsy", "DISEASE", 297, 311], ["cerebral infarct", "DISEASE", 329, 345], ["porencephalic cyst", "DISEASE", 347, 365], ["hypoxic-ischemic encephalopathy", "DISEASE", 367, 398], ["Stillbirth", "DISEASE", 398, 408], ["Intrauterine growth restriction", "DISEASE", 419, 450], ["Maternal diabetes mellitus", "DISEASE", 476, 502], ["Maternal autoimmune disease", "DISEASE", 511, 538], ["lupus", "DISEASE", 540, 545], ["acute respiratory syndrome", "DISEASE", 606, 632], ["Toxoplasma gondii", "DISEASE", 656, 673], ["Transverse limb reduction", "DISEASE", 680, 705], ["Maternal thrombophilic state", "DISEASE", 712, 740], ["cord", "ORGAN", 182, 186], ["cord", "ORGAN", 197, 201], ["cerebral", "ORGAN", 329, 337], ["anticardiolipin antibodies", "GENE_OR_GENE_PRODUCT", 547, 573], ["Cytomegalovirus", "ORGANISM", 639, 654], ["Toxoplasma gondii", "ORGANISM", 656, 673], ["limb", "ORGANISM_SUBDIVISION", 691, 695], ["anticardiolipin antibodies", "PROTEIN", 547, 573], ["Toxoplasma gondii", "SPECIES", 656, 673], ["Toxoplasma gondii", "SPECIES", 656, 673], ["growth restriction", "PROBLEM", 34, 52], ["neurologic injury", "PROBLEM", 54, 71], ["perinatal death", "PROBLEM", 77, 92], ["Clinical Associations", "PROBLEM", 136, 157], ["SequelaeObstructive cord lesion", "PROBLEM", 162, 193], ["Neonatal encephalopathy", "PROBLEM", 270, 293], ["Cerebral palsy (rare)", "PROBLEM", 297, 318], ["cerebral infarct", "PROBLEM", 329, 345], ["porencephalic cyst", "PROBLEM", 347, 365], ["hypoxic-ischemic encephalopathyStillbirth", "PROBLEM", 367, 408], ["Intrauterine growth restriction", "PROBLEM", 419, 450], ["OligohydramniosMaternal diabetes mellitus", "PROBLEM", 461, 502], ["Maternal autoimmune disease", "PROBLEM", 511, 538], ["lupus", "PROBLEM", 540, 545], ["anticardiolipin antibodies", "PROBLEM", 547, 573], ["Severe acute respiratory syndrome", "PROBLEM", 599, 632], ["Cytomegalovirus, Toxoplasma gondii", "PROBLEM", 639, 673], ["Transverse limb reduction", "PROBLEM", 680, 705], ["Maternal thrombophilic state", "PROBLEM", 712, 740], ["most serious", "OBSERVATION_MODIFIER", 4, 16], ["growth restriction", "OBSERVATION", 34, 52], ["neurologic injury", "OBSERVATION", 54, 71], ["cord", "ANATOMY", 182, 186], ["lesion", "OBSERVATION", 187, 193], ["cord", "ANATOMY", 197, 201], ["encephalopathy", "OBSERVATION", 279, 293], ["Cerebral", "ANATOMY", 297, 305], ["palsy", "OBSERVATION", 306, 311], ["cerebral", "ANATOMY", 329, 337], ["infarct", "OBSERVATION", 338, 345], ["porencephalic", "ANATOMY", 347, 360], ["cyst", "OBSERVATION", 361, 365], ["hypoxic", "OBSERVATION_MODIFIER", 367, 374], ["ischemic", "OBSERVATION_MODIFIER", 375, 383], ["encephalopathy", "OBSERVATION", 384, 398], ["Oligohydramnios", "OBSERVATION", 461, 476], ["autoimmune disease", "OBSERVATION", 520, 538], ["lupus", "OBSERVATION", 540, 545], ["Severe", "OBSERVATION_MODIFIER", 599, 605], ["acute", "OBSERVATION_MODIFIER", 606, 611], ["respiratory syndrome", "OBSERVATION", 612, 632], ["Cytomegalovirus", "OBSERVATION", 639, 654], ["limb", "ANATOMY", 691, 695], ["thrombophilic", "OBSERVATION", 721, 734]]]], "PMC7252111": [], "82b38fa7781532229473f51b428090a26f3ab79c": [["EMERGENT AND REEMERGING VIRAL INFECTIONSAn emerging infectious disease is defined as an infectious disease whose incidence has increased over the past 20 years and may increase in the future.", [["infectious disease", "DISEASE", 52, 70], ["infectious", "OBSERVATION", 52, 62], ["infectious", "OBSERVATION_MODIFIER", 88, 98], ["increased", "OBSERVATION_MODIFIER", 127, 136]]], ["Emerging infections account for more than 10% of human diseases (Mackey et al., 2014 ).", [["infections", "DISEASE", 9, 19], ["human", "ORGANISM", 49, 54], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 49, 54], ["Emerging infections", "PROBLEM", 0, 19], ["human diseases", "PROBLEM", 49, 63], ["infections", "OBSERVATION", 9, 19]]], ["An emerging pathogen may be defined as an infectious agent whose frequency or geographic range increases following its first introduction into a new host population, while a reemerging pathogen is one whose incidence or geographic distribution is increasing in an existing host population as a result of long-term changes in its underlying epidemiology.", [["An emerging pathogen", "PROBLEM", 0, 20], ["an infectious agent", "PROBLEM", 39, 58], ["a new host population", "TREATMENT", 143, 164], ["long-term changes", "PROBLEM", 304, 321], ["pathogen", "OBSERVATION", 12, 20], ["infectious", "OBSERVATION", 42, 52], ["geographic", "OBSERVATION_MODIFIER", 220, 230], ["distribution", "OBSERVATION_MODIFIER", 231, 243], ["increasing", "OBSERVATION_MODIFIER", 247, 257], ["long-term", "OBSERVATION_MODIFIER", 304, 313]]], ["The emergence of pathogens may be based on subjective criteria, which may reflect increasing awareness, improved diagnosis, discovery of previously unrecognized infectious agents as well as any objective epidemiological data (Woolhouse, 2002; Engering et al., 2013) .EMERGENT AND REEMERGING VIRAL INFECTIONSMany viruses are classified as emerging pathogens according to the WHO, including MERS-CoV, SARS-CoV, and IBV that are the focus of this work.TAXONOMYPhylogenetically, Coronaviridae belongs to Nidovirales in group IV, with a single genomic RNA fragment, oriented in a positive direction.NidoviralesNidovirales is an order that contains four families (Arteriviridae, Coronaviridae, Mesoniviridae, and Roniviridae) according to the genomic classification (Fig. 7 .1) (Cavanagh, 1997) .", [["Nidovirales", "CHEMICAL", 605, 616], ["MERS-CoV", "ORGANISM", 389, 397], ["SARS-CoV", "ORGANISM", 399, 407], ["IBV", "ORGANISM", 413, 416], ["Mesoniviridae", "GENE_OR_GENE_PRODUCT", 688, 701], ["genomic RNA fragment", "DNA", 539, 559], ["MERS-CoV", "SPECIES", 389, 397], ["SARS-CoV", "SPECIES", 399, 407], ["IBV", "SPECIES", 413, 416], ["pathogens", "PROBLEM", 17, 26], ["previously unrecognized infectious agents", "PROBLEM", 137, 178], ["REEMERGING VIRAL INFECTIONSMany viruses", "PROBLEM", 280, 319], ["IBV", "TREATMENT", 413, 416], ["TAXONOMYPhylogenetically", "TREATMENT", 449, 473], ["Coronaviridae", "TREATMENT", 475, 488], ["Nidovirales in group IV", "TREATMENT", 500, 523], ["a single genomic RNA fragment", "PROBLEM", 530, 559], ["NidoviralesNidovirales", "TREATMENT", 594, 616], ["Arteriviridae", "TREATMENT", 658, 671], ["Coronaviridae", "TREATMENT", 673, 686], ["Mesoniviridae", "TREATMENT", 688, 701], ["Roniviridae", "TREATMENT", 707, 718], ["pathogens", "OBSERVATION", 17, 26], ["may reflect", "UNCERTAINTY", 70, 81], ["increasing", "OBSERVATION_MODIFIER", 82, 92], ["infectious", "OBSERVATION", 161, 171], ["RNA fragment", "OBSERVATION", 547, 559]]], ["The name Nidovirales originates from the fact that the viruses belonging to this order have the capacity to produce during infection a 3 0 -multiplexed complex of subgenomic messenger RNA (mRNA), hence the word \"nidus\" in Latin, which means to nest (De Vries et al., 1997) .NidoviralesThe main common traits between Nidovirales are as follows:Nidovirales\u2022 Their unfragmented genome of RNA type with positive orientation of the genome (Cavanagh, 1997) . \u2022 Nidovirales encodes structural proteins that are separated from nonstructural functional proteins (Balasuriya and Snijder, 2008) . \u2022 The attachment to their host cell is done through receptors on the cell surface. \u2022 After which the fusion of the viral and cellular membrane is presumed to be mediated by one of the viral surface glycoproteins.NidoviralesThis fusion event (either plasma or endosomal membrane) releases the nucleocapsid into the cytoplasm of the host cell.", [["cell", "ANATOMY", 617, 621], ["cell surface", "ANATOMY", 655, 667], ["cellular membrane", "ANATOMY", 711, 728], ["surface", "ANATOMY", 776, 783], ["plasma", "ANATOMY", 835, 841], ["endosomal membrane", "ANATOMY", 845, 863], ["cytoplasm", "ANATOMY", 900, 909], ["cell", "ANATOMY", 922, 926], ["infection", "DISEASE", 123, 132], ["Nidovirales", "SIMPLE_CHEMICAL", 316, 327], ["Nidovirales", "SIMPLE_CHEMICAL", 455, 466], ["host cell", "CELL", 612, 621], ["cell surface", "CELLULAR_COMPONENT", 655, 667], ["cellular membrane", "CELLULAR_COMPONENT", 711, 728], ["plasma", "ORGANISM_SUBSTANCE", 835, 841], ["endosomal membrane", "CELLULAR_COMPONENT", 845, 863], ["nucleocapsid", "CELLULAR_COMPONENT", 878, 890], ["cytoplasm", "ORGANISM_SUBSTANCE", 900, 909], ["host cell", "CELL", 917, 926], ["subgenomic messenger RNA", "RNA", 163, 187], ["mRNA", "RNA", 189, 193], ["unfragmented genome", "DNA", 362, 381], ["structural proteins", "PROTEIN", 475, 494], ["nonstructural functional proteins", "PROTEIN", 519, 552], ["viral surface glycoproteins", "PROTEIN", 770, 797], ["host cell", "CELL_TYPE", 917, 926], ["the viruses", "PROBLEM", 51, 62], ["the capacity", "PROBLEM", 92, 104], ["infection", "PROBLEM", 123, 132], ["Nidovirales", "TREATMENT", 274, 285], ["Nidovirales", "TREATMENT", 343, 354], ["Nidovirales encodes structural proteins", "PROBLEM", 455, 494], ["the fusion", "TREATMENT", 683, 693], ["the viral and cellular membrane", "PROBLEM", 697, 728], ["Nidovirales", "TREATMENT", 798, 809], ["infection", "OBSERVATION", 123, 132], ["subgenomic messenger RNA", "OBSERVATION", 163, 187], ["main", "OBSERVATION_MODIFIER", 289, 293], ["RNA type", "OBSERVATION_MODIFIER", 385, 393], ["positive", "OBSERVATION_MODIFIER", 399, 407], ["orientation", "OBSERVATION_MODIFIER", 408, 419], ["structural proteins", "OBSERVATION", 475, 494], ["host cell", "OBSERVATION", 612, 621], ["cell", "OBSERVATION_MODIFIER", 655, 659], ["surface", "OBSERVATION_MODIFIER", 660, 667], ["fusion", "OBSERVATION", 687, 693], ["viral", "OBSERVATION", 701, 706], ["cellular membrane", "OBSERVATION", 711, 728], ["presumed to be", "UNCERTAINTY", 732, 746], ["viral surface glycoproteins", "OBSERVATION", 770, 797], ["host cell", "OBSERVATION", 917, 926]]], ["Following genome takeoff, translation of two open replicase reading frames (ORFs) is initiated by ribosomes of the host, to produce large polyprotein precursors that undergo autoproteolysis to produce a replicase/transcriptase complex (Gorbalenya et al., 2006) .CoronaviridaeThe CoV family (Coronaviridae) has been described as a model in virology, because it infects more than 200 different hosts.", [["ribosomes", "CELLULAR_COMPONENT", 98, 107], ["CoV", "GENE_OR_GENE_PRODUCT", 279, 282], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 291, 304], ["open replicase reading frames", "DNA", 45, 74], ["ORFs", "DNA", 76, 80], ["replicase/transcriptase complex", "PROTEIN", 203, 234], ["genome takeoff", "TREATMENT", 10, 24], ["two open replicase", "TREATMENT", 41, 59], ["large polyprotein precursors", "PROBLEM", 132, 160], ["a replicase/transcriptase complex", "PROBLEM", 201, 234], ["takeoff", "OBSERVATION_MODIFIER", 17, 24], ["large", "OBSERVATION_MODIFIER", 132, 137], ["polyprotein precursors", "OBSERVATION", 138, 160]]], ["SARS-CoV is compared to Cinderella.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["CoV", "OBSERVATION", 5, 8]]], ["CoVs are spherical (120\u00c0220 nm in diameter) and appear as special crowns because of the presence of pointed glycoproteins ( Fig. 7 .2) (Masters, 2006) .", [["CoVs", "ANATOMY", 0, 4], ["CoVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["pointed glycoproteins", "PROBLEM", 100, 121], ["spherical", "OBSERVATION_MODIFIER", 9, 18], ["120\u00c0220 nm", "OBSERVATION_MODIFIER", 20, 30]]], ["They use to replicate a similar and distinct \"nested set\" transcription strategy, in which the expression of genes encoding structural viral proteins is mediated by a nested set of 3 0 -coterminal subgenomic mRNAs.", [["structural viral proteins", "PROTEIN", 124, 149], ["3 0 -coterminal subgenomic mRNAs", "RNA", 181, 213], ["distinct \"nested set\" transcription strategy", "TREATMENT", 36, 80], ["genes encoding structural viral proteins", "PROBLEM", 109, 149], ["subgenomic mRNAs", "OBSERVATION", 197, 213]]], ["Virus Taxonomy: Ninth Report of the International Committee on Taxonomy of Viruses.", [["Viruses", "OBSERVATION", 75, 82]]], ["This figure has license from Elsevier under number 4285901264744.CoronaviridaeCoVs are enveloped viruses that contain the largest linear genome of known positive-sense single-stranded viral RNA (Siddell et al., 1983) .", [["CoronaviridaeCoVs", "CHEMICAL", 65, 82], ["CoronaviridaeCoVs", "GENE_OR_GENE_PRODUCT", 65, 82], ["linear genome", "DNA", 130, 143], ["CoronaviridaeCoVs", "TREATMENT", 65, 82], ["enveloped viruses", "PROBLEM", 87, 104], ["enveloped", "OBSERVATION_MODIFIER", 87, 96], ["viruses", "OBSERVATION", 97, 104], ["largest", "OBSERVATION_MODIFIER", 122, 129], ["linear", "OBSERVATION_MODIFIER", 130, 136], ["genome", "OBSERVATION", 137, 143], ["positive", "OBSERVATION_MODIFIER", 153, 161], ["viral RNA", "OBSERVATION_MODIFIER", 184, 193]]], ["They are characterized by a structural organization of a crown around the envelope, hence their name Coronaviridae (Fig. 7.4) .CoronaviridaeAlthough the first CoV, IBV, was discovered in 1932 (Hudson and Beaudette, 1932) , Coronaviridae was proposed as a taxonomic family 30 years later after the discovery of human CoV in humans, patients with cold (Tyrrell and Bynoe, 1965; Tyrrell et al., 1975) .CoronaviridaeIn recent years, Coronaviridae have been considered among the most popular viral families because a number of its members were responsible for several human and animal epidemiological pathologies.", [["CoronaviridaeAlthough", "CHEMICAL", 127, 148], ["CoV", "ORGANISM", 159, 162], ["IBV", "ORGANISM", 164, 167], ["human", "ORGANISM", 310, 315], ["CoV", "ORGANISM", 316, 319], ["humans", "ORGANISM", 323, 329], ["patients", "ORGANISM", 331, 339], ["human", "ORGANISM", 563, 568], ["human", "SPECIES", 310, 315], ["humans", "SPECIES", 323, 329], ["patients", "SPECIES", 331, 339], ["human", "SPECIES", 563, 568], ["IBV", "SPECIES", 164, 167], ["human CoV", "SPECIES", 310, 319], ["humans", "SPECIES", 323, 329], ["human", "SPECIES", 563, 568], ["a crown around the envelope", "PROBLEM", 55, 82], ["Coronaviridae", "TREATMENT", 223, 236], ["Coronaviridae", "TREATMENT", 429, 442], ["animal epidemiological pathologies", "PROBLEM", 573, 607], ["crown", "OBSERVATION_MODIFIER", 57, 62]]], ["These include the murine epidemic in 2005 (Weiss and Navas-Martin, 2005) , the SARS in 2003 (Fleck, 2003) , the SARS pandemic in 2015\u00c016 in Russia and Ukraine (Berger, 2017) , the MERS-CoV 2012\u00c017 (WHO2), and the CoV IBV (Riedel, 2006) .CoronaviridaeCoVs have diverse host ranges ( Fig. 7 .3).", [["SARS", "DISEASE", 79, 83], ["SARS", "DISEASE", 112, 116], ["CoronaviridaeCoVs", "CHEMICAL", 237, 254], ["murine", "ORGANISM", 18, 24], ["CoV IBV", "ORGANISM", 213, 220], ["CoronaviridaeCoVs", "GENE_OR_GENE_PRODUCT", 237, 254], ["murine", "SPECIES", 18, 24], ["MERS-CoV", "SPECIES", 180, 188], ["CoV IBV", "SPECIES", 213, 220], ["diverse", "OBSERVATION_MODIFIER", 260, 267], ["host ranges", "OBSERVATION", 268, 279]]], ["They affect most terrestrial and marine animals and humans, including dolphins, birds, cattle, woodpeckers, fish, etc. It has been shown that a virus can infect various hosts, for example, SARS and MERS-CoV (Wang et al., 2005; Tang et al., 2006; Belouzard et al., 2012) .CoronaviridaeThe viral infection caused by this family is considered, in most cases, as a severe infection.", [["woodpeckers", "ANATOMY", 95, 106], ["SARS", "DISEASE", 189, 193], ["Coronaviridae", "CHEMICAL", 271, 284], ["viral infection", "DISEASE", 288, 303], ["infection", "DISEASE", 368, 377], ["humans", "ORGANISM", 52, 58], ["dolphins", "ORGANISM_SUBDIVISION", 70, 78], ["cattle", "ORGANISM", 87, 93], ["fish", "ORGANISM_SUBDIVISION", 108, 112], ["MERS-CoV", "ORGANISM", 198, 206], ["humans", "SPECIES", 52, 58], ["cattle", "SPECIES", 87, 93], ["humans", "SPECIES", 52, 58], ["cattle", "SPECIES", 87, 93], ["MERS-CoV", "SPECIES", 198, 206], ["Coronaviridae", "SPECIES", 271, 284], ["a virus", "PROBLEM", 142, 149], ["SARS", "PROBLEM", 189, 193], ["Coronaviridae", "TREATMENT", 271, 284], ["The viral infection", "PROBLEM", 284, 303], ["a severe infection", "PROBLEM", 359, 377], ["most terrestrial", "OBSERVATION_MODIFIER", 12, 28], ["virus", "OBSERVATION", 144, 149], ["viral", "OBSERVATION_MODIFIER", 288, 293], ["infection", "OBSERVATION", 294, 303], ["severe", "OBSERVATION_MODIFIER", 361, 367], ["infection", "OBSERVATION", 368, 377]]], ["It is mainly located in the respiratory and gastroenteric tracts by targeting routes according to the host and the infectious virus.CoronaviridaeCoronaviridae include two subfamilies: Coronavirinae and Torovirinae.", [["respiratory", "ANATOMY", 28, 39], ["gastroenteric tracts", "ANATOMY", 44, 64], ["gastroenteric tracts", "MULTI-TISSUE_STRUCTURE", 44, 64], ["infectious virus", "ORGANISM", 115, 131], ["the infectious virus", "PROBLEM", 111, 131], ["CoronaviridaeCoronaviridae", "TREATMENT", 132, 158], ["Coronavirinae", "TREATMENT", 184, 197], ["Torovirinae", "TREATMENT", 202, 213], ["respiratory", "ANATOMY", 28, 39], ["gastroenteric tracts", "ANATOMY", 44, 64], ["infectious", "OBSERVATION", 115, 125]]], ["According to the molecular and serological characteristics of Coronavirinae, the classification reveals a subdivision into four groups (alpha coronavirus, beta coronavirus, delta coronavirus, and gamma coronavirus) and twoGENOMIC ORGANIZATION AND PROTEOMICS OF CORONAVIRIDAECoronaviridae is positive RNA viruses with an unsegmented genome of 26\u00c033 kb in length.", [["alpha coronavirus", "ORGANISM", 136, 153], ["beta coronavirus", "ORGANISM", 155, 171], ["delta coronavirus", "ORGANISM", 173, 190], ["gamma coronavirus", "ORGANISM", 196, 213], ["unsegmented genome", "DNA", 320, 338], ["beta coronavirus", "SPECIES", 155, 171], ["delta coronavirus", "SPECIES", 173, 190], ["gamma coronavirus", "SPECIES", 196, 213], ["alpha coronavirus", "SPECIES", 136, 153], ["beta coronavirus, delta coronavirus", "SPECIES", 155, 190], ["gamma coronavirus", "SPECIES", 196, 213], ["the classification", "TEST", 77, 95], ["alpha coronavirus", "PROBLEM", 136, 153], ["beta coronavirus", "PROBLEM", 155, 171], ["delta coronavirus", "PROBLEM", 173, 190], ["gamma coronavirus", "PROBLEM", 196, 213], ["CORONAVIRIDAECoronaviridae", "TEST", 261, 287], ["positive RNA viruses", "PROBLEM", 291, 311], ["alpha coronavirus", "ANATOMY", 136, 153], ["gamma coronavirus", "OBSERVATION", 196, 213], ["positive RNA viruses", "OBSERVATION", 291, 311], ["length", "OBSERVATION_MODIFIER", 354, 360]]], ["They are generally of similar genomic and structural construction, containing 5 0 -end ORF series that encode nonstructural proteins that are primarily involved in pathogenicity.", [["5 0 -end ORF series", "DNA", 78, 97], ["nonstructural proteins", "PROTEIN", 110, 132], ["encode nonstructural proteins", "PROBLEM", 103, 132], ["nonstructural proteins", "OBSERVATION", 110, 132], ["pathogenicity", "OBSERVATION", 164, 177]]], ["The number of ORFs differs by species, and it has a significant portion of Coronaviridae genomes, followed by the coding regions of structural proteins, more than two-thirds of the CoV genome is composed of an open reading code (ORF) coding for the replicase polyprotein 1a/1b, and the remainder contains ORFs encoding the structural proteins: spicules (S), envelope (E), membrane (M), nucleoprotein (N), and a variable collection of accessory proteins (Woo et al., 2009; Liu et al., 2014) ( Fig. 7.4) .GENOMIC ORGANIZATION AND PROTEOMICS OF CORONAVIRIDAECoVs encode membrane-associated proteins that are incorporated into virions: spike (S), envelope (E), membrane (M), and nucleoprotein (N).", [["membrane", "ANATOMY", 372, 380], ["membrane", "ANATOMY", 567, 575], ["virions", "ANATOMY", 623, 630], ["membrane", "ANATOMY", 657, 665], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 75, 88], ["CoV", "ORGANISM", 181, 184], ["spicules (S), envelope (E)", "GENE_OR_GENE_PRODUCT", 344, 370], ["membrane", "CELLULAR_COMPONENT", 372, 380], ["membrane", "CELLULAR_COMPONENT", 567, 575], ["membrane", "CELLULAR_COMPONENT", 657, 665], ["ORFs", "DNA", 14, 18], ["Coronaviridae genomes", "DNA", 75, 96], ["structural proteins", "PROTEIN", 132, 151], ["CoV genome", "DNA", 181, 191], ["open reading code", "DNA", 210, 227], ["ORF", "DNA", 229, 232], ["replicase polyprotein 1a/1b", "DNA", 249, 276], ["ORFs", "DNA", 305, 309], ["structural proteins", "PROTEIN", 323, 342], ["S", "PROTEIN", 354, 355], ["envelope (E), membrane (M)", "PROTEIN", 358, 384], ["nucleoprotein", "PROTEIN", 386, 399], ["N", "PROTEIN", 401, 402], ["accessory proteins", "PROTEIN", 434, 452], ["membrane-associated proteins", "PROTEIN", 567, 595], ["spike (S), envelope (E), membrane (M)", "PROTEIN", 632, 669], ["nucleoprotein (N)", "PROTEIN", 675, 692], ["Coronaviridae genomes", "TREATMENT", 75, 96], ["structural proteins", "PROBLEM", 132, 151], ["spicules (S", "TEST", 344, 355], ["envelope (E), membrane (M), nucleoprotein (N)", "TEST", 358, 403], ["a variable collection of accessory proteins", "PROBLEM", 409, 452], ["CORONAVIRIDAECoVs encode membrane", "PROBLEM", 542, 575], ["associated proteins", "PROBLEM", 576, 595], ["significant", "OBSERVATION_MODIFIER", 52, 63], ["Coronaviridae genomes", "OBSERVATION", 75, 96], ["structural proteins", "OBSERVATION", 132, 151], ["CoV genome", "OBSERVATION", 181, 191]]], ["These four proteins occur in the S\u00c0E\u00c0M\u00c0N order in all known CoV lineages (Woo et al., 2014) .GENOMIC ORGANIZATION AND PROTEOMICS OF CORONAVIRIDAEAmong the spike envelope membrane and nucleoprotein (SEMN) genes, CoVs encode species-specific accessory proteins, many of which appear to be incorporated into virions at low levels, ranging from an accessory in alpha-CoVs, including human CoV NL63 (Pyrc et al., 2004) , to nine accessories provided in gamma-CoV HKU22 (Woo et al., 2014) .", [["spike envelope membrane", "ANATOMY", 155, 178], ["virions", "ANATOMY", 305, 312], ["CoV", "ORGANISM", 60, 63], ["envelope membrane", "CELLULAR_COMPONENT", 161, 178], ["nucleoprotein", "CELLULAR_COMPONENT", 183, 196], ["SEMN", "GENE_OR_GENE_PRODUCT", 198, 202], ["CoVs", "GENE_OR_GENE_PRODUCT", 211, 215], ["alpha-CoVs", "GENE_OR_GENE_PRODUCT", 357, 367], ["human", "ORGANISM", 379, 384], ["CoV NL63", "ORGANISM", 385, 393], ["gamma-CoV", "GENE_OR_GENE_PRODUCT", 448, 457], ["spike envelope membrane and nucleoprotein (SEMN) genes", "DNA", 155, 209], ["CoVs", "DNA", 211, 215], ["accessory proteins", "PROTEIN", 240, 258], ["alpha-CoVs", "PROTEIN", 357, 367], ["human", "SPECIES", 379, 384], ["human CoV", "SPECIES", 379, 388], ["the spike envelope membrane", "PROBLEM", 151, 178], ["nucleoprotein (SEMN) genes", "PROBLEM", 183, 209], ["CoVs encode species", "PROBLEM", 211, 230], ["specific accessory proteins", "PROBLEM", 231, 258], ["CoV lineages", "OBSERVATION", 60, 72], ["accessory", "OBSERVATION_MODIFIER", 344, 353]]], ["The genomic position of these accessory genes varies with S-encoded accessories in some beta-CoV, between S and E in most lineages, between M and N in most lineages, and after N rarely in alpha-CoVs and gamma-CoV and commonly in delta-CoVs.", [["beta-CoV", "GENE_OR_GENE_PRODUCT", 88, 96], ["alpha-CoVs", "GENE_OR_GENE_PRODUCT", 188, 198], ["gamma-CoV", "GENE_OR_GENE_PRODUCT", 203, 212], ["delta-CoVs", "GENE_OR_GENE_PRODUCT", 229, 239], ["accessory genes", "DNA", 30, 45], ["S", "DNA", 58, 59], ["beta-CoV", "DNA", 88, 96], ["alpha-CoVs", "DNA", 188, 198], ["gamma-CoV", "PROTEIN", 203, 212], ["delta-CoVs", "DNA", 229, 239], ["beta-CoV", "SPECIES", 88, 96], ["gamma-CoV", "SPECIES", 203, 212], ["alpha", "TEST", 188, 193], ["gamma-CoV", "TEST", 203, 212], ["position", "OBSERVATION_MODIFIER", 12, 20], ["accessory genes", "OBSERVATION", 30, 45], ["gamma-CoV", "OBSERVATION", 203, 212]]], ["The M gene seems to follow the E gene directly through Coronaviridae, although there is no obvious transcriptional or transrational reason for which this should necessarily be the case ( Fig. 7 .5).GENOMIC ORGANIZATION AND PROTEOMICS OF CORONAVIRIDAEPhylogenetic studies on RNA-dependent RNA polymerase (RdRp) sequences, aimed at studying divergence, suggested that the common ancestor, the most recent of the CoVs infecting mammals, appeared about 7000\u00c08000 years ago, while the most recent common ancestor of avian CoVs dates back 10,000 years (Vijgen et al., 2006) .", [["E", "GENE_OR_GENE_PRODUCT", 31, 32], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 274, 302], ["CoVs", "GENE_OR_GENE_PRODUCT", 410, 414], ["avian", "ORGANISM", 511, 516], ["CoVs", "CELL", 517, 521], ["M gene", "DNA", 4, 10], ["E gene", "DNA", 31, 37], ["RNA-dependent RNA polymerase (RdRp) sequences", "DNA", 274, 319], ["Coronaviridae", "TREATMENT", 55, 68], ["CORONAVIRIDAEPhylogenetic studies", "TEST", 237, 270], ["RNA", "TEST", 274, 277], ["RdRp) sequences", "TEST", 304, 319], ["no obvious", "UNCERTAINTY", 88, 98]]], ["However, current estimates roughly coincide with the dispersion of the human population in the world from about 50,000\u00c0100,000 years ago and have increased significantly over the last 10,000 years during the first historical transition (Chan et al., 2013) .", [["human", "ORGANISM", 71, 76], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76], ["increased", "OBSERVATION_MODIFIER", 146, 155], ["significantly", "OBSERVATION_MODIFIER", 156, 169]]], ["However, referring to the history of mankind, this epoch corresponds to the beginning of agriculture and animal husbandry.GENOMIC ORGANIZATION AND PROTEOMICS OF CORONAVIRIDAECoVs are characterized by the property of transcribing code mRNAs for each protein.", [["mRNAs", "RNA", 234, 239]]], ["This property allows the virus to control the rate of protein synthesis according to the state requirements of virus and host cell.", [["cell", "ANATOMY", 126, 130], ["host cell", "CELL", 121, 130], ["host cell", "CELL_TYPE", 121, 130], ["the virus", "TREATMENT", 21, 30], ["protein synthesis", "TREATMENT", 54, 71], ["virus", "PROBLEM", 111, 116], ["host cell", "OBSERVATION", 121, 130]]], ["There is a similarity between human and animal coronaviruses at the organization level of their genome.", [["human", "ORGANISM", 30, 35], ["animal coronaviruses", "ORGANISM", 40, 60], ["genome", "CELLULAR_COMPONENT", 96, 102], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 30, 35], ["a similarity between human and animal coronaviruses", "PROBLEM", 9, 60], ["animal coronaviruses", "OBSERVATION", 40, 60], ["their genome", "OBSERVATION", 90, 102]]], ["All coronaviruses encode ORF replica 1a/1b and structural proteins (S), envelope (E), membrane (M), and nucleoprotein (N).", [["membrane", "ANATOMY", 86, 94], ["ORF replica 1a/1b", "GENE_OR_GENE_PRODUCT", 25, 42], ["envelope (E)", "GENE_OR_GENE_PRODUCT", 72, 84], ["membrane", "CELLULAR_COMPONENT", 86, 94], ["ORF replica 1a/1b and structural proteins", "PROTEIN", 25, 66], ["S", "PROTEIN", 68, 69], ["envelope (E), membrane (M)", "PROTEIN", 72, 98], ["nucleoprotein (N)", "PROTEIN", 104, 121], ["All coronaviruses", "TEST", 0, 17]]], ["In addition, each strain encodes several accessory proteins.", [["accessory proteins", "PROTEIN", 41, 59], ["several accessory proteins", "PROBLEM", 33, 59]]], ["Gene sizes are not designed for a specific scale.Gene Responsible for PathogenicityProtein S plays a key role in the power of pathogenicity.", [["Pathogenicity", "DISEASE", 70, 83], ["a specific scale", "TEST", 32, 48], ["Pathogenicity", "PROBLEM", 70, 83], ["Protein", "TEST", 83, 90], ["sizes", "OBSERVATION_MODIFIER", 5, 10], ["Responsible for", "UNCERTAINTY", 54, 69], ["Pathogenicity", "OBSERVATION", 70, 83], ["pathogenicity", "OBSERVATION", 126, 139]]], ["This glycoprotein (S) is an important component in the species specificity, pathogenesis, and escape of immunity.", [["glycoprotein (S)", "GENE_OR_GENE_PRODUCT", 5, 21], ["glycoprotein (S)", "PROTEIN", 5, 21], ["pathogenesis", "PROBLEM", 76, 88], ["important component", "OBSERVATION_MODIFIER", 28, 47]]], ["Like human immunodeficiency virus (HIV) gp160, influenza hemagglutinin, and Ebola virus glycoprotein, the CoV spike (S) glycoprotein protein is a class I viral fusion protein that mediates virus binding and fusion, allowing virus to enter the host cell .", [["cell", "ANATOMY", 248, 252], ["human immunodeficiency virus (HIV) gp160", "DISEASE", 5, 45], ["human immunodeficiency virus (HIV) gp160", "ORGANISM", 5, 45], ["influenza hemagglutinin", "ORGANISM", 47, 70], ["Ebola virus glycoprotein", "ORGANISM", 76, 100], ["CoV spike (S) glycoprotein", "GENE_OR_GENE_PRODUCT", 106, 132], ["host cell", "CELL", 243, 252], ["influenza hemagglutinin", "PROTEIN", 47, 70], ["Ebola virus glycoprotein", "PROTEIN", 76, 100], ["CoV spike (S) glycoprotein protein", "PROTEIN", 106, 140], ["class I viral fusion protein", "PROTEIN", 146, 174], ["host cell", "CELL_TYPE", 243, 252], ["human", "SPECIES", 5, 10], ["immunodeficiency virus", "SPECIES", 11, 33], ["Ebola virus", "SPECIES", 76, 87], ["human immunodeficiency virus", "SPECIES", 5, 33], ["HIV", "SPECIES", 35, 38], ["Ebola virus", "SPECIES", 76, 87], ["human immunodeficiency virus", "PROBLEM", 5, 33], ["gp160", "TEST", 40, 45], ["influenza hemagglutinin", "PROBLEM", 47, 70], ["Ebola virus glycoprotein", "PROBLEM", 76, 100], ["the CoV spike", "TEST", 102, 115], ["glycoprotein protein", "TEST", 120, 140], ["a class I viral fusion protein", "TREATMENT", 144, 174], ["virus binding", "PROBLEM", 189, 202], ["fusion", "TREATMENT", 207, 213], ["virus", "PROBLEM", 224, 229], ["immunodeficiency virus", "OBSERVATION", 11, 33], ["host cell", "OBSERVATION", 243, 252]]], ["Like other class I fusion proteins, the S-glycoprotein contains two functional domains, S1 and S2, linked by a protease cleavage site .", [["S-glycoprotein", "GENE_OR_GENE_PRODUCT", 40, 54], ["S1", "GENE_OR_GENE_PRODUCT", 88, 90], ["S2", "GENE_OR_GENE_PRODUCT", 95, 97], ["class I fusion proteins", "PROTEIN", 11, 34], ["S-glycoprotein", "PROTEIN", 40, 54], ["S1", "PROTEIN", 88, 90], ["S2", "PROTEIN", 95, 97], ["protease cleavage site", "PROTEIN", 111, 133], ["the S-glycoprotein", "TEST", 36, 54], ["a protease cleavage site", "TREATMENT", 109, 133], ["two", "OBSERVATION_MODIFIER", 64, 67], ["functional domains", "OBSERVATION", 68, 86], ["S2", "ANATOMY", 95, 97]]], ["The S1 domain (17\u00c0756aa) contains the receptorbinding domain (RBD) (318\u00c0510aa) while the S2 region (757\u00c01225aa) contains the two heptad repeat (HR) regions that facilitate viral fusion and a transmembrane domain (1189\u00c01227aa) which anchors the tip on the viral envelope .", [["transmembrane", "ANATOMY", 191, 204], ["17\u00c0756aa", "AMINO_ACID", 15, 23], ["S1 domain", "PROTEIN", 4, 13], ["17\u00c0756aa", "PROTEIN", 15, 23], ["receptorbinding domain", "PROTEIN", 38, 60], ["RBD", "PROTEIN", 62, 65], ["318\u00c0510aa", "PROTEIN", 68, 77], ["S2 region", "PROTEIN", 89, 98], ["757\u00c01225aa", "PROTEIN", 100, 110], ["heptad repeat (HR) regions", "PROTEIN", 129, 155], ["transmembrane domain", "PROTEIN", 191, 211], ["1189\u00c01227aa", "PROTEIN", 213, 224], ["the receptorbinding domain (RBD)", "PROBLEM", 34, 66], ["the two heptad repeat (HR) regions", "TREATMENT", 121, 155], ["viral fusion", "TREATMENT", 172, 184], ["a transmembrane domain", "TEST", 189, 211], ["the viral envelope", "PROBLEM", 251, 269], ["S1", "ANATOMY", 4, 6], ["S2", "ANATOMY", 89, 91], ["region", "ANATOMY_MODIFIER", 92, 98], ["viral fusion", "OBSERVATION", 172, 184], ["tip", "OBSERVATION_MODIFIER", 244, 247], ["viral envelope", "OBSERVATION", 255, 269]]], ["CoVs are thought to accumulate in cells by the following sequence of events: cell-receptor binding ACE2, DPP4, and APN to affect tropism in the cell by endocytosis and cleavage of SARS-CoV S by cathepsin-cell protease.", [["cells", "ANATOMY", 34, 39], ["cell", "ANATOMY", 77, 81], ["cell", "ANATOMY", 144, 148], ["CoVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["cells", "CELL", 34, 39], ["cell", "CELL", 77, 81], ["ACE2", "GENE_OR_GENE_PRODUCT", 99, 103], ["DPP4", "GENE_OR_GENE_PRODUCT", 105, 109], ["APN", "GENE_OR_GENE_PRODUCT", 115, 118], ["cell", "CELL", 144, 148], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 180, 190], ["cathepsin-cell protease", "GENE_OR_GENE_PRODUCT", 194, 217], ["CoVs", "PROTEIN", 0, 4], ["ACE2", "PROTEIN", 99, 103], ["DPP4", "PROTEIN", 105, 109], ["APN", "PROTEIN", 115, 118], ["SARS-CoV S", "PROTEIN", 180, 190], ["cathepsin-cell protease", "PROTEIN", 194, 217], ["SARS-CoV", "SPECIES", 180, 188], ["CoVs", "PROBLEM", 0, 4], ["DPP4", "TEST", 105, 109], ["APN", "TREATMENT", 115, 118], ["SARS", "PROBLEM", 180, 184], ["CoV S", "TEST", 185, 190], ["cathepsin-cell protease", "TREATMENT", 194, 217]]], ["L causes a rearrangement of S1 and S2 subunits inducing fusion of the viral membrane and the host to deposit the viral/nucleocapsid genome complex in the cytoplasm where replication occurs.Gene Responsible for PathogenicityThe glycoprotein of CoV S is an essential element of species specificity, which is also the main determinant of pathogenesis because a virus that is incapable of infection is unlikely to cause disease.", [["membrane", "ANATOMY", 76, 84], ["cytoplasm", "ANATOMY", 154, 163], ["Pathogenicity", "DISEASE", 210, 223], ["infection", "DISEASE", 385, 394], ["S1", "GENE_OR_GENE_PRODUCT", 28, 30], ["S2 subunits", "GENE_OR_GENE_PRODUCT", 35, 46], ["membrane", "CELLULAR_COMPONENT", 76, 84], ["cytoplasm", "ORGANISM_SUBSTANCE", 154, 163], ["CoV S", "GENE_OR_GENE_PRODUCT", 243, 248], ["S1 and S2 subunits", "PROTEIN", 28, 46], ["viral/nucleocapsid genome complex", "PROTEIN", 113, 146], ["glycoprotein", "PROTEIN", 227, 239], ["CoV S", "PROTEIN", 243, 248], ["a rearrangement of S1 and S2 subunits", "PROBLEM", 9, 46], ["the viral membrane", "PROBLEM", 66, 84], ["the viral/nucleocapsid genome complex", "PROBLEM", 109, 146], ["Pathogenicity", "PROBLEM", 210, 223], ["species specificity", "PROBLEM", 276, 295], ["a virus", "PROBLEM", 356, 363], ["infection", "PROBLEM", 385, 394], ["disease", "PROBLEM", 416, 423], ["S1", "ANATOMY", 28, 30], ["fusion", "OBSERVATION", 56, 62], ["viral membrane", "OBSERVATION", 70, 84], ["viral", "OBSERVATION", 113, 118], ["nucleocapsid genome", "OBSERVATION", 119, 138], ["Responsible for", "UNCERTAINTY", 194, 209], ["Pathogenicity", "OBSERVATION", 210, 223], ["CoV S", "OBSERVATION_MODIFIER", 243, 248], ["essential element", "OBSERVATION_MODIFIER", 255, 272], ["species specificity", "OBSERVATION", 276, 295], ["virus", "OBSERVATION", 358, 363], ["infection", "OBSERVATION", 385, 394], ["unlikely to", "UNCERTAINTY", 398, 409]]], ["Using reverse genetics, the substitution of mouse hepatitis virus (MHV) protein S for feline infectious peritonitis virus protein S alone was sufficient for the murine tropic virus to infect feline cells.", [["cells", "ANATOMY", 198, 203], ["hepatitis virus", "DISEASE", 50, 65], ["peritonitis", "DISEASE", 104, 115], ["mouse hepatitis virus (MHV)", "ORGANISM", 44, 71], ["feline infectious peritonitis virus", "ORGANISM", 86, 121], ["murine tropic virus", "ORGANISM", 161, 180], ["feline", "ORGANISM", 191, 197], ["cells", "CELL", 198, 203], ["mouse hepatitis virus (MHV) protein S", "PROTEIN", 44, 81], ["feline infectious peritonitis virus protein S", "PROTEIN", 86, 131], ["feline cells", "CELL_TYPE", 191, 203], ["mouse", "SPECIES", 44, 49], ["hepatitis virus", "SPECIES", 50, 65], ["feline infectious peritonitis virus", "SPECIES", 86, 121], ["murine", "SPECIES", 161, 167], ["feline", "SPECIES", 191, 197], ["mouse hepatitis virus", "SPECIES", 44, 65], ["MHV", "SPECIES", 67, 70], ["feline infectious peritonitis virus", "SPECIES", 86, 121], ["murine tropic virus", "SPECIES", 161, 180], ["the substitution of mouse hepatitis virus (MHV)", "TREATMENT", 24, 71], ["protein S", "TEST", 72, 81], ["feline infectious peritonitis virus protein S", "PROBLEM", 86, 131], ["the murine tropic virus", "PROBLEM", 157, 180], ["infectious", "OBSERVATION_MODIFIER", 93, 103], ["peritonitis", "OBSERVATION", 104, 115]]], ["In less extreme examples the host range of CoV can be modulated by a few point mutations in S-glycoprotein that focuses either in RBD or in the fusogenic domain (de Haan et al., 2005) .Gene Responsible for PathogenicityAlthough the earlier CoV dogma suggests that expansion of the host range is mediated by mutation in the S1 region, McRoy et al. reported an expansion of the host range of MHV that may also be mediated by changes in the host range, amino acids in fusion equipment of the S2 region.", [["Pathogenicity", "DISEASE", 206, 219], ["amino acids", "CHEMICAL", 450, 461], ["amino acids", "CHEMICAL", 450, 461], ["CoV", "ORGANISM", 43, 46], ["S-glycoprotein", "GENE_OR_GENE_PRODUCT", 92, 106], ["CoV", "ORGANISM", 240, 243], ["MHV", "ORGANISM", 390, 393], ["amino acids", "AMINO_ACID", 450, 461], ["S-glycoprotein", "PROTEIN", 92, 106], ["RBD", "PROTEIN", 130, 133], ["fusogenic domain", "PROTEIN", 144, 160], ["S1 region", "DNA", 323, 332], ["S2 region", "PROTEIN", 489, 498], ["MHV", "SPECIES", 390, 393], ["CoV", "PROBLEM", 43, 46], ["a few point mutations in S-glycoprotein", "PROBLEM", 67, 106], ["RBD", "PROBLEM", 130, 133], ["Pathogenicity", "PROBLEM", 206, 219], ["mutation in the S1 region", "PROBLEM", 307, 332], ["amino acids in fusion equipment", "TREATMENT", 450, 481], ["less extreme", "OBSERVATION_MODIFIER", 3, 15], ["Responsible for", "UNCERTAINTY", 190, 205], ["Pathogenicity", "OBSERVATION", 206, 219], ["expansion", "OBSERVATION_MODIFIER", 264, 273], ["host range", "OBSERVATION", 281, 291], ["mutation", "OBSERVATION", 307, 315], ["S1", "ANATOMY", 323, 325], ["region", "ANATOMY_MODIFIER", 326, 332], ["expansion", "OBSERVATION_MODIFIER", 359, 368], ["host range", "OBSERVATION_MODIFIER", 376, 386], ["MHV", "OBSERVATION", 390, 393], ["may also be", "UNCERTAINTY", 399, 410], ["S2", "ANATOMY", 489, 491], ["region", "ANATOMY_MODIFIER", 492, 498]]], ["A prime and relevant example of a CoV host range change due to mutations in the S1 region was observed during the evolution of the SARS-CoV epidemic strain, SARS Urbani (de Haan et al., 2005) The SARS-CoV (S) peak gene sequences isolated from human cases during the early phase of the epidemic in 2002\u00c003 and during the reemergence of 2003\u00c004 are very similar to strain SZ16.", [["SARS", "DISEASE", 131, 135], ["SARS", "DISEASE", 157, 161], ["CoV", "ORGANISM", 34, 37], ["SARS-CoV", "ORGANISM", 131, 139], ["SARS-CoV (S)", "GENE_OR_GENE_PRODUCT", 196, 208], ["human", "ORGANISM", 243, 248], ["S1 region", "DNA", 80, 89], ["SARS-CoV (S) peak gene sequences", "DNA", 196, 228], ["human", "SPECIES", 243, 248], ["SARS-CoV", "SPECIES", 131, 139], ["SARS-CoV", "SPECIES", 196, 204], ["human", "SPECIES", 243, 248], ["a CoV host range change", "TREATMENT", 32, 55], ["mutations in the S1 region", "PROBLEM", 63, 89], ["the SARS", "PROBLEM", 127, 135], ["CoV epidemic strain", "PROBLEM", 136, 155], ["The SARS", "TEST", 192, 200], ["peak gene sequences", "TEST", 209, 228], ["S1", "ANATOMY", 80, 82], ["region", "ANATOMY_MODIFIER", 83, 89]]], ["SZ16 was isolated from palm tree crops in live animal markets in the Guangdong region of China during the outbreak, and its protein S differs from the epidemic strain, SARS Urbani, in 18 amino acids, 16 of which are in the S1 domain containing the RBD.", [["SZ16", "CHEMICAL", 0, 4], ["SARS", "DISEASE", 168, 172], ["amino acids", "CHEMICAL", 187, 198], ["RBD", "DISEASE", 248, 251], ["amino acids", "CHEMICAL", 187, 198], ["SZ16", "GENE_OR_GENE_PRODUCT", 0, 4], ["amino acids", "AMINO_ACID", 187, 198], ["protein S", "PROTEIN", 124, 133], ["S1 domain", "PROTEIN", 223, 232], ["RBD", "PROTEIN", 248, 251], ["SZ16", "SPECIES", 0, 4], ["SARS Urbani", "SPECIES", 168, 179], ["its protein S", "TEST", 120, 133], ["the epidemic strain", "PROBLEM", 147, 166], ["SARS Urbani", "TEST", 168, 179], ["18 amino acids", "TREATMENT", 184, 198], ["palm", "OBSERVATION_MODIFIER", 23, 27], ["tree crops", "OBSERVATION", 28, 38], ["S1", "ANATOMY", 223, 225], ["RBD", "OBSERVATION", 248, 251]]], ["The crystalline structure of ACE2-receptor-bound SARS-CoV RBD and biochemical experimentation demonstrated that the critical amino acids (K479, T487) in the SZ16 S civet RBD inhibited its binding to the human ACE2 receptor (hACE2), thereby providing a block in the expansion of host range and human pathogenesis (Sheahan and Baric, 2010) .", [["amino acids", "CHEMICAL", 125, 136], ["amino acids", "CHEMICAL", 125, 136], ["K479", "CHEMICAL", 138, 142], ["T487", "CHEMICAL", 144, 148], ["ACE2", "GENE_OR_GENE_PRODUCT", 29, 33], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 49, 57], ["amino acids", "AMINO_ACID", 125, 136], ["human", "ORGANISM", 203, 208], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 209, 222], ["hACE2", "GENE_OR_GENE_PRODUCT", 224, 229], ["human", "ORGANISM", 293, 298], ["ACE2", "PROTEIN", 29, 33], ["SARS-CoV RBD", "PROTEIN", 49, 61], ["SZ16 S civet RBD", "PROTEIN", 157, 173], ["human ACE2 receptor", "PROTEIN", 203, 222], ["hACE2", "PROTEIN", 224, 229], ["human", "SPECIES", 203, 208], ["human", "SPECIES", 293, 298], ["human", "SPECIES", 203, 208], ["human", "SPECIES", 293, 298], ["ACE2", "TEST", 29, 33], ["CoV RBD", "TEST", 54, 61], ["biochemical experimentation", "TEST", 66, 93], ["the critical amino acids", "TEST", 112, 136], ["K479", "TEST", 138, 142], ["the SZ16 S civet RBD", "PROBLEM", 153, 173], ["a block", "TREATMENT", 250, 257], ["crystalline structure", "OBSERVATION", 4, 25], ["host range", "OBSERVATION", 278, 288]]], ["Using a pseudotyped retrovirus with mutant or wild versions of the zoonotic (SZ16) or epidemic (Urbani) glycoprotein, Li et al. demonstrated that K479 and T487 were critical residues inhibiting the binding of the civet tip to the hACE2 receptor.Gene Responsible for PathogenicityUnfortunately, the pseudotyped system is able to evaluate the efficiency of binding and entry, but not the growth kinetics of the virus.", [["Pathogenicity", "DISEASE", 266, 279], ["pseudotyped retrovirus", "ORGANISM", 8, 30], ["K479", "SIMPLE_CHEMICAL", 146, 150], ["hACE2 receptor", "GENE_OR_GENE_PRODUCT", 230, 244], ["pseudotyped", "ORGANISM", 298, 309], ["glycoprotein", "PROTEIN", 104, 116], ["civet tip", "PROTEIN", 213, 222], ["hACE2 receptor", "PROTEIN", 230, 244], ["a pseudotyped retrovirus", "TREATMENT", 6, 30], ["epidemic (Urbani) glycoprotein", "TREATMENT", 86, 116], ["K479", "TEST", 146, 150], ["critical residues", "PROBLEM", 165, 182], ["Pathogenicity", "PROBLEM", 266, 279], ["the pseudotyped system", "PROBLEM", 294, 316], ["the virus", "PROBLEM", 405, 414], ["pseudotyped retrovirus", "OBSERVATION", 8, 30], ["Responsible for", "UNCERTAINTY", 250, 265], ["Pathogenicity", "OBSERVATION", 266, 279]]], ["By using recombinant SARS-CoV carrying a variety of zoonotic, epidermal intermediate S-glycoproteins in a one-step growth pattern, data on binding, entry, and growth can be elucidated.", [["SARS-CoV", "ORGANISM", 21, 29], ["S-glycoproteins", "GENE_OR_GENE_PRODUCT", 85, 100], ["epidermal intermediate S-glycoproteins", "PROTEIN", 62, 100], ["SARS-CoV", "SPECIES", 21, 29]]], ["In addition, infection of the cells expressing the civet (cACE2) or hACE2 of the SARS-CoV receptor with recombinant variants of SARS-CoV S-glycoproteins makes it possible to study the ability to grow and use receptors in both the amplifier and the epidemic host.", [["cells", "ANATOMY", 30, 35], ["infection", "DISEASE", 13, 22], ["SARS", "DISEASE", 81, 85], ["cells", "CELL", 30, 35], ["civet", "GENE_OR_GENE_PRODUCT", 51, 56], ["cACE2", "GENE_OR_GENE_PRODUCT", 58, 63], ["hACE2", "GENE_OR_GENE_PRODUCT", 68, 73], ["SARS-CoV receptor", "GENE_OR_GENE_PRODUCT", 81, 98], ["SARS-CoV S-glycoproteins", "GENE_OR_GENE_PRODUCT", 128, 152], ["civet", "PROTEIN", 51, 56], ["cACE2", "PROTEIN", 58, 63], ["hACE2", "PROTEIN", 68, 73], ["SARS-CoV receptor", "PROTEIN", 81, 98], ["SARS-CoV S-glycoproteins", "PROTEIN", 128, 152], ["SARS-CoV", "SPECIES", 81, 89], ["SARS-CoV", "SPECIES", 128, 136], ["infection of the cells", "PROBLEM", 13, 35], ["the SARS", "PROBLEM", 77, 85], ["CoV receptor", "TREATMENT", 86, 98], ["SARS", "PROBLEM", 128, 132], ["CoV S-glycoproteins", "TREATMENT", 133, 152], ["receptors", "TREATMENT", 208, 217], ["infection", "OBSERVATION", 13, 22]]], ["In evaluating the growth of the SARS glycoprotein variant in CACE2 or hACE2 cell cultures, we deduced that the epidemic strain retained growth ability in cell cultures expressed by CACE2 and hACE2 (Sheahan and Baric, 2010) .Viral Cycle of CoronaviridaeHere, we present the viral cycle of Coronaviridae by discussing the replication cycle of MERS-CoV as an example.", [["CACE2", "ANATOMY", 61, 66], ["hACE2 cell cultures", "ANATOMY", 70, 89], ["cell cultures", "ANATOMY", 154, 167], ["SARS", "DISEASE", 32, 36], ["CACE2", "CELL", 61, 66], ["hACE2 cell cultures", "CELL", 70, 89], ["cell cultures", "CELL", 154, 167], ["CACE2", "GENE_OR_GENE_PRODUCT", 181, 186], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 341, 349], ["SARS glycoprotein variant", "PROTEIN", 32, 57], ["CACE2", "CELL_LINE", 61, 66], ["hACE2 cell cultures", "CELL_LINE", 70, 89], ["cell cultures", "CELL_LINE", 154, 167], ["CACE2", "PROTEIN", 181, 186], ["MERS-CoV", "SPECIES", 341, 349], ["the SARS glycoprotein variant in CACE2", "PROBLEM", 28, 66], ["hACE2 cell cultures", "PROBLEM", 70, 89], ["the epidemic strain", "PROBLEM", 107, 126], ["cell cultures", "TEST", 154, 167], ["CoronaviridaeHere", "TREATMENT", 239, 256], ["Coronaviridae", "TREATMENT", 288, 301], ["growth", "OBSERVATION_MODIFIER", 18, 24]]], ["The viral cycle of MERS-CoV is different from other beta-CoVs that do not code for hemagglutinin esterase , (Fig. 7.7) .Viral Cycle of CoronaviridaeMERS-CoV binds to its DPP4 cellular receptor via the S protein, then it enters the target cells, followed by fusion of the endosomes and membranes of the virus resulting in the release of the genome of the viral RNA into the cytoplasm.", [["cellular", "ANATOMY", 175, 183], ["cells", "ANATOMY", 238, 243], ["endosomes", "ANATOMY", 271, 280], ["membranes", "ANATOMY", 285, 294], ["cytoplasm", "ANATOMY", 373, 382], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 19, 27], ["beta-CoVs", "GENE_OR_GENE_PRODUCT", 52, 61], ["hemagglutinin esterase", "GENE_OR_GENE_PRODUCT", 83, 105], ["CoronaviridaeMERS", "GENE_OR_GENE_PRODUCT", 135, 152], ["DPP4 cellular receptor", "GENE_OR_GENE_PRODUCT", 170, 192], ["cells", "CELL", 238, 243], ["endosomes", "CELLULAR_COMPONENT", 271, 280], ["membranes", "CELLULAR_COMPONENT", 285, 294], ["cytoplasm", "ORGANISM_SUBSTANCE", 373, 382], ["beta-CoVs", "DNA", 52, 61], ["hemagglutinin esterase", "PROTEIN", 83, 105], ["CoronaviridaeMERS", "PROTEIN", 135, 152], ["DPP4 cellular receptor", "PROTEIN", 170, 192], ["S protein", "PROTEIN", 201, 210], ["target cells", "CELL_TYPE", 231, 243], ["viral RNA", "RNA", 354, 363], ["MERS-CoV", "SPECIES", 19, 27], ["The viral cycle of MERS", "PROBLEM", 0, 23], ["CoV", "PROBLEM", 24, 27], ["other beta-CoVs", "PROBLEM", 46, 61], ["hemagglutinin esterase", "TEST", 83, 105], ["Fig.", "TEST", 109, 113], ["CoronaviridaeMERS-CoV binds", "TREATMENT", 135, 162], ["the S protein", "TEST", 197, 210], ["the virus", "PROBLEM", 298, 307], ["viral cycle", "OBSERVATION", 4, 15], ["target cells", "OBSERVATION", 231, 243], ["virus", "OBSERVATION", 302, 307], ["viral RNA", "OBSERVATION", 354, 363], ["cytoplasm", "OBSERVATION_MODIFIER", 373, 382]]], ["The open reading frame (ORF), 1a and 1b, in the viral genomic RNA is translated into PP1a and PP1ab replicase polyproteins, respectively, and then optionally cleaved by a papain protease (PLpro), (Yang et al., 2014) a type 3C cysteine protease (3CLpro, principle protease) and other viral proteinases, in 16 nonstructural proteins (nsp1\u00c016) (Durai et al., 2015) .Viral Cycle of CoronaviridaeA negative-stranded genomic length RNA is synthesized as a template for replication of viral genomic RNA. mRNAs of different lengths of the negative strand subgenome (sg mRNAs) are formed from the viral genome as discontinuous RNAs and used as a template to transcribe sg mRNAs.", [["cysteine", "CHEMICAL", 226, 234], ["1a", "GENE_OR_GENE_PRODUCT", 30, 32], ["1b", "GENE_OR_GENE_PRODUCT", 37, 39], ["PP1a", "GENE_OR_GENE_PRODUCT", 85, 89], ["PP1", "GENE_OR_GENE_PRODUCT", 94, 97], ["papain protease", "GENE_OR_GENE_PRODUCT", 171, 186], ["type 3C cysteine protease", "GENE_OR_GENE_PRODUCT", 218, 243], ["3CLpro", "GENE_OR_GENE_PRODUCT", 245, 251], ["sg mRNAs", "GENE_OR_GENE_PRODUCT", 558, 566], ["sg", "GENE_OR_GENE_PRODUCT", 660, 662], ["open reading frame", "DNA", 4, 22], ["ORF", "DNA", 24, 27], ["1a and 1b", "DNA", 30, 39], ["viral genomic RNA", "RNA", 48, 65], ["PP1a", "PROTEIN", 85, 89], ["PP1", "PROTEIN", 94, 97], ["papain protease", "PROTEIN", 171, 186], ["type 3C cysteine protease", "PROTEIN", 218, 243], ["3CLpro", "PROTEIN", 245, 251], ["protease", "PROTEIN", 263, 271], ["viral proteinases", "PROTEIN", 283, 300], ["16 nonstructural proteins", "PROTEIN", 305, 330], ["nsp1\u00c016", "PROTEIN", 332, 339], ["CoronaviridaeA negative-stranded genomic length RNA", "RNA", 378, 429], ["viral genomic RNA", "RNA", 478, 495], ["mRNAs", "RNA", 497, 502], ["negative strand subgenome", "RNA", 531, 556], ["sg mRNAs", "RNA", 558, 566], ["viral genome", "DNA", 588, 600], ["discontinuous RNAs", "RNA", 604, 622], ["sg mRNAs", "RNA", 660, 668], ["the viral genomic RNA", "PROBLEM", 44, 65], ["PP1ab replicase polyproteins", "TREATMENT", 94, 122], ["a papain protease (PLpro)", "TREATMENT", 169, 194], ["a type 3C cysteine protease", "TREATMENT", 216, 243], ["3CLpro", "TREATMENT", 245, 251], ["principle protease", "TREATMENT", 253, 271], ["other viral proteinases", "PROBLEM", 277, 300], ["Viral Cycle", "TEST", 363, 374], ["CoronaviridaeA", "TEST", 378, 392], ["stranded genomic length RNA", "PROBLEM", 402, 429], ["a template", "TREATMENT", 448, 458], ["viral genomic RNA", "PROBLEM", 478, 495], ["viral", "OBSERVATION", 48, 53], ["genomic RNA", "OBSERVATION", 54, 65], ["viral genomic RNA", "OBSERVATION", 478, 495], ["different", "OBSERVATION_MODIFIER", 506, 515], ["lengths", "OBSERVATION_MODIFIER", 516, 523], ["negative", "OBSERVATION_MODIFIER", 531, 539], ["strand subgenome", "OBSERVATION", 540, 556], ["viral genome", "OBSERVATION", 588, 600]]], ["N viral protein is assembled with genomic RNA in the cytoplasm (Zumla et al., 2015) .Viral Cycle of CoronaviridaeThe synthesized S, M, and E proteins are collected in the endoplasmic reticulum (ER) and transported to the ER-Golgi intermediate compartment where they interact with the N-RNA complex and assemble into viral particles.", [["cytoplasm", "ANATOMY", 53, 62], ["endoplasmic reticulum", "ANATOMY", 171, 192], ["ER", "ANATOMY", 194, 196], ["ER-Golgi intermediate compartment", "ANATOMY", 221, 254], ["cytoplasm", "ORGANISM_SUBSTANCE", 53, 62], ["E", "SIMPLE_CHEMICAL", 139, 140], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 171, 192], ["ER", "GENE_OR_GENE_PRODUCT", 194, 196], ["ER", "GENE_OR_GENE_PRODUCT", 221, 223], ["Golgi", "CELLULAR_COMPONENT", 224, 229], ["N viral protein", "PROTEIN", 0, 15], ["genomic RNA", "RNA", 34, 45], ["S, M, and E proteins", "PROTEIN", 129, 149], ["ER", "PROTEIN", 194, 196], ["ER", "PROTEIN", 221, 223], ["N-RNA complex", "PROTEIN", 284, 297], ["N viral protein", "TEST", 0, 15], ["genomic RNA in the cytoplasm", "PROBLEM", 34, 62], ["Coronaviridae", "TREATMENT", 100, 113], ["The synthesized S, M, and E proteins", "TEST", 113, 149], ["viral protein", "OBSERVATION", 2, 15], ["genomic RNA", "OBSERVATION", 34, 45], ["cytoplasm", "OBSERVATION_MODIFIER", 53, 62], ["endoplasmic reticulum", "ANATOMY", 171, 192], ["viral particles", "OBSERVATION", 316, 331]]], ["These become mature in the Golgi body and are released into cells (Kuo et al., 2016) .MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUSThe most infectious members of Coronaviridae belong to the beta group, particularly in lineage C where SARS and MERS-CoV are found to be highly pathogenic to humans and are responsible for severe epidemics worldwide, including the 2015\u00c016 SARS pandemic in Russia, Ukraine (Berger, 2017) , and the current global epidemics of MERS according to the epidemiological history of this family ( Fig. 7.8 ).MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUSLack of vaccines or approved drugs is currently a roadblock to fight the epidemic and the spread of the disease (Wang et al., 2017) .MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUSMERS-CoV is a pathogen that infects most mammals and higher animals, as well as humans.", [["Golgi body", "ANATOMY", 27, 37], ["cells", "ANATOMY", 60, 65], ["SARS", "DISEASE", 233, 237], ["SARS", "DISEASE", 369, 373], ["MERS", "DISEASE", 455, 459], ["Golgi body", "CELLULAR_COMPONENT", 27, 37], ["cells", "CELL", 60, 65], ["beta", "GENE_OR_GENE_PRODUCT", 189, 193], ["lineage C", "CELL", 217, 226], ["MERS-CoV", "ORGANISM", 242, 250], ["humans", "ORGANISM", 288, 294], ["humans", "ORGANISM", 830, 836], ["humans", "SPECIES", 288, 294], ["humans", "SPECIES", 830, 836], ["MERS-CoV", "SPECIES", 242, 250], ["humans", "SPECIES", 288, 294], ["humans", "SPECIES", 830, 836], ["MIDDLE EAST RESPIRATORY SYNDROME", "PROBLEM", 86, 118], ["Coronaviridae", "TREATMENT", 161, 174], ["SARS", "PROBLEM", 233, 237], ["MERS", "PROBLEM", 242, 246], ["CoV", "PROBLEM", 247, 250], ["severe epidemics worldwide", "PROBLEM", 319, 345], ["MIDDLE EAST RESPIRATORY SYNDROME", "PROBLEM", 529, 561], ["CORONAVIRUSLack of vaccines", "TREATMENT", 562, 589], ["drugs", "TREATMENT", 602, 607], ["a roadblock", "TREATMENT", 621, 632], ["the epidemic", "PROBLEM", 642, 654], ["the disease", "PROBLEM", 673, 684], ["MIDDLE EAST RESPIRATORY SYNDROME", "PROBLEM", 706, 738], ["a pathogen", "PROBLEM", 762, 772], ["mature", "OBSERVATION", 13, 19], ["Golgi", "ANATOMY_MODIFIER", 27, 32], ["body", "ANATOMY", 33, 37], ["RESPIRATORY SYNDROME", "OBSERVATION", 98, 118], ["RESPIRATORY SYNDROME", "OBSERVATION", 541, 561], ["RESPIRATORY SYNDROME", "OBSERVATION", 718, 738], ["higher", "OBSERVATION_MODIFIER", 803, 809]]], ["Camels represent CoV MERS nature reserves (Alagaili et al., 2014) .", [["CoV", "ORGANISM", 17, 20], ["CoV", "OBSERVATION", 17, 20]]], ["On the other hand, viruses are isolated from bats, and other mainly domestic animals such as mice, cattle, rats, etc. The infection is mainly due to the interaction with the DPP4 receptor for mammals and the ACE2 in bats.", [["infection", "DISEASE", 122, 131], ["mice", "ORGANISM", 93, 97], ["cattle", "ORGANISM", 99, 105], ["rats", "ORGANISM", 107, 111], ["DPP4 receptor", "GENE_OR_GENE_PRODUCT", 174, 187], ["ACE2", "GENE_OR_GENE_PRODUCT", 208, 212], ["DPP4 receptor", "PROTEIN", 174, 187], ["ACE2", "PROTEIN", 208, 212], ["mice", "SPECIES", 93, 97], ["cattle", "SPECIES", 99, 105], ["rats", "SPECIES", 107, 111], ["mice", "SPECIES", 93, 97], ["cattle", "SPECIES", 99, 105], ["viruses", "PROBLEM", 19, 26], ["The infection", "PROBLEM", 118, 131], ["the DPP4 receptor", "TREATMENT", 170, 187], ["viruses", "OBSERVATION", 19, 26], ["infection", "OBSERVATION", 122, 131]]], ["However, recently Widagdo et al. (2017) found that the DPP4 isolated from the intestinal and respiratory tissues from bats resembles those of camels and humans with an absence of DPP4 at the level of respiratory cells.MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUSThe CoV responsible for the MERS-CoV was first identified in Saudi Arabia in 2012 from a man with atypical pneumonia .", [["intestinal", "ANATOMY", 78, 88], ["respiratory tissues", "ANATOMY", 93, 112], ["respiratory cells", "ANATOMY", 200, 217], ["pneumonia", "DISEASE", 369, 378], ["DPP4", "GENE_OR_GENE_PRODUCT", 55, 59], ["intestinal", "ORGAN", 78, 88], ["respiratory tissues", "TISSUE", 93, 112], ["camels", "ORGANISM", 142, 148], ["humans", "ORGANISM", 153, 159], ["DPP4", "GENE_OR_GENE_PRODUCT", 179, 183], ["respiratory cells", "CELL", 200, 217], ["CoV", "ORGANISM", 266, 269], ["MERS-CoV", "ORGANISM", 290, 298], ["man", "ORGANISM", 351, 354], ["DPP4", "PROTEIN", 55, 59], ["DPP4", "PROTEIN", 179, 183], ["respiratory cells", "CELL_TYPE", 200, 217], ["humans", "SPECIES", 153, 159], ["man", "SPECIES", 351, 354], ["humans", "SPECIES", 153, 159], ["MERS-CoV", "SPECIES", 290, 298], ["the DPP4", "TEST", 51, 59], ["the intestinal and respiratory tissues", "PROBLEM", 74, 112], ["DPP4", "TREATMENT", 179, 183], ["MIDDLE EAST RESPIRATORY SYNDROME", "PROBLEM", 218, 250], ["atypical pneumonia", "PROBLEM", 360, 378], ["intestinal", "ANATOMY", 78, 88], ["respiratory tissues", "ANATOMY", 93, 112], ["respiratory cells", "OBSERVATION", 200, 217], ["RESPIRATORY SYNDROME", "OBSERVATION", 230, 250], ["atypical", "OBSERVATION_MODIFIER", 360, 368], ["pneumonia", "OBSERVATION", 369, 378]]], ["Since then, more than 1936 infections and more than 690 deaths have been reported (WHO3, 2017).", [["infections", "DISEASE", 27, 37], ["deaths", "DISEASE", 56, 62]]], ["The ongoing MERS-CoV epidemic is mainly concentrated in the Middle East and Saudi Arabia, but cases have been exported by travelers to over 27 countries causing occasional secondary spread (WHO3, 2017).", [["MERS-CoV", "ORGANISM", 12, 20], ["MERS-CoV", "SPECIES", 12, 20], ["CoV epidemic", "PROBLEM", 17, 29], ["occasional secondary spread", "PROBLEM", 161, 188], ["MERS", "OBSERVATION", 12, 16], ["CoV", "OBSERVATION_MODIFIER", 17, 20], ["mainly", "OBSERVATION_MODIFIER", 33, 39], ["concentrated", "OBSERVATION_MODIFIER", 40, 52], ["Middle", "ANATOMY_MODIFIER", 60, 66], ["secondary spread", "OBSERVATION", 172, 188]]], ["In addition, the most notable epidemic outside of Saudi Arabia occurred in South Korea in 2015, resulting in 186 new cases (Korea Centers for Disease Control and Prevention, 2015) (Figs.", [["Disease Control", "TREATMENT", 142, 157]]], ["7.6\u00c07.9).The Genomic and Proteomic ConstructionMERS-CoV is an enveloped virus, with a spherical coronary structure, and a nonsegmented, positively oriented, single-stranded RNA genome with a size of the order of 30 kb.", [["coronary", "ANATOMY", 96, 104], ["CoV", "ORGANISM", 52, 55], ["coronary", "MULTI-TISSUE_STRUCTURE", 96, 104], ["nonsegmented, positively oriented, single-stranded RNA genome", "DNA", 122, 183], ["an enveloped virus", "PROBLEM", 59, 77], ["enveloped", "OBSERVATION_MODIFIER", 62, 71], ["virus", "OBSERVATION", 72, 77], ["coronary", "ANATOMY", 96, 104], ["size", "OBSERVATION_MODIFIER", 191, 195]]], ["It is related to strains hCoV-OC43 and hCoV-229E being prototype meadows and IBV being a prototype of all Coronaviridae (Chan et al., 2013) .", [["hCoV-OC43", "GENE_OR_GENE_PRODUCT", 25, 34], ["hCoV-229E", "GENE_OR_GENE_PRODUCT", 39, 48], ["IBV", "ORGANISM", 77, 80], ["hCoV-OC43", "SPECIES", 25, 34], ["hCoV-229E", "SPECIES", 39, 48], ["IBV", "SPECIES", 77, 80], ["strains hCoV", "TEST", 17, 29], ["OC43", "PROBLEM", 30, 34], ["hCoV", "TEST", 39, 43], ["IBV", "TREATMENT", 77, 80]]], ["MERS, Middle East respiratory syndrome.", [["Middle East respiratory syndrome", "DISEASE", 6, 38], ["Middle East respiratory syndrome", "PROBLEM", 6, 38], ["Middle", "ANATOMY_MODIFIER", 6, 12], ["respiratory syndrome", "OBSERVATION", 18, 38]]], ["GuanineCystosine content (GC) represents 41% of the genome of MERS-CoV ( van Boheemen et al., 2012) .", [["GuanineCystosine", "CHEMICAL", 0, 16], ["GuanineCystosine", "CHEMICAL", 0, 16], ["GuanineCystosine", "SIMPLE_CHEMICAL", 0, 16], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 62, 70], ["MERS-CoV", "SPECIES", 62, 70], ["GuanineCystosine content", "TEST", 0, 24]]], ["The genome is capped at the 5 0 end and 3 0 polyadenylated.", [["5 0 end and 3 0 polyadenylated", "RNA", 28, 58], ["genome", "OBSERVATION", 4, 10], ["capped", "OBSERVATION_MODIFIER", 14, 20]]], ["At the 5 0 end of MERS-CoV as in all Coronaviridae, there is an untranslated region (5 0 -UTR) of about 200 nucleotides (nts) before the initiation codon for the ORF.The Genomic and Proteomic ConstructionORF1 is translated by nonstructural proteins, a second ORF2 exists after the S gene and before the E gene codes for 3 nonstructural proteins which are 3a, 3b, 3c, and 3d.", [["nucleotides", "CHEMICAL", 108, 119], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 18, 26], ["ORF2", "GENE_OR_GENE_PRODUCT", 259, 263], ["5 0 end", "DNA", 7, 14], ["MERS-CoV", "DNA", 18, 26], ["untranslated region", "DNA", 64, 83], ["5 0 -UTR", "DNA", 85, 93], ["initiation codon", "DNA", 137, 153], ["ORF", "DNA", 162, 165], ["Genomic and Proteomic ConstructionORF1", "DNA", 170, 208], ["nonstructural proteins", "PROTEIN", 226, 248], ["ORF2", "DNA", 259, 263], ["S gene", "DNA", 281, 287], ["E gene", "DNA", 303, 309], ["nonstructural proteins", "PROTEIN", 322, 344], ["MERS-CoV", "SPECIES", 18, 26], ["an untranslated region", "PROBLEM", 61, 83], ["the initiation codon", "TREATMENT", 133, 153], ["the ORF", "PROBLEM", 158, 165], ["a second ORF2", "TREATMENT", 250, 263], ["the S gene", "TREATMENT", 277, 287], ["the E gene codes", "TREATMENT", 299, 315], ["3 nonstructural proteins", "PROBLEM", 320, 344], ["untranslated", "OBSERVATION", 64, 76], ["Proteomic ConstructionORF1", "OBSERVATION", 182, 208]]], ["The structural genes are, respectively, spicule (S), envelope (E), membrane (M), and nucleocapsid (N).", [["membrane", "ANATOMY", 67, 75], ["membrane", "CELLULAR_COMPONENT", 67, 75], ["structural genes", "DNA", 4, 20], ["nucleocapsid (N)", "PROTEIN", 85, 101], ["structural genes", "OBSERVATION", 4, 20]]], ["The MERS virus has the distinction of being more conserved in all hosts and citing humans with the exception of the mutation at position 1020 at the level of the gene coding for S which characterizes the strains infecting humans Cotten et al. (2014) .The Genomic and Proteomic ConstructionThe ORF1a products have proteolytic roles, interactions with interferon antagonist as well as DeiSGylation; however, ORF1b codes for RdRp and Helicase (Hel), which are important enzymes involved in the transcription and replication of CoVs.", [["MERS virus", "ORGANISM", 4, 14], ["humans", "ORGANISM", 83, 89], ["humans", "ORGANISM", 222, 228], ["ORF1a", "GENE_OR_GENE_PRODUCT", 293, 298], ["interferon antagonist", "GENE_OR_GENE_PRODUCT", 350, 371], ["ORF1b", "GENE_OR_GENE_PRODUCT", 406, 411], ["RdRp", "GENE_OR_GENE_PRODUCT", 422, 426], ["Helicase", "GENE_OR_GENE_PRODUCT", 431, 439], ["Hel", "GENE_OR_GENE_PRODUCT", 441, 444], ["CoVs", "GENE_OR_GENE_PRODUCT", 524, 528], ["position 1020", "DNA", 128, 141], ["ORF1a products", "PROTEIN", 293, 307], ["interferon", "PROTEIN", 350, 360], ["ORF1b", "PROTEIN", 406, 411], ["RdRp", "PROTEIN", 422, 426], ["Helicase", "PROTEIN", 431, 439], ["Hel", "PROTEIN", 441, 444], ["CoVs", "PROTEIN", 524, 528], ["humans", "SPECIES", 83, 89], ["humans", "SPECIES", 222, 228], ["MERS virus", "SPECIES", 4, 14], ["humans", "SPECIES", 83, 89], ["The MERS virus", "PROBLEM", 0, 14], ["the mutation", "PROBLEM", 112, 124], ["The Genomic and Proteomic Construction", "TREATMENT", 251, 289], ["The ORF1a products", "TREATMENT", 289, 307], ["proteolytic roles", "TREATMENT", 313, 330], ["interferon antagonist", "TREATMENT", 350, 371], ["RdRp", "TREATMENT", 422, 426], ["CoVs", "PROBLEM", 524, 528], ["MERS virus", "OBSERVATION", 4, 14]]], ["This is the result of cleavage of the polyprotein, ORF product a/b, by the papain-like protein cysteine protease (PLpro) and the protein 3C-like serine protease (3CLpro) (Stadler et al., 2003) .", [["cysteine", "CHEMICAL", 95, 103], ["serine", "CHEMICAL", 145, 151], ["papain-like protein cysteine protease", "GENE_OR_GENE_PRODUCT", 75, 112], ["PLpro", "GENE_OR_GENE_PRODUCT", 114, 119], ["polyprotein", "PROTEIN", 38, 49], ["ORF product", "PROTEIN", 51, 62], ["papain-like protein cysteine protease", "PROTEIN", 75, 112], ["PLpro", "PROTEIN", 114, 119], ["protein 3C-like serine protease", "PROTEIN", 129, 160], ["3CLpro", "PROTEIN", 162, 168], ["the polyprotein", "PROBLEM", 34, 49], ["the papain-like protein cysteine protease", "TREATMENT", 71, 112], ["the protein 3C", "TREATMENT", 125, 139], ["serine protease", "TREATMENT", 145, 160]]], ["Protein S is a glycoprotein expressed on the surface of viruses, and it plays key roles in the internalization of the virus and attachment to the host cell.", [["surface", "ANATOMY", 45, 52], ["cell", "ANATOMY", 151, 155], ["Protein S", "GENE_OR_GENE_PRODUCT", 0, 9], ["surface", "CELLULAR_COMPONENT", 45, 52], ["host cell", "CELL", 146, 155], ["Protein S", "PROTEIN", 0, 9], ["glycoprotein", "PROTEIN", 15, 27], ["host cell", "CELL_TYPE", 146, 155], ["Protein S", "TEST", 0, 9], ["a glycoprotein", "PROBLEM", 13, 27], ["viruses", "PROBLEM", 56, 63], ["the virus", "PROBLEM", 114, 123], ["viruses", "OBSERVATION", 56, 63], ["virus", "OBSERVATION", 118, 123], ["host cell", "OBSERVATION", 146, 155]]], ["The attachment of the virus to the host cell is essentially ensured by the dominance of RDB links and the HR regions (Xia et al., 2014) .", [["cell", "ANATOMY", 40, 44], ["host cell", "CELL", 35, 44], ["RDB", "GENE_OR_GENE_PRODUCT", 88, 91], ["RDB", "PROTEIN", 88, 91], ["virus", "OBSERVATION", 22, 27], ["host cell", "OBSERVATION", 35, 44], ["dominance", "OBSERVATION_MODIFIER", 75, 84]]], ["It consists of two subunits: the subunit S1 which ensures the fusion with the host cell at the amino-terminal and the subunit S2 which ensures the fusion at the carboxyl-terminal (Xia et al., 2014) .The Genomic and Proteomic ConstructionThe S1 subunit (including the N-terminal domain and the RBD) and S2 (encoding fusion peptides and conserved HR).", [["cell", "ANATOMY", 83, 87], ["amino", "CHEMICAL", 95, 100], ["carboxyl", "CHEMICAL", 161, 169], ["S1", "GENE_OR_GENE_PRODUCT", 41, 43], ["host cell", "CELL", 78, 87], ["amino-terminal", "AMINO_ACID", 95, 109], ["S2", "GENE_OR_GENE_PRODUCT", 126, 128], ["S2", "GENE_OR_GENE_PRODUCT", 302, 304], ["subunit S1", "PROTEIN", 33, 43], ["amino-terminal", "PROTEIN", 95, 109], ["subunit S2", "PROTEIN", 118, 128], ["carboxyl-terminal", "PROTEIN", 161, 178], ["S1 subunit", "PROTEIN", 241, 251], ["N-terminal domain", "PROTEIN", 267, 284], ["RBD", "PROTEIN", 293, 296], ["S2", "PROTEIN", 302, 304], ["HR", "PROTEIN", 345, 347], ["the fusion", "TREATMENT", 58, 68], ["the fusion", "TREATMENT", 143, 153], ["the N-terminal domain", "TREATMENT", 263, 284], ["S2 (encoding fusion peptides", "TREATMENT", 302, 330], ["S1", "ANATOMY", 41, 43], ["fusion", "OBSERVATION", 62, 68], ["host cell", "OBSERVATION", 78, 87], ["amino", "ANATOMY_MODIFIER", 95, 100], ["-terminal", "ANATOMY_MODIFIER", 100, 109], ["subunit", "ANATOMY_MODIFIER", 118, 125], ["S2", "ANATOMY", 126, 128], ["fusion", "OBSERVATION", 147, 153], ["RBD", "ANATOMY", 293, 296], ["S2", "ANATOMY", 302, 304]]], ["RBD is characterized by two core and extern subdomains, the latter of which is less conserved and involved in the binding of CoVs with their receptors (Wang et al., 2016) .", [["RBD", "DISEASE", 0, 3], ["CoVs", "GENE_OR_GENE_PRODUCT", 125, 129], ["RBD", "PROTEIN", 0, 3], ["CoVs", "PROTEIN", 125, 129], ["two core and extern subdomains", "PROBLEM", 24, 54], ["two", "OBSERVATION_MODIFIER", 24, 27], ["core", "OBSERVATION_MODIFIER", 28, 32], ["extern", "OBSERVATION_MODIFIER", 37, 43], ["subdomains", "OBSERVATION_MODIFIER", 44, 54], ["less conserved", "OBSERVATION_MODIFIER", 79, 93]]], ["Recently, Lu et al. (2016) showed a deletion mutation of 530 nucleotides in the S2 subunit, but the RDB region is highly conserved.", [["nucleotides", "CHEMICAL", 61, 72], ["S2", "GENE_OR_GENE_PRODUCT", 80, 82], ["S2 subunit", "PROTEIN", 80, 90], ["RDB region", "DNA", 100, 110], ["a deletion mutation", "PROBLEM", 34, 53], ["S2 subunit", "ANATOMY_MODIFIER", 80, 90]]], ["Other studies have also revealed that the S gene has developed several mutations that can negatively influence the therapeutic strategies of protein targeting S.The Genomic and Proteomic ConstructionSpicules S bind to MERS-CoV with DPP4, which is a proteolytic enzyme dipeptidyl peptidase 4, they are intrinsic glycoproteins and assigned exopeptidases (Silva J\u00fa nior et al., 2015) , which cleave dipeptides at the N-terminus end of a peptide as they have immune and vital roles for cells to cite: the interaction with CD26 (Raj et al., 2013) .INFECTIOUS BRONCHITIS VIRUSThe IBV, a member of Coronaviridae (Cavanagh, 2007) , is a highly pathogenic respiratory agent responsible for infectious bronchitis that is a major disease in the poultry field and may be associated fertility, nephritis, and respiratory problems as well as effects on the production of hatched eggs.", [["cells", "ANATOMY", 482, 487], ["respiratory", "ANATOMY", 647, 658], ["respiratory", "ANATOMY", 796, 807], ["eggs", "ANATOMY", 865, 869], ["infectious bronchitis", "DISEASE", 681, 702], ["nephritis", "DISEASE", 781, 790], ["respiratory problems", "DISEASE", 796, 816], ["dipeptides", "CHEMICAL", 396, 406], ["N", "CHEMICAL", 414, 415], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 218, 226], ["DPP4", "GENE_OR_GENE_PRODUCT", 232, 236], ["dipeptidyl peptidase 4", "GENE_OR_GENE_PRODUCT", 268, 290], ["cells", "CELL", 482, 487], ["CD26", "GENE_OR_GENE_PRODUCT", 518, 522], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 865, 869], ["S gene", "DNA", 42, 48], ["MERS-CoV", "PROTEIN", 218, 226], ["DPP4", "PROTEIN", 232, 236], ["proteolytic enzyme", "PROTEIN", 249, 267], ["dipeptidyl peptidase 4", "PROTEIN", 268, 290], ["N-terminus end", "PROTEIN", 414, 428], ["CD26", "PROTEIN", 518, 522], ["MERS-CoV", "SPECIES", 218, 226], ["IBV", "SPECIES", 574, 577], ["Other studies", "TEST", 0, 13], ["several mutations", "PROBLEM", 63, 80], ["protein targeting", "TREATMENT", 141, 158], ["DPP4", "TREATMENT", 232, 236], ["a proteolytic enzyme dipeptidyl peptidase", "TREATMENT", 247, 288], ["intrinsic glycoproteins", "PROBLEM", 301, 324], ["a peptide", "TREATMENT", 432, 441], ["Coronaviridae (Cavanagh", "TREATMENT", 591, 614], ["a highly pathogenic respiratory agent", "PROBLEM", 627, 664], ["infectious bronchitis", "PROBLEM", 681, 702], ["a major disease in the poultry field", "PROBLEM", 711, 747], ["nephritis", "PROBLEM", 781, 790], ["respiratory problems", "PROBLEM", 796, 816], ["hatched eggs", "PROBLEM", 857, 869], ["respiratory agent", "OBSERVATION", 647, 664], ["responsible for", "UNCERTAINTY", 665, 680], ["infectious", "OBSERVATION_MODIFIER", 681, 691], ["bronchitis", "OBSERVATION", 692, 702], ["major", "OBSERVATION_MODIFIER", 713, 718], ["disease", "OBSERVATION", 719, 726], ["may be associated", "UNCERTAINTY", 752, 769], ["fertility", "OBSERVATION", 770, 779], ["nephritis", "OBSERVATION", 781, 790], ["respiratory problems", "OBSERVATION", 796, 816]]], ["(Cavanagh, 2007) Like all Coronaviridae, it has a single-strand linear positive-sense RNA genome.", [["single-strand linear positive-sense RNA genome", "DNA", 50, 96], ["all Coronaviridae", "TREATMENT", 22, 39], ["RNA genome", "OBSERVATION", 86, 96]]], ["Although the structural similarity of Coronaviridae is round, IBV has a diameter of 100\u00c0160 nm and long petal-shaped spikes (spicules S) on the surface of the virus (Gonzalez et al., 2003) .", [["surface", "ANATOMY", 144, 151], ["IBV", "ORGANISM", 62, 65], ["surface", "CELLULAR_COMPONENT", 144, 151], ["IBV", "SPECIES", 62, 65], ["IBV", "PROBLEM", 62, 65], ["a diameter", "TEST", 70, 80], ["long petal-shaped spikes (spicules S", "PROBLEM", 99, 135], ["round", "OBSERVATION_MODIFIER", 55, 60], ["IBV", "OBSERVATION", 62, 65], ["diameter", "OBSERVATION_MODIFIER", 72, 80], ["long", "OBSERVATION_MODIFIER", 99, 103], ["petal", "OBSERVATION_MODIFIER", 104, 109], ["-shaped", "OBSERVATION_MODIFIER", 109, 116], ["spikes", "OBSERVATION_MODIFIER", 117, 123], ["spicules", "OBSERVATION_MODIFIER", 125, 133], ["virus", "OBSERVATION", 159, 164]]], ["Characterized by S, E, M, and N proteins, it differs in accessory proteins and genome size (Figs.", [["S, E, M, and N proteins", "PROTEIN", 17, 40], ["accessory proteins", "PROTEIN", 56, 74], ["S, E, M, and N proteins", "TEST", 17, 40], ["size", "OBSERVATION_MODIFIER", 86, 90]]], ["IBVs are counted as prototypes of Coronaviridae (Chan et al., 2013) .INFECTIOUS BRONCHITIS VIRUSThe first replications of the virus are at the level of tracheal epithelial cells.", [["tracheal epithelial cells", "ANATOMY", 152, 177], ["IBVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["tracheal epithelial cells", "CELL", 152, 177], ["tracheal epithelial cells", "CELL_TYPE", 152, 177], ["IBVs", "TREATMENT", 0, 4], ["INFECTIOUS BRONCHITIS VIRUS", "PROBLEM", 69, 96], ["the virus", "PROBLEM", 122, 131], ["virus", "OBSERVATION", 126, 131], ["tracheal epithelial", "ANATOMY", 152, 171], ["cells", "OBSERVATION", 172, 177]]], ["Viral infection with IBV causes several pathological mucosal changes, including ciliary loss, degeneration and necrosis of epithelial cells, glandular degeneration, inflammatory cell infiltration, and epithelial hyperplasia (Okino et al., 2014) .", [["mucosal", "ANATOMY", 53, 60], ["ciliary", "ANATOMY", 80, 87], ["epithelial cells", "ANATOMY", 123, 139], ["glandular", "ANATOMY", 141, 150], ["inflammatory cell", "ANATOMY", 165, 182], ["epithelial", "ANATOMY", 201, 211], ["Viral infection", "DISEASE", 0, 15], ["IBV", "DISEASE", 21, 24], ["ciliary loss", "DISEASE", 80, 92], ["necrosis", "DISEASE", 111, 119], ["epithelial hyperplasia", "DISEASE", 201, 223], ["Viral", "ORGANISM", 0, 5], ["IBV", "ORGANISM", 21, 24], ["mucosal", "PATHOLOGICAL_FORMATION", 53, 60], ["ciliary", "MULTI-TISSUE_STRUCTURE", 80, 87], ["epithelial cells", "CELL", 123, 139], ["glandular", "TISSUE", 141, 150], ["inflammatory cell", "CELL", 165, 182], ["epithelial", "TISSUE", 201, 211], ["epithelial cells", "CELL_TYPE", 123, 139], ["IBV", "SPECIES", 21, 24], ["Viral infection", "PROBLEM", 0, 15], ["IBV", "PROBLEM", 21, 24], ["several pathological mucosal changes", "PROBLEM", 32, 68], ["ciliary loss", "PROBLEM", 80, 92], ["degeneration", "PROBLEM", 94, 106], ["necrosis", "PROBLEM", 111, 119], ["epithelial cells", "PROBLEM", 123, 139], ["glandular degeneration", "PROBLEM", 141, 163], ["inflammatory cell infiltration", "PROBLEM", 165, 195], ["epithelial hyperplasia", "PROBLEM", 201, 223], ["infection", "OBSERVATION", 6, 15], ["IBV", "OBSERVATION", 21, 24], ["several", "OBSERVATION_MODIFIER", 32, 39], ["pathological mucosal changes", "OBSERVATION", 40, 68], ["ciliary loss", "OBSERVATION", 80, 92], ["degeneration", "OBSERVATION", 94, 106], ["necrosis", "OBSERVATION_MODIFIER", 111, 119], ["epithelial cells", "OBSERVATION", 123, 139], ["glandular degeneration", "OBSERVATION", 141, 163], ["inflammatory", "OBSERVATION_MODIFIER", 165, 177], ["cell infiltration", "OBSERVATION", 178, 195], ["epithelial", "ANATOMY_MODIFIER", 201, 211], ["hyperplasia", "OBSERVATION", 212, 223]]], ["According to Cavanagh (2007) , IBV serotypes that share more than 95% amino acid identity in S1 should have cross protection, while IBV strains share less than 85% amino acid identity but do not protect each other (Cavanagh, 2007) (Fig. 7.10) .INFECTIOUS BRONCHITIS VIRUSAlthough a large number of IBV strains and variants have been described in the recent years (De Wit et al., 2011) , most studies have been limited to the classification and differentiation of IBV strains in genotyping, pathotyping, protections, and serotypes, with a remarkable lack of studies dealing with the specific immunity components and mechanisms involved in the pathogenesis of this virus: this would allow us to understand the depth and the system semantic epidemic virus.", [["amino acid", "CHEMICAL", 70, 80], ["amino acid", "CHEMICAL", 164, 174], ["amino acid", "CHEMICAL", 70, 80], ["amino acid", "CHEMICAL", 164, 174], ["IBV", "ORGANISM", 31, 34], ["amino acid", "AMINO_ACID", 70, 80], ["IBV strains", "ORGANISM", 132, 143], ["amino acid", "AMINO_ACID", 164, 174], ["IBV", "ORGANISM", 298, 301], ["IBV", "ORGANISM", 463, 466], ["S1", "PROTEIN", 93, 95], ["IBV", "SPECIES", 31, 34], ["IBV", "SPECIES", 132, 135], ["IBV", "SPECIES", 298, 301], ["IBV", "SPECIES", 463, 466], ["IBV serotypes", "TREATMENT", 31, 44], ["amino acid identity in S1", "PROBLEM", 70, 95], ["cross protection", "TREATMENT", 108, 124], ["IBV strains", "TEST", 132, 143], ["amino acid identity", "TEST", 164, 183], ["INFECTIOUS BRONCHITIS", "PROBLEM", 244, 265], ["IBV strains and variants", "PROBLEM", 298, 322], ["IBV strains", "PROBLEM", 463, 474], ["pathotyping", "TREATMENT", 490, 501], ["protections", "TREATMENT", 503, 514], ["serotypes", "PROBLEM", 520, 529], ["the specific immunity components", "PROBLEM", 578, 610], ["this virus", "PROBLEM", 658, 668], ["large", "OBSERVATION_MODIFIER", 282, 287], ["number", "OBSERVATION_MODIFIER", 288, 294], ["IBV strains", "OBSERVATION", 298, 309]]], ["At the level of virus replication, they are similar to all CoVs.INFECTIOUS BRONCHITIS VIRUSSpecific receptors are still poorly known, but \u03b1-2, 3-linked sialic acid has been shown to be essential for attachment of spicules (Abd El Rahman et al., 2009; Promkuntod et al., 2014) .", [["\u03b1-2, 3-linked sialic acid", "CHEMICAL", 138, 163], ["sialic acid", "CHEMICAL", 152, 163], ["CoVs", "GENE_OR_GENE_PRODUCT", 59, 63], ["\u03b1-2", "GENE_OR_GENE_PRODUCT", 138, 141], ["3-linked sialic acid", "SIMPLE_CHEMICAL", 143, 163], ["CoVs", "DNA", 59, 63], ["VIRUSSpecific receptors", "PROTEIN", 86, 109], ["\u03b1", "PROTEIN", 138, 139], ["virus replication", "TREATMENT", 16, 33], ["INFECTIOUS BRONCHITIS VIRUSSpecific receptors", "PROBLEM", 64, 109], ["sialic acid", "TEST", 152, 163], ["attachment of spicules", "PROBLEM", 199, 221], ["virus replication", "OBSERVATION", 16, 33], ["CoVs", "OBSERVATION", 59, 63], ["Abd", "ANATOMY", 223, 226]]], ["In addition to the replicase gene, the final 5 0 and 3 0 UTR sequences, with certain specific secondary structures, are required for replication of the genomic RNA.", [["replicase gene", "DNA", 19, 33], ["5 0 and 3 0 UTR sequences", "DNA", 45, 70], ["genomic RNA", "RNA", 152, 163], ["UTR sequences", "TEST", 57, 70], ["the genomic RNA", "PROBLEM", 148, 163], ["genomic RNA", "OBSERVATION", 152, 163]]], ["Nucleocapsid (N) is also needed for efficient synthesis of viral RNA (Verheije et al., 2010; Zuniga et al., 2010) .Isolation of Infectious Bronchitis Virus From EggsSpecific pathogen-free embryonated chicken eggs are recommended for primary isolation of IBV.", [["eggs", "ANATOMY", 208, 212], ["Infectious Bronchitis Virus", "DISEASE", 128, 155], ["Nucleocapsid", "GENE_OR_GENE_PRODUCT", 0, 12], ["Infectious Bronchitis Virus", "ORGANISM", 128, 155], ["EggsSpecific pathogen", "ORGANISM", 161, 182], ["chicken", "ORGANISM", 200, 207], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 208, 212], ["IBV", "ORGANISM", 254, 257], ["viral RNA", "RNA", 59, 68], ["chicken", "SPECIES", 200, 207], ["Infectious Bronchitis Virus", "SPECIES", 128, 155], ["chicken", "SPECIES", 200, 207], ["IBV", "SPECIES", 254, 257], ["efficient synthesis of viral RNA", "PROBLEM", 36, 68], ["Infectious Bronchitis Virus", "PROBLEM", 128, 155], ["EggsSpecific pathogen", "PROBLEM", 161, 182], ["free embryonated chicken eggs", "TREATMENT", 183, 212], ["IBV", "PROBLEM", 254, 257], ["viral RNA", "OBSERVATION", 59, 68], ["Infectious", "OBSERVATION_MODIFIER", 128, 138], ["Bronchitis", "OBSERVATION", 139, 149]]], ["Treated samples (10%\u00c020% w/v) in phosphate buffered saline are used for egg inoculation, after being clarified by low-speed centrifugation and filtration through bacteriological filters.", [["samples", "ANATOMY", 8, 15], ["egg", "ANATOMY", 72, 75], ["phosphate", "CHEMICAL", 33, 42], ["phosphate", "CHEMICAL", 33, 42], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 33, 58], ["egg", "ORGANISM_SUBSTANCE", 72, 75], ["phosphate buffered saline", "TREATMENT", 33, 58], ["egg inoculation", "PROBLEM", 72, 87], ["low-speed centrifugation", "TREATMENT", 114, 138], ["filtration", "TREATMENT", 143, 153], ["bacteriological filters", "TREATMENT", 162, 185], ["bacteriological filters", "OBSERVATION", 162, 185]]], ["FIGURE 7.10 Coloration immunofluorescente de la section de paraffine r\u00e9nale du rein A volume of 100\u00c0200 \u03bcL of the treated sample are inoculated into the allantoic cavity of 9\u00c011 day embryos (Delaplane, 1947) .", [["sample", "ANATOMY", 122, 128], ["allantoic cavity", "ANATOMY", 153, 169], ["embryos", "ANATOMY", 182, 189], ["allantoic cavity", "MULTI-TISSUE_STRUCTURE", 153, 169], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 182, 189], ["FIGURE", "TEST", 0, 6], ["allantoic cavity", "ANATOMY", 153, 169]]], ["Embryo mortality in the first 24 hours is considered nonspecific death.", [["Embryo", "ANATOMY", 0, 6], ["death", "DISEASE", 65, 70], ["Embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 0, 6], ["Embryo mortality", "PROBLEM", 0, 16], ["nonspecific death", "PROBLEM", 53, 70], ["nonspecific", "OBSERVATION_MODIFIER", 53, 64]]], ["The allantoic fluids of the inoculated eggs (36\u00c048 hours postinoculation) are harvested and pooled (Cunningham, 1973; Cunningham and El Dardiry, 1948) .", [["allantoic fluids", "ANATOMY", 4, 20], ["eggs", "ANATOMY", 39, 43], ["allantoic fluids", "MULTI-TISSUE_STRUCTURE", 4, 20], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 39, 43], ["The allantoic fluids", "TREATMENT", 0, 20], ["the inoculated eggs", "TREATMENT", 24, 43], ["allantoic", "OBSERVATION_MODIFIER", 4, 13], ["fluids", "OBSERVATION_MODIFIER", 14, 20]]], ["Blind passage to another set of eggs for up to three to four passes is made.Isolation of Infectious Bronchitis Virus From EggsThe last passage is left for 7 days to detect the presence of pathognomonic embryonic changes: stunted embryos and wound with feather dystrophy and urate deposits in the mesonephros.", [["embryonic", "ANATOMY", 202, 211], ["embryos", "ANATOMY", 229, 236], ["wound", "ANATOMY", 241, 246], ["mesonephros", "ANATOMY", 296, 307], ["Infectious Bronchitis Virus", "DISEASE", 89, 116], ["dystrophy", "DISEASE", 260, 269], ["urate", "CHEMICAL", 274, 279], ["urate", "CHEMICAL", 274, 279], ["Infectious Bronchitis Virus", "ORGANISM", 89, 116], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 202, 211], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 229, 236], ["wound", "PATHOLOGICAL_FORMATION", 241, 246], ["urate", "SIMPLE_CHEMICAL", 274, 279], ["mesonephros", "ORGAN", 296, 307], ["Infectious Bronchitis Virus", "SPECIES", 89, 116], ["Blind passage", "PROBLEM", 0, 13], ["Infectious Bronchitis Virus", "PROBLEM", 89, 116], ["pathognomonic embryonic changes", "PROBLEM", 188, 219], ["stunted embryos", "PROBLEM", 221, 236], ["wound", "PROBLEM", 241, 246], ["feather dystrophy", "PROBLEM", 252, 269], ["urate deposits in the mesonephros", "PROBLEM", 274, 307], ["Infectious", "OBSERVATION_MODIFIER", 89, 99], ["Bronchitis", "OBSERVATION", 100, 110], ["left", "ANATOMY_MODIFIER", 146, 150], ["pathognomonic", "OBSERVATION_MODIFIER", 188, 201], ["embryonic changes", "OBSERVATION", 202, 219], ["stunted embryos", "OBSERVATION", 221, 236], ["wound", "ANATOMY", 241, 246], ["urate deposits", "OBSERVATION", 274, 288], ["mesonephros", "ANATOMY", 296, 307]]], ["These lesions could also appear at the second pass (Delaplane, 1947) .", [["lesions", "ANATOMY", 6, 13], ["lesions", "PATHOLOGICAL_FORMATION", 6, 13], ["These lesions", "PROBLEM", 0, 13], ["lesions", "OBSERVATION", 6, 13]]], ["The embryo-adapted strains induce greater embryo mortality.", [["embryo", "ANATOMY", 42, 48], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 42, 48], ["The embryo-adapted strains", "PROBLEM", 0, 26], ["greater embryo mortality", "PROBLEM", 34, 58], ["greater", "OBSERVATION_MODIFIER", 34, 41], ["embryo mortality", "OBSERVATION", 42, 58]]], ["Isolation of IBV should be confirmed by serum neutralization or reverse transcription polymerase chain reaction (PCR).Tracheal CultureTracheal cycle culture (0.5\u00c01.0 mm thick) of 19-to 20-day embryos can be used for primary isolation of IBV directly from field samples (Cook et al., 1996) .", [["serum", "ANATOMY", 40, 45], ["Tracheal", "ANATOMY", 118, 126], ["embryos", "ANATOMY", 192, 199], ["samples", "ANATOMY", 261, 268], ["IBV", "ORGANISM", 13, 16], ["serum", "ORGANISM_SUBSTANCE", 40, 45], ["embryos", "ORGANISM", 192, 199], ["IBV", "ORGANISM", 237, 240], ["IBV", "SPECIES", 13, 16], ["IBV", "SPECIES", 237, 240], ["Isolation of IBV", "TREATMENT", 0, 16], ["serum neutralization", "TEST", 40, 60], ["reverse transcription polymerase chain reaction", "PROBLEM", 64, 111], ["PCR", "TEST", 113, 116], ["Tracheal CultureTracheal cycle culture", "TEST", 118, 156], ["thick", "TEST", 169, 174], ["IBV", "PROBLEM", 237, 240], ["IBV", "OBSERVATION", 13, 16]]], ["The rings are maintained in N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid Eagle's medium in roller drums (15 revolutions/h) (OIE, 2013) .", [["N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid", "CHEMICAL", 28, 81], ["N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid", "CHEMICAL", 28, 81], ["N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid", "SIMPLE_CHEMICAL", 28, 81], ["The rings", "TREATMENT", 0, 9], ["hydroxyethylpiperazine", "TREATMENT", 32, 54], ["rings", "ANATOMY_MODIFIER", 4, 9]]], ["Ciliostasis within 24\u00c048 hours is an indication for virus multiplication; however, other viruses could produce similar lesions so further identification of the virus is needed.Tracheal CultureThe diagnosis of infectious diseases is made by the direct and/or indirect detection of infectious agents.", [["lesions", "ANATOMY", 119, 126], ["Ciliostasis", "DISEASE", 0, 11], ["infectious diseases", "DISEASE", 209, 228], ["lesions", "PATHOLOGICAL_FORMATION", 119, 126], ["virus multiplication", "PROBLEM", 52, 72], ["other viruses", "PROBLEM", 83, 96], ["similar lesions", "PROBLEM", 111, 126], ["the virus", "PROBLEM", 156, 165], ["Tracheal Culture", "TEST", 176, 192], ["infectious diseases", "PROBLEM", 209, 228], ["infectious agents", "TREATMENT", 280, 297], ["indication for", "UNCERTAINTY", 37, 51], ["virus", "OBSERVATION", 52, 57], ["similar", "OBSERVATION_MODIFIER", 111, 118], ["lesions", "OBSERVATION", 119, 126], ["infectious", "OBSERVATION", 209, 219], ["infectious", "OBSERVATION", 280, 290]]], ["By direct methods, the particles of the agents and/or their components, such as nucleic acids, structural or nonstructural proteins, enzymes, etc., are detected.", [["nucleic acids", "CHEMICAL", 80, 93], ["nucleic acids", "SIMPLE_CHEMICAL", 80, 93], ["nonstructural proteins", "PROTEIN", 109, 131], ["enzymes", "PROTEIN", 133, 140], ["the agents", "TREATMENT", 36, 46], ["nucleic acids", "TEST", 80, 93], ["nonstructural proteins", "TEST", 109, 131], ["enzymes", "TEST", 133, 140]]], ["Indirect methods demonstrate the presence of antibodies induced by infections.Tracheal CultureThe most common methods for direct detection are isolation or in vitro culture, electron microscopy, immunofluorescence, immunohistochemistry, enzyme immunoassays (ELISA), nucleic acid hybridization, and various nucleic acid amplification techniques such as the PCR.Tracheal CultureThe most common methods of indirect detection of infectious agents are serological tests, such as viral neutralization, ELISA, hemagglutination inhibition tests, etc.INTERSPIECES VIRAL TRANSMISSIONAlthough viruses and microorganisms have the property of host specificity due to various factors, we quoteINTERSPIECES VIRAL TRANSMISSIONThe sensitivity of the cell to a virus via the presence of receptors allows the tropism of viruses and the presence of the factors necessary for the replication of the virus in the host cell (Segondy, 2010) .", [["cell", "ANATOMY", 733, 737], ["cell", "ANATOMY", 896, 900], ["infections", "DISEASE", 67, 77], ["nucleic acid", "CHEMICAL", 266, 278], ["cell", "CELL", 733, 737], ["host cell", "CELL", 891, 900], ["antibodies", "PROTEIN", 45, 55], ["Indirect methods", "TEST", 0, 16], ["antibodies", "PROBLEM", 45, 55], ["infections", "PROBLEM", 67, 77], ["Tracheal Culture", "TEST", 78, 94], ["direct detection", "TEST", 122, 138], ["vitro culture", "TEST", 159, 172], ["electron microscopy", "TEST", 174, 193], ["immunofluorescence", "TEST", 195, 213], ["immunohistochemistry", "TEST", 215, 235], ["enzyme immunoassays", "TEST", 237, 256], ["ELISA", "TEST", 258, 263], ["nucleic acid hybridization", "TEST", 266, 292], ["various nucleic acid amplification techniques", "TREATMENT", 298, 343], ["the PCR", "TEST", 352, 359], ["Tracheal Culture", "TEST", 360, 376], ["infectious agents", "TREATMENT", 425, 442], ["serological tests", "TEST", 447, 464], ["viral neutralization", "TEST", 474, 494], ["ELISA", "TEST", 496, 501], ["hemagglutination inhibition tests", "TEST", 503, 536], ["VIRAL TRANSMISSIONAlthough viruses", "PROBLEM", 555, 589], ["microorganisms", "PROBLEM", 594, 608], ["various factors", "PROBLEM", 654, 669], ["a virus", "PROBLEM", 741, 748], ["the tropism of viruses", "PROBLEM", 786, 808], ["the virus", "PROBLEM", 874, 883], ["antibodies", "OBSERVATION", 45, 55], ["infections", "OBSERVATION", 67, 77], ["most common", "OBSERVATION_MODIFIER", 380, 391], ["infectious", "OBSERVATION", 425, 435], ["virus", "OBSERVATION", 878, 883], ["host cell", "OBSERVATION", 891, 900]]], ["Coronaviridae are the exception, as several viruses that are detected in humans have phylogenetic and genetic similarity to those isolated from other animal hosts (Woo et al., 2009; Chan et al., 2013) .", [["Coronaviridae", "GENE_OR_GENE_PRODUCT", 0, 13], ["humans", "ORGANISM", 73, 79], ["humans", "SPECIES", 73, 79], ["humans", "SPECIES", 73, 79], ["Coronaviridae", "TREATMENT", 0, 13], ["several viruses", "PROBLEM", 36, 51], ["viruses", "OBSERVATION", 44, 51]]], ["These nonspecific properties that CoVs possess may be due to accessory CoV genes, which are already thought to play a role in host tropism and adaptation to a new host.INTERSPIECES VIRAL TRANSMISSIONS-Glycoprotein appears to be the main determinant for the success of initial events of infection between species.INTERSPIECES VIRAL TRANSMISSIONBats are home to a wide range of CoVs, including the acute respiratory syndrome (SARS-CoV) and acute respiratory syndrome virus (MERS-CoV) CoV viruses.", [["infection", "DISEASE", 286, 295], ["acute respiratory syndrome (SARS-CoV)", "DISEASE", 396, 433], ["acute respiratory syndrome virus", "DISEASE", 438, 470], ["CoVs", "GENE_OR_GENE_PRODUCT", 34, 38], ["CoV", "GENE_OR_GENE_PRODUCT", 71, 74], ["TRANSMISSIONS-Glycoprotein", "GENE_OR_GENE_PRODUCT", 187, 213], ["CoVs", "CANCER", 376, 380], ["SARS-CoV", "ORGANISM", 424, 432], ["acute respiratory syndrome virus", "ORGANISM", 438, 470], ["MERS-CoV) CoV viruses", "ORGANISM", 472, 493], ["accessory CoV genes", "DNA", 61, 80], ["Glycoprotein", "PROTEIN", 201, 213], ["SARS-CoV", "SPECIES", 424, 432], ["MERS-CoV", "SPECIES", 472, 480], ["accessory CoV genes", "PROBLEM", 61, 80], ["Glycoprotein", "TREATMENT", 201, 213], ["infection between species", "PROBLEM", 286, 311], ["CoVs", "PROBLEM", 376, 380], ["the acute respiratory syndrome", "PROBLEM", 392, 422], ["SARS", "PROBLEM", 424, 428], ["acute respiratory syndrome virus", "PROBLEM", 438, 470], ["CoV viruses", "PROBLEM", 482, 493], ["may be due to", "UNCERTAINTY", 47, 60], ["accessory", "OBSERVATION", 61, 70], ["CoV genes", "OBSERVATION", 71, 80], ["infection", "OBSERVATION", 286, 295], ["acute", "OBSERVATION_MODIFIER", 396, 401], ["respiratory syndrome", "OBSERVATION", 402, 422], ["acute", "OBSERVATION_MODIFIER", 438, 443], ["respiratory syndrome", "OBSERVATION", 444, 464]]], ["SARS-CoV has crossed the species barrier in masked palm civets and other animals in live animal markets in China; genetic analysis suggests that this occurred at the end of 2002.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "ORGANISM", 0, 8], ["palm", "ORGANISM_SUBDIVISION", 51, 55], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["genetic analysis", "TEST", 114, 130]]], ["Several people in the immediate vicinity of palm civets were infected with SARS-CoV.", [["SARS-CoV", "DISEASE", 75, 83], ["people", "ORGANISM", 8, 14], ["palm", "ORGANISM_SUBDIVISION", 44, 48], ["SARS-CoV", "ORGANISM", 75, 83], ["people", "SPECIES", 8, 14], ["SARS-CoV", "SPECIES", 75, 83]]], ["Ancestral MERS-CoV virus crossed the species barrier in camel camels; serological evidence suggests that this occurred more than 30 years ago (de Wit et al., 2016) .", [["MERS-CoV virus", "ORGANISM", 10, 24], ["camel", "ORGANISM", 56, 61], ["camels", "ORGANISM_SUBDIVISION", 62, 68], ["CoV virus", "SPECIES", 15, 24], ["camel", "SPECIES", 56, 61], ["MERS-CoV virus", "SPECIES", 10, 24], ["camel", "SPECIES", 56, 61], ["Ancestral MERS", "PROBLEM", 0, 14], ["CoV virus", "PROBLEM", 15, 24]]], ["Abundant MERS-CoV circulation in camel camels results in frequent zoonotic transmission of this virus.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 9, 17], ["camel", "ORGANISM", 33, 38], ["camels", "ORGANISM_SUBDIVISION", 39, 45], ["camel", "SPECIES", 33, 38], ["MERS-CoV", "SPECIES", 9, 17], ["camel", "SPECIES", 33, 38], ["Abundant MERS", "PROBLEM", 0, 13], ["CoV circulation in camel camels", "PROBLEM", 14, 45], ["this virus", "PROBLEM", 91, 101], ["MERS", "OBSERVATION", 9, 13]]], ["SARS-CoV and MERS-CoV spread among humans primarily through nosocomial transmission, resulting in the infection of healthcare workers and patients at a higher frequency than the infection of their loved ones.", [["SARS", "DISEASE", 0, 4], ["nosocomial transmission", "DISEASE", 60, 83], ["infection", "DISEASE", 102, 111], ["infection", "DISEASE", 178, 187], ["SARS-CoV", "ORGANISM", 0, 8], ["MERS-CoV", "ORGANISM", 13, 21], ["humans", "ORGANISM", 35, 41], ["patients", "ORGANISM", 138, 146], ["humans", "SPECIES", 35, 41], ["patients", "SPECIES", 138, 146], ["SARS-CoV", "SPECIES", 0, 8], ["MERS-CoV", "SPECIES", 13, 21], ["humans", "SPECIES", 35, 41], ["SARS", "PROBLEM", 0, 4], ["CoV", "PROBLEM", 5, 8], ["MERS", "PROBLEM", 13, 17], ["CoV spread", "PROBLEM", 18, 28], ["infection", "OBSERVATION", 102, 111], ["infection", "OBSERVATION", 178, 187]]]], "92d5cf0a27a6385cefcb939a47bccc08fc608851": [["SARS-CoV-2; Biosafety Laboratory; Emergency ManagementThe coronavirus disease 2019 (COVID-19) outbreak started in China in December 2019, and the disease is now a global pandemic.", [["SARS", "DISEASE", 0, 4], ["coronavirus disease", "DISEASE", 58, 77], ["COVID-19", "CHEMICAL", 84, 92], ["coronavirus disease 2019 (COVID-19", "SPECIES", 58, 92], ["Emergency Management", "TREATMENT", 34, 54], ["The coronavirus disease", "PROBLEM", 54, 77], ["COVID", "TEST", 84, 89], ["outbreak", "PROBLEM", 94, 102], ["the disease", "PROBLEM", 142, 153], ["a global pandemic", "PROBLEM", 161, 178], ["coronavirus disease", "OBSERVATION", 58, 77], ["disease", "OBSERVATION", 146, 153], ["global", "OBSERVATION_MODIFIER", 163, 169], ["pandemic", "OBSERVATION", 170, 178]]], ["As a basic and guaranteed platform for the research of emerging infectious diseases, a biosafety level 3 (BSL-3) laboratory provides the hardware support for humans to recognize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and study the COVID-19 prevention and treatment methods.", [["infectious diseases", "DISEASE", 64, 83], ["acute respiratory syndrome coronavirus", "DISEASE", 185, 223], ["humans", "ORGANISM", 158, 164], ["humans", "SPECIES", 158, 164], ["humans", "SPECIES", 158, 164], ["severe acute respiratory syndrome coronavirus", "SPECIES", 178, 223], ["SARS-CoV-2", "SPECIES", 227, 237], ["emerging infectious diseases", "PROBLEM", 55, 83], ["a biosafety level", "TEST", 85, 102], ["BSL", "TEST", 106, 109], ["the hardware support", "TREATMENT", 133, 153], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 178, 223], ["CoV", "TEST", 232, 235], ["the COVID", "TEST", 249, 258], ["treatment methods", "TREATMENT", 277, 294], ["infectious", "OBSERVATION", 64, 74], ["hardware", "OBSERVATION", 137, 145], ["severe", "OBSERVATION_MODIFIER", 178, 184], ["acute", "OBSERVATION_MODIFIER", 185, 190], ["respiratory syndrome", "OBSERVATION", 191, 211]]], ["With the existing hardware facilities, safe and effective operations in biosafety laboratories depend on taking the appropriate emergency management measures to protect the personnel, pathogens, and laboratory environment.Biosafety level 3 laboratoryBSL-3 laboratories are the most numerous and frequently used laboratories among the high-level biosafety laboratories.", [["the existing hardware facilities", "TREATMENT", 5, 37], ["effective operations", "TREATMENT", 48, 68], ["the appropriate emergency management measures", "TREATMENT", 112, 157], ["Biosafety level", "TEST", 222, 237], ["laboratoryBSL", "TEST", 240, 253], ["hardware", "OBSERVATION", 18, 26]]], ["The animal biosafety level 3 (ABSL-3) laboratory consists of primary barriers, such as biological safety cabinets, animal isolation equipment, and personal protective equipment (PPE), and secondary barriers, such as architectural structures and electrical and control systems.", [["The animal biosafety level", "TEST", 0, 26], ["ABSL", "TEST", 30, 34], ["primary barriers", "TREATMENT", 61, 77], ["biological safety cabinets", "TREATMENT", 87, 113], ["animal isolation equipment", "TREATMENT", 115, 141], ["personal protective equipment", "TREATMENT", 147, 176], ["secondary barriers", "PROBLEM", 188, 206], ["electrical and control systems", "TREATMENT", 245, 275]]], ["1 Through the appropriate hardware facilities and management measures, a BSL-3 laboratory protects the staff, the environment, and the general public from the hazards of pathogenic microorganisms.", [["management measures", "TREATMENT", 50, 69], ["a BSL", "TEST", 71, 76], ["pathogenic microorganisms", "PROBLEM", 170, 195]]], ["These laboratories are mainly used for experiments with highly pathogenic microorganisms, such as SARS-CoV, MERS-CoV, HIV, among others.", [["SARS-CoV", "DISEASE", 98, 106], ["SARS-CoV", "ORGANISM", 98, 106], ["MERS-CoV", "ORGANISM", 108, 116], ["HIV", "ORGANISM", 118, 121], ["HIV", "SPECIES", 118, 121], ["SARS-CoV", "SPECIES", 98, 106], ["MERS-CoV", "SPECIES", 108, 116], ["HIV", "SPECIES", 118, 121], ["These laboratories", "TEST", 0, 18], ["highly pathogenic microorganisms", "PROBLEM", 56, 88], ["SARS", "PROBLEM", 98, 102], ["CoV", "PROBLEM", 113, 116], ["HIV", "PROBLEM", 118, 121]]], ["2Emergency management of SARS-CoV-2Considering the bounded cognition in the case of SARS-CoV-2, the laboratory PPE often has either excessive or insufficient defense, which may cause extreme panic and wastage of the protective equipment, thus increasing the risk of infection for the staff.Emergency management of SARS-CoV-2In order to ensure personnel and environmental safety while considering the comfort factor and reducing the harmful effects of disinfectants on personnel and facilities, the potential risks were identified and the risk assessment process guidelines and statements were constantly revised based on our knowledge of COVID-19 and SARS-CoV-2, which changed from \"not pathogenic\" to \"highly pathogenic\", and from \"cannot be transmitted from person to person\" to \"does not exclude person to person\" to \"affirmed person to person\".Risk assessment managementRisk assessment is a key step toward taking the appropriate emergency management measures to protect the people, pathogens, and the environment.", [["SARS", "DISEASE", 84, 88], ["panic", "DISEASE", 191, 196], ["infection", "DISEASE", 266, 275], ["SARS", "DISEASE", 314, 318], ["SARS", "DISEASE", 651, 655], ["SARS-CoV", "ORGANISM", 25, 33], ["people", "ORGANISM", 979, 985], ["person", "SPECIES", 760, 766], ["person", "SPECIES", 770, 776], ["person", "SPECIES", 799, 805], ["person", "SPECIES", 809, 815], ["person", "SPECIES", 830, 836], ["person", "SPECIES", 840, 846], ["people", "SPECIES", 979, 985], ["SARS-CoV", "SPECIES", 84, 92], ["SARS-CoV", "SPECIES", 651, 659], ["2Emergency management", "TREATMENT", 0, 21], ["SARS-CoV", "PROBLEM", 25, 33], ["SARS", "PROBLEM", 84, 88], ["extreme panic", "PROBLEM", 183, 196], ["the protective equipment", "TREATMENT", 212, 236], ["infection", "PROBLEM", 266, 275], ["SARS", "PROBLEM", 314, 318], ["the comfort factor", "PROBLEM", 396, 414], ["the risk assessment", "TEST", 534, 553], ["COVID", "TEST", 638, 643], ["SARS", "PROBLEM", 651, 655], ["CoV", "TEST", 656, 659], ["Risk assessment management", "TREATMENT", 848, 874], ["Risk assessment", "TEST", 874, 889], ["the appropriate emergency management measures", "TREATMENT", 918, 963], ["pathogens", "PROBLEM", 987, 996], ["infection", "OBSERVATION", 266, 275]]], ["At the beginning of the COVID-19 outbreak, the highest level of PPE was required, since the cause and route of transmission were unknown.", [["the COVID", "TEST", 20, 29], ["PPE", "PROBLEM", 64, 67]]], ["At present, there are four known routes of infection of this disease: the respiratory tract, digestive tract, blood, and skin contact, among which the aerosol transmission from the respiratory tract requires the highest level of protection.", [["respiratory tract", "ANATOMY", 74, 91], ["digestive tract", "ANATOMY", 93, 108], ["blood", "ANATOMY", 110, 115], ["skin", "ANATOMY", 121, 125], ["respiratory tract", "ANATOMY", 181, 198], ["infection", "DISEASE", 43, 52], ["respiratory tract", "ORGANISM_SUBDIVISION", 74, 91], ["digestive tract", "ORGANISM_SUBDIVISION", 93, 108], ["blood", "ORGANISM_SUBSTANCE", 110, 115], ["skin", "ORGAN", 121, 125], ["respiratory tract", "ORGANISM_SUBDIVISION", 181, 198], ["infection", "PROBLEM", 43, 52], ["this disease", "PROBLEM", 56, 68], ["the respiratory tract", "PROBLEM", 70, 91], ["digestive tract, blood, and skin contact", "PROBLEM", 93, 133], ["the aerosol transmission", "TREATMENT", 147, 171], ["the respiratory tract", "PROBLEM", 177, 198], ["infection", "OBSERVATION", 43, 52], ["respiratory tract", "ANATOMY", 74, 91], ["digestive tract", "ANATOMY", 93, 108], ["skin", "ANATOMY", 121, 125], ["respiratory tract", "ANATOMY", 181, 198]]], ["Therefore, people involved in experimental activities need to wear disposable N95 masks, two layers of protective clothing, and two layers of disposable gloves.", [["people", "ORGANISM", 11, 17], ["people", "SPECIES", 11, 17], ["disposable N95 masks", "TREATMENT", 67, 87], ["protective clothing", "TREATMENT", 103, 122], ["disposable gloves", "TREATMENT", 142, 159], ["protective clothing", "OBSERVATION", 103, 122], ["disposable gloves", "OBSERVATION", 142, 159]]], ["Considering the comfort of the personnel and the convenience of operation, and according to the criterion \"cannot be transmitted from person to person\", it was not recommended to wear positive pressure protective clothing or head cover.Risk assessment managementThe pathogen was then successfully isolated and suggested to be a new type of coronavirus 3 , which was classified as \"SARS-related\" or \"SARS-like\" coronavirus.", [["head", "ANATOMY", 225, 229], ["SARS", "DISEASE", 381, 385], ["SARS", "DISEASE", 399, 403], ["head", "ORGANISM_SUBDIVISION", 225, 229], ["coronavirus 3", "ORGANISM", 340, 353], ["coronavirus", "ORGANISM", 410, 421], ["person", "SPECIES", 134, 140], ["person", "SPECIES", 144, 150], ["operation", "TREATMENT", 64, 73], ["positive pressure protective clothing", "TREATMENT", 184, 221], ["head cover", "TREATMENT", 225, 235], ["Risk assessment management", "TREATMENT", 236, 262], ["The pathogen", "PROBLEM", 262, 274], ["coronavirus", "PROBLEM", 340, 351], ["SARS", "PROBLEM", 381, 385], ["\"SARS", "PROBLEM", 398, 403], ["coronavirus", "PROBLEM", 410, 421], ["head", "ANATOMY", 225, 229]]], ["The clinical diagnosis results showed that the patients had white blood cell counts and chest radiograph symptoms similar to those observed in the cases of SARS coronavirus infections.", [["white blood cell", "ANATOMY", 60, 76], ["chest", "ANATOMY", 88, 93], ["SARS coronavirus infections", "DISEASE", 156, 183], ["patients", "ORGANISM", 47, 55], ["white blood cell", "CELL", 60, 76], ["chest", "ORGANISM_SUBDIVISION", 88, 93], ["SARS coronavirus", "ORGANISM", 156, 172], ["patients", "SPECIES", 47, 55], ["SARS coronavirus", "SPECIES", 156, 172], ["white blood cell counts", "TEST", 60, 83], ["chest radiograph symptoms", "PROBLEM", 88, 113], ["SARS coronavirus infections", "PROBLEM", 156, 183], ["chest", "ANATOMY", 88, 93], ["SARS coronavirus infections", "OBSERVATION", 156, 183]]], ["4 Therefore, the risk assessment process was revised for the first time to take into account the biological and epidemiological characteristics, potential consequences of exposure, and precautionary measures against the SARS coronavirus.", [["SARS coronavirus", "DISEASE", 220, 236], ["SARS coronavirus", "ORGANISM", 220, 236], ["SARS coronavirus", "SPECIES", 220, 236], ["the risk assessment", "TEST", 13, 32], ["precautionary measures", "TREATMENT", 185, 207], ["the SARS coronavirus", "PROBLEM", 216, 236]]], ["Although no obvious evidence of human-to-human transmission existed at that time, the staff was still required to take strict respiratory protection measures.Risk assessment managementIn mid-January, the \"Guidelines for Biosafety of New Coronavirus Laboratories\" clarified the severity of the virus and temporarily managed it according to the category of highly pathogenic microorganisms.", [["respiratory", "ANATOMY", 126, 137], ["human", "ORGANISM", 32, 37], ["human", "ORGANISM", 41, 46], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 41, 46], ["strict respiratory protection measures", "TREATMENT", 119, 157], ["Risk assessment management", "TREATMENT", 158, 184], ["New Coronavirus Laboratories", "TEST", 233, 261], ["the virus", "PROBLEM", 289, 298], ["highly pathogenic microorganisms", "PROBLEM", 355, 387], ["no obvious", "UNCERTAINTY", 9, 19], ["virus", "OBSERVATION", 293, 298]]], ["However, the guidelines stated that nonpropagative diagnostic laboratory work in biosafety level 2 (BSL-2) laboratories should use the PPE of BSL-3 laboratories.", [["BSL", "TEST", 100, 103], ["BSL", "TEST", 142, 145]]], ["5, 6 BSL-3 protection levels ensure a higher level of safety than that needed for handling SARS-CoV, which suggested that SARS-CoV-2 may be more harmful than SARS-CoV; thus, the risk assessment guidelines were revised once again.", [["SARS", "DISEASE", 91, 95], ["SARS", "DISEASE", 122, 126], ["BSL-3", "GENE_OR_GENE_PRODUCT", 5, 10], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 91, 99], ["SARS-CoV-2", "ORGANISM", 122, 132], ["SARS-CoV", "ORGANISM", 158, 166], ["SARS-CoV", "SPECIES", 91, 99], ["SARS-CoV", "SPECIES", 122, 130], ["SARS-CoV", "SPECIES", 158, 166], ["handling SARS", "PROBLEM", 82, 95], ["SARS", "PROBLEM", 122, 126], ["the risk assessment", "TEST", 174, 193]]], ["Based on the existing levels of safety provided by the currently available PPE, the basic management principles of \"reduction of procedures and peakto-peak deviations\" were proposed.", [["PPE", "TREATMENT", 75, 78], ["the basic management", "TREATMENT", 80, 100], ["\"reduction of procedures", "TREATMENT", 115, 139], ["peakto-peak deviations\"", "TREATMENT", 144, 167]]], ["The entry time was staggered and the amount time of time spent by the personnel in the laboratories was reduced by controlling the number of single pathogenic operations, increasing the number of staff, and formulating experimental plans in advance.", [["single pathogenic operations", "TREATMENT", 141, 169]]], ["In addition, personnel in different containment areas of the laboratories were required to stagger their departure time by more than half an hour in order to fully clean the public area.Risk assessment managementWith subsequent progression of the COVID-19 epidemic, the new coronavirus was confirmed to be transmitted by person-to-person contact and showed a possibility of causing conjunctival infection.", [["conjunctival", "ANATOMY", 382, 394], ["coronavirus", "DISEASE", 274, 285], ["conjunctival infection", "DISEASE", 382, 404], ["coronavirus", "ORGANISM", 274, 285], ["conjunctival", "ORGAN", 382, 394], ["person", "SPECIES", 321, 327], ["person", "SPECIES", 331, 337], ["Risk assessment", "TEST", 186, 201], ["the COVID", "TEST", 243, 252], ["the new coronavirus", "PROBLEM", 266, 285], ["conjunctival infection", "PROBLEM", 382, 404], ["clean", "OBSERVATION", 164, 169], ["conjunctival", "ANATOMY", 382, 394], ["infection", "OBSERVATION", 395, 404]]], ["7 As a result, an immediate third revision in the risk assessment process guidelines was made.", [["an immediate third revision", "TREATMENT", 15, 42], ["the risk assessment", "TEST", 46, 65], ["revision", "OBSERVATION", 34, 42]]], ["Goggles or disposable protective masks were added to the respiratory protection equipment for protection against aerosols to prevent potential conjunctival infection.", [["respiratory", "ANATOMY", 57, 68], ["conjunctival", "ANATOMY", 143, 155], ["conjunctival infection", "DISEASE", 143, 165], ["conjunctival", "PATHOLOGICAL_FORMATION", 143, 155], ["Goggles", "TREATMENT", 0, 7], ["disposable protective masks", "TREATMENT", 11, 38], ["the respiratory protection equipment", "TREATMENT", 53, 89], ["protection", "TREATMENT", 94, 104], ["aerosols", "TREATMENT", 113, 121], ["potential conjunctival infection", "PROBLEM", 133, 165], ["conjunctival", "ANATOMY", 143, 155], ["infection", "OBSERVATION", 156, 165]]], ["As more advanced research, clinical diagnoses, and autopsy of the new coronavirus patients were conducted, the biological characteristics of the virus were better defined.", [["coronavirus", "DISEASE", 70, 81], ["coronavirus", "ORGANISM", 70, 81], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["autopsy", "TEST", 51, 58], ["the new coronavirus patients", "PROBLEM", 62, 90], ["the virus", "PROBLEM", 141, 150], ["virus", "OBSERVATION", 145, 150]]], ["By closely following the continuously updated \"Guidelines for the Diagnosis and Treatment of Novel Coronavirus (2019-nCov) Infection\" of the National Health Commission and the openly published scientific papers and clinical diagnosis results in China and abroad, the risk assessment process was continuously improved and the staff members were guided to make the transition from \"top level protection\" at the initial stage to \"reasonable protection\" with pertinence.", [["Novel Coronavirus", "PROBLEM", 93, 110], ["Infection", "PROBLEM", 123, 132], ["the risk assessment", "TEST", 263, 282], ["\"top level protection", "TREATMENT", 379, 400]]], ["8, 9 The laboratory technicians were now required to wear a disposable N95 mask, two layers of protective clothing, two layers of disposable gloves, and disposable protective face shields.", [["a disposable N95 mask", "TREATMENT", 58, 79], ["protective clothing", "TREATMENT", 95, 114], ["disposable gloves", "TREATMENT", 130, 147], ["disposable protective face shields", "TREATMENT", 153, 187], ["disposable gloves", "OBSERVATION", 130, 147]]], ["In the process of cultivating viruses or in animal anatomy experiments, there may be a risk of infection from aerosols or fluid splashes.", [["fluid", "ANATOMY", 122, 127], ["infection", "DISEASE", 95, 104], ["cultivating viruses", "PROBLEM", 18, 37], ["infection", "PROBLEM", 95, 104], ["aerosols", "PROBLEM", 110, 118], ["fluid splashes", "PROBLEM", 122, 136], ["viruses", "OBSERVATION", 30, 37], ["may be a risk of", "UNCERTAINTY", 78, 94], ["infection", "OBSERVATION", 95, 104], ["fluid splashes", "OBSERVATION", 122, 136]]], ["The experimental personnel can wear a positive-pressure-powered air-filter hood and a onetime reverse operating suit, which can be replaced conveniently after being contaminated.Personnel ManagementPersonnel management involves the problems of formulating standard operating procedures according to the risk assessment, conducting special training for laboratory personnel, guiding the staff on how and why to follow certain protocols and procedures, and sensitizing them regarding the necessity of these actions.", [["a onetime reverse operating suit", "TREATMENT", 84, 116], ["Personnel Management", "TREATMENT", 178, 198], ["Personnel management", "TREATMENT", 198, 218], ["standard operating procedures", "TREATMENT", 256, 285], ["the risk assessment", "TEST", 299, 318], ["procedures", "TREATMENT", 439, 449], ["these actions", "TREATMENT", 499, 512]]], ["Personnel safety does not only include selecting the appropriate PPE but also developing and maintaining the standards for the donning and doffing of PPE.", [["PPE", "TREATMENT", 150, 153]]], ["In personnel management, the administrators should actively communicate with the laboratory personnel and pay attention to their requirements and other details to build trust, discover the loopholes in the processes in time, and urge them to comply with the regulations.", [["personnel management", "TREATMENT", 3, 23]]], ["It is beneficial for the administrators to comprehend the mental health of the laboratory personnel and perform good psychological counseling in time.Disinfection managementDisinfection management is an important aspect of environmental safety in laboratories.", [["Disinfection management", "TREATMENT", 150, 173], ["Disinfection management", "TREATMENT", 173, 196]]], ["Selecting a suitable disinfectant not only ensures effective and efficient disinfection but also minimizes damage to the personnel, facilities, and equipment.Disinfection managementWhen dealing with an unknown pathogen, the most serious pathogen is set as the standard for disinfection.", [["Disinfection management", "TREATMENT", 158, 181], ["an unknown pathogen", "PROBLEM", 199, 218], ["disinfection", "PROBLEM", 273, 285], ["disinfection", "OBSERVATION", 75, 87], ["pathogen", "OBSERVATION", 210, 218]]], ["Considering the disinfection effect and safety, the disinfectant containing 0.55% effective chlorine was selected to disinfect the experimental table and samples, while hydrogen peroxide or peracetic acid was selected to disinfect the laboratory environment.", [["samples", "ANATOMY", 154, 161], ["chlorine", "CHEMICAL", 92, 100], ["hydrogen peroxide", "CHEMICAL", 169, 186], ["peracetic acid", "CHEMICAL", 190, 204], ["chlorine", "CHEMICAL", 92, 100], ["hydrogen peroxide", "CHEMICAL", 169, 186], ["peracetic acid", "CHEMICAL", 190, 204], ["chlorine", "SIMPLE_CHEMICAL", 92, 100], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 169, 186], ["peracetic acid", "SIMPLE_CHEMICAL", 190, 204], ["the disinfection effect", "TREATMENT", 12, 35], ["the disinfectant", "TREATMENT", 48, 64], ["0.55% effective chlorine", "TREATMENT", 76, 100], ["hydrogen peroxide", "TREATMENT", 169, 186], ["peracetic acid", "TREATMENT", 190, 204], ["disinfection", "OBSERVATION", 16, 28]]], ["6, 10 Although formaldehyde can kill all pathogenic microorganisms and their spores, its use is not recommended because of its carcinogenicity and the damage it causes to the facilities.", [["spores", "ANATOMY", 77, 83], ["formaldehyde", "CHEMICAL", 15, 27], ["formaldehyde", "CHEMICAL", 15, 27], ["formaldehyde", "SIMPLE_CHEMICAL", 15, 27], ["all pathogenic microorganisms", "PROBLEM", 37, 66], ["its carcinogenicity", "PROBLEM", 123, 142], ["the damage", "PROBLEM", 147, 157], ["carcinogenicity", "OBSERVATION", 127, 142]]], ["10 It is well known that 75% alcohol is a common disinfectant in biosafety laboratories, but it cannot kill all the nonlipid viruses.", [["alcohol", "CHEMICAL", 29, 36], ["alcohol", "CHEMICAL", 29, 36], ["alcohol", "SIMPLE_CHEMICAL", 29, 36]]], ["10 Seventy-five percent alcohol was not chosen at the early stage of the epidemic because its disinfection effect cannot be verified when the pathogen is unknown.", [["alcohol", "CHEMICAL", 24, 31], ["alcohol", "CHEMICAL", 24, 31], ["alcohol", "SIMPLE_CHEMICAL", 24, 31], ["the pathogen", "PROBLEM", 138, 150]]], ["However, when the pathogen was identified as a new type of coronavirus, the disinfection effect of 75% alcohol was verified and it was proved that it could be effective against coronavirus.", [["coronavirus", "DISEASE", 59, 70], ["alcohol", "CHEMICAL", 103, 110], ["coronavirus", "DISEASE", 177, 188], ["alcohol", "CHEMICAL", 103, 110], ["coronavirus", "ORGANISM", 59, 70], ["alcohol", "SIMPLE_CHEMICAL", 103, 110], ["coronavirus", "ORGANISM", 177, 188], ["the pathogen", "PROBLEM", 14, 26], ["coronavirus", "PROBLEM", 59, 70], ["coronavirus", "PROBLEM", 177, 188], ["coronavirus", "OBSERVATION", 59, 70]]], ["9, 10 Thus, considering the safety of the disinfectant for the laboratory personnel, 75% alcohol was added as an effective disinfectant.Management of experimental activitiesThe management of SARS-CoV-2 experimental activities is crucial to ensure normal operation of the laboratories and to avoid accidents.", [["alcohol", "CHEMICAL", 89, 96], ["SARS", "DISEASE", 191, 195], ["accidents", "DISEASE", 297, 306], ["alcohol", "CHEMICAL", 89, 96], ["alcohol", "SIMPLE_CHEMICAL", 89, 96], ["SARS", "PROBLEM", 191, 195], ["CoV", "TEST", 196, 199], ["experimental activities", "OBSERVATION", 150, 173]]], ["Since virus cultivation should strictly control the number of single operations, we suggest not operating for prolonged periods of time but operating frequently and shortening the operation time.Management of experimental activitiesThe designated areas of the items placed in the biosafety cabinet from left to right are the clean area, work area, and dirt area, and the items should be placed such that theyConclusionIn this period of the global pandemic of COVID-19, BSL-3 laboratories provide the hardware support to study the biological characteristics, prevention, and treatment of SARS-CoV-2.", [["SARS", "DISEASE", 587, 591], ["SARS-CoV-2", "ORGANISM", 587, 597], ["SARS-CoV", "SPECIES", 587, 595], ["virus cultivation", "TREATMENT", 6, 23], ["single operations", "TREATMENT", 62, 79], ["COVID", "TEST", 459, 464], ["BSL", "TEST", 469, 472], ["the hardware support", "TREATMENT", 496, 516], ["SARS", "PROBLEM", 587, 591], ["CoV", "TEST", 592, 595], ["experimental activities", "OBSERVATION", 209, 232], ["areas", "OBSERVATION_MODIFIER", 247, 252], ["left", "ANATOMY_MODIFIER", 303, 307], ["right", "ANATOMY_MODIFIER", 311, 316], ["clean", "OBSERVATION", 325, 330], ["hardware", "OBSERVATION", 500, 508]]], ["By closely tracking the clinical information and taking appropriate emergency management measures to standardize the use of PPE and personnel behaviors, the risk assessment process guidelines have been constantly revised to ensure the safety of the personnel, pathogens, and environment and the effective operation of such laboratories.Conflict of interestNone.", [["appropriate emergency management measures", "TREATMENT", 56, 97], ["PPE", "TREATMENT", 124, 127], ["the risk assessment", "TEST", 153, 172], ["pathogens", "PROBLEM", 260, 269], ["such laboratories", "TEST", 318, 335]]]], "3b64ff8c2c65a1b78b9b4e0a38850e412a9be254": [["IntroductionStrength training and development is considered an essential component for the increase of the population's physical condition 1 and essential for delivering support and maintenance of body posture.", [["body", "ANATOMY", 197, 201], ["body", "ORGANISM_SUBDIVISION", 197, 201], ["IntroductionStrength training", "TREATMENT", 0, 29], ["delivering support", "TREATMENT", 159, 177], ["increase", "OBSERVATION_MODIFIER", 91, 99]]], ["2 It is a fact that the daily movements that people exercise need strength, and that some of these physical efforts are sustained over an extended period 3 ; for these last efforts, strength-resistance (S-R) plays a fundamental role.", [["people", "ORGANISM", 45, 51], ["people", "SPECIES", 45, 51]]], ["S-R is defined as the capacity that a muscle group possesses to maintain repeated contractions against a load (resistance) during a prolonged period.", [["muscle", "ANATOMY", 38, 44], ["S-R", "GENE_OR_GENE_PRODUCT", 0, 3], ["muscle", "ORGAN", 38, 44], ["a muscle group possesses", "TREATMENT", 36, 60], ["muscle", "ANATOMY", 38, 44]]], ["4 This physical capacity has become an important agent within the physical condition and should be taken into account when evaluating the musculoskeletal functions 5 and the physical capacities of the population.", [["musculoskeletal", "ANATOMY", 138, 153], ["This physical capacity", "PROBLEM", 2, 24], ["musculoskeletal", "ANATOMY", 138, 153]]], ["6 There are a large number of tests to evaluate physical abilities.", [["tests", "TEST", 30, 35], ["large", "OBSERVATION_MODIFIER", 14, 19]]], ["7 Some of these tests are carried out in laboratories 8 and others directly in the field.", [["these tests", "TEST", 10, 21]]], ["6 The most used field tests to evaluate the physical condition are situps, push-ups, deep squats, and burpees, among others; however, it is essential to mention that, for evaluating S-R of both upper and lower extremities, these tests must be performed until exhaustion.", [["squats", "ANATOMY", 90, 96], ["upper", "ANATOMY", 194, 199], ["lower extremities", "ANATOMY", 204, 221], ["S-R", "GENE_OR_GENE_PRODUCT", 182, 185], ["upper", "ORGANISM_SUBDIVISION", 194, 199], ["lower extremities", "ORGANISM_SUBDIVISION", 204, 221], ["field tests", "TEST", 16, 27], ["these tests", "TEST", 223, 234], ["exhaustion", "PROBLEM", 259, 269], ["deep squats", "ANATOMY", 85, 96], ["both", "ANATOMY_MODIFIER", 189, 193], ["upper", "ANATOMY_MODIFIER", 194, 199], ["lower extremities", "ANATOMY", 204, 221]]], ["9 Although these tests evaluate specific muscle groups, there are several execution protocols in the sports field; within these variations we can mention the execution time, the joint ranges, and the evaluation planes.", [["muscle", "ANATOMY", 41, 47], ["muscle", "ORGAN", 41, 47], ["these tests", "TEST", 11, 22], ["the evaluation planes", "TEST", 196, 217], ["joint", "ANATOMY", 178, 183]]], ["10, 11 Physical tests measuring S-R in different muscle groups have been independently validated in different populations.", [["muscle", "ANATOMY", 49, 55], ["S-R", "GENE_OR_GENE_PRODUCT", 32, 35], ["muscle", "ORGAN", 49, 55], ["Physical tests", "TEST", 7, 21], ["muscle", "ANATOMY", 49, 55]]], ["6, 12, 13 Thus, the tests for abdominal muscles, elbow, hip, and knee flexo-extensors, which allow predicting the performance of both muscle strength and S-R, 14 have been validated in an isolated way and not as a whole.", [["abdominal muscles", "ANATOMY", 30, 47], ["elbow", "ANATOMY", 49, 54], ["hip", "ANATOMY", 56, 59], ["knee", "ANATOMY", 65, 69], ["muscle", "ANATOMY", 134, 140], ["abdominal muscles", "MULTI-TISSUE_STRUCTURE", 30, 47], ["elbow", "ORGANISM_SUBDIVISION", 49, 54], ["hip", "ORGANISM_SUBDIVISION", 56, 59], ["knee", "ORGANISM_SUBDIVISION", 65, 69], ["extensors", "ORGANISM_SUBDIVISION", 76, 85], ["muscle", "ORGAN", 134, 140], ["S-R", "GENE_OR_GENE_PRODUCT", 154, 157], ["the tests", "TEST", 16, 25], ["abdominal muscles, elbow, hip, and knee flexo-extensors", "PROBLEM", 30, 85], ["abdominal muscles", "ANATOMY", 30, 47], ["elbow", "ANATOMY", 49, 54], ["hip", "ANATOMY", 56, 59], ["knee", "ANATOMY", 65, 69], ["muscle", "ANATOMY", 134, 140]]], ["6, 14 In this sense, some studies have reported a good association between the flexo-extension test of elbows and the press-bench test of a maximum repetition (1RM).", [["elbows", "ORGANISM_SUBDIVISION", 103, 109], ["some studies", "TEST", 21, 33], ["elbows", "ANATOMY", 103, 109]]], ["15 Also, some investigations have concluded that an adequate level of S-R, evaluated through the flexo-extension test of elbows, is associated with better metabolic health.", [["elbows", "ANATOMY", 121, 127], ["S-R", "GENE_OR_GENE_PRODUCT", 70, 73], ["elbows", "ORGANISM_SUBDIVISION", 121, 127], ["some investigations", "TEST", 9, 28], ["the flexo-extension test", "TEST", 93, 117], ["elbows", "ANATOMY", 121, 127]]], ["16 On the other hand, it has been shown that an increase in the Body Mass Index (BMI) has a negative influence on S-R levels.", [["S-R", "GENE_OR_GENE_PRODUCT", 114, 117], ["an increase", "PROBLEM", 45, 56], ["the Body Mass Index", "TEST", 60, 79], ["S-R levels", "TEST", 114, 124], ["increase", "OBSERVATION_MODIFIER", 48, 56], ["Body", "OBSERVATION_MODIFIER", 64, 68], ["Mass", "OBSERVATION", 69, 73]]], ["14, 17 However, as far as knowledge goes, a test's validity and reliability to measure S-R with four consecutive and continuous exercises in healthy adults from 18 to 25 years old have not been determined.IntroductionOn the other hand, and as a result of the pandemic generated by the COVID-19, government authorities worldwide have implemented stringent health measures for the population.", [["S-R", "GENE_OR_GENE_PRODUCT", 87, 90], ["a test's validity", "TEST", 42, 59]]], ["Among the first measures is the isolation of symptomatic patients; however, as the days go by, other measures have been developed, such as the prohibition of mass gatherings, the mandatory closure of educational establishments, and even confinement in private homes for unspecified periods.", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["mass", "PROBLEM", 158, 162], ["symptomatic", "OBSERVATION_MODIFIER", 45, 56], ["mass", "OBSERVATION", 158, 162]]], ["18 Confinement measures, which are intended to prevent the spread of the virus, could negatively affect the population.", [["the virus", "PROBLEM", 69, 78], ["virus", "OBSERVATION", 73, 78]]], ["19 Thus, it has been observed that this confinement generates a lower level of physical activity and more significant sedentary behavior.", [["significant", "OBSERVATION_MODIFIER", 106, 117], ["sedentary", "OBSERVATION", 118, 127]]], ["20 This condition can cause a decrease in the quality of life of the people.", [["people", "ORGANISM", 69, 75], ["people", "SPECIES", 69, 75], ["decrease", "OBSERVATION_MODIFIER", 30, 38]]], ["21 As a result of the confinement, a large part of the population has not been able to access physical training centers (gyms, clubs, sports schools) nor develop the physical exercise routines correctly; similarly, competitive athletes have not been able to attend the high-performance centers or the laboratories to develop and evaluate the different parameters of the physical condition.", [["the laboratories", "TEST", 297, 313], ["large", "OBSERVATION_MODIFIER", 37, 42]]], ["19 For this reason, in this period of confinement, it is essential to have valid and reliable tests to evaluate physical condition parameters.", [["reliable tests", "TEST", 85, 99], ["physical condition parameters", "TEST", 112, 141]]], ["Currently, there is no test to evaluate S-R with four consecutive and continuous self-loading exercises at low cost and with qualitative scales indicating different levels of S-R for both men and women.", [["S-R", "GENE_OR_GENE_PRODUCT", 40, 43], ["S-R", "GENE_OR_GENE_PRODUCT", 175, 178], ["men", "ORGANISM", 188, 191], ["women", "ORGANISM", 196, 201], ["men", "SPECIES", 188, 191], ["women", "SPECIES", 196, 201], ["test", "TEST", 23, 27], ["continuous self-loading exercises", "TREATMENT", 70, 103], ["qualitative scales", "TEST", 125, 143], ["no", "UNCERTAINTY", 20, 22]]], ["1 Consequently, this study's primary purpose was to determine the validity and reliability of the Muscular Fitness Test (MFT) to evaluate self-loading body strength-resistance in healthy and physically active young adults from 18 to 25 years old.", [["Muscular", "ANATOMY", 98, 106], ["body", "ANATOMY", 151, 155], ["body", "ORGANISM_SUBDIVISION", 151, 155], ["this study", "TEST", 16, 26], ["the Muscular Fitness Test", "TEST", 94, 119]]], ["As a secondary objective, the MFT qualitative scales were created to evaluate the different levels of body S-R in men and women.Research designResearch with a quantitative focus, exploratory-descriptive scope, non-experimental design of the predictive crosssectional type.", [["body", "ANATOMY", 102, 106], ["body", "ORGANISM_SUBDIVISION", 102, 106], ["S-R", "GENE_OR_GENE_PRODUCT", 107, 110], ["men", "ORGANISM", 114, 117], ["women", "ORGANISM", 122, 127], ["men", "SPECIES", 114, 117], ["women", "SPECIES", 122, 127], ["the MFT qualitative scales", "TEST", 26, 52], ["a quantitative focus", "PROBLEM", 157, 177], ["exploratory-descriptive scope", "TEST", 179, 208]]], ["22 To determine the validity and reliability of the MFT, five sessions separated by 48 h were executed: session 1) briefing, informed consent acceptance (google.docs \u00ae ) and anthropometric assessment; sessions 2 and 3) familiarization with exercises and MFT; session 4) first application of MFT, and session 5) second application of MFT (Fig. 1a ).ProceduresAs a first action, all participants who voluntarily accepted to participate in the study (non-probabilistic sample) were invited and gathered to be informed.", [["participants", "SPECIES", 381, 393], ["anthropometric assessment", "TEST", 174, 199], ["the study", "TEST", 437, 446]]], ["In the informative talk, the purpose and procedures of the study were clarified.", [["the study", "TEST", 55, 64]]], ["The inclusion criteria were that all participants should be healthy, physically active 23 and between 18 and 25 years old, while the exclusion criteria were: positive COVID-19 diagnosis, the prevalence of musculoskeletal injuries, pre-existing cardiac pathologies, abnormal respiratory and cardiac responses during the familiarization period and inability to perform MFT.", [["musculoskeletal", "ANATOMY", 205, 220], ["cardiac", "ANATOMY", 244, 251], ["respiratory", "ANATOMY", 274, 285], ["cardiac", "ANATOMY", 290, 297], ["musculoskeletal injuries", "DISEASE", 205, 229], ["cardiac pathologies", "DISEASE", 244, 263], ["participants", "ORGANISM", 37, 49], ["cardiac", "ORGAN", 244, 251], ["cardiac", "ORGAN", 290, 297], ["participants", "SPECIES", 37, 49], ["musculoskeletal injuries", "PROBLEM", 205, 229], ["pre-existing cardiac pathologies", "PROBLEM", 231, 263], ["abnormal respiratory and cardiac responses", "PROBLEM", 265, 307], ["musculoskeletal", "ANATOMY", 205, 220], ["injuries", "OBSERVATION", 221, 229], ["cardiac", "ANATOMY", 244, 251], ["pathologies", "OBSERVATION", 252, 263], ["cardiac", "ANATOMY", 290, 297]]], ["All participants were asked to refrain from physical activities that generate nervous or musculoskeletal fatigue 48 h before the measurements and to refrain from caffeine or any substance that could increase their metabolism during the assessment.", [["nervous", "ANATOMY", 78, 85], ["musculoskeletal", "ANATOMY", 89, 104], ["musculoskeletal fatigue", "DISEASE", 89, 112], ["caffeine", "CHEMICAL", 162, 170], ["caffeine", "CHEMICAL", 162, 170], ["nervous", "ANATOMICAL_SYSTEM", 78, 85], ["caffeine", "SIMPLE_CHEMICAL", 162, 170], ["participants", "SPECIES", 4, 16], ["musculoskeletal fatigue", "PROBLEM", 89, 112], ["caffeine", "TREATMENT", 162, 170], ["the assessment", "TEST", 232, 246]]], ["Finally, only those participants who accepted informed consent were subjected to MFT.", [["participants", "ORGANISM", 20, 32], ["participants", "SPECIES", 20, 32]]], ["All sessions were conducted virtually and synchronously with participants through the Zoom \u00ae platform.ParticipantsFour hundred eighty-nine (489) healthy and physically active young adults volunteered to participate in this study +Model APUNSM-335; No. of Pages 9 Validity and reliability of the Muscular Fitness ( Table 1 ).", [["Muscular", "ANATOMY", 295, 303], ["adults", "ORGANISM", 181, 187], ["participants", "SPECIES", 61, 73], ["Participants", "SPECIES", 102, 114], ["this study", "TEST", 218, 228]]], ["All participants were informed of the study objective and possible risks of the experiment.", [["participants", "SPECIES", 4, 16], ["the study objective", "TEST", 34, 53]]], ["Also, all participants accepted informed consent before the application of the protocols.", [["participants", "SPECIES", 10, 22], ["the protocols", "TREATMENT", 75, 88]]], ["The informed consent and the study wereMaterialsAnthropometric self-assessment In order to avoid physical contact, participants were asked to self-evaluate their height (cm) and weight (kg) with the following considerations: height was measured through a stadiometer from the feet to the vertex (Frankfort plane), while weight was evaluated through a digital scale, with participants barefoot, in shorts and wearing a light shirt.", [["feet", "ORGANISM_SUBDIVISION", 276, 280], ["participants", "SPECIES", 115, 127], ["participants", "SPECIES", 371, 383], ["the study", "TEST", 25, 34], ["height", "TEST", 225, 231], ["weight", "TEST", 320, 326], ["a digital scale", "TEST", 349, 364], ["feet", "ANATOMY", 276, 280], ["vertex", "ANATOMY_MODIFIER", 288, 294]]], ["In case the participants did not have access to these instruments, it was considered the last personal evaluation of theseStandardized warm-upFor both the first and second MFT evaluations, the warm-up consisted of four minutes (min) of upper and lower extremity joint mobility (flexions, extensions, adduction, and shoulder and hip abductions, respectively), 30 seconds (s) of Skipping, 30 s of heels to buttocks, 30 s of jumping with hip flexions, 30 s of jumping with ankle flexions (stiffness), and four min of gentle stretching.", [["lower extremity joint", "ANATOMY", 246, 267], ["shoulder", "ANATOMY", 315, 323], ["hip", "ANATOMY", 328, 331], ["buttocks", "ANATOMY", 404, 412], ["hip", "ANATOMY", 435, 438], ["ankle", "ANATOMY", 470, 475], ["participants", "ORGANISM", 12, 24], ["upper", "ORGANISM_SUBDIVISION", 236, 241], ["shoulder", "ORGANISM_SUBDIVISION", 315, 323], ["buttocks", "ORGANISM_SUBDIVISION", 404, 412], ["participants", "SPECIES", 12, 24], ["personal evaluation", "TEST", 94, 113], ["second MFT evaluations", "TEST", 165, 187], ["upper and lower extremity joint mobility", "PROBLEM", 236, 276], ["extensions", "TEST", 288, 298], ["adduction", "TEST", 300, 309], ["Skipping", "PROBLEM", 377, 385], ["hip flexions", "TEST", 435, 447], ["gentle stretching", "TREATMENT", 514, 531], ["upper", "ANATOMY_MODIFIER", 236, 241], ["lower", "ANATOMY_MODIFIER", 246, 251], ["extremity joint", "ANATOMY", 252, 267], ["shoulder", "ANATOMY", 315, 323], ["hip", "ANATOMY", 328, 331], ["heels", "ANATOMY", 395, 400], ["buttocks", "ANATOMY", 404, 412], ["hip flexions", "ANATOMY", 435, 447], ["ankle flexions", "ANATOMY", 470, 484], ["stretching", "OBSERVATION", 521, 531]]], ["After this warm-up and before running the MFT, there was a break of 5 min (Fig. 1b) .Muscular fitness testThe MFT is intended to evaluate the body's S-R with selfloading.", [["Muscular", "ANATOMY", 85, 93], ["body", "ANATOMY", 142, 146], ["body", "ORGANISM_SUBDIVISION", 142, 146], ["S-R", "GENE_OR_GENE_PRODUCT", 149, 152], ["Muscular fitness test", "TEST", 85, 106], ["selfloading", "PROBLEM", 158, 169]]], ["It consists of four tests that must be executed continuously and always in the following order: hip flexoextensions (sit-ups), push-ups, deep squats, and burpees.", [["hip", "ANATOMY", 96, 99], ["squats", "ANATOMY", 142, 148], ["hip", "ORGANISM_SUBDIVISION", 96, 99], ["four tests", "TEST", 15, 25], ["hip flexoextensions", "TREATMENT", 96, 115], ["hip", "ANATOMY", 96, 99], ["deep squats", "ANATOMY", 137, 148]]], ["Each one of the tests must be executed for 60 s.", [["the tests", "TEST", 12, 21]]], ["Each participant has to perform the greatest number of repetitions during this time; between each exercise, there is a 10 s micropause.", [["participant", "SPECIES", 5, 16]]], ["This micropause is intended for the participant to adopt the following exercise (Fig. 1b) .Muscular fitness testHip flexo-extensions (sit-ups): test that measures the S-R of the abdominal musculature.", [["Muscular", "ANATOMY", 91, 99], ["abdominal musculature", "ANATOMY", 178, 199], ["S-R", "GENE_OR_GENE_PRODUCT", 167, 170], ["abdominal musculature", "MULTI-TISSUE_STRUCTURE", 178, 199], ["participant", "SPECIES", 36, 47], ["Muscular fitness", "TEST", 91, 107], ["abdominal musculature", "ANATOMY", 178, 199]]], ["This test is executed starting from the dorsal decubitus position with both legs together and knees extended, both arms behind with elbows extended resting on the floor.", [["dorsal decubitus", "ANATOMY", 40, 56], ["legs", "ANATOMY", 76, 80], ["knees", "ANATOMY", 94, 99], ["elbows", "ANATOMY", 132, 138], ["dorsal decubitus", "ORGANISM_SUBDIVISION", 40, 56], ["legs", "ORGANISM_SUBDIVISION", 76, 80], ["knees", "ORGANISM_SUBDIVISION", 94, 99], ["elbows", "ORGANISM_SUBDIVISION", 132, 138], ["This test", "TEST", 0, 9], ["dorsal", "ANATOMY_MODIFIER", 40, 46], ["decubitus", "ANATOMY", 47, 56], ["both", "ANATOMY_MODIFIER", 71, 75], ["legs", "ANATOMY", 76, 80], ["knees", "ANATOMY", 94, 99], ["elbows", "ANATOMY", 132, 138]]], ["At first, the participant must bend his hips and knees until he is seated with his feet on the floor, his arms embracing the knees and his forehead exceeding the knees' line.", [["knees", "ANATOMY", 125, 130], ["forehead", "ANATOMY", 139, 147], ["knees", "ANATOMY", 162, 167], ["hips", "ORGANISM_SUBDIVISION", 40, 44], ["knees", "ORGANISM_SUBDIVISION", 49, 54], ["feet", "ORGANISM_SUBDIVISION", 83, 87], ["floor", "ORGANISM_SUBDIVISION", 95, 100], ["knees", "ORGANISM_SUBDIVISION", 125, 130], ["forehead", "ORGANISM_SUBDIVISION", 139, 147], ["participant", "SPECIES", 14, 25], ["hips", "ANATOMY", 40, 44], ["knees", "ANATOMY", 49, 54], ["knees", "ANATOMY", 125, 130], ["forehead", "ANATOMY", 139, 147], ["knees", "ANATOMY", 162, 167], ["' line", "OBSERVATION", 167, 173]]], ["He will then return to the starting position lying on his back until his shoulder blades touch the floor, knees fully extended, arms behind, and elbows fully extended (Fig. 2a) .", [["shoulder", "ANATOMY", 73, 81], ["knees", "ANATOMY", 106, 111], ["shoulder", "ORGANISM_SUBDIVISION", 73, 81], ["floor", "ORGANISM_SUBDIVISION", 99, 104], ["knees", "ORGANISM_SUBDIVISION", 106, 111], ["shoulder", "ANATOMY", 73, 81], ["knees", "ANATOMY", 106, 111], ["elbows", "ANATOMY", 145, 151]]], ["Push-ups: test that measures the S-R of the elbow extensors.", [["elbow", "ANATOMY", 44, 49], ["S-R", "GENE_OR_GENE_PRODUCT", 33, 36], ["elbow", "ORGANISM_SUBDIVISION", 44, 49], ["extensors", "ORGANISM_SUBDIVISION", 50, 59], ["test", "TEST", 10, 14], ["elbow extensors", "ANATOMY", 44, 59]]], ["This test is performed starting from the abdominal position, with elbows extended and palms of the hands resting on the floor at chest level, while the trunk, thighs, and legs must be aligned throughout the execution.", [["abdominal", "ANATOMY", 41, 50], ["elbows", "ANATOMY", 66, 72], ["palms", "ANATOMY", 86, 91], ["hands", "ANATOMY", 99, 104], ["chest", "ANATOMY", 129, 134], ["trunk", "ANATOMY", 152, 157], ["thighs", "ANATOMY", 159, 165], ["legs", "ANATOMY", 171, 175], ["abdominal", "ORGANISM_SUBDIVISION", 41, 50], ["elbows", "ORGANISM_SUBDIVISION", 66, 72], ["palms", "ORGANISM_SUBDIVISION", 86, 91], ["floor", "ORGANISM_SUBDIVISION", 120, 125], ["chest", "ORGANISM_SUBDIVISION", 129, 134], ["trunk", "ORGANISM_SUBDIVISION", 152, 157], ["thighs", "ORGANISM_SUBDIVISION", 159, 165], ["legs", "ORGANISM_SUBDIVISION", 171, 175], ["This test", "TEST", 0, 9], ["abdominal", "ANATOMY", 41, 50], ["elbows", "ANATOMY", 66, 72], ["palms", "OBSERVATION_MODIFIER", 86, 91], ["hands", "ANATOMY", 99, 104], ["chest", "ANATOMY", 129, 134], ["trunk", "ANATOMY", 152, 157], ["thighs", "ANATOMY", 159, 165], ["legs", "ANATOMY", 171, 175], ["aligned", "OBSERVATION", 184, 191]]], ["At first, the participant must bend the elbows symmetrically until reaching a lower angle of 90 \u2022 between the arm and forearm.", [["elbows", "ANATOMY", 40, 46], ["arm", "ANATOMY", 110, 113], ["forearm", "ANATOMY", 118, 125], ["elbows", "ORGANISM_SUBDIVISION", 40, 46], ["arm", "ORGANISM_SUBDIVISION", 110, 113], ["forearm", "ORGANISM_SUBDIVISION", 118, 125], ["participant", "SPECIES", 14, 25], ["elbows", "ANATOMY", 40, 46], ["arm", "ANATOMY", 110, 113], ["forearm", "ANATOMY", 118, 125]]], ["He will then extend his elbows to return to the starting position (Fig. 2b) .", [["elbows", "ORGANISM_SUBDIVISION", 24, 30], ["elbows", "ANATOMY", 24, 30]]], ["Deep squats: test that measures the S-R of the extensor muscles of the knees and hips.", [["extensor muscles", "ANATOMY", 47, 63], ["knees", "ANATOMY", 71, 76], ["S-R", "GENE_OR_GENE_PRODUCT", 36, 39], ["extensor muscles", "ORGAN", 47, 63], ["knees", "MULTI-TISSUE_STRUCTURE", 71, 76], ["Deep squats: test", "TEST", 0, 17], ["the S", "TEST", 32, 37], ["extensor muscles", "ANATOMY", 47, 63], ["knees", "ANATOMY", 71, 76], ["hips", "ANATOMY", 81, 85]]], ["This test is executed starting from the standing position with arms in front, elbows fully extended, and in front of the shoulders during the whole execution.", [["shoulders", "ANATOMY", 121, 130], ["elbows", "ORGANISM_SUBDIVISION", 78, 84], ["shoulders", "ORGANISM_SUBDIVISION", 121, 130], ["This test", "TEST", 0, 9], ["arms", "ANATOMY", 63, 67], ["elbows", "ANATOMY", 78, 84], ["shoulders", "ANATOMY", 121, 130]]], ["To start, the participant must bend his knees and hips symmetrically until reaching an angle of less than 90 \u2022 between the thighs and legs.", [["knees", "ANATOMY", 40, 45], ["thighs", "ANATOMY", 123, 129], ["legs", "ANATOMY", 134, 138], ["knees", "ORGANISM_SUBDIVISION", 40, 45], ["thighs", "ORGANISM_SUBDIVISION", 123, 129], ["legs", "ORGANISM_SUBDIVISION", 134, 138], ["participant", "SPECIES", 14, 25], ["knees", "ANATOMY", 40, 45], ["hips", "ANATOMY", 50, 54], ["symmetrically", "ANATOMY_MODIFIER", 55, 68], ["thighs", "ANATOMY", 123, 129], ["legs", "ANATOMY", 134, 138]]], ["He will then extend his knees and hips to return to the starting position (Fig. 2c) .", [["knees", "ANATOMY", 24, 29], ["knees", "ORGANISM_SUBDIVISION", 24, 29], ["knees", "ANATOMY", 24, 29], ["hips", "ANATOMY", 34, 38]]], ["Burpees: test that measures the S-R of the abdominal musculature, back, chest, arms and legs, simultaneously and in a coordinated manner.", [["abdominal musculature", "ANATOMY", 43, 64], ["back", "ANATOMY", 66, 70], ["chest", "ANATOMY", 72, 77], ["legs", "ANATOMY", 88, 92], ["S-R", "GENE_OR_GENE_PRODUCT", 32, 35], ["abdominal musculature", "ORGANISM_SUBDIVISION", 43, 64], ["chest", "ORGANISM_SUBDIVISION", 72, 77], ["legs", "ORGANISM_SUBDIVISION", 88, 92], ["abdominal musculature", "ANATOMY", 43, 64], ["back", "ANATOMY", 66, 70], ["chest", "ANATOMY", 72, 77], ["arms", "ANATOMY", 79, 83], ["legs", "ANATOMY", 88, 92]]], ["This test is executed starting from the standing position with the arms at the side of the body.", [["body", "ANATOMY", 91, 95], ["body", "ORGANISM_SUBDIVISION", 91, 95], ["This test", "TEST", 0, 9], ["arms", "ANATOMY", 67, 71], ["body", "ANATOMY", 91, 95]]], ["From that position, the participant descends to squatting position with the palms of the hands resting on the floor.", [["palms", "ANATOMY", 76, 81], ["palms", "ORGANISM_SUBDIVISION", 76, 81], ["floor", "ORGANISM_SUBDIVISION", 110, 115], ["participant", "SPECIES", 24, 35], ["position", "OBSERVATION_MODIFIER", 10, 18], ["hands", "ANATOMY", 89, 94]]], ["Afterward, the participant brings both legs back to extend the knees as far as possible, keeping the elbows extended and the hands' support parallel to the height of the shoulders.", [["legs", "ANATOMY", 39, 43], ["elbows", "ANATOMY", 101, 107], ["shoulders", "ANATOMY", 170, 179], ["legs", "ORGANISM_SUBDIVISION", 39, 43], ["knees", "ORGANISM_SUBDIVISION", 63, 68], ["elbows", "ORGANISM_SUBDIVISION", 101, 107], ["shoulders", "ORGANISM_SUBDIVISION", 170, 179], ["participant", "SPECIES", 15, 26], ["legs", "ANATOMY", 39, 43], ["knees", "ANATOMY", 63, 68], ["elbows", "ANATOMY", 101, 107], ["shoulders", "ANATOMY", 170, 179]]], ["Later, he returns to the squatting position and, from there, makes a vertical jump, keeping elbows extended and arms up and over the head.", [["head", "ANATOMY", 133, 137], ["elbows", "ORGANISM_SUBDIVISION", 92, 98], ["head", "ORGANISM_SUBDIVISION", 133, 137], ["a vertical jump", "PROBLEM", 67, 82], ["vertical jump", "OBSERVATION", 69, 82], ["elbows", "ANATOMY", 92, 98], ["head", "ANATOMY", 133, 137]]], ["Finally, he lands with his feet together and on tiptoes (Fig. 2d) .Muscular fitness testHeart rate: The current confinement situation meant that HR could not be evaluated with electronic devices that would ensure the reliability of the measurement.", [["Muscular", "ANATOMY", 67, 75], ["Heart", "ANATOMY", 88, 93], ["feet", "ORGANISM_SUBDIVISION", 27, 31], ["Heart", "ORGAN", 88, 93], ["Muscular fitness test", "TEST", 67, 88], ["Heart rate", "TEST", 88, 98], ["electronic devices", "TREATMENT", 176, 194], ["the measurement", "TEST", 232, 247], ["feet", "ANATOMY", 27, 31]]], ["Despite this and in order to estimate the intensity of the MFT, participants were asked to evaluate the heart rate in two moments (at rest and at the end of the MFT).", [["heart", "ANATOMY", 104, 109], ["heart", "ORGAN", 104, 109], ["participants", "SPECIES", 64, 76], ["the heart rate", "TEST", 100, 114], ["heart", "ANATOMY", 104, 109]]], ["To estimate the resting heart rate and the final heart rate, participants were asked to count the number of heartbeats in the carotid artery by 10 s (this value was multiplied by 6).", [["heart", "ANATOMY", 24, 29], ["heart", "ANATOMY", 49, 54], ["carotid artery", "ANATOMY", 126, 140], ["heart", "ORGAN", 24, 29], ["heart", "ORGAN", 49, 54], ["carotid artery", "MULTI-TISSUE_STRUCTURE", 126, 140], ["participants", "SPECIES", 61, 73], ["the resting heart rate", "TEST", 12, 34], ["heart", "ANATOMY", 24, 29], ["heart", "ANATOMY", 49, 54], ["carotid artery", "ANATOMY", 126, 140]]], ["25 The resting heart rate and final heart rate values were considered as resting heart rate (restHR) and final heart rate (FHR), respectively.", [["heart", "ANATOMY", 15, 20], ["heart", "ANATOMY", 36, 41], ["heart", "ANATOMY", 81, 86], ["heart", "ANATOMY", 111, 116], ["heart", "ORGAN", 15, 20], ["heart", "ORGAN", 36, 41], ["heart", "ORGAN", 81, 86], ["heart", "ORGAN", 111, 116], ["The resting heart rate", "TEST", 3, 25], ["final heart rate values", "TEST", 30, 53], ["resting heart rate", "TEST", 73, 91], ["final heart rate", "TEST", 105, 121], ["heart", "ANATOMY", 15, 20], ["heart", "ANATOMY", 36, 41], ["heart", "ANATOMY", 111, 116]]], ["On the other hand, to calculate the maximum heart rate (maxHR), the following formula was used: (208 \u2212 [0.7 \u00d7 age]) beats per min (bpm).", [["heart", "ANATOMY", 44, 49], ["heart", "ORGAN", 44, 49], ["the maximum heart rate", "TEST", 32, 54], ["heart", "ANATOMY", 44, 49]]], ["26 Thus, to calculate the term intensity associated with the reserve heart rate (resHR), the following formula was used: Final Intensity (% resHR) = ([FHR \u2212 restHR]/[maxHR \u2212 restHR]) \u00d7 100.", [["heart", "ANATOMY", 69, 74], ["heart", "ORGAN", 69, 74], ["the reserve heart rate", "TEST", 57, 79], ["restHR", "TEST", 157, 163], ["heart", "ANATOMY", 69, 74]]], ["26 Rating of Perceived Exertion (RPE): in order to evaluate the level of demand experienced by the participants at the end of the MFT, the RPE scale (1---10) was applied.", [["RPE", "ANATOMY", 139, 142], ["RPE", "TISSUE", 33, 36], ["RPE", "TISSUE", 139, 142], ["participants", "SPECIES", 99, 111], ["the RPE scale", "TEST", 135, 148]]], ["The normal distribution of the data was confirmed by the Shapiro---Wilk test (p > 0.05).", [["the Shapiro---Wilk test", "TEST", 53, 76], ["normal", "OBSERVATION", 4, 10], ["distribution", "OBSERVATION_MODIFIER", 11, 23]]], ["The MFT validity was determined by relating the mean values of FHR, Final Intensity (% of resHR), RPE, and the time of execution (4 min 30 s).", [["RPE", "TISSUE", 98, 101], ["The MFT validity", "TEST", 0, 16], ["RPE", "TEST", 98, 101]]], ["Acceptable reliability was determined as a CV < 10% and a ICC > 0.85.", [["a CV", "TEST", 41, 45], ["a ICC", "TEST", 56, 61]]], ["28 The t-tests for related samples and the Bland---Altman technique were used to evaluate the concordance between the MFT test and re-test.", [["the MFT test", "TEST", 114, 126], ["re-test", "TEST", 131, 138]]], ["All other statistical analyses were performed with SPSS software version 22.0 (SPSS, Chicago, IL, USA).", [["All other statistical analyses", "TEST", 0, 30], ["SPSS software version", "TEST", 51, 72], ["SPSS", "TEST", 79, 83]]], ["The significance level for all statistical analyses was p < 0.05.ResultsTo determine the validity and reliability of the MFT, 77 of the 489 participants were evaluated in two instances separated by 48 h (test and re-test).", [["participants", "ORGANISM", 140, 152], ["participants", "SPECIES", 140, 152], ["all statistical analyses", "TEST", 27, 51]]], ["The variables used to determine MFT validity were the FHR (bpm), final intensity (% of resHR) and RPE (scale 1---10).", [["RPE", "ANATOMY", 98, 101], ["RPE", "TISSUE", 98, 101], ["MFT validity", "TEST", 32, 44], ["RPE", "TEST", 98, 101], ["scale", "TEST", 103, 108]]], ["In relation to the post-exercise intensity, the analysis showed that the FHR was 172.", [["the post-exercise intensity", "TEST", 15, 42], ["the analysis", "TEST", 44, 56], ["the FHR", "TEST", 69, 76]]], ["The variables used to determine the MFT reliability were the number of repetitions performed in the four exercises and the sum of all the repetitions of the MFT in both the test and the re-test.", [["the MFT", "TEST", 153, 160], ["the test", "TEST", 169, 177], ["the re-test", "TEST", 182, 193]]], ["There was a maximum CV of 4.63% for the squats, while the minimum CV was 2.02% for the sit-ups.", [["a maximum CV", "TEST", 10, 22], ["the minimum CV", "TEST", 54, 68]]], ["Simultaneously, the lowest ICC was 0.92 in deep squats and burpees, while the highest ICC was 0.98 in push-ups.", [["deep squats", "ANATOMY", 43, 54], ["deep squats", "OBSERVATION", 43, 54]]], ["When women were analyzed separately (29 cases), a maximum CV of \u22121.26% was observed for burpees, while the minimum CV was 0.59% for total MFT repetitions.", [["women", "ORGANISM", 5, 10], ["women", "SPECIES", 5, 10], ["a maximum CV", "TEST", 48, 60], ["the minimum CV", "TEST", 103, 117], ["total MFT repetitions", "TEST", 132, 153]]], ["In parallel, the lowest ICC was 0.95 for burpees, while the highest ICC was 0.99 for push-ups.", [["parallel", "OBSERVATION_MODIFIER", 3, 11]]], ["When analyzing men separately (48 cases), a maximum CV of 6.74% was observed for deep squats, while the minimum CV was 3.42% for sit-ups; while the highest ICC was 0.95 for push-ups and the total number of repetitions in the MFT, while the lowest ICC was 0.90 for deep squats and burpees.", [["squats", "ANATOMY", 269, 275], ["men", "ORGANISM", 15, 18], ["men", "SPECIES", 15, 18], ["a maximum CV", "TEST", 42, 54], ["the minimum CV", "TEST", 100, 114]]], ["The CVs and ICCs of all analyses are reported in Table 2 and Fig. 3 .", [["The CVs", "TEST", 0, 7], ["all analyses", "TEST", 20, 32]]], ["Validity and reliability of the Muscular Fitness Test 7ResultsFor the creation of the MFT qualitative scales, the number of repetitions made in the four exercises and the sum of all the repetitions of the MFT were used (489 cases).", [["Muscular", "ANATOMY", 32, 40], ["the Muscular Fitness Test", "TEST", 28, 53]]], ["For the creation of these scales, the participants were evaluated in one instance (test).", [["participants", "ORGANISM", 38, 50], ["participants", "SPECIES", 38, 50]]], ["The different ranges and criteria are reported in Table 3 .DiscussionConcerning the main objective of the study, the four variables evaluated for the determination of the validity of the MFT (time, FHR, % of the resHR and RPE), showed that the MFT is valid to evaluate the corporal S-R with self-load in young healthy and physically active adults from 18 to 25 years.", [["RPE", "TISSUE", 222, 225], ["S-R", "GENE_OR_GENE_PRODUCT", 282, 285], ["the study", "TEST", 102, 111], ["FHR", "TEST", 198, 201], ["the MFT", "TEST", 240, 247], ["the corporal S", "TEST", 269, 283], ["different", "OBSERVATION_MODIFIER", 4, 13], ["ranges", "OBSERVATION_MODIFIER", 14, 20]]], ["Considering that the intensity of the exercise is the fundamental axis on which the metabolic predominance of the physical exercises turns, 26 the convergence of the FHR (172.7 bpm), the final intensity of the MFT (81.7% of the resHR), the RPE experienced by the participants (8.1 out of 10.0) 27 and the duration of the MFT (4 min 30 s), indicate that this test allows evaluating the muscular S-R.", [["RPE", "ANATOMY", 240, 243], ["muscular S-R.", "ANATOMY", 385, 398], ["RPE", "TISSUE", 240, 243], ["participants", "SPECIES", 263, 275], ["the FHR", "TEST", 162, 169], ["the MFT", "TEST", 206, 213], ["the MFT", "TEST", 317, 324], ["this test", "TEST", 353, 362], ["muscular", "ANATOMY", 385, 393]]], ["Specifically, it evaluates the capacity of work of the muscular fibers type I and IIa in the muscles involved in the different exercises.", [["muscular fibers", "ANATOMY", 55, 70], ["muscles", "ANATOMY", 93, 100], ["IIa", "GENE_OR_GENE_PRODUCT", 82, 85], ["muscles", "ORGAN", 93, 100], ["muscles", "ANATOMY", 93, 100]]], ["In parallel and considering the relationship between the resHR and the consumption of reserve oxygen, the MFT could be used to evaluate the state of the mixed aerobic-anaerobic metabolism.", [["oxygen", "CHEMICAL", 94, 100], ["oxygen", "CHEMICAL", 94, 100], ["oxygen", "SIMPLE_CHEMICAL", 94, 100], ["reserve oxygen", "TREATMENT", 86, 100], ["the mixed aerobic-anaerobic metabolism", "PROBLEM", 149, 187], ["anaerobic metabolism", "OBSERVATION", 167, 187]]], ["30 However, to reliably determine the energy metabolism involved in MFT, in addition to the final intensity of the MFT, a direct assessment of oxygen consumption 31 and a lactic threshold test 32 should also be applied.", [["oxygen", "CHEMICAL", 143, 149], ["oxygen", "CHEMICAL", 143, 149], ["oxygen", "SIMPLE_CHEMICAL", 143, 149], ["a direct assessment", "TEST", 120, 139], ["oxygen consumption", "TEST", 143, 161], ["a lactic threshold test", "TEST", 169, 192]]], ["In turn, the CV, ICC, and SEM for the four exercises and the sum of all the MFT repetitions (CV: 2.02---4.63%; ICC: 0.92---0.98; SEM: 0.19---0.77), indicate that the MFT presents a high degree of reliability.", [["the MFT repetitions", "TEST", 72, 91], ["CV", "TEST", 93, 95], ["ICC", "TEST", 111, 114], ["SEM", "TEST", 129, 132], ["high degree", "OBSERVATION_MODIFIER", 181, 192]]], ["28 Before the application of MFT, and as far as knowledge goes, there were only validation studies for tests that evaluated S-R muscle groups or body segments in isolation.", [["muscle", "ANATOMY", 128, 134], ["body", "ANATOMY", 145, 149], ["body segments", "MULTI-TISSUE_STRUCTURE", 145, 158], ["validation studies", "TEST", 80, 98], ["tests", "TEST", 103, 108], ["body segments in isolation", "PROBLEM", 145, 171], ["muscle", "ANATOMY", 128, 134], ["body segments", "ANATOMY", 145, 158]]], ["6, 13 In this sense, the study by Bianco et al. 6 examined the sit up test to evaluate muscular S-R in sedentary individuals of both sexes; in this research, upper-extremity S-R was also evaluated through push-ups and lower-extremity S-R through squats; At the end of the study and considering the low correlation coefficient between the different tests (r 2 = 0.23; r = 0.49; p < 0.001 for the sit up test versus the push-up test; r 2 = 0.31; r = 0.57; p < 0.001 for the sit up test versus the weighted squat test), the researchers concluded that it is not optimal to use a single test for the global evaluation of muscular S-R.", [["muscular", "ANATOMY", 87, 95], ["muscular S-R.", "ANATOMY", 616, 629], ["S-R", "GENE_OR_GENE_PRODUCT", 96, 99], ["S-R", "GENE_OR_GENE_PRODUCT", 174, 177], ["the study", "TEST", 21, 30], ["the sit up test", "TEST", 59, 74], ["muscular S", "TEST", 87, 97], ["the study", "TEST", 268, 277], ["the different tests", "TEST", 334, 353], ["the sit up test", "TEST", 391, 406], ["the push-up test", "TEST", 414, 430], ["the sit up test", "TEST", 468, 483], ["the weighted squat test", "TEST", 491, 514], ["a single test", "TEST", 573, 586], ["the global evaluation", "TEST", 591, 612], ["upper-extremity", "ANATOMY", 158, 173], ["lower", "ANATOMY_MODIFIER", 218, 223], ["extremity", "ANATOMY", 224, 233], ["muscular", "ANATOMY", 616, 624]]], ["In the same line, Nikolaidis et al. 13 evaluated the most used methods for the election of different tests that measure muscular S-R, concluding that push-ups and squats, both timed, are the most recurrent exercises to evaluate that physical capacity.", [["muscular", "ANATOMY", 120, 128], ["different tests", "TEST", 91, 106]]], ["The same authors conclude that the election of a test to evaluate muscular S-R should consider the most relevant specific muscle groups associated with the specific tasks.", [["muscular", "ANATOMY", 66, 74], ["muscle", "ANATOMY", 122, 128], ["muscle", "ORGAN", 122, 128], ["a test", "TEST", 47, 53], ["muscular S", "TEST", 66, 76]]], ["13 Based on this background, MFT is a pioneer in the evaluation of body S-R with self-loading; besides, it is a tool that can be used by Physical Education teachers, technicians and professionals of Physical Activity and Sport, simply, remotely and synchronously (Zoom \u00ae or other digital platforms), even more in this period of confinement generated by the COVID-19.", [["body", "ANATOMY", 67, 71], ["body", "ORGANISM_SUBDIVISION", 67, 71], ["the evaluation", "TEST", 49, 63], ["body S", "TEST", 67, 73], ["self-loading", "TREATMENT", 81, 93], ["the COVID", "TEST", 353, 362]]], ["18 Concerning the secondary objective of the study, after calculating percentiles for all exercises and the sum of all MFT repetitions, for both women and men, two qualitative scales were constructed for the evaluation of body S-R with self-loading in healthy young adults from 18 to 25 years old.", [["body", "ANATOMY", 222, 226], ["women", "ORGANISM", 145, 150], ["men", "ORGANISM", 155, 158], ["body", "ORGANISM_SUBDIVISION", 222, 226], ["women", "SPECIES", 145, 150], ["men", "SPECIES", 155, 158], ["the study", "TEST", 41, 50], ["all exercises", "TREATMENT", 86, 99], ["all MFT repetitions", "TEST", 115, 134], ["the evaluation", "TEST", 204, 218]]], ["These scales allow us to identify the level of muscular S-R in a general way and by segments; in addition, it will allow us to monitor the advances of this physical capacity product of the physical training.", [["muscular", "ANATOMY", 47, 55]]], ["About the latter, Lesinski et al. 12 characterized the dose-response relationship of training associated with muscular S-R in athletes; the researchers showed a moderate effect size (ES) of this type of training on vertical jump (ES: 0.8---1.09) and a small ES on the linear velocity of specific sports (ES: 0.58---0.75).", [["muscular", "ANATOMY", 110, 118], ["muscular S", "TEST", 110, 120], ["a moderate effect size", "PROBLEM", 159, 181], ["vertical jump", "TEST", 215, 228], ["a small ES", "PROBLEM", 250, 260], ["ES", "TEST", 304, 306], ["moderate", "OBSERVATION_MODIFIER", 161, 169], ["effect", "OBSERVATION_MODIFIER", 170, 176], ["size", "OBSERVATION_MODIFIER", 177, 181], ["small", "OBSERVATION_MODIFIER", 252, 257], ["linear", "OBSERVATION_MODIFIER", 268, 274], ["velocity", "OBSERVATION_MODIFIER", 275, 283]]], ["At the same time, the same researchers stated that a training period longer than 23 weeks, which includes a minimum of 6 series, 6---8 exercises and intensity between 80 and 89% with a 3---4 min break are effective ways to improve muscle S-R (ES: 2.09---3.40).", [["muscle", "ANATOMY", 231, 237], ["muscle", "ORGAN", 231, 237], ["S-R", "GENE_OR_GENE_PRODUCT", 238, 241], ["intensity", "TEST", 149, 158], ["muscle S", "TEST", 231, 239], ["muscle", "ANATOMY", 231, 237]]], ["12Methodological limitationsConsidering that carbohydrate metabolism is the energy pathway that mainly supports the execution of MFT (transition aerobic-anaerobic zones), 26 it would be essential to evaluate post-exercise and recovery blood lactate ([La]) concentrations, 32 as well as recovery HR with electronic devices.", [["blood", "ANATOMY", 235, 240], ["lactate", "CHEMICAL", 241, 248], ["carbohydrate", "CHEMICAL", 45, 57], ["lactate", "CHEMICAL", 241, 248], ["carbohydrate", "SIMPLE_CHEMICAL", 45, 57], ["blood", "ORGANISM_SUBSTANCE", 235, 240], ["lactate", "SIMPLE_CHEMICAL", 241, 248], ["blood lactate", "TEST", 235, 248], ["electronic devices", "TREATMENT", 303, 321]]], ["Unfortunately, given the modality of MFT execution to validate this study (through video call using the Zoom \u00ae platform), it was not possible to evaluate this variable.ConclusionConsidering the time of execution of the MFT (4 min 30 s), the final intensity (% of resHR), RPE, CV, ICC, and SEM, it is concluded that the MFT is valid and reliable to evaluate the body S-R with self-loading in healthy and physically active young adults between 18 and 25 years old.Practical applicationsFor trainers who apply the MFT, it is recommended to consider the following aspects before applying the test: (a) have a period of familiarization with the participants, (b) correct recurrent errors of execution, including the extension of body segments and execution in planes and vectors indicated for each exercise, (c) teach and use the RPE scale previously.", [["RPE", "ANATOMY", 271, 274], ["body", "ANATOMY", 361, 365], ["body", "ANATOMY", 724, 728], ["RPE", "ANATOMY", 825, 828], ["RPE", "TISSUE", 271, 274], ["body", "ORGANISM_SUBDIVISION", 724, 728], ["RPE", "TISSUE", 825, 828], ["participants", "SPECIES", 640, 652], ["this study", "TEST", 63, 73], ["the MFT", "TEST", 215, 222], ["RPE", "TEST", 271, 274], ["Practical applications", "TREATMENT", 462, 484], ["recurrent errors of execution", "PROBLEM", 666, 695], ["execution in planes and vectors", "TREATMENT", 742, 773], ["the RPE scale", "TEST", 821, 834]]], ["During the MFT execution, it is recommended to consider the following aspects: (a) verbally encourage participants to perform as many repetitions as possible in each exercise, and (b) correct any poorly performed exercise.", [["participants", "SPECIES", 102, 114]]], ["At the end of the MFT, it is suggested to consider the following: (a) evaluate the final and recovery HR with some electronic device, (b) evaluate the post-stress and recovery lactate concentrations, and (c) record the participants' RPE.Practical applicationsFor the interpretation of the MFT results, the qualitative scale allows evaluating the general S-R (sum of all the repetitions executed in the test) and the body segments in better or worse condition.", [["RPE", "ANATOMY", 233, 236], ["body", "ANATOMY", 416, 420], ["lactate", "CHEMICAL", 176, 183], ["lactate", "CHEMICAL", 176, 183], ["lactate", "SIMPLE_CHEMICAL", 176, 183], ["RPE", "TISSUE", 233, 236], ["body", "ORGANISM_SUBDIVISION", 416, 420], ["participants", "SPECIES", 219, 231], ["some electronic device", "TREATMENT", 110, 132], ["recovery lactate concentrations", "TEST", 167, 198], ["Practical applications", "TREATMENT", 237, 259], ["the qualitative scale", "TEST", 302, 323], ["the test", "TEST", 398, 406]]], ["For example, a participant may have a ''very good'' general S-R, but the S-R of the elbows' flexo-extensor muscles may be ''poor.''", [["elbows", "ANATOMY", 84, 90], ["flexo-extensor muscles", "ANATOMY", 92, 114], ["S-R", "GENE_OR_GENE_PRODUCT", 60, 63], ["S-R", "GENE_OR_GENE_PRODUCT", 73, 76], ["elbows", "ORGANISM_SUBDIVISION", 84, 90], ["flexo-extensor muscles", "TISSUE", 92, 114], ["participant", "SPECIES", 15, 26], ["the S", "TEST", 69, 74], ["elbows", "ANATOMY", 84, 90], ["extensor muscles", "ANATOMY", 98, 114]]], ["This last aspect could indicate the guidelines for a possible physical training program oriented to the muscular S-R.Future studiesFuture studies that consider the application of MFT should include evaluation of post-effort [La] (32) , an evaluation of VO 2max in the laboratory for participants (31) , FHR, and recovery HR with electronic devices.", [["muscular", "ANATOMY", 104, 112], ["participants", "SPECIES", 283, 295], ["physical training program", "TREATMENT", 62, 87], ["Future studies", "TEST", 131, 145], ["evaluation", "TEST", 198, 208], ["an evaluation of VO 2max", "TEST", 236, 260], ["FHR", "TEST", 303, 306], ["electronic devices", "TREATMENT", 329, 347]]], ["In this way, the doubt of the predominant metabolism during the test execution and the ventilatory implication in the results will be cleared up.Conflict of interestThe authors declare no conflict of interest.", [["the predominant metabolism", "PROBLEM", 26, 52], ["the test execution", "TEST", 60, 78], ["predominant", "OBSERVATION_MODIFIER", 30, 41], ["metabolism", "OBSERVATION", 42, 52]]]], "74101832f6633fe1442eb97b40134582d999978e": [["Do we need to conserve parasite species?Pandas, tigers, right whales and gorillas are emblematic and charismatic species worldwide and a consensus exists for the need of their conservation.", [["right whales", "ANATOMY", 56, 68], ["gorillas", "ORGANISM", 73, 81], ["parasite species", "PROBLEM", 23, 39], ["Pandas", "PROBLEM", 40, 46], ["emblematic", "PROBLEM", 86, 96], ["charismatic species", "PROBLEM", 101, 120], ["tigers", "OBSERVATION_MODIFIER", 48, 54], ["right", "ANATOMY_MODIFIER", 56, 61], ["gorillas", "OBSERVATION_MODIFIER", 73, 81]]], ["The same is true for economically important species such as salmonids and sturgeons.", [["sturgeons", "ANATOMY", 74, 83], ["sturgeons", "CANCER", 74, 83]]], ["But do we really need the conservation of parasitic species?", [["parasitic species", "PROBLEM", 42, 59], ["parasitic species", "OBSERVATION", 42, 59]]], ["During our childhood, we all have favourite stuffed animals (representing one of these emblematic species) we take to sleep.", [["these emblematic species", "TREATMENT", 81, 105]]], ["However, do you ever see a child squeezing a stuffed worm, flea or tick?", [["child", "ORGANISM", 27, 32], ["worm", "ORGANISM_SUBDIVISION", 53, 57], ["flea", "ORGANISM_SUBDIVISION", 59, 63]]], ["The lack of affect for cryptic species and the perception of parasites as disgusting creatures among the public certainly leads to a disinterest among governmental and conservation agencies to preserve them.", [["cryptic species", "PROBLEM", 23, 38], ["parasites", "PROBLEM", 61, 70]]], ["Five years later he pleaded once more for parasite conservation in an editorial that appeared in \"Conservation Biology\" (Windsor 1995) .", [["parasite conservation", "TREATMENT", 42, 63]]], ["During the same time, the ominous term \"co-extinction\" was proposed to characterize the dual extinction of a host and its specialized parasite (Stork and Lyal 1993) .", [["the ominous term \"co-extinction", "PROBLEM", 22, 53], ["ominous", "OBSERVATION_MODIFIER", 26, 33]]], ["Despite the passing of 15 years since these passionate declarations and the exponential increase of an interest in conservation biology, we can point out that parasitic species are far from being in a leading position among current conservation priorities.", [["parasitic species", "PROBLEM", 159, 176], ["exponential", "OBSERVATION_MODIFIER", 76, 87], ["increase", "OBSERVATION_MODIFIER", 88, 96], ["parasitic species", "OBSERVATION", 159, 176]]], ["Very few parasites are listed on the IUCN Red List of Threatened Species (IUCN, 2003; Whiteman and Parker 2005) .", [["Very few parasites", "PROBLEM", 0, 18], ["few", "OBSERVATION_MODIFIER", 5, 8], ["parasites", "OBSERVATION", 9, 18]]], ["Some parasite extinctions have been even intentionally provoked as revealed by the will to remove parasites from hosts in captive breeding programs (Stork and Lyal 1993) .Do we need to conserve parasite species?To convince resource managers that parasites are an important component of all ecosystems, the following arguments, which mainly rely on their potential utilitarian effects, are advocated by the parasites' defenders.", [["Some parasite extinctions", "PROBLEM", 0, 25], ["parasites", "PROBLEM", 98, 107], ["parasite species", "PROBLEM", 194, 210], ["parasites", "PROBLEM", 246, 255], ["parasite", "OBSERVATION_MODIFIER", 5, 13], ["extinctions", "OBSERVATION", 14, 25]]], ["First, parasites are living organisms and are de facto part of biodiversity.", [["parasites", "PROBLEM", 7, 16], ["parasites", "OBSERVATION", 7, 16]]], ["Moreover, parasites could maintain biodiversity by mediating competitive interactions between different members of an ecosystem.", [["parasites", "PROBLEM", 10, 19]]], ["Because the rate of molecular evolution is usually faster in parasite DNA than that within the homologous loci of their hosts (Moran et al. 1995; Nieberding et al. 2004) , the study of the evolution of parasite DNA sequences could provide valuable information on past population dynamics, evolutionary history and current demographic processes of endangered hosts (Whiteman and Parker 2005) .", [["DNA", "CELLULAR_COMPONENT", 70, 73], ["DNA", "CELLULAR_COMPONENT", 211, 214], ["parasite DNA sequences", "DNA", 202, 224], ["parasite DNA", "PROBLEM", 61, 73], ["the study", "TEST", 172, 181], ["parasite DNA sequences", "PROBLEM", 202, 224], ["molecular evolution", "OBSERVATION", 20, 39], ["faster", "OBSERVATION_MODIFIER", 51, 57]]], ["Parasites could thus be used as a biological \"magnifying glass\" (Nieberding et al. 2004) .", [["Parasites", "CELL", 0, 9], ["Parasites", "PROBLEM", 0, 9]]], ["Another utilitarian effect of parasites is their potential use as indicators of environ-mental quality and ecosystem health (Marcogliese 2005) .", [["parasites", "PROBLEM", 30, 39], ["parasites", "OBSERVATION", 30, 39]]], ["Indeed, parasites may be used as accumulation indicators of heavy metal contamination, particularly in aquatic ecosystems (Sures et al. 1999 ).", [["parasites", "PROBLEM", 8, 17], ["heavy metal contamination", "PROBLEM", 60, 85], ["parasites", "OBSERVATION", 8, 17], ["heavy", "OBSERVATION_MODIFIER", 60, 65], ["metal contamination", "OBSERVATION", 66, 85]]], ["In addition, parasite species and composition revealed perturbations in ecosystem structure and function (Marcogliese 2005) .", [["parasite species", "TEST", 13, 29], ["perturbations in ecosystem structure", "PROBLEM", 55, 91], ["parasite species", "OBSERVATION", 13, 29], ["ecosystem structure", "OBSERVATION", 72, 91]]], ["Furthermore, the use of parasite in human medicine is a new promising field of investigation, as illustrated by the use of helminths as therapeutic agents for inflammatory disease (Hunter and McKay 2004 ).Parasite resistance and stress 2.Environmental stress and parasite susceptibilityWild animals in their natural habitat have to cope not only with predictable environmental changes such as the cycles of seasons and their associated modifications in resource availability and temperature but also with unpredictable events such as catastrophes, spread of new diseases and human disturbances.", [["inflammatory disease", "DISEASE", 159, 179], ["human", "ORGANISM", 36, 41], ["human", "ORGANISM", 575, 580], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 575, 580], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 575, 580], ["parasite in human medicine", "TREATMENT", 24, 50], ["therapeutic agents", "TREATMENT", 136, 154], ["inflammatory disease", "PROBLEM", 159, 179], ["Parasite resistance", "TEST", 205, 224], ["stress 2", "PROBLEM", 229, 237], ["Environmental stress and parasite susceptibility", "PROBLEM", 238, 286], ["unpredictable events", "PROBLEM", 505, 525], ["catastrophes", "PROBLEM", 534, 546], ["new diseases", "PROBLEM", 558, 570], ["human disturbances", "PROBLEM", 575, 593], ["stress", "OBSERVATION", 229, 235], ["parasite susceptibility", "OBSERVATION", 263, 286], ["catastrophes", "OBSERVATION", 534, 546], ["new", "OBSERVATION_MODIFIER", 558, 561], ["diseases", "OBSERVATION", 562, 570]]], ["Whereas animals react adaptively by behavioural and physiological modifications to predictable changes, unpredictable disturbances may have negative effects on population dynamics of living organisms.", [["predictable changes", "PROBLEM", 83, 102], ["unpredictable disturbances", "PROBLEM", 104, 130], ["living organisms", "PROBLEM", 183, 199]]], ["Increasingly rapid disappearing and fragmentation of habitats, which may be considered as unpredictable environmental changes, translates in a cascade of negative effects and can result in physiological stress on animals (Suorsa et al. 2003 (Suorsa et al. , 2004 .", [["Increasingly rapid disappearing and fragmentation of habitats", "PROBLEM", 0, 61], ["physiological stress", "PROBLEM", 189, 209], ["rapid", "OBSERVATION_MODIFIER", 13, 18], ["disappearing", "OBSERVATION_MODIFIER", 19, 31], ["fragmentation", "OBSERVATION_MODIFIER", 36, 49], ["may be considered", "UNCERTAINTY", 69, 86]]], ["The first physiological responses of an animal to stressful stimuli include cardiovascular effects and a hormonal response involving synthesis and secretion of glucocorticosteroids (Romero 2004) .", [["cardiovascular", "ANATOMY", 76, 90], ["cardiovascular", "ANATOMICAL_SYSTEM", 76, 90], ["glucocorticosteroids", "SIMPLE_CHEMICAL", 160, 180], ["stressful stimuli", "TEST", 50, 67], ["cardiovascular effects", "PROBLEM", 76, 98], ["a hormonal response", "PROBLEM", 103, 122], ["synthesis and secretion of glucocorticosteroids", "TREATMENT", 133, 180]]], ["Consequently, a corticosteroid response might be a good indicator of a stress response (Hofer and East 1998) .", [["a corticosteroid response", "PROBLEM", 14, 39], ["a stress response", "PROBLEM", 69, 86]]], ["It is, therefore, not surprising that corticosteroid level is measured in many studies in ecology and conservation biology that have evaluated the effect of different environmental and human perturbations on the stress level of wild animals (Creel et al. 1997; Creel et al. 2002; Mostl and Palme 2002; Romero 2004; Palme et al. 2005) .", [["corticosteroid", "SIMPLE_CHEMICAL", 38, 52], ["human", "ORGANISM", 185, 190], ["human", "SPECIES", 185, 190], ["human", "SPECIES", 185, 190], ["corticosteroid level", "TEST", 38, 58], ["Mostl", "TEST", 280, 285], ["Romero", "TEST", 302, 308]]], ["The consequences of a stress response on parasite resistance are complex and alter host immunocompetence in different ways (Apanius 1998 ).", [["a stress response", "PROBLEM", 20, 37], ["parasite resistance", "PROBLEM", 41, 60], ["stress response", "OBSERVATION", 22, 37], ["parasite resistance", "OBSERVATION", 41, 60]]], ["The immune system appears to be down regulated under stressful environmental conditions (von Holst 1998), particularly under severe chronic stress with prolonged periods of high cortisol concentrations (Mostl and Palme 2002) .", [["immune system", "ANATOMY", 4, 17], ["cortisol", "CHEMICAL", 178, 186], ["cortisol", "CHEMICAL", 178, 186], ["cortisol", "SIMPLE_CHEMICAL", 178, 186], ["severe chronic stress", "PROBLEM", 125, 146], ["high cortisol concentrations", "PROBLEM", 173, 201], ["severe", "OBSERVATION_MODIFIER", 125, 131], ["chronic", "OBSERVATION_MODIFIER", 132, 139], ["stress", "OBSERVATION", 140, 146]]], ["Stress stimuli may arise due to different factors in a perturbed environment.", [["Stress stimuli", "TEST", 0, 14]]], ["Habitat fragmentation may be related to chronic food shortage (Zanette et al. 2000) .", [["Habitat fragmentation", "PROBLEM", 0, 21], ["fragmentation", "OBSERVATION", 8, 21], ["may be related to", "UNCERTAINTY", 22, 39], ["chronic", "OBSERVATION_MODIFIER", 40, 47]]], ["Thus degradation of environmental conditions may decrease resource availability that in turn affects body condition and immune defences (Chandra and Newberne 1977; Klasing 1998; Christe et al. 2003) .", [["body", "ANATOMY", 101, 105], ["body", "ORGANISM_SUBDIVISION", 101, 105], ["environmental conditions", "PROBLEM", 20, 44]]], ["As body condition is usually positively correlated with immune defences , individuals with poor body condition will be especially vulnerable to attacks of parasites Christe et al. 2000) .", [["body", "ANATOMY", 3, 7], ["body", "ANATOMY", 96, 100], ["body", "ORGANISM_SUBDIVISION", 3, 7], ["body", "ORGANISM_SUBDIVISION", 96, 100], ["immune defences", "PROBLEM", 56, 71], ["poor body condition", "PROBLEM", 91, 110], ["parasites", "PROBLEM", 155, 164]]], ["Edge effect due to fragmentation may also be a source of stress because predators may have easy access to dense forest patches which were previously inaccessible.", [["Edge effect", "PROBLEM", 0, 11], ["fragmentation", "PROBLEM", 19, 32], ["stress", "PROBLEM", 57, 63], ["dense forest patches", "PROBLEM", 106, 126], ["fragmentation", "OBSERVATION", 19, 32], ["dense", "OBSERVATION_MODIFIER", 106, 111], ["forest patches", "OBSERVATION", 112, 126]]], ["It has been experimentally demonstrated that exposure to predators reduced the ability of hosts to cope with parasitism mediated through effects on immune function (Navarro et al. 2004) .", [["parasitism", "PROBLEM", 109, 119], ["immune function", "TREATMENT", 148, 163]]], ["Consequently parasitism may be favoured in fragmented habitat through the effect of predators.", [["parasitism", "PROBLEM", 13, 23], ["parasitism", "OBSERVATION", 13, 23], ["may be", "UNCERTAINTY", 24, 30], ["fragmented", "OBSERVATION_MODIFIER", 43, 53], ["habitat", "OBSERVATION", 54, 61]]], ["Thus, parasites, which can also be considered as an environmental stressor, may reinforce the effect of habitat degradation and participate in the reduction of a population.Parasite resistance and stress 2.Environmental stress and parasite susceptibilityIn addition to habitat degradation and fragmentation, anthropogenic factors such as environmental pollution, hunting, tourism and leisure activities exert a negative pressure on wildlife and are thought to cause stress (Fowler 1999; Mullner et al. 2004) .", [["parasites", "PROBLEM", 6, 15], ["habitat degradation", "TREATMENT", 104, 123], ["Parasite resistance", "TEST", 173, 192], ["stress 2", "PROBLEM", 197, 205], ["Environmental stress and parasite susceptibility", "PROBLEM", 206, 254], ["habitat degradation", "PROBLEM", 269, 288], ["fragmentation", "PROBLEM", 293, 306], ["anthropogenic factors", "PROBLEM", 308, 329], ["stress", "PROBLEM", 466, 472], ["parasites", "OBSERVATION", 6, 15], ["stress", "OBSERVATION", 197, 203], ["parasite susceptibility", "OBSERVATION", 231, 254], ["habitat degradation", "OBSERVATION", 269, 288], ["fragmentation", "OBSERVATION", 293, 306], ["anthropogenic factors", "OBSERVATION", 308, 329]]], ["Clearly, more studies are needed to investigate the relationship between anthropogenic factors, level of stress and parasitism in endangered populations.Review of theory on parasitism and extinction risksConservation biology deals with two major paradigms: population invasion and population decline.", [["stress", "PROBLEM", 105, 111], ["parasitism in endangered populations", "PROBLEM", 116, 152], ["parasitism", "PROBLEM", 173, 183], ["extinction risks", "PROBLEM", 188, 204], ["population invasion", "PROBLEM", 257, 276], ["population decline", "PROBLEM", 281, 299], ["parasitism", "OBSERVATION", 116, 126], ["endangered populations", "OBSERVATION", 130, 152], ["parasitism", "OBSERVATION", 173, 183], ["population", "OBSERVATION_MODIFIER", 257, 267], ["invasion", "OBSERVATION", 268, 276], ["population", "OBSERVATION_MODIFIER", 281, 291], ["decline", "OBSERVATION_MODIFIER", 292, 299]]], ["Both are related to each other (i.e. decline may be a result of an invasion) and both emphasize the potential roles of parasites and/or pathogens (Prenter et al. 2004) .Review of theory on parasitism and extinction risksTheoretical, experimental and empirical studies have established clearly that parasites play important roles in regulating population dynamics (Scott 1987; Scott and Dobson 1989; Albon et al. 2002; Rosa et al. in this volume) and structuring free-living communities (Minchella and Scott 1991; Morand and Arias Gonzalez 1997; Hudson and Greenman 1998; Tompkins et al. 2001) .", [["an invasion", "PROBLEM", 64, 75], ["parasites", "PROBLEM", 119, 128], ["pathogens", "PROBLEM", 136, 145], ["parasitism", "PROBLEM", 189, 199], ["extinction risks", "PROBLEM", 204, 220], ["empirical studies", "TEST", 250, 267], ["invasion", "OBSERVATION", 67, 75], ["parasites", "OBSERVATION", 119, 128], ["parasitism", "OBSERVATION", 189, 199], ["free", "OBSERVATION_MODIFIER", 462, 466]]], ["Parasites then have a large impact on biological conservation (Dobson and May 1988; McCallum and Dobson 1995; Sasal et al. 2000) , as parasites and pathogens may compromise reintroduction or translocation programs (Viggers et al. 1993) .", [["Parasites", "PROBLEM", 0, 9], ["parasites", "PROBLEM", 134, 143], ["pathogens", "PROBLEM", 148, 157], ["large", "OBSERVATION_MODIFIER", 22, 27]]], ["They may have a higher impact on threatened species generally characterized by a lower level of genetic variability, particularly on genes associated to immune system (Hedrick, 2003) .Threshold in host-parasite population dynamicsSmall-sized host populations may be prone to extinction due to stochastic events.", [["immune system", "ANATOMY", 153, 166], ["threatened species", "PROBLEM", 33, 51], ["a lower level of genetic variability", "PROBLEM", 79, 115], ["Small-sized host populations", "PROBLEM", 230, 258], ["stochastic events", "PROBLEM", 293, 310], ["higher", "OBSERVATION_MODIFIER", 16, 22], ["genetic variability", "OBSERVATION", 96, 115], ["parasite", "OBSERVATION_MODIFIER", 202, 210], ["Small", "OBSERVATION_MODIFIER", 230, 235], ["-sized", "OBSERVATION_MODIFIER", 235, 241], ["host populations", "OBSERVATION", 242, 258]]], ["Several processes, including the Allee effect ; see below), may increase the probability of extinction of small populations.", [["Several processes", "PROBLEM", 0, 17], ["small populations", "PROBLEM", 106, 123], ["extinction", "OBSERVATION_MODIFIER", 92, 102], ["small", "OBSERVATION_MODIFIER", 106, 111], ["populations", "OBSERVATION_MODIFIER", 112, 123]]], ["These processes operate when host population size decreases to under a critical or threshold level, below which populations are almost doomed.", [["size", "OBSERVATION_MODIFIER", 45, 49]]], ["Population viability analysis is one approach that has been developed for management purposes of small-sized endangered populations.Threshold in host-parasite population dynamicsThreshold size has been also extensively studied in the case of hostparasite dynamics (Dobson 1989) .", [["Population viability analysis", "TEST", 0, 29], ["small-sized endangered populations", "PROBLEM", 97, 131], ["small", "OBSERVATION_MODIFIER", 97, 102], ["sized", "OBSERVATION_MODIFIER", 103, 108], ["endangered", "OBSERVATION_MODIFIER", 109, 119], ["populations", "OBSERVATION_MODIFIER", 120, 131], ["parasite", "OBSERVATION_MODIFIER", 150, 158], ["size", "OBSERVATION_MODIFIER", 188, 192]]], ["The basic reproductive number, R 0 , is the major concept in host-parasite population dynamics.", [["reproductive", "OBSERVATION_MODIFIER", 10, 22], ["number", "OBSERVATION_MODIFIER", 23, 29], ["parasite population", "OBSERVATION", 66, 85]]], ["This quantity is defined as the number of new infections occurring after introduction of one parasite, or one infected host, into a na\u00efve and susceptible host population.", [["infections", "DISEASE", 46, 56], ["new infections", "PROBLEM", 42, 56], ["number", "OBSERVATION_MODIFIER", 32, 38], ["new", "OBSERVATION_MODIFIER", 42, 45], ["infections", "OBSERVATION", 46, 56], ["susceptible", "OBSERVATION_MODIFIER", 142, 153], ["host population", "OBSERVATION", 154, 169]]], ["R 0 is positively linked to host density in the case of direct-transmitted parasites (see Rosa in this book).", [["R 0", "GENE_OR_GENE_PRODUCT", 0, 3], ["transmitted parasites", "PROBLEM", 63, 84], ["host density", "OBSERVATION_MODIFIER", 28, 40], ["parasites", "OBSERVATION", 75, 84]]], ["Parasites, or infection, can spread in the population when R 0 >1 and as R 0 depends on host density, the condition of parasite invasion corresponds to a case when the density of host population exceeds a threshold density.", [["infection", "DISEASE", 14, 23], ["Parasites", "CELL", 0, 9], ["Parasites", "PROBLEM", 0, 9], ["infection", "PROBLEM", 14, 23], ["parasite invasion", "PROBLEM", 119, 136], ["infection", "OBSERVATION", 14, 23], ["host density", "OBSERVATION_MODIFIER", 88, 100], ["parasite", "OBSERVATION_MODIFIER", 119, 127], ["invasion", "OBSERVATION", 128, 136], ["host", "OBSERVATION_MODIFIER", 179, 183], ["population", "OBSERVATION", 184, 194], ["threshold density", "OBSERVATION", 205, 222]]], ["Obviously, host-parasite dynamics are viewed in terms of parasite invasion or parasite invisibility.", [["host-parasite dynamics", "TEST", 11, 33], ["parasite invasion", "PROBLEM", 57, 74], ["parasite invisibility", "PROBLEM", 78, 99], ["parasite", "OBSERVATION_MODIFIER", 57, 65], ["invasion", "OBSERVATION", 66, 74], ["parasite invisibility", "OBSERVATION", 78, 99]]], ["The task of disease management is then to decrease R 0 below one, i.e., below the threshold density.Threshold in host-parasite population dynamicsThe interplay between host and parasite thresholds has not been considered adequately.", [["disease management", "TREATMENT", 12, 30], ["host and parasite thresholds", "TREATMENT", 168, 196], ["disease", "OBSERVATION", 12, 19], ["density", "OBSERVATION", 92, 99], ["parasite", "OBSERVATION_MODIFIER", 118, 126]]], ["Deredec and Courchamp (2003) emphasized the importance of the relative position of the host and parasite thresholds: when the parasite threshold is higher than that of the host, the parasite is driven to extinction and the host population is relieved of its parasite; when the host population threshold is higher than that of the parasite, the host is driven to extinction while the parasite continues to exert strong pressure on the host until it reaches its own threshold.", [["parasite thresholds", "TEST", 96, 115], ["the parasite threshold", "TEST", 122, 144], ["its parasite", "PROBLEM", 254, 266]]], ["Hence, mathematical epidemiology and population dynamics are important tools for investigating thresholds and persistence of both hosts and parasites.", [["investigating thresholds", "TEST", 81, 105], ["parasites", "PROBLEM", 140, 149]]], ["They may help in determining the conditions to maintain a high level of parasite threshold in comparison to the host threshold.Which diseases are important for conservation?Microparasites are generally considered as an important threat in conservation biology (Daszak et al. 2000; Cleaveland et al. 2001 ).", [["Microparasites", "DISEASE", 173, 187]]], ["All conservation textbooks refer to the canine distemper virus, rinderpest and the avian malaria as examples of pathogen-driven extinction.", [["canine distemper virus", "DISEASE", 40, 62], ["rinderpest", "DISEASE", 64, 74], ["avian malaria", "DISEASE", 83, 96], ["canine distemper virus", "ORGANISM", 40, 62], ["canine distemper virus", "SPECIES", 40, 62], ["rinderpest", "SPECIES", 64, 74], ["avian", "SPECIES", 83, 88], ["canine distemper virus", "SPECIES", 40, 62], ["the canine distemper virus", "PROBLEM", 36, 62], ["the avian malaria", "PROBLEM", 79, 96], ["pathogen", "PROBLEM", 112, 120]]], ["Introduced diseases have been implicated in the local extinction of a number of species (McCallum and Dobson 1995; Vitousek et al. 1997 ) and the global species extinction of Hawaiian birds (VanRiper et al. 1986 ) and the thylacine (Guiler 1961) among others.", [["thylacine", "CHEMICAL", 222, 231], ["thylacine", "CHEMICAL", 222, 231], ["thylacine", "SIMPLE_CHEMICAL", 222, 231], ["Introduced diseases", "PROBLEM", 0, 19], ["diseases", "OBSERVATION", 11, 19]]], ["Daszak et al (2000) , in their review, mentioned 19 microparasites and no macroparasites as important threats for conservation and as zoonotic threats for human health through spill-over.", [["human", "ORGANISM", 155, 160], ["human", "SPECIES", 155, 160], ["human", "SPECIES", 155, 160], ["macroparasites", "TREATMENT", 74, 88]]], ["The lack of reference to macroparasites may suggest that they are indeed less important, and that their survey is not of major interest, with the notable exception of ectoparasites (ticks, fleas) because of their roles as vectors of numerous virus, bacteria and protozoans.Which diseases are important for conservation?Moreover, results based on comparative analyses in carnivores show that host species that live in low density within a restricted geographic area experience low parasitic pressure in terms of parasite species diversity, suggesting that parasites may not represent a particularly important risk for these host species (Torres et al. 2006) .", [["ectoparasites", "PROBLEM", 167, 180], ["numerous virus", "PROBLEM", 233, 247], ["bacteria", "PROBLEM", 249, 257], ["protozoans", "PROBLEM", 262, 272], ["comparative analyses", "TEST", 346, 366], ["host species", "PROBLEM", 391, 403], ["low density", "PROBLEM", 417, 428], ["low parasitic pressure", "PROBLEM", 476, 498], ["parasite species diversity", "PROBLEM", 511, 537], ["parasites", "PROBLEM", 555, 564], ["these host species", "PROBLEM", 617, 635], ["ectoparasites", "OBSERVATION", 167, 180], ["low density", "OBSERVATION_MODIFIER", 417, 428], ["restricted", "OBSERVATION_MODIFIER", 438, 448], ["geographic", "OBSERVATION_MODIFIER", 449, 459], ["low", "OBSERVATION_MODIFIER", 476, 479], ["parasitic pressure", "OBSERVATION", 480, 498], ["parasite species diversity", "OBSERVATION", 511, 537], ["parasites", "OBSERVATION", 555, 564], ["may not represent", "UNCERTAINTY", 565, 582]]], ["In contrast, widespread host species that live in high density are exposed to a wide range of parasite species that may affect drastically the population dynamics of these carnivores, suggesting that macroparasites may regulate them at least locally.", [["macroparasites", "GENE_OR_GENE_PRODUCT", 200, 214], ["widespread host species", "PROBLEM", 13, 36], ["high density", "PROBLEM", 50, 62], ["parasite species", "PROBLEM", 94, 110], ["macroparasites", "PROBLEM", 200, 214], ["widespread", "OBSERVATION_MODIFIER", 13, 23], ["host species", "OBSERVATION", 24, 36], ["high density", "OBSERVATION_MODIFIER", 50, 62], ["wide range", "OBSERVATION_MODIFIER", 80, 90], ["parasite species", "OBSERVATION", 94, 110]]], ["These results lead to the paradox that parasite infection, and particularly that of macroparasites, is less crucial for small and isolated populations than for large populations.", [["parasite infection", "DISEASE", 39, 57], ["parasite infection", "PROBLEM", 39, 57], ["macroparasites", "PROBLEM", 84, 98], ["small and isolated populations", "PROBLEM", 120, 150], ["large populations", "PROBLEM", 160, 177], ["parasite", "OBSERVATION_MODIFIER", 39, 47], ["infection", "OBSERVATION", 48, 57], ["less crucial", "OBSERVATION_MODIFIER", 103, 115], ["small", "OBSERVATION_MODIFIER", 120, 125], ["large", "OBSERVATION_MODIFIER", 160, 165], ["populations", "OBSERVATION", 166, 177]]], ["This paradox is apparent and resolved by considering the investment in immune defences, which is directly related to the prevalence and/or diversity of parasites as a mean to control infection (Martin et al. 2001) .", [["infection", "DISEASE", 183, 192], ["parasites", "PROBLEM", 152, 161], ["immune defences", "OBSERVATION", 71, 86]]], ["Evidence comes again from comparative studies, which suggest that hosts allocate their investment in immune function as a function of their probability of exposure to parasites (M\u00f8ller and Legendre 2001; M\u00f8ller et al. 2005) .", [["comparative studies", "TEST", 26, 45], ["parasites", "PROBLEM", 167, 176]]], ["Large populations are composed of highly immunocompetent individuals and small populations of low immunocompetent ones.", [["Large populations", "PROBLEM", 0, 17], ["highly immunocompetent individuals", "PROBLEM", 34, 68], ["low immunocompetent ones", "PROBLEM", 94, 118], ["populations", "OBSERVATION", 6, 17], ["highly", "OBSERVATION_MODIFIER", 34, 40], ["immunocompetent", "OBSERVATION", 41, 56], ["small", "OBSERVATION_MODIFIER", 73, 78], ["populations", "OBSERVATION_MODIFIER", 79, 90], ["low immunocompetent", "OBSERVATION_MODIFIER", 94, 113]]], ["Hence, parasites and pathogens are threats to small and isolated populations because of poor performance of their immune system against pathogen introduction, but parasites (and parasite diversity) are probably necessary to maintain high levels of immune defence, which helps against new pathogens.Allee effectThe Allee effect may be defined as \"a positive relationship between any component of individual fitness and either numbers or density of conspecifics\" .", [["immune system", "ANATOMY", 114, 127], ["immune system", "ANATOMICAL_SYSTEM", 114, 127], ["parasites", "PROBLEM", 7, 16], ["pathogens", "PROBLEM", 21, 30], ["small and isolated populations", "PROBLEM", 46, 76], ["pathogen introduction", "TREATMENT", 136, 157], ["parasites", "PROBLEM", 163, 172], ["high levels of immune defence", "PROBLEM", 233, 262], ["new pathogens", "PROBLEM", 284, 297], ["Allee effect", "PROBLEM", 298, 310], ["individual fitness", "PROBLEM", 395, 413], ["parasites", "OBSERVATION", 7, 16], ["small", "OBSERVATION_MODIFIER", 46, 51], ["immune defence", "OBSERVATION", 248, 262], ["new", "OBSERVATION_MODIFIER", 284, 287], ["pathogens", "OBSERVATION", 288, 297]]], ["The beneficial effects of conspecifics not only include antipredator vigilance, predator dilution, social thermoregulation, reduction of inbreeding but also social facilitation of reproduction through helpers Courchamp et al. 2000) .", [["predator dilution", "TREATMENT", 80, 97], ["social thermoregulation", "TREATMENT", 99, 122], ["inbreeding", "PROBLEM", 137, 147]]], ["When population size reaches a low density, animal species that are subject to an Allee effect will suffer from a reduction in some aspects of their fitness that in turn will affect negatively growth rate of populations.", [["a low density", "PROBLEM", 29, 42], ["animal species", "PROBLEM", 44, 58], ["a reduction", "PROBLEM", 112, 123], ["size", "OBSERVATION_MODIFIER", 16, 20], ["low density", "OBSERVATION_MODIFIER", 31, 42]]], ["Because of their potential role in extinctions of declining species, the Allee effects have thus become much studied in conservation biology Lafferty and Gerber 2002) .", [["declining species", "PROBLEM", 50, 67]]], ["Interestingly, Allee effects and parasitism have several features in common that are of interest when studying population dynamics in conservation biology (Deredec 2005) .", [["parasitism", "PROBLEM", 33, 43], ["Allee effects", "OBSERVATION", 15, 28]]], ["For example, theoretical models demonstrated the importance of host density in the probability for a parasite to become established in a host population (see above) and empirical studies have shown a positive relationship between host sociality or density and parasite prevalence and intensities (Anderson and May 1978; Brown and Brown 1986; M\u00f8ller et al. 1993; Stanko et al. 2002; Altizer et al. 2003) .", [["a parasite", "PROBLEM", 99, 109], ["empirical studies", "TEST", 169, 186], ["host density", "OBSERVATION_MODIFIER", 63, 75], ["parasite", "OBSERVATION", 101, 109], ["density", "OBSERVATION", 248, 255]]], ["Thus, animal species that aggregated as a behavioural response to the strong Allee effects, would be more prone to suffer the negative effects of parasites.", [["animal species", "PROBLEM", 6, 20], ["parasites", "PROBLEM", 146, 155], ["negative", "OBSERVATION", 126, 134]]], ["Parasite species may also be subject to the Allee effects that influence the occurrence and the severity of epidemics as illustrated by patchy distributions of worms in hosts as a result of the necessity for female worms to find a mate in order to reproduce (Cornell et al. 2004 ).Allee effectIt has been suggested that sexual selection, in particular female mate preferences, could lead to an Allee effect (M\u00f8ller and Legendre 2001) .", [["worms", "SPECIES", 160, 165], ["worms", "SPECIES", 215, 220], ["Parasite species", "PROBLEM", 0, 16], ["epidemics", "PROBLEM", 108, 117], ["patchy distributions of worms in hosts", "PROBLEM", 136, 174], ["Allee effect", "PROBLEM", 281, 293], ["may also be", "UNCERTAINTY", 17, 28], ["patchy", "OBSERVATION_MODIFIER", 136, 142]]], ["Parasite-mediated sexual selection has been the focus of numerous studies since the influential hypothesis of Hamilton and Zuk (1982) .", [["numerous studies", "TEST", 57, 73]]], ["A meta-analysis of the available studies related to this topic has revealed a negative relationship between parasite load, immunocompetence and the expression of male secondary sexual characters (M\u00f8ller et al. 1999) .", [["the available studies", "TEST", 19, 40], ["parasite load", "PROBLEM", 108, 121], ["negative", "OBSERVATION", 78, 86], ["parasite load", "OBSERVATION", 108, 121]]], ["Thus, parasites, by decreasing the expression of male secondary sexual characters, may contribute and reinforce the potential Allee effects created by sexual selection.Parasite mediated competitionMediation of competition by parasites is one mechanism of parasite interference (Anderson 1972; Hudson and Greenman 1998; Poulin 1999) .", [["parasites", "PROBLEM", 6, 15], ["parasites", "OBSERVATION", 6, 15]]], ["Parasite-mediated competition is inferred when two different host species have different susceptibilities to the same non-specific parasite species.", [["Parasite", "CELL", 0, 8], ["different susceptibilities", "PROBLEM", 79, 105], ["the same non-specific parasite species", "PROBLEM", 109, 147], ["non-specific", "OBSERVATION_MODIFIER", 118, 130], ["parasite species", "OBSERVATION", 131, 147]]], ["The presence of a given host species may decrease the fitness of the other host species simply by transmitting a pathogen to the more vulnerable host species (Hudson and Greenman 1998) .", [["host species", "PROBLEM", 24, 36], ["the other host species", "PROBLEM", 65, 87], ["a pathogen", "PROBLEM", 111, 121]]], ["The abundance of the more vulnerable host to the parasite is then depleted, potentially under the host threshold.", [["abundance", "OBSERVATION_MODIFIER", 4, 13], ["more vulnerable", "OBSERVATION_MODIFIER", 21, 36], ["parasite", "OBSERVATION", 49, 57], ["depleted", "OBSERVATION", 66, 74], ["host threshold", "OBSERVATION_MODIFIER", 98, 112]]], ["Moreover, as the parasite infects two host species, the parasite threshold is obviously low.", [["the parasite infects two host species", "PROBLEM", 13, 50], ["the parasite threshold", "TEST", 52, 74], ["parasite", "OBSERVATION_MODIFIER", 17, 25], ["infects", "OBSERVATION_MODIFIER", 26, 33], ["host species", "OBSERVATION", 38, 50], ["obviously", "OBSERVATION_MODIFIER", 78, 87], ["low", "OBSERVATION_MODIFIER", 88, 91]]], ["Strong evidence of this competition was obtained not only from experiments but also from the field (Tompkins et al. 2000) , e.g. red and grey squirrels in England (Tompkins et al. 2002b ) and pheasant and grey partridge in England (Tompkins et al. 2002a) .", [["grey squirrels", "SPECIES", 137, 151]]], ["Parasite-mediated competition may operate for introduced host species, as they can be best competitors simply by introducing and transmitting a new parasite to the na\u00efve native species.", [["a new parasite", "PROBLEM", 142, 156]]], ["Immune-na\u00efve residents will be weakened or even killed by the new pathogens.Parasite mediated competitionThe most famous example of such a process comes from the history of the expansion of European humans through America where million of native people were killed by the influenza and other pathogens that accompanied conquistadors.Parasite release hypothesisParasite mediated competition is not the only way by which parasites may interfere in competition processes.", [["influenza", "DISEASE", 272, 281], ["conquistadors", "DISEASE", 319, 332], ["residents", "ORGANISM", 13, 22], ["Parasite", "CELL", 76, 84], ["humans", "ORGANISM", 199, 205], ["people", "ORGANISM", 246, 252], ["Parasite", "CELL", 333, 341], ["humans", "SPECIES", 199, 205], ["people", "SPECIES", 246, 252], ["European humans", "SPECIES", 190, 205], ["the new pathogens", "PROBLEM", 58, 75], ["the influenza and other pathogens", "PROBLEM", 268, 301], ["Parasite release hypothesis", "PROBLEM", 333, 360]]], ["This could be responsible for the demographic explosion of some introduced species, formulated as the \"parasite release hypothesis\".Parasite release hypothesisThe parasite release hypothesis was proposed as an ecological mechanism to explain the success of introduced species.", [["Parasite", "CELL", 132, 140], ["some introduced species", "PROBLEM", 59, 82], ["Parasite release hypothesis", "PROBLEM", 132, 159], ["The parasite release hypothesis", "PROBLEM", 159, 190], ["introduced species", "PROBLEM", 257, 275], ["could be responsible for", "UNCERTAINTY", 5, 29]]], ["Mitchell and Power (2003) and Torchin et al. (2003) found that parasitism is significantly reduced in organisms in their introduced range, supporting the \"parasite release hypothesis\".", [["parasitism", "PROBLEM", 63, 73], ["parasitism", "OBSERVATION", 63, 73], ["significantly", "OBSERVATION_MODIFIER", 77, 90], ["reduced", "OBSERVATION_MODIFIER", 91, 98]]], ["One cause to explain that invaders may leave behind their parasites is that many parasites have complex life cycle stages with more than one host.", [["many parasites", "PROBLEM", 76, 90]]], ["If one of those hosts is absent in the new colonized area, the life-cycle of the parasite would be disrupted.ImmunityIn the invasion process, invasive host species harbouring a high diversity of parasites in their native habitat have advantages as they lose a large number of parasites and pathogens (see above).", [["area", "ANATOMY", 53, 57], ["the parasite", "PROBLEM", 77, 89], ["the invasion process", "PROBLEM", 120, 140], ["invasive host species", "PROBLEM", 142, 163], ["parasites", "PROBLEM", 276, 285], ["pathogens", "PROBLEM", 290, 299], ["absent", "OBSERVATION", 25, 31], ["new", "OBSERVATION_MODIFIER", 39, 42], ["colonized", "OBSERVATION_MODIFIER", 43, 52], ["parasite", "OBSERVATION", 81, 89], ["disrupted", "OBSERVATION", 99, 108], ["invasion", "OBSERVATION", 124, 132], ["invasive", "OBSERVATION_MODIFIER", 142, 150], ["high diversity", "OBSERVATION_MODIFIER", 177, 191], ["large", "OBSERVATION_MODIFIER", 260, 265], ["number", "OBSERVATION_MODIFIER", 266, 272], ["parasites", "OBSERVATION", 276, 285]]], ["Invasive host species have another advantage if they have invested in strong immune defences in their natural range, which may then subsequently confer a better capacity to control parasites that they may acquire in the introduced habitat.", [["Invasive host species", "PROBLEM", 0, 21]]], ["Hosts having evolved strong immune defences are prime candidates for successful invasion (and also more resistant towards invaders).", [["successful invasion", "PROBLEM", 69, 88], ["strong", "OBSERVATION_MODIFIER", 21, 27], ["immune defences", "OBSERVATION", 28, 43], ["invasion", "OBSERVATION", 80, 88]]], ["In contrast, hosts that are exposed to a low diversity of parasites may invest less in immune defences.", [["a low diversity of parasites", "PROBLEM", 39, 67], ["low diversity", "OBSERVATION_MODIFIER", 41, 54], ["parasites", "OBSERVATION", 58, 67], ["immune defences", "OBSERVATION", 87, 102]]], ["Maintaining a strong immune system for threatened host species, or for individual hosts maintained in captivity in the view of reintroduction, is a new task for conservation biologists.Genetic diversity and pathogen resistanceHabitat fragmentation and its degradation is probably one of the main factors leading to the disappearance of many species.", [["threatened host species", "PROBLEM", 39, 62], ["Genetic diversity", "PROBLEM", 185, 202], ["pathogen resistance", "PROBLEM", 207, 226], ["Habitat fragmentation", "PROBLEM", 226, 247], ["its degradation", "PROBLEM", 252, 267], ["many species", "PROBLEM", 336, 348], ["diversity", "OBSERVATION", 193, 202], ["pathogen resistance", "OBSERVATION", 207, 226], ["fragmentation", "OBSERVATION", 234, 247], ["many", "OBSERVATION_MODIFIER", 336, 340], ["species", "OBSERVATION", 341, 348]]], ["Indeed, it often leads to a decrease in population sizes as well as to the appearance of barriers to gene flow between isolated populations.", [["a decrease in population sizes", "PROBLEM", 26, 56], ["decrease", "OBSERVATION_MODIFIER", 28, 36], ["population", "OBSERVATION_MODIFIER", 40, 50], ["sizes", "OBSERVATION_MODIFIER", 51, 56], ["populations", "OBSERVATION_MODIFIER", 128, 139]]], ["The small populations that result from this fragmentation often suffer from reduction of genetic diversity associated with genetic drift and inbreeding effects.", [["The small populations", "PROBLEM", 0, 21], ["this fragmentation", "PROBLEM", 39, 57], ["genetic diversity", "PROBLEM", 89, 106], ["genetic drift", "PROBLEM", 123, 136], ["inbreeding effects", "PROBLEM", 141, 159], ["small", "OBSERVATION_MODIFIER", 4, 9], ["populations", "OBSERVATION", 10, 21], ["reduction", "OBSERVATION_MODIFIER", 76, 85], ["genetic diversity", "OBSERVATION", 89, 106], ["genetic drift", "OBSERVATION", 123, 136]]], ["This loss of genetic variation can result in a rapid reduction of fitness (lower possibility to adapt to long term changes in environment, poor reproductive ability associated with a lower sperm quality, higher juvenile mortality, lower general survival, etc) (O'Brien 1994) .", [["sperm", "ANATOMY", 189, 194], ["This loss of genetic variation", "PROBLEM", 0, 30], ["a rapid reduction of fitness", "PROBLEM", 45, 73], ["long term changes in environment", "PROBLEM", 105, 137], ["poor reproductive ability", "PROBLEM", 139, 164], ["a lower sperm quality", "PROBLEM", 181, 202], ["rapid", "OBSERVATION_MODIFIER", 47, 52], ["reduction", "OBSERVATION_MODIFIER", 53, 62]]], ["Several recent studies (Cassinello et al. 2001; Keller and Waller 2002; Spielman et al. 2004 ) also showed that populations with a low genetic variability are generally more susceptible to infectious viruses, bacteria and other pathogens.", [["infectious viruses", "DISEASE", 189, 207], ["Several recent studies", "TEST", 0, 22], ["a low genetic variability", "PROBLEM", 129, 154], ["infectious viruses", "PROBLEM", 189, 207], ["bacteria", "PROBLEM", 209, 217], ["other pathogens", "PROBLEM", 222, 237], ["infectious", "OBSERVATION", 189, 199]]], ["The case of the cheetah (Acinonyx jubatus) is probably one of the best known concerning this phenomenon., The two major subspecies of cheetah (A. jubatus jubatus from southern Africa and A. jubatus raineyi from eastern Africa) display markedly reduced levels of genetic variability compared to other mammal species (O'Brien 1994) .", [["cheetah", "ORGANISM", 16, 23], ["Acinonyx jubatus", "ORGANISM", 25, 41], ["cheetah", "ORGANISM", 134, 141], ["A. jubatus jubatus", "ORGANISM", 143, 161], ["A. jubatus raineyi", "ORGANISM", 187, 205], ["Acinonyx jubatus", "SPECIES", 25, 41], ["A. jubatus", "SPECIES", 143, 153], ["jubatus", "SPECIES", 154, 161], ["A. jubatus raineyi", "SPECIES", 187, 205], ["Acinonyx jubatus", "SPECIES", 25, 41], ["A. jubatus jubatus", "SPECIES", 143, 161], ["A. jubatus raineyi", "SPECIES", 187, 205], ["this phenomenon", "PROBLEM", 88, 103], ["markedly reduced levels of genetic variability", "PROBLEM", 235, 281], ["cheetah", "ANATOMY", 16, 23], ["two", "OBSERVATION_MODIFIER", 110, 113], ["major", "OBSERVATION_MODIFIER", 114, 119], ["subspecies", "OBSERVATION_MODIFIER", 120, 130], ["cheetah", "OBSERVATION_MODIFIER", 134, 141], ["markedly", "OBSERVATION_MODIFIER", 235, 243], ["reduced", "OBSERVATION_MODIFIER", 244, 251], ["genetic variability", "OBSERVATION", 262, 281]]], ["This would result in intensive inbreeding.", [["intensive inbreeding", "PROBLEM", 21, 41]]], ["When a breeding colony of this species was contaminated by feline infectious peritonitis (FIP) in Oregon state (USA), 100% of the captive animals showed morbidity symptoms and 60% of them died (O'Brien 1994) .", [["feline infectious peritonitis", "DISEASE", 59, 88], ["FIP", "DISEASE", 90, 93], ["feline", "ORGANISM", 59, 65], ["animals", "ORGANISM", 138, 145], ["feline", "SPECIES", 59, 65], ["this species", "PROBLEM", 26, 38], ["feline infectious peritonitis", "PROBLEM", 59, 88], ["morbidity symptoms", "PROBLEM", 153, 171], ["infectious", "OBSERVATION_MODIFIER", 66, 76], ["peritonitis", "OBSERVATION", 77, 88]]], ["In contrast, in domestic cats, the mortality incidence of this virus is very rare (around 1%).", [["cats", "ORGANISM", 25, 29], ["cats", "SPECIES", 25, 29], ["this virus", "PROBLEM", 58, 68], ["virus", "OBSERVATION", 63, 68]]], ["According to O'Brien (1994) , the high sensitivity of this cheetah colony to the FIP would be directly linked to the very low (almost monomorphic) level of variation of the Major Histocompatibility (MHC) genes characterising the cheetah.Genetic diversity and pathogen resistanceA wide variety of gene classes (where the MHC is the most notable but see also the eosinophil-associated RNase (EARs) genes, the tumor necrosis factor gene promoter, the interleukine receptor or the -interferon receptors ; Hill 1998; Zhang et al. 2000) are normally variable in natural populations and could contribute to disease resistance.", [["colony", "ANATOMY", 67, 73], ["eosinophil", "ANATOMY", 361, 371], ["FIP", "DISEASE", 81, 84], ["tumor", "DISEASE", 407, 412], ["necrosis", "DISEASE", 413, 421], ["cheetah", "ORGANISM", 59, 66], ["eosinophil-associated RNase", "GENE_OR_GENE_PRODUCT", 361, 388], ["EARs", "GENE_OR_GENE_PRODUCT", 390, 394], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 407, 428], ["interleukine receptor", "GENE_OR_GENE_PRODUCT", 448, 469], ["Major Histocompatibility (MHC) genes", "DNA", 173, 209], ["MHC", "DNA", 320, 323], ["eosinophil-associated RNase (EARs) genes", "DNA", 361, 401], ["tumor necrosis factor gene promoter", "DNA", 407, 442], ["interleukine receptor", "PROTEIN", 448, 469], ["interferon receptors", "PROTEIN", 478, 498], ["Genetic diversity", "PROBLEM", 237, 254], ["pathogen resistanceA wide variety of gene classes", "PROBLEM", 259, 308], ["the eosinophil", "TEST", 357, 371], ["RNase (EARs) genes", "PROBLEM", 383, 401], ["the tumor necrosis factor gene promoter", "PROBLEM", 403, 442], ["the interleukine receptor", "TREATMENT", 444, 469], ["the -interferon receptors", "TREATMENT", 473, 498], ["disease resistance", "PROBLEM", 600, 618], ["FIP", "OBSERVATION", 81, 84], ["pathogen", "OBSERVATION_MODIFIER", 259, 267], ["wide", "OBSERVATION_MODIFIER", 280, 284], ["variety", "OBSERVATION_MODIFIER", 285, 292], ["tumor", "OBSERVATION_MODIFIER", 407, 412], ["necrosis", "OBSERVATION", 413, 421], ["variable", "OBSERVATION_MODIFIER", 544, 552], ["could contribute to", "UNCERTAINTY", 580, 599], ["disease resistance", "OBSERVATION", 600, 618]]], ["MHC genes encode cellsurface glycoproteins, binding antigens derived from pathogens and parasites and constitute the most polymorphic genes in vertebrates (Parham 1999; Charbonnel et al. in this volume) .", [["MHC", "GENE_OR_GENE_PRODUCT", 0, 3], ["cellsurface glycoproteins", "GENE_OR_GENE_PRODUCT", 17, 42], ["MHC genes", "DNA", 0, 9], ["cellsurface glycoproteins", "PROTEIN", 17, 42], ["binding antigens", "PROTEIN", 44, 60], ["MHC genes encode cellsurface glycoproteins", "PROBLEM", 0, 42], ["binding antigens", "TEST", 44, 60], ["pathogens", "PROBLEM", 74, 83], ["parasites", "PROBLEM", 88, 97], ["Charbonnel et al", "TREATMENT", 169, 185]]], ["They present antigens to Tlymphocytes which develop the appropriate immune responses.", [["Tlymphocytes", "ANATOMY", 25, 37], ["Tlymphocytes", "CELL", 25, 37], ["Tlymphocytes", "CELL_TYPE", 25, 37]]], ["Two major groups of MHC genes are recognised: the MHC class I genes are specific to the immune defence against intracellular pathogens by binding peptides mainly derived from viral proteins or cancer infected cells.", [["intracellular", "ANATOMY", 111, 124], ["cancer", "ANATOMY", 193, 199], ["cells", "ANATOMY", 209, 214], ["cancer infected", "DISEASE", 193, 208], ["MHC", "GENE_OR_GENE_PRODUCT", 20, 23], ["MHC class I", "GENE_OR_GENE_PRODUCT", 50, 61], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 111, 124], ["cancer", "CELL", 193, 199], ["cells", "CELL", 209, 214], ["MHC genes", "DNA", 20, 29], ["MHC class I genes", "DNA", 50, 67], ["viral proteins", "PROTEIN", 175, 189], ["cancer infected cells", "CELL_TYPE", 193, 214], ["intracellular pathogens", "PROBLEM", 111, 134], ["binding peptides", "PROBLEM", 138, 154], ["viral proteins", "PROBLEM", 175, 189], ["cancer infected cells", "PROBLEM", 193, 214], ["MHC genes", "OBSERVATION", 20, 29], ["viral proteins", "OBSERVATION", 175, 189], ["cancer", "OBSERVATION", 193, 199]]], ["The MHC class II genes present with T-lymphocytes, peptides essentially derived from extra-cellular parasites (bacteria, nematodes, cestodes, etc.).", [["T-lymphocytes", "ANATOMY", 36, 49], ["extra-cellular parasites", "ANATOMY", 85, 109], ["MHC class II", "GENE_OR_GENE_PRODUCT", 4, 16], ["T-lymphocytes", "CELL", 36, 49], ["MHC class II genes", "DNA", 4, 22], ["T-lymphocytes", "CELL_TYPE", 36, 49], ["peptides", "PROBLEM", 51, 59], ["extra-cellular parasites", "PROBLEM", 85, 109], ["bacteria", "PROBLEM", 111, 119], ["nematodes", "PROBLEM", 121, 130], ["extra-cellular parasites", "OBSERVATION", 85, 109]]], ["The variability of MHC genes is correlated with the diversity of the T-lymphocyte receptors, which, in turn, determine the resistance of an organism to pathogens and parasites (Parham 1999) .Genetic diversity and pathogen resistanceTherefore, the cheetah, with its very low variability of MHC genes, is not well protected against the FIP and probably against many other pathogens and therefore is at a high risk of extinction.", [["T-lymphocyte", "ANATOMY", 69, 81], ["FIP", "DISEASE", 334, 337], ["MHC", "GENE_OR_GENE_PRODUCT", 19, 22], ["T-lymphocyte receptors", "GENE_OR_GENE_PRODUCT", 69, 91], ["MHC", "GENE_OR_GENE_PRODUCT", 289, 292], ["MHC genes", "DNA", 19, 28], ["T-lymphocyte receptors", "PROTEIN", 69, 91], ["MHC genes", "DNA", 289, 298], ["an organism to pathogens", "PROBLEM", 137, 161], ["Genetic diversity", "PROBLEM", 191, 208], ["pathogen resistance", "PROBLEM", 213, 232], ["the FIP", "PROBLEM", 330, 337], ["many other pathogens", "PROBLEM", 359, 379], ["variability", "OBSERVATION_MODIFIER", 4, 15], ["MHC genes", "OBSERVATION", 19, 28], ["diversity", "OBSERVATION", 199, 208], ["pathogen resistance", "OBSERVATION", 213, 232], ["FIP", "OBSERVATION", 334, 337], ["probably against", "UNCERTAINTY", 342, 358], ["pathogens", "OBSERVATION", 370, 379], ["extinction", "OBSERVATION", 415, 425]]], ["However, according to several recent studies, several processes would help to maintain high levels of MHC genes diversity.", [["MHC", "GENE_OR_GENE_PRODUCT", 102, 105], ["MHC genes", "DNA", 102, 111], ["several recent studies", "TEST", 22, 44], ["MHC genes", "OBSERVATION", 102, 111]]], ["Indeed, these studies demonstrated that the anti-gen binding sites (ABS) display more non-synonymous than synonymous substitutions compared to what would be observed under neutral theory (in this condition, the rate of synonymous substitution is predicted to be larger than the rate of non-synonymous substitution as the latter change the amino acid composition and would be likely deleterious) (Sommer 2005) .", [["amino acid", "CHEMICAL", 339, 349], ["amino acid", "CHEMICAL", 339, 349], ["anti-gen", "GENE_OR_GENE_PRODUCT", 44, 52], ["amino acid", "AMINO_ACID", 339, 349], ["anti-gen binding sites", "DNA", 44, 66], ["ABS", "DNA", 68, 71], ["these studies", "TEST", 8, 21], ["more non-synonymous than synonymous substitutions", "PROBLEM", 81, 130], ["synonymous substitution", "PROBLEM", 219, 242], ["non-synonymous substitution", "TREATMENT", 286, 313], ["the amino acid composition", "TREATMENT", 335, 361], ["synonymous substitutions", "OBSERVATION", 106, 130], ["synonymous substitution", "OBSERVATION", 219, 242]]], ["This phenomenon cannot be explained by higher mutation rates in this region (Hughes and Yeager 1998) and the hypothesis accepted at present is that this particular nucleotide diversity in MHC genes would be the result of balancing selection.", [["nucleotide", "CHEMICAL", 164, 174], ["nucleotide", "CHEMICAL", 164, 174], ["MHC", "GENE_OR_GENE_PRODUCT", 188, 191], ["MHC genes", "DNA", 188, 197], ["higher mutation rates", "PROBLEM", 39, 60], ["balancing selection", "PROBLEM", 221, 240], ["cannot be explained", "UNCERTAINTY", 16, 35], ["balancing selection", "OBSERVATION", 221, 240]]], ["This would allow the maintenance of large numbers of alleles in populations and also the persistence of allelic diversity over long periods of time.", [["alleles in populations", "PROBLEM", 53, 75], ["allelic diversity", "PROBLEM", 104, 121], ["large", "OBSERVATION_MODIFIER", 36, 41], ["numbers", "OBSERVATION_MODIFIER", 42, 49], ["allelic diversity", "OBSERVATION", 104, 121]]], ["Following this strategy, the binding of a large set of antigens would be possible.Genetic diversity and pathogen resistanceTwo main types of balancing selection have been proposed to explain high levels of genetic diversity in MHC genes of vertebrates:Genetic diversity and pathogen resistance-\"Overdominance\" strategy (Hedrick 1998; Richman 2000) , where the heterozygotes are expected to have higher fitness than parental homozygotes as the latter will carry less divergent allelic sequences and, therefore, will have less chance to resist a large panel of antigens and/or multiple types of pathogens and parasites.Genetic diversity and pathogen resistance-\"Frequency dependent selection\" strategy (Hedrick 1998) .", [["antigens", "PROTEIN", 55, 63], ["MHC genes", "DNA", 227, 236], ["divergent allelic sequences", "DNA", 466, 493], ["antigens", "PROTEIN", 559, 567], ["this strategy", "TREATMENT", 10, 23], ["a large set of antigens", "TREATMENT", 40, 63], ["Genetic diversity", "PROBLEM", 82, 99], ["pathogen resistance", "PROBLEM", 104, 123], ["balancing selection", "TREATMENT", 141, 160], ["Genetic diversity", "PROBLEM", 252, 269], ["pathogen resistance", "PROBLEM", 274, 293], ["the heterozygotes", "PROBLEM", 356, 373], ["parental homozygotes", "PROBLEM", 415, 435], ["a large panel of antigens", "PROBLEM", 542, 567], ["pathogens", "PROBLEM", 593, 602], ["parasites", "PROBLEM", 607, 616], ["Genetic diversity", "PROBLEM", 617, 634], ["pathogen resistance", "PROBLEM", 639, 658], ["diversity", "OBSERVATION", 90, 99], ["pathogen resistance", "OBSERVATION", 104, 123], ["main", "OBSERVATION_MODIFIER", 127, 131], ["balancing selection", "OBSERVATION", 141, 160], ["pathogen resistance", "OBSERVATION", 274, 293], ["pathogens", "OBSERVATION", 593, 602], ["pathogen resistance", "OBSERVATION", 639, 658]]], ["This occurs when an allele or genotype is favoured at one frequency, but disadvantaged at another frequency.", [["allele", "DNA", 20, 26]]], ["This hypothesis is based on the fact that hostparasite dynamics is considered as a co-evolutionary race.", [["hostparasite dynamics", "PROBLEM", 42, 63]]], ["Pathogens adapt to infect the most common genotype, leaving rare genotypes least infected.", [["Pathogens", "PROBLEM", 0, 9], ["infected", "OBSERVATION", 81, 89]]], ["If alleles are favoured when they are rare, but selected against when they are common, this will result in a balanced polymorphism (Sommer 2005) Different studies confirmed the effect of balancing selection on the high MHC diversity.", [["MHC", "PROTEIN", 219, 222], ["alleles", "PROBLEM", 3, 10], ["Different studies", "TEST", 145, 162], ["balancing selection", "TREATMENT", 187, 206], ["high MHC diversity", "OBSERVATION", 214, 232]]], ["One of the best examples concerns the Nicolas Island fox (Urocyon littoralis dickeyi) (Aguilar et al. 2004 ).", [["Urocyon littoralis dickeyi", "ORGANISM", 58, 84], ["Urocyon littoralis", "SPECIES", 58, 76], ["dickeyi", "SPECIES", 77, 84], ["Nicolas Island fox", "SPECIES", 38, 56], ["Urocyon littoralis dickeyi", "SPECIES", 58, 84], ["the Nicolas Island fox (Urocyon littoralis dickeyi", "TREATMENT", 34, 84]]], ["On the basis of different neutral markers (microsatellites, minisatellites and allozymes), this species is considered as one of the most monomorphic among sexually reproducing species.", [["minisatellites", "DNA", 60, 74], ["different neutral markers (microsatellites, minisatellites and allozymes", "PROBLEM", 16, 88], ["this species", "PROBLEM", 91, 103]]], ["Regarding the low variability of these markers, this species would have many problems of fitness as well as low resistance to pathogens.", [["the low variability", "PROBLEM", 10, 29], ["these markers", "TEST", 33, 46], ["this species", "PROBLEM", 48, 60], ["low resistance to pathogens", "PROBLEM", 108, 135], ["low variability", "OBSERVATION_MODIFIER", 14, 29]]], ["However, it is characterised by a surprising high level of MHC diversity which makes it much more resistant to what could be expected.", [["MHC", "GENE_OR_GENE_PRODUCT", 59, 62], ["MHC", "PROTEIN", 59, 62], ["MHC diversity", "OBSERVATION", 59, 72], ["more resistant", "OBSERVATION_MODIFIER", 93, 107]]], ["This observation is interpreted as being the result of intense periodic balancing selection at the MHC which may have allowed the persistence of variation within this species despite strong genetic drift.Inbreeding, MHC and risk of extinctionUnder some circumstances (for example, particular historical events such as bottlenecks or founder effects), strength of selection acting on MHC genes can be insufficient to maintain variation in small or fragmented populations over a long period of time (Sommer 2005) .", [["MHC", "PROTEIN", 99, 102], ["MHC", "PROTEIN", 216, 219], ["MHC genes", "DNA", 383, 392], ["This observation", "TEST", 0, 16], ["intense periodic balancing selection at the MHC", "PROBLEM", 55, 102], ["this species", "PROBLEM", 162, 174], ["strong genetic drift", "PROBLEM", 183, 203], ["small or fragmented populations", "PROBLEM", 438, 469], ["genetic drift", "OBSERVATION", 190, 203], ["small", "OBSERVATION_MODIFIER", 438, 443], ["fragmented", "OBSERVATION_MODIFIER", 447, 457], ["populations", "OBSERVATION_MODIFIER", 458, 469]]], ["In these cases, the power of genetic drifts can be stronger than the power of selection.", [["power", "OBSERVATION_MODIFIER", 20, 25], ["genetic drifts", "OBSERVATION", 29, 43]]], ["This can lead to a loss of genetic diversity not only on the neutral markers but also on the MHC genes.", [["MHC", "GENE_OR_GENE_PRODUCT", 93, 96], ["MHC genes", "DNA", 93, 102], ["a loss of genetic diversity", "PROBLEM", 17, 44], ["the neutral markers", "TEST", 57, 76], ["loss", "OBSERVATION_MODIFIER", 19, 23]]], ["This would explain the very low genetic variability in highly threatened species such as the cheetah (Acinonyx jubatus) (see above), the Asian lion (Pantera leo persica) (O'Brien, 1994) , the common hamster (Cricetus cricetus) in the Netherlands (Smulders et al. 2003) , the Scandinavian beaver (Castor fiber) (Ellegren et al. 1993) , the Northern elephant seal (Mirounga angustirostris) (Hoelzel et al. 1999 ) and the Scandinavian moose (Alces alces) (Ellegren et al. 1996) .", [["Acinonyx jubatus", "ORGANISM", 102, 118], ["Pantera leo persica", "ORGANISM", 149, 168], ["hamster", "ORGANISM", 199, 206], ["Cricetus cricetus", "ORGANISM", 208, 225], ["Mirounga angustirostris", "ORGANISM", 363, 386], ["Acinonyx jubatus", "SPECIES", 102, 118], ["Pantera", "SPECIES", 149, 156], ["leo persica", "SPECIES", 157, 168], ["hamster", "SPECIES", 199, 206], ["Cricetus cricetus", "SPECIES", 208, 225], ["Mirounga angustirostris", "SPECIES", 363, 386], ["Acinonyx jubatus", "SPECIES", 102, 118], ["Asian lion", "SPECIES", 137, 147], ["Pantera leo persica", "SPECIES", 149, 168], ["hamster", "SPECIES", 199, 206], ["Cricetus cricetus", "SPECIES", 208, 225], ["Scandinavian beaver", "SPECIES", 275, 294], ["Northern elephant seal", "SPECIES", 339, 361], ["Mirounga angustirostris", "SPECIES", 363, 386], ["Scandinavian moose", "SPECIES", 419, 437], ["the very low genetic variability", "PROBLEM", 19, 51], ["highly threatened species", "PROBLEM", 55, 80], ["the Scandinavian beaver (Castor fiber", "TREATMENT", 271, 308], ["the Northern elephant seal", "TREATMENT", 335, 361], ["very", "OBSERVATION_MODIFIER", 23, 27], ["low genetic", "OBSERVATION_MODIFIER", 28, 39], ["variability", "OBSERVATION_MODIFIER", 40, 51], ["highly", "OBSERVATION_MODIFIER", 55, 61], ["threatened", "OBSERVATION", 62, 72], ["common hamster", "ANATOMY", 192, 206]]], ["Under these circumstances, threatened species present a high risk of extinction as they can be very sensitive to new diseases and changes in environment.Inbreeding, MHC and risk of extinctionHowever, other studies demonstrated that endangered species such as the Przewalski's horse (Equus przewalski) (Hedrick et al. 1999) , the Arabian oryx (Oryx leucoryx) (Hedrick et al. 2000) and the Malagasy giant jumping rat (Hypogeomys antimena) (Sommer 2003) are characterised by a low number of MHC alleles but which are separated by a high level of nucleotide and amino acid divergence.", [["nucleotide", "CHEMICAL", 543, 553], ["amino acid", "CHEMICAL", 558, 568], ["nucleotide", "CHEMICAL", 543, 553], ["amino acid", "CHEMICAL", 558, 568], ["horse", "ORGANISM", 276, 281], ["Equus przewalski", "ORGANISM", 283, 299], ["Arabian oryx", "ORGANISM", 329, 341], ["Oryx leucoryx", "ORGANISM", 343, 356], ["rat", "ORGANISM", 411, 414], ["Hypogeomys antimena", "ORGANISM", 416, 435], ["amino acid", "AMINO_ACID", 558, 568], ["MHC", "PROTEIN", 165, 168], ["MHC alleles", "DNA", 488, 499], ["horse", "SPECIES", 276, 281], ["Equus przewalski", "SPECIES", 283, 299], ["Oryx leucoryx", "SPECIES", 343, 356], ["rat", "SPECIES", 411, 414], ["Hypogeomys antimena", "SPECIES", 416, 435], ["Przewalski's horse", "SPECIES", 263, 281], ["Equus przewalski", "SPECIES", 283, 299], ["Arabian oryx", "SPECIES", 329, 341], ["Oryx leucoryx", "SPECIES", 343, 356], ["Malagasy giant jumping rat", "SPECIES", 388, 414], ["Hypogeomys antimena", "SPECIES", 416, 435], ["new diseases", "PROBLEM", 113, 125], ["Inbreeding", "PROBLEM", 153, 163], ["extinction", "PROBLEM", 181, 191], ["other studies", "TEST", 200, 213], ["endangered species", "PROBLEM", 232, 250], ["nucleotide", "TREATMENT", 543, 553], ["amino acid divergence", "TREATMENT", 558, 579], ["extinction", "OBSERVATION", 181, 191]]], ["Analysis at the ABS showed that non-synonymous substitutions were higher than synonymous ones, suggesting selection leading to an increase of amino acids changes in the ABS region and thus to higher divergences between MHC alleles (Sommer 2003) .", [["amino acids", "CHEMICAL", 142, 153], ["amino acids", "CHEMICAL", 142, 153], ["amino acids", "AMINO_ACID", 142, 153], ["ABS", "DNA", 16, 19], ["ABS region", "DNA", 169, 179], ["MHC alleles", "DNA", 219, 230], ["Analysis", "TEST", 0, 8], ["the ABS", "TEST", 12, 19], ["non-synonymous substitutions", "PROBLEM", 32, 60], ["amino acids changes in the ABS region", "PROBLEM", 142, 179], ["non-synonymous substitutions", "OBSERVATION", 32, 60], ["higher", "OBSERVATION_MODIFIER", 66, 72], ["increase", "OBSERVATION_MODIFIER", 130, 138], ["amino acids", "OBSERVATION", 142, 153]]], ["These studies indicated that other selection processes are able to maintain some MHC polymorphism (not on the number of alleles but rather on the genetic difference between the existing alleles) even in species surviving bottlenecks.", [["MHC", "PROTEIN", 81, 84], ["These studies", "TEST", 0, 13], ["other selection processes", "PROBLEM", 29, 54]]], ["This would be sufficient to prevent immediate pathogen-induced declines.", [["immediate pathogen", "PROBLEM", 36, 54]]], ["However, such kind of adaptive processes to changing conditions is probably limited and does not predict the outcome effects of introduced pathogens, which differ from commonly encountered diseases.", [["adaptive processes", "TREATMENT", 22, 40], ["introduced pathogens", "PROBLEM", 128, 148], ["commonly encountered diseases", "PROBLEM", 168, 197]]], ["Probably, the maintenance or even renewal of variation in functional important regions of the MHC, either from mutation, recombination or immigration from other populations, would be an important genetic component to allow an appropriate immune response (Sommer 2005) .", [["MHC", "GENE_OR_GENE_PRODUCT", 94, 97], ["MHC", "PROTEIN", 94, 97], ["mutation", "PROBLEM", 111, 119]]], ["However, too strong genetic bottlenecks, leading to important inbreeding depressions, do not permit such kind of processes to operate and this explains why some species like the cheetah or the Asian lion are so sensitive nowadays to diseases.Breeding program and risk of parasite transmissionAs mentioned by McCallum and Dobson (1995) , \"diseases and parasites pose particularly severe problems in captive populations, in which animals are held at high density, may be stressed and may be exposed to crossspecies transmission\".", [["inbreeding depressions", "DISEASE", 62, 84], ["parasite transmissionAs", "DISEASE", 271, 294], ["diseases and parasites", "DISEASE", 338, 360], ["Asian lion", "SPECIES", 193, 203], ["important inbreeding depressions", "PROBLEM", 52, 84], ["Breeding program", "TREATMENT", 242, 258], ["parasite transmissionAs", "PROBLEM", 271, 294], ["diseases", "PROBLEM", 338, 346], ["parasites", "PROBLEM", 351, 360], ["severe problems in captive populations", "PROBLEM", 379, 417], ["parasite transmissionAs", "OBSERVATION", 271, 294]]], ["During the last 20 years, a great amount of zoos worldwide have participated in the management of endangered species., Many threatened species have captive populations that act as insurance against extinction in the wild and, indeed, captive breeding programs have saved some endangered species from extinction (e.g. P\u00e8re David's deer, European bison, etc) (Frankham et al. 2002) .", [["endangered species", "PROBLEM", 98, 116], ["Many threatened species", "PROBLEM", 119, 142], ["captive breeding programs", "TREATMENT", 234, 259], ["endangered species", "OBSERVATION", 98, 116]]], ["Because parasites may have negative effects on their host, veterinarians in zoos take great care to reduce or even to remove entirely parasite loads on captive animals.", [["parasites", "PROBLEM", 8, 17]]], ["As the ultimate goal of breeding programs in zoos is to increase threatened populations or to reintroduce individuals into the wild, parasites play an important role.", [["breeding programs", "TREATMENT", 24, 41]]], ["The potential risk is to release into the wild individuals that have lost their defences against pathogens and diseases.", [["pathogens", "PROBLEM", 97, 106], ["diseases", "PROBLEM", 111, 119]]], ["Once in the wild, they will be in contact with a vast array of parasite species and may be unable to resist to their detrimental effects.", [["parasite species", "PROBLEM", 63, 79]]], ["Maintaining some parasites on individual hosts kept in captivity could be a way to solve part of this problem.Beneficial effects of parasites and parasite conservation in captive breeding programMacroparasites, because of chronic infections, have evolved several kinds of immune evasion strategies (Charbonnel et al. in this volume) .", [["chronic infections", "DISEASE", 222, 240], ["parasites", "PROBLEM", 132, 141], ["parasite conservation", "TREATMENT", 146, 167], ["captive breeding programMacroparasites", "TREATMENT", 171, 209], ["chronic infections", "PROBLEM", 222, 240], ["immune evasion strategies", "TREATMENT", 272, 297], ["Charbonnel et al", "TREATMENT", 299, 315], ["some", "OBSERVATION_MODIFIER", 12, 16], ["parasites", "OBSERVATION", 17, 26], ["parasites", "OBSERVATION", 132, 141], ["parasite", "OBSERVATION_MODIFIER", 146, 154], ["chronic", "OBSERVATION_MODIFIER", 222, 229], ["infections", "OBSERVATION", 230, 240], ["immune evasion", "OBSERVATION", 272, 286]]], ["Some strategies of immunomodulation displayed by many macroparasites may have some beneficial effects on their hosts by regulating Th1/Th2 cytokine responses (Weinstock et al. 2004 ).", [["Th1", "GENE_OR_GENE_PRODUCT", 131, 134], ["Th2", "GENE_OR_GENE_PRODUCT", 135, 138], ["cytokine", "PROTEIN", 139, 147], ["immunomodulation", "TREATMENT", 19, 35]]], ["Th1 responses induce inflammatory cell activity to control intracellular infections while Th2 responses drive humoral immune responses to control extra-cellular parasites (see Weil et al. in this volume) .Beneficial effects of parasites and parasite conservation in captive breeding programMice with helminths have blunted Th1 responses while helminths promote Th2 responses associated with production of interleukin 4 (IL-4), which helps impede Th1 cell differentiation.", [["cell", "ANATOMY", 34, 38], ["intracellular", "ANATOMY", 59, 72], ["Th1 cell", "ANATOMY", 446, 454], ["infections", "DISEASE", 73, 83], ["inflammatory cell", "CELL", 21, 38], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 59, 72], ["Th1", "GENE_OR_GENE_PRODUCT", 323, 326], ["interleukin 4", "GENE_OR_GENE_PRODUCT", 405, 418], ["IL-4", "GENE_OR_GENE_PRODUCT", 420, 424], ["Th1 cell", "CELL", 446, 454], ["interleukin 4", "PROTEIN", 405, 418], ["IL-4", "PROTEIN", 420, 424], ["inflammatory cell activity", "PROBLEM", 21, 47], ["intracellular infections", "PROBLEM", 59, 83], ["humoral immune responses", "TREATMENT", 110, 134], ["extra-cellular parasites", "PROBLEM", 146, 170], ["parasites", "PROBLEM", 227, 236], ["parasite conservation", "TREATMENT", 241, 262], ["captive breeding programMice", "TREATMENT", 266, 294], ["blunted Th1 responses", "PROBLEM", 315, 336], ["interleukin 4 (IL", "TREATMENT", 405, 422], ["inflammatory cell activity", "OBSERVATION", 21, 47], ["infections", "OBSERVATION", 73, 83], ["parasites", "OBSERVATION", 227, 236], ["Th1 cell differentiation", "OBSERVATION", 446, 470]]], ["Thus, induction of IL-4 could underlie the alterations seen in host immunity (i.e. high inflammatory activities).", [["IL-4", "GENE_OR_GENE_PRODUCT", 19, 23], ["IL-4", "PROTEIN", 19, 23], ["IL-4", "TREATMENT", 19, 23], ["the alterations", "PROBLEM", 39, 54], ["high inflammatory activities", "PROBLEM", 83, 111], ["inflammatory", "OBSERVATION_MODIFIER", 88, 100]]], ["Helminths also appear to protect the host from aberrant Th2 diseases such as asthma and food allergy (Weinstock et al. 2004) , and there is now an immunological basis for protection by helminths.", [["Th2 diseases", "DISEASE", 56, 68], ["asthma", "DISEASE", 77, 83], ["food allergy", "DISEASE", 88, 100], ["aberrant Th2 diseases", "PROBLEM", 47, 68], ["asthma", "PROBLEM", 77, 83], ["food allergy", "PROBLEM", 88, 100], ["aberrant", "OBSERVATION_MODIFIER", 47, 55], ["Th2 diseases", "OBSERVATION", 56, 68]]], ["Human epidemiological data and several animal studies support the notion that helminths protect the host from immunological disease (Elliott et al. 2005) , particularly those caused by the activation of the Th1 response by microparasites.", [["immunological disease", "DISEASE", 110, 131], ["Human", "ORGANISM", 0, 5], ["Th1", "GENE_OR_GENE_PRODUCT", 207, 210], ["Human", "SPECIES", 0, 5], ["Human epidemiological data", "TEST", 0, 26], ["several animal studies", "TEST", 31, 53], ["immunological disease", "PROBLEM", 110, 131]]], ["For example, helminths protect mice and rats from experimental autoimmune encephalomyelitis, as welll as other diseases of immunity.", [["autoimmune encephalomyelitis", "DISEASE", 63, 91], ["mice", "ORGANISM", 31, 35], ["rats", "ORGANISM", 40, 44], ["mice", "SPECIES", 31, 35], ["rats", "SPECIES", 40, 44], ["mice", "SPECIES", 31, 35], ["experimental autoimmune encephalomyelitis", "PROBLEM", 50, 91], ["other diseases of immunity", "PROBLEM", 105, 131], ["autoimmune encephalomyelitis", "OBSERVATION", 63, 91]]], ["Thus, natural exposure to helminths may guard animals from developing severe immunological diseases, suggesting that helminths should be useful in conserving both endangered and captive species.", [["helminths", "DISEASE", 26, 35], ["immunological diseases", "DISEASE", 77, 99], ["helminths", "DISEASE", 117, 126], ["developing severe immunological diseases", "PROBLEM", 59, 99], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["immunological diseases", "OBSERVATION", 77, 99], ["captive species", "OBSERVATION", 178, 193]]], ["Gompper and Williams (1998) proposed a series of measures to maintain endangered parasite species originating from threatened hosts in captive breeding program.", [["a series of measures", "TREATMENT", 37, 57], ["endangered parasite species", "PROBLEM", 70, 97], ["endangered", "OBSERVATION_MODIFIER", 70, 80], ["parasite species", "OBSERVATION", 81, 97]]], ["However, they pointed out that because most of the public disapprove of protecting parasite species, attempts to conserve unique species of parasites could result in a hostile public response against efforts to preserve hosts.", [["parasite species", "PROBLEM", 83, 99], ["unique species of parasites", "PROBLEM", 122, 149], ["parasite species", "OBSERVATION", 83, 99]]], ["Therefore they proposed a series of measures aimed to save parasite species without damaging attempts to conserve hosts.", [["a series of measures", "TREATMENT", 24, 44], ["parasite species", "PROBLEM", 59, 75]]], ["One of those measures was to find alternative hosts to maintain parasite populations for potential reintroduction once the host population was restored.", [["alternative hosts", "TREATMENT", 34, 51], ["parasite populations", "TREATMENT", 64, 84]]], ["However, the problem of parasite conservation concerns mainly highly host-specific parasites.", [["parasites", "CELL", 83, 92], ["parasite conservation", "TREATMENT", 24, 45]]], ["To find alternative hosts on which specialist parasite populations would be viable may be a difficult task because experiments on cross-species infection have shown a strong decrease on both parasite survival and reproductive success on the foreign host, even if this new host species belongs to the same host genus (Giorgi et al. 2004) .Concluding remarksThe consequence of human population growth is closer contact between human and reservoir hosts of numerous diseases.", [["infection", "DISEASE", 144, 153], ["parasite populations", "CELL", 46, 66], ["human", "ORGANISM", 375, 380], ["human", "ORGANISM", 425, 430], ["human", "SPECIES", 375, 380], ["human", "SPECIES", 425, 430], ["human", "SPECIES", 375, 380], ["human", "SPECIES", 425, 430], ["a difficult task", "PROBLEM", 90, 106], ["cross-species infection", "PROBLEM", 130, 153], ["human population growth", "PROBLEM", 375, 398], ["numerous diseases", "PROBLEM", 454, 471], ["strong", "OBSERVATION_MODIFIER", 167, 173], ["decrease", "OBSERVATION_MODIFIER", 174, 182], ["numerous", "OBSERVATION_MODIFIER", 454, 462], ["diseases", "OBSERVATION", 463, 471]]], ["The spread of disease to endangered wildlife species due to contact with humans and domestic animals, and vice versa, increases as humans and their domestic animals get in more contact with these species due to habitat fragmentation.", [["humans", "ORGANISM", 73, 79], ["humans", "ORGANISM", 131, 137], ["humans", "SPECIES", 73, 79], ["humans", "SPECIES", 131, 137], ["humans", "SPECIES", 73, 79], ["humans", "SPECIES", 131, 137], ["disease", "PROBLEM", 14, 21], ["these species", "PROBLEM", 190, 203], ["habitat fragmentation", "PROBLEM", 211, 232], ["spread", "OBSERVATION_MODIFIER", 4, 10], ["disease", "OBSERVATION", 14, 21], ["habitat fragmentation", "OBSERVATION", 211, 232]]], ["Emergence of new diseases and particularly those from small mammals such as rodents or bats are of great public health concern (Leroy et al. 2005) .", [["new diseases", "PROBLEM", 13, 25], ["new", "OBSERVATION_MODIFIER", 13, 16], ["diseases", "OBSERVATION", 17, 25]]], ["Conservation medicine, a new theme within the field of conservation biology, has been viewed as the application of medicine to improve the conserva-tion of wildlife and ecosystems .", [["Conservation medicine", "TREATMENT", 0, 21], ["medicine", "TREATMENT", 115, 123]]], ["Conservation medicine, according to Otsfeld et al. (2002) is \"devoted to understanding the interactions among human-induced and natural changes in (1) climate, habitat and land use; (2) pathogens, parasites, and pollutants; (3) biodiversity and health within animal communities; (4) health of humans\" .", [["human", "ORGANISM", 110, 115], ["humans", "ORGANISM", 293, 299], ["human", "SPECIES", 110, 115], ["humans", "SPECIES", 293, 299], ["human", "SPECIES", 110, 115], ["humans", "SPECIES", 293, 299], ["Conservation medicine", "TREATMENT", 0, 21], ["pathogens", "PROBLEM", 186, 195], ["parasites", "PROBLEM", 197, 206]]], ["The 2005 \"Anus horribilis\" for bats worldwide illustrates the importance of this new field of investigations.", [["Anus horribilis", "ORGANISM", 10, 25], ["Anus horribilis", "SPECIES", 10, 25]]], ["While it was discovered in China that bats are the reservoir of SARS virus (Lau et al. 2005; Li et al. 2005) , it was found in Africa that they are probably the reservoir for Ebola virus (Leroy et al. 2005) .Concluding remarksWe strongly hope that this chapter will convince ecologists and conservation biologists that pathogens and parasites, mostly investigated by veterinarians and physicians, should not be ignored or eradicated because of their crucial importance to wild and domestic animals and humans.", [["SARS", "DISEASE", 64, 68], ["Ebola virus", "DISEASE", 175, 186], ["SARS virus", "ORGANISM", 64, 74], ["Ebola virus", "ORGANISM", 175, 186], ["humans", "ORGANISM", 502, 508], ["Ebola virus", "SPECIES", 175, 186], ["humans", "SPECIES", 502, 508], ["SARS virus", "SPECIES", 64, 74], ["Ebola virus", "SPECIES", 175, 186], ["humans", "SPECIES", 502, 508], ["SARS virus", "PROBLEM", 64, 74], ["Ebola virus", "PROBLEM", 175, 186], ["pathogens", "PROBLEM", 319, 328], ["parasites", "PROBLEM", 333, 342]]]], "PMC7324915": [["IntroductionDiffuse alveolar hemorrhage (DAH) is a catastrophic clinical syndrome potentially leading to respiratory failure [1].", [["alveolar", "ANATOMY", 20, 28], ["respiratory", "ANATOMY", 105, 116], ["alveolar hemorrhage", "DISEASE", 20, 39], ["DAH", "DISEASE", 41, 44], ["respiratory failure", "DISEASE", 105, 124], ["alveolar", "MULTI-TISSUE_STRUCTURE", 20, 28], ["IntroductionDiffuse alveolar hemorrhage", "PROBLEM", 0, 39], ["DAH", "PROBLEM", 41, 44], ["a catastrophic clinical syndrome", "PROBLEM", 49, 81], ["respiratory failure", "PROBLEM", 105, 124], ["alveolar", "ANATOMY_MODIFIER", 20, 28], ["hemorrhage", "OBSERVATION", 29, 39], ["catastrophic", "OBSERVATION_MODIFIER", 51, 63], ["respiratory failure", "OBSERVATION", 105, 124]]], ["It usually presents with hemoptysis, anemia, and diffuse alveolar infiltrates, but the findings are nonspecific [1,2].", [["alveolar", "ANATOMY", 57, 65], ["hemoptysis", "DISEASE", 25, 35], ["anemia", "DISEASE", 37, 43], ["alveolar infiltrates", "PATHOLOGICAL_FORMATION", 57, 77], ["hemoptysis", "PROBLEM", 25, 35], ["anemia", "PROBLEM", 37, 43], ["diffuse alveolar infiltrates", "PROBLEM", 49, 77], ["hemoptysis", "OBSERVATION", 25, 35], ["anemia", "OBSERVATION", 37, 43], ["diffuse", "OBSERVATION_MODIFIER", 49, 56], ["alveolar", "ANATOMY_MODIFIER", 57, 65], ["infiltrates", "OBSERVATION", 66, 77], ["nonspecific", "OBSERVATION_MODIFIER", 100, 111]]], ["Despite advances in the identification and management of DAH, mortality remains high ranging from 30% to 100%, depending on the underlying etiology [1].", [["DAH", "DISEASE", 57, 60], ["the identification", "TEST", 20, 38], ["management", "TREATMENT", 43, 53], ["DAH", "PROBLEM", 57, 60], ["mortality", "TEST", 62, 71], ["DAH", "OBSERVATION", 57, 60]]], ["Early recognition is crucial as prompt diagnosis and treatment increase the chances of survival [2].", [["treatment", "TREATMENT", 53, 62]]], ["Up to 88% of the cases of DAH are caused by pulmonary capillaritis associated with systemic vasculitis [1,2].", [["pulmonary", "ANATOMY", 44, 53], ["DAH", "DISEASE", 26, 29], ["pulmonary capillaritis", "DISEASE", 44, 66], ["systemic vasculitis", "DISEASE", 83, 102], ["pulmonary", "ORGAN", 44, 53], ["DAH", "PROBLEM", 26, 29], ["pulmonary capillaritis", "PROBLEM", 44, 66], ["systemic vasculitis", "PROBLEM", 83, 102], ["DAH", "OBSERVATION", 26, 29], ["pulmonary", "ANATOMY", 44, 53], ["capillaritis", "OBSERVATION", 54, 66], ["systemic", "OBSERVATION_MODIFIER", 83, 91], ["vasculitis", "OBSERVATION", 92, 102]]], ["In immunocompetent patients, lung infections are rarely reported as the etiology of DAH [3].", [["lung", "ANATOMY", 29, 33], ["lung infections", "DISEASE", 29, 44], ["DAH", "DISEASE", 84, 87], ["patients", "ORGANISM", 19, 27], ["lung", "ORGAN", 29, 33], ["patients", "SPECIES", 19, 27], ["lung infections", "PROBLEM", 29, 44], ["DAH", "PROBLEM", 84, 87], ["immunocompetent", "OBSERVATION_MODIFIER", 3, 18], ["lung", "ANATOMY", 29, 33], ["infections", "OBSERVATION", 34, 44], ["DAH", "OBSERVATION", 84, 87]]], ["Human metapneumovirus (hMPV) mostly causes upper and lower respiratory tract infections in young children.", [["lower respiratory tract", "ANATOMY", 53, 76], ["Human metapneumovirus (hMPV)", "DISEASE", 0, 28], ["respiratory tract infections", "DISEASE", 59, 87], ["Human metapneumovirus", "ORGANISM", 0, 21], ["hMPV", "ORGANISM", 23, 27], ["upper", "ORGANISM_SUBDIVISION", 43, 48], ["lower", "ORGANISM_SUBDIVISION", 53, 58], ["respiratory tract", "ORGANISM_SUBDIVISION", 59, 76], ["children", "ORGANISM", 97, 105], ["Human", "SPECIES", 0, 5], ["metapneumovirus", "SPECIES", 6, 21], ["children", "SPECIES", 97, 105], ["Human metapneumovirus", "SPECIES", 0, 21], ["hMPV", "SPECIES", 23, 27], ["Human metapneumovirus (hMPV", "PROBLEM", 0, 27], ["upper and lower respiratory tract infections", "PROBLEM", 43, 87], ["metapneumovirus", "OBSERVATION", 6, 21], ["upper", "ANATOMY_MODIFIER", 43, 48], ["lower", "ANATOMY_MODIFIER", 53, 58], ["respiratory tract", "ANATOMY", 59, 76], ["infections", "OBSERVATION", 77, 87]]], ["Still, it is also a common unidentified trigger in adult patients with asthma and chronic obstructive pulmonary disease (COPD) [4,5].", [["pulmonary", "ANATOMY", 102, 111], ["asthma", "DISEASE", 71, 77], ["chronic obstructive pulmonary disease", "DISEASE", 82, 119], ["COPD", "DISEASE", 121, 125], ["patients", "ORGANISM", 57, 65], ["pulmonary", "ORGAN", 102, 111], ["patients", "SPECIES", 57, 65], ["asthma", "PROBLEM", 71, 77], ["chronic obstructive pulmonary disease (COPD)", "PROBLEM", 82, 126], ["asthma", "OBSERVATION", 71, 77], ["chronic", "OBSERVATION_MODIFIER", 82, 89], ["obstructive", "OBSERVATION_MODIFIER", 90, 101], ["pulmonary", "ANATOMY", 102, 111], ["disease", "OBSERVATION", 112, 119], ["COPD", "OBSERVATION", 121, 125]]], ["Lethal hMPV infections in adults have been classically described in immunosuppressed patients [6].", [["hMPV infections", "DISEASE", 7, 22], ["hMPV", "ORGANISM", 7, 11], ["adults", "ORGANISM", 26, 32], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["hMPV", "SPECIES", 7, 11], ["Lethal hMPV infections", "PROBLEM", 0, 22], ["infections", "OBSERVATION", 12, 22]]], ["We present a case of DAH secondary to human metapneumovirus infection in the setting of end-stage liver disease.Case descriptionA 62-year-old woman with no known past medical history presented on February 23, 2020, with sudden onset shortness of breath at rest for one week associated with hemoptysis.", [["liver", "ANATOMY", 98, 103], ["DAH", "DISEASE", 21, 24], ["human metapneumovirus infection", "DISEASE", 38, 69], ["end-stage liver disease", "DISEASE", 88, 111], ["shortness of breath", "DISEASE", 233, 252], ["hemoptysis", "DISEASE", 290, 300], ["human", "ORGANISM", 38, 43], ["metapneumovirus", "ORGANISM", 44, 59], ["liver", "ORGAN", 98, 103], ["woman", "ORGANISM", 142, 147], ["human", "SPECIES", 38, 43], ["woman", "SPECIES", 142, 147], ["human metapneumovirus", "SPECIES", 38, 59], ["DAH", "PROBLEM", 21, 24], ["human metapneumovirus infection", "PROBLEM", 38, 69], ["end-stage liver disease", "PROBLEM", 88, 111], ["sudden onset shortness of breath", "PROBLEM", 220, 252], ["hemoptysis", "PROBLEM", 290, 300], ["metapneumovirus infection", "OBSERVATION", 44, 69], ["stage", "OBSERVATION_MODIFIER", 92, 97], ["liver", "ANATOMY", 98, 103], ["disease", "OBSERVATION", 104, 111], ["hemoptysis", "OBSERVATION", 290, 300]]], ["On interrogation, she referred intermittent yellow sclera for one month, and her son mentioned heavy alcohol consumption.", [["alcohol", "CHEMICAL", 101, 108], ["alcohol", "CHEMICAL", 101, 108], ["alcohol", "SIMPLE_CHEMICAL", 101, 108], ["interrogation", "TEST", 3, 16], ["intermittent yellow sclera", "PROBLEM", 31, 57], ["yellow sclera", "ANATOMY", 44, 57]]], ["She migrated from Mexico more than 30 years ago and was never in contact with a known tuberculosis case.", [["tuberculosis", "DISEASE", 86, 98], ["a known tuberculosis case", "PROBLEM", 78, 103], ["tuberculosis", "OBSERVATION", 86, 98]]], ["Given her illegal alien immigrant status, she had limited access to health care and had no regular follow-ups with primary care physicians.Case descriptionOn presentation in the emergency department, she was tachypneic and tachycardiac with significant respiratory distress.", [["respiratory", "ANATOMY", 253, 264], ["tachycardiac", "DISEASE", 223, 235], ["respiratory distress", "DISEASE", 253, 273], ["tachypneic", "PROBLEM", 208, 218], ["tachycardiac", "PROBLEM", 223, 235], ["significant respiratory distress", "PROBLEM", 241, 273], ["significant", "OBSERVATION_MODIFIER", 241, 252], ["respiratory distress", "OBSERVATION", 253, 273]]], ["She was placed on a nonrebreather mask, started on broad-spectrum antibiotic therapy as per sepsis protocol, and transferred to a progressive care unit (PCU).", [["sepsis", "DISEASE", 92, 98], ["a nonrebreather mask", "TREATMENT", 18, 38], ["broad-spectrum antibiotic therapy", "TREATMENT", 51, 84], ["sepsis protocol", "TREATMENT", 92, 107], ["antibiotic therapy", "OBSERVATION", 66, 84]]], ["In the PCU, she was further upgraded to bilevel positive airway pressure.", [["airway", "ANATOMY", 57, 63], ["PCU", "CANCER", 7, 10], ["airway", "MULTI-TISSUE_STRUCTURE", 57, 63], ["bilevel positive airway pressure", "TREATMENT", 40, 72], ["airway pressure", "OBSERVATION", 57, 72]]], ["Her exam was significant for scleral icterus and dried blood on lips and chin, diffuse crackles over bilateral lower lung fields, and bilateral lower extremity pitting edema.Case descriptionInitial lab results showed a white blood cell count of 25.7 k/mm3 (4.0 - 11.0 k/mm3), hemoglobin of 10.1 g/dL (12.0 - 15.3 g/dL), and platelet count of 71,000 k/mm3 (150 - 450 k/mm3).", [["scleral icterus", "ANATOMY", 29, 44], ["blood", "ANATOMY", 55, 60], ["lips", "ANATOMY", 64, 68], ["lower lung", "ANATOMY", 111, 121], ["lower extremity pitting edema", "ANATOMY", 144, 173], ["white blood cell", "ANATOMY", 219, 235], ["platelet", "ANATOMY", 324, 332], ["icterus", "DISEASE", 37, 44], ["edema", "DISEASE", 168, 173], ["blood", "ORGANISM_SUBSTANCE", 55, 60], ["lips", "ORGANISM_SUBDIVISION", 64, 68], ["chin", "ORGANISM_SUBDIVISION", 73, 77], ["lung", "ORGAN", 117, 121], ["lower extremity", "ORGANISM_SUBDIVISION", 144, 159], ["edema", "PATHOLOGICAL_FORMATION", 168, 173], ["blood cell", "CELL", 225, 235], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 276, 286], ["platelet", "CELL", 324, 332], ["hemoglobin", "PROTEIN", 276, 286], ["Her exam", "TEST", 0, 8], ["scleral icterus", "PROBLEM", 29, 44], ["dried blood on lips and chin", "PROBLEM", 49, 77], ["diffuse crackles over bilateral lower lung fields", "PROBLEM", 79, 128], ["bilateral lower extremity pitting edema", "PROBLEM", 134, 173], ["a white blood cell count", "TEST", 217, 241], ["k", "TEST", 250, 251], ["mm3", "TEST", 252, 255], ["hemoglobin", "TEST", 276, 286], ["dL", "TEST", 297, 299], ["platelet count", "TEST", 324, 338], ["k", "TEST", 349, 350], ["mm3", "TEST", 351, 354], ["scleral", "ANATOMY", 29, 36], ["icterus", "OBSERVATION", 37, 44], ["dried blood", "OBSERVATION", 49, 60], ["lips", "ANATOMY", 64, 68], ["chin", "ANATOMY", 73, 77], ["diffuse", "OBSERVATION_MODIFIER", 79, 86], ["crackles", "OBSERVATION", 87, 95], ["bilateral", "ANATOMY_MODIFIER", 101, 110], ["lower", "ANATOMY_MODIFIER", 111, 116], ["lung", "ANATOMY", 117, 121], ["fields", "ANATOMY_MODIFIER", 122, 128], ["bilateral", "ANATOMY_MODIFIER", 134, 143], ["lower extremity", "ANATOMY", 144, 159], ["pitting", "OBSERVATION_MODIFIER", 160, 167], ["edema", "OBSERVATION", 168, 173], ["platelet count", "OBSERVATION_MODIFIER", 324, 338]]], ["Other lab values of note included albumin of 2.9 g/dL (3.5 - 5.7 g/dL), alkaline phosphatase 172 IU/L (35 - 104 IU/L), aspartate aminotransferase (AST) 133 IU/L (13 - 39 IU/L), alanine aminotransferase (ALT) 32 IU/L (7.0 - 52.0 IU/L), bilirubin 12.4 mg/dL (0.0 - 1.0 mg/dL), lactate 2.2 mmol/L (0.7 - 2.0 mmol/L), BNP 886 pg/mL (0.0 - 100 pg/mL), high-sensitivity troponin 449 pg/mL (0 - 12 pg/mL), D-Dimer 29,578 ng/mL (0 - 622 ng/mL), fibrinogen 183 mg/dL (163 - 463 mg/dL), elevated INR 1.8 (0.9 - 1.1), and PT 20.9 (10.1 - 13.1 sec).Case descriptionChest x-ray showed bilateral multifocal patchy opacities (Fig. 1a), and a CT chest showed extensive patchy parenchymal airspace opacities involving all lobes of the lung (Fig. 1b and c).", [["chest", "ANATOMY", 630, 635], ["parenchymal airspace opacities", "ANATOMY", 660, 690], ["lobes", "ANATOMY", 705, 710], ["lung", "ANATOMY", 718, 722], ["aspartate", "CHEMICAL", 119, 128], ["alanine", "CHEMICAL", 177, 184], ["bilirubin", "CHEMICAL", 235, 244], ["lactate", "CHEMICAL", 275, 282], ["aspartate", "CHEMICAL", 119, 128], ["alanine", "CHEMICAL", 177, 184], ["bilirubin", "CHEMICAL", 235, 244], ["lactate", "CHEMICAL", 275, 282], ["albumin", "GENE_OR_GENE_PRODUCT", 34, 41], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 72, 92], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 119, 145], ["AST", "SIMPLE_CHEMICAL", 147, 150], ["alanine aminotransferase", "SIMPLE_CHEMICAL", 177, 201], ["ALT", "SIMPLE_CHEMICAL", 203, 206], ["bilirubin", "SIMPLE_CHEMICAL", 235, 244], ["lactate", "SIMPLE_CHEMICAL", 275, 282], ["BNP", "GENE_OR_GENE_PRODUCT", 314, 317], ["troponin", "GENE_OR_GENE_PRODUCT", 364, 372], ["D-Dimer", "GENE_OR_GENE_PRODUCT", 399, 406], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 437, 447], ["parenchymal airspace", "PATHOLOGICAL_FORMATION", 660, 680], ["lobes", "ORGAN", 705, 710], ["lung", "ORGAN", 718, 722], ["albumin", "PROTEIN", 34, 41], ["alkaline phosphatase", "PROTEIN", 72, 92], ["aspartate aminotransferase", "PROTEIN", 119, 145], ["AST", "PROTEIN", 147, 150], ["alanine aminotransferase", "PROTEIN", 177, 201], ["ALT", "PROTEIN", 203, 206], ["fibrinogen", "PROTEIN", 437, 447], ["INR", "PROTEIN", 486, 489], ["Other lab values", "TEST", 0, 16], ["albumin", "TEST", 34, 41], ["dL", "TEST", 51, 53], ["alkaline phosphatase", "TEST", 72, 92], ["IU", "TEST", 97, 99], ["aspartate aminotransferase", "TEST", 119, 145], ["AST", "TEST", 147, 150], ["IU/L", "TEST", 156, 160], ["IU", "TEST", 170, 172], ["alanine aminotransferase", "TEST", 177, 201], ["ALT", "TEST", 203, 206], ["IU/L", "TEST", 211, 215], ["IU", "TEST", 228, 230], ["bilirubin", "TEST", 235, 244], ["dL", "TEST", 253, 255], ["lactate", "TEST", 275, 282], ["mmol", "TEST", 287, 291], ["L", "TEST", 292, 293], ["BNP", "TEST", 314, 317], ["troponin", "TEST", 364, 372], ["D-Dimer", "TEST", 399, 406], ["fibrinogen", "TEST", 437, 447], ["mg/dL", "TEST", 452, 457], ["elevated INR", "PROBLEM", 477, 489], ["PT", "TEST", 511, 513], ["Case descriptionChest x-ray", "TEST", 537, 564], ["bilateral multifocal patchy opacities", "PROBLEM", 572, 609], ["a CT chest", "TEST", 625, 635], ["extensive patchy parenchymal airspace opacities", "PROBLEM", 643, 690], ["bilateral", "ANATOMY_MODIFIER", 572, 581], ["multifocal", "OBSERVATION_MODIFIER", 582, 592], ["patchy", "OBSERVATION_MODIFIER", 593, 599], ["opacities", "OBSERVATION", 600, 609], ["chest", "ANATOMY", 630, 635], ["extensive", "OBSERVATION_MODIFIER", 643, 652], ["patchy", "OBSERVATION_MODIFIER", 653, 659], ["parenchymal", "ANATOMY_MODIFIER", 660, 671], ["airspace", "ANATOMY_MODIFIER", 672, 680], ["opacities", "OBSERVATION", 681, 690], ["all", "ANATOMY_MODIFIER", 701, 704], ["lobes", "ANATOMY_MODIFIER", 705, 710], ["lung", "ANATOMY", 718, 722]]], ["CT abdomen revealed diffusely heterogeneous enhancement and nodularity throughout the liver parenchyma, suspicious for liver cirrhosis.", [["abdomen", "ANATOMY", 3, 10], ["liver parenchyma", "ANATOMY", 86, 102], ["liver cirrhosis", "ANATOMY", 119, 134], ["nodularity throughout the liver parenchyma", "DISEASE", 60, 102], ["liver cirrhosis", "DISEASE", 119, 134], ["liver parenchyma", "MULTI-TISSUE_STRUCTURE", 86, 102], ["liver", "ORGAN", 119, 124], ["CT abdomen", "TEST", 0, 10], ["diffusely heterogeneous enhancement", "PROBLEM", 20, 55], ["nodularity throughout the liver parenchyma", "PROBLEM", 60, 102], ["liver cirrhosis", "PROBLEM", 119, 134], ["abdomen", "ANATOMY", 3, 10], ["diffusely", "OBSERVATION_MODIFIER", 20, 29], ["heterogeneous", "OBSERVATION_MODIFIER", 30, 43], ["enhancement", "OBSERVATION", 44, 55], ["nodularity", "OBSERVATION", 60, 70], ["liver", "ANATOMY", 86, 91], ["parenchyma", "ANATOMY_MODIFIER", 92, 102], ["suspicious for", "UNCERTAINTY", 104, 118], ["liver", "ANATOMY", 119, 124], ["cirrhosis", "OBSERVATION", 125, 134]]], ["The pancreas and spleen had a healthy contrast-enhanced CT appearance.Case descriptionShe subsequently developed severe respiratory acidosis, as manifested on a blood gas (pH 7.24, pCO2 68.9), prompting intubation and transfer to the intensive care unit.", [["pancreas", "ANATOMY", 4, 12], ["spleen", "ANATOMY", 17, 23], ["respiratory", "ANATOMY", 120, 131], ["blood", "ANATOMY", 161, 166], ["respiratory acidosis", "DISEASE", 120, 140], ["pancreas", "ORGAN", 4, 12], ["spleen", "ORGAN", 17, 23], ["blood", "ORGANISM_SUBSTANCE", 161, 166], ["severe respiratory acidosis", "PROBLEM", 113, 140], ["a blood gas", "TEST", 159, 170], ["pH", "TEST", 172, 174], ["pCO2", "TEST", 181, 185], ["intubation", "TREATMENT", 203, 213], ["pancreas", "ANATOMY", 4, 12], ["spleen", "ANATOMY", 17, 23], ["severe", "OBSERVATION_MODIFIER", 113, 119], ["respiratory acidosis", "OBSERVATION", 120, 140]]], ["She was then started on intravenous (IV) steroids due to high suspicion for DAH secondary to systemic vasculitis.", [["intravenous", "ANATOMY", 24, 35], ["steroids", "CHEMICAL", 41, 49], ["DAH", "DISEASE", 76, 79], ["vasculitis", "DISEASE", 102, 112], ["steroids", "CHEMICAL", 41, 49], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 24, 35], ["intravenous (IV) steroids", "TREATMENT", 24, 49], ["DAH", "PROBLEM", 76, 79], ["systemic vasculitis", "PROBLEM", 93, 112], ["systemic", "OBSERVATION_MODIFIER", 93, 101], ["vasculitis", "OBSERVATION", 102, 112]]], ["Bronchoalveolar lavage after intubation was performed.", [["Bronchoalveolar lavage", "ANATOMY", 0, 22], ["Bronchoalveolar lavage", "TEST", 0, 22], ["intubation", "TREATMENT", 29, 39], ["lavage", "OBSERVATION", 16, 22]]], ["The airways were observed erythematous, and the lavage was with a bloody return, confirming alveolar hemorrhage.", [["airways", "ANATOMY", 4, 11], ["lavage", "ANATOMY", 48, 54], ["alveolar", "ANATOMY", 92, 100], ["alveolar hemorrhage", "DISEASE", 92, 111], ["airways", "MULTI-TISSUE_STRUCTURE", 4, 11], ["alveolar", "MULTI-TISSUE_STRUCTURE", 92, 100], ["erythematous", "PROBLEM", 26, 38], ["the lavage", "TEST", 44, 54], ["a bloody return", "PROBLEM", 64, 79], ["alveolar hemorrhage", "PROBLEM", 92, 111], ["airways", "ANATOMY", 4, 11], ["erythematous", "OBSERVATION", 26, 38], ["lavage", "OBSERVATION", 48, 54], ["alveolar", "ANATOMY", 92, 100], ["hemorrhage", "OBSERVATION", 101, 111]]], ["The cytology exam demonstrated benign respiratory epithelium with reactive changes, acute inflammation, macrophages, and red blood cells.", [["benign respiratory epithelium", "ANATOMY", 31, 60], ["macrophages", "ANATOMY", 104, 115], ["red blood cells", "ANATOMY", 121, 136], ["inflammation", "DISEASE", 90, 102], ["respiratory epithelium", "TISSUE", 38, 60], ["macrophages", "CELL", 104, 115], ["red blood cells", "CELL", 121, 136], ["macrophages", "CELL_TYPE", 104, 115], ["red blood cells", "CELL_TYPE", 121, 136], ["The cytology exam", "TEST", 0, 17], ["benign respiratory epithelium", "PROBLEM", 31, 60], ["reactive changes", "PROBLEM", 66, 82], ["acute inflammation", "PROBLEM", 84, 102], ["macrophages", "PROBLEM", 104, 115], ["red blood cells", "TEST", 121, 136], ["benign", "OBSERVATION_MODIFIER", 31, 37], ["respiratory epithelium", "ANATOMY", 38, 60], ["reactive changes", "OBSERVATION", 66, 82], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["inflammation", "OBSERVATION", 90, 102], ["macrophages", "OBSERVATION", 104, 115], ["red blood cells", "OBSERVATION", 121, 136]]], ["Acid-fast stain and cultures were negative, as well as a Pneumocystis jiroveci smear.Case descriptionFurther laboratory testing was negative for autoimmune disease, including normal IgG and IgM cardiolipin antibodies, normal Beta-2-Glycoprotein IgG and IgM antibodies, negative anti-nuclear antibodies (ANA), negative anti-neutrophil cytoplasmic antibodies (P-ANCA and C-ANCA), negative rheumatoid factor, and negative anti-glomerular basement membrane antibody.", [["cultures", "ANATOMY", 20, 28], ["anti-glomerular basement membrane", "ANATOMY", 419, 452], ["Pneumocystis jiroveci smear", "DISEASE", 57, 84], ["autoimmune disease", "DISEASE", 145, 163], ["cardiolipin", "CHEMICAL", 194, 205], ["Acid", "SIMPLE_CHEMICAL", 0, 4], ["IgG", "GENE_OR_GENE_PRODUCT", 182, 185], ["IgM cardiolipin antibodies", "GENE_OR_GENE_PRODUCT", 190, 216], ["Beta-2-Glycoprotein IgG", "GENE_OR_GENE_PRODUCT", 225, 248], ["IgM antibodies", "GENE_OR_GENE_PRODUCT", 253, 267], ["anti-nuclear antibodies", "GENE_OR_GENE_PRODUCT", 278, 301], ["ANA", "GENE_OR_GENE_PRODUCT", 303, 306], ["anti-neutrophil cytoplasmic antibodies", "GENE_OR_GENE_PRODUCT", 318, 356], ["C-ANCA", "GENE_OR_GENE_PRODUCT", 369, 375], ["rheumatoid factor", "GENE_OR_GENE_PRODUCT", 387, 404], ["anti-glomerular basement membrane antibody", "GENE_OR_GENE_PRODUCT", 419, 461], ["IgG", "PROTEIN", 182, 185], ["IgM cardiolipin antibodies", "PROTEIN", 190, 216], ["Beta-2", "PROTEIN", 225, 231], ["Glycoprotein IgG", "PROTEIN", 232, 248], ["IgM antibodies", "PROTEIN", 253, 267], ["negative anti-nuclear antibodies", "PROTEIN", 269, 301], ["ANA", "PROTEIN", 303, 306], ["negative anti-neutrophil cytoplasmic antibodies", "PROTEIN", 309, 356], ["P", "PROTEIN", 358, 359], ["ANCA", "PROTEIN", 360, 364], ["C", "PROTEIN", 369, 370], ["ANCA", "PROTEIN", 371, 375], ["negative rheumatoid factor", "PROTEIN", 378, 404], ["negative anti-glomerular basement membrane antibody", "PROTEIN", 410, 461], ["Pneumocystis jiroveci", "SPECIES", 57, 78], ["Pneumocystis jiroveci", "SPECIES", 57, 78], ["Acid-fast stain", "TEST", 0, 15], ["cultures", "TEST", 20, 28], ["a Pneumocystis jiroveci smear", "TEST", 55, 84], ["Case descriptionFurther laboratory testing", "TEST", 85, 127], ["autoimmune disease", "PROBLEM", 145, 163], ["IgG", "TEST", 182, 185], ["IgM cardiolipin antibodies", "TEST", 190, 216], ["Glycoprotein IgG", "TEST", 232, 248], ["IgM antibodies", "TEST", 253, 267], ["anti-nuclear antibodies", "TEST", 278, 301], ["ANA", "TEST", 303, 306], ["anti-neutrophil cytoplasmic antibodies", "TEST", 318, 356], ["P", "TEST", 358, 359], ["ANCA", "TEST", 360, 364], ["C", "TEST", 369, 370], ["ANCA", "TEST", 371, 375], ["rheumatoid factor", "PROBLEM", 387, 404], ["anti-glomerular basement membrane antibody", "TEST", 419, 461], ["Pneumocystis jiroveci", "OBSERVATION", 57, 78], ["negative for", "UNCERTAINTY", 132, 144], ["anti-neutrophil cytoplasmic antibodies", "OBSERVATION", 318, 356], ["negative", "UNCERTAINTY", 378, 386], ["rheumatoid factor", "OBSERVATION", 387, 404], ["anti-glomerular basement membrane antibody", "OBSERVATION", 419, 461]]], ["Infectious disease workups were also negative, except for the respiratory viral panel collected from a nasopharyngeal swap that confirmed the presence of human metapneumovirus by PCR.", [["nasopharyngeal", "ANATOMY", 103, 117], ["nasopharyngeal", "ORGAN", 103, 117], ["human", "ORGANISM", 154, 159], ["metapneumovirus", "ORGANISM", 160, 175], ["human", "SPECIES", 154, 159], ["metapneumovirus", "SPECIES", 160, 175], ["human metapneumovirus", "SPECIES", 154, 175], ["Infectious disease workups", "TEST", 0, 26], ["the respiratory viral panel", "TEST", 58, 85], ["a nasopharyngeal swap", "TEST", 101, 122], ["human metapneumovirus", "PROBLEM", 154, 175], ["nasopharyngeal", "ANATOMY", 103, 117], ["metapneumovirus", "OBSERVATION", 160, 175]]], ["These tests included negative HIV-1/2 antibodies and HIV-1 antigen, negative Histoplasma galactomannan urine antigen, negative Legionella and Pneumococcus urine antigens, negative Epstein-Barr DNA PCR, negative hepatitis viral panel, negative Blastomyces dermatitidis antibodies, negative Aspergillus galactomannan antigen and galactomannan index, negative Mycoplasma, West Nile virus, cytomegalovirus and dengue virus serum IgM and IgG antibodies, negative blood cultures, negative urine cultures, and negative bronchial brushing cultures (including negative fungal cultures).", [["serum", "ANATOMY", 419, 424], ["blood cultures", "ANATOMY", 458, 472], ["urine cultures", "ANATOMY", 483, 497], ["bronchial", "ANATOMY", 512, 521], ["cultures", "ANATOMY", 567, 575], ["hepatitis", "DISEASE", 211, 220], ["Blastomyces dermatitidis", "DISEASE", 243, 267], ["HIV-1/2 antibodies", "GENE_OR_GENE_PRODUCT", 30, 48], ["HIV-1 antigen", "GENE_OR_GENE_PRODUCT", 53, 66], ["urine", "ORGANISM_SUBSTANCE", 103, 108], ["Pneumococcus urine antigens", "GENE_OR_GENE_PRODUCT", 142, 169], ["Blastomyces dermatitidis", "ORGANISM", 243, 267], ["Aspergillus galactomannan antigen", "GENE_OR_GENE_PRODUCT", 289, 322], ["galactomannan", "GENE_OR_GENE_PRODUCT", 327, 340], ["West Nile virus", "ORGANISM", 369, 384], ["cytomegalovirus", "ORGANISM", 386, 401], ["dengue virus", "ORGANISM", 406, 418], ["serum", "ORGANISM_SUBSTANCE", 419, 424], ["IgM", "ORGANISM_SUBSTANCE", 425, 428], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 433, 447], ["blood", "ORGANISM_SUBSTANCE", 458, 463], ["urine", "ORGANISM_SUBSTANCE", 483, 488], ["negative HIV-1/2 antibodies", "PROTEIN", 21, 48], ["HIV-1 antigen", "PROTEIN", 53, 66], ["negative Histoplasma galactomannan urine antigen", "PROTEIN", 68, 116], ["negative Legionella and Pneumococcus urine antigens", "PROTEIN", 118, 169], ["negative Blastomyces dermatitidis antibodies", "PROTEIN", 234, 278], ["negative Aspergillus galactomannan antigen", "PROTEIN", 280, 322], ["cytomegalovirus and dengue virus serum IgM", "PROTEIN", 386, 428], ["IgG antibodies", "PROTEIN", 433, 447], ["negative bronchial brushing cultures", "CELL_LINE", 503, 539], ["HIV-", "SPECIES", 30, 34], ["HIV-1", "SPECIES", 53, 58], ["Blastomyces dermatitidis", "SPECIES", 243, 267], ["West Nile virus", "SPECIES", 369, 384], ["dengue virus", "SPECIES", 406, 418], ["HIV-1/2", "SPECIES", 30, 37], ["HIV-1", "SPECIES", 53, 58], ["Blastomyces dermatitidis", "SPECIES", 243, 267], ["West Nile virus", "SPECIES", 369, 384], ["dengue virus", "SPECIES", 406, 418], ["These tests", "TEST", 0, 11], ["HIV", "TEST", 30, 33], ["antibodies", "TEST", 38, 48], ["HIV", "TEST", 53, 56], ["Histoplasma galactomannan urine antigen", "TEST", 77, 116], ["Legionella", "TEST", 127, 137], ["Pneumococcus urine antigens", "TEST", 142, 169], ["Epstein", "TEST", 180, 187], ["Barr DNA PCR", "TEST", 188, 200], ["hepatitis viral panel", "TEST", 211, 232], ["Blastomyces dermatitidis antibodies", "TEST", 243, 278], ["Aspergillus galactomannan antigen", "TEST", 289, 322], ["galactomannan index", "TEST", 327, 346], ["Mycoplasma", "PROBLEM", 357, 367], ["West Nile virus", "PROBLEM", 369, 384], ["cytomegalovirus", "PROBLEM", 386, 401], ["dengue virus serum IgM", "TEST", 406, 428], ["IgG antibodies", "TEST", 433, 447], ["blood cultures", "TEST", 458, 472], ["urine cultures", "TEST", 483, 497], ["bronchial brushing cultures", "TEST", 512, 539], ["fungal cultures", "TEST", 560, 575], ["Blastomyces dermatitidis", "OBSERVATION", 243, 267], ["bronchial", "ANATOMY", 512, 521]]], ["The Illinois Department of Public Health was contacted for coronavirus disease 2019 (COVID-19) testing, but the request was denied as the patient did not meet the criteria for trial at that point.", [["coronavirus disease", "DISEASE", 59, 78], ["patient", "ORGANISM", 138, 145], ["patient", "SPECIES", 138, 145], ["coronavirus disease", "PROBLEM", 59, 78], ["COVID", "TEST", 85, 90], ["testing", "TEST", 95, 102]]], ["She had no history of recent travels, no sick contacts, and community transmission was not suspected in the State of Illinois at that time.Case descriptionOn admission day 4, she was started on vasopressors due to shock.", [["shock", "DISEASE", 214, 219], ["vasopressors", "TREATMENT", 194, 206], ["shock", "PROBLEM", 214, 219], ["shock", "OBSERVATION", 214, 219]]], ["On day eight, she was placed in a prone position for 24 hours due to worsening hypoxia.", [["hypoxia", "DISEASE", 79, 86], ["worsening hypoxia", "PROBLEM", 69, 86], ["worsening", "OBSERVATION_MODIFIER", 69, 78], ["hypoxia", "OBSERVATION", 79, 86]]], ["On days 9 and 10, she required hemodialysis for severe acute kidney injury (creatinine 4.83 mg/dL) with acidosis (pH 7.21).", [["kidney", "ANATOMY", 61, 67], ["acute kidney injury", "DISEASE", 55, 74], ["creatinine", "CHEMICAL", 76, 86], ["acidosis", "DISEASE", 104, 112], ["creatinine", "CHEMICAL", 76, 86], ["kidney", "ORGAN", 61, 67], ["hemodialysis", "TREATMENT", 31, 43], ["severe acute kidney injury", "PROBLEM", 48, 74], ["creatinine", "TEST", 76, 86], ["acidosis", "PROBLEM", 104, 112], ["pH", "TEST", 114, 116], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["acute", "OBSERVATION_MODIFIER", 55, 60], ["kidney", "ANATOMY", 61, 67], ["injury", "OBSERVATION", 68, 74], ["acidosis", "OBSERVATION", 104, 112]]], ["On day 11 she developed disseminated intravascular coagulation (platelet count k/mm3, D-dimer 36,469 ng/mL and fibrinogen 91 mg/dL).", [["intravascular", "ANATOMY", 37, 50], ["platelet", "ANATOMY", 64, 72], ["intravascular coagulation", "DISEASE", 37, 62], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 37, 50], ["platelet", "CELL", 64, 72], ["D-dimer", "GENE_OR_GENE_PRODUCT", 86, 93], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 111, 121], ["fibrinogen", "PROTEIN", 111, 121], ["disseminated intravascular coagulation", "PROBLEM", 24, 62], ["platelet count", "TEST", 64, 78], ["k", "TEST", 79, 80], ["mm3", "TEST", 81, 84], ["D-dimer", "TEST", 86, 93], ["fibrinogen", "TEST", 111, 121], ["disseminated", "OBSERVATION_MODIFIER", 24, 36], ["intravascular coagulation", "OBSERVATION", 37, 62]]], ["CT head without contrast showed scattered small bilateral subarachnoid hemorrhages.", [["head", "ANATOMY", 3, 7], ["subarachnoid", "ANATOMY", 58, 70], ["subarachnoid hemorrhages", "DISEASE", 58, 82], ["head", "ORGAN", 3, 7], ["subarachnoid hemorrhages", "PATHOLOGICAL_FORMATION", 58, 82], ["CT head without contrast", "TEST", 0, 24], ["scattered small bilateral subarachnoid hemorrhages", "PROBLEM", 32, 82], ["head", "ANATOMY", 3, 7], ["scattered", "OBSERVATION_MODIFIER", 32, 41], ["small", "OBSERVATION_MODIFIER", 42, 47], ["bilateral", "ANATOMY_MODIFIER", 48, 57], ["subarachnoid", "ANATOMY", 58, 70], ["hemorrhages", "OBSERVATION", 71, 82]]], ["She ultimately developed multi-organ failure, had a cardiac arrest, and was declared dead after unsuccessful attempts at resuscitation.DiscussionDiffuse alveolar hemorrhage is a critical condition that presents with hemoptysis, anemia, diffuse radiographic pulmonary infiltrates, and hypoxemic respiratory failure [1,2].", [["multi-organ", "ANATOMY", 25, 36], ["cardiac", "ANATOMY", 52, 59], ["alveolar", "ANATOMY", 153, 161], ["pulmonary", "ANATOMY", 257, 266], ["respiratory", "ANATOMY", 294, 305], ["multi-organ failure", "DISEASE", 25, 44], ["cardiac arrest", "DISEASE", 52, 66], ["alveolar hemorrhage", "DISEASE", 153, 172], ["hemoptysis", "DISEASE", 216, 226], ["anemia", "DISEASE", 228, 234], ["hypoxemic respiratory failure", "DISEASE", 284, 313], ["multi-organ", "ORGAN", 25, 36], ["alveolar", "MULTI-TISSUE_STRUCTURE", 153, 161], ["pulmonary", "ORGAN", 257, 266], ["multi-organ failure", "PROBLEM", 25, 44], ["a cardiac arrest", "PROBLEM", 50, 66], ["resuscitation", "TREATMENT", 121, 134], ["Diffuse alveolar hemorrhage", "PROBLEM", 145, 172], ["a critical condition", "PROBLEM", 176, 196], ["hemoptysis", "PROBLEM", 216, 226], ["anemia", "PROBLEM", 228, 234], ["diffuse radiographic pulmonary infiltrates", "PROBLEM", 236, 278], ["hypoxemic respiratory failure", "PROBLEM", 284, 313], ["multi-organ failure", "OBSERVATION", 25, 44], ["cardiac", "ANATOMY", 52, 59], ["arrest", "OBSERVATION", 60, 66], ["Diffuse", "OBSERVATION_MODIFIER", 145, 152], ["alveolar", "ANATOMY_MODIFIER", 153, 161], ["hemorrhage", "OBSERVATION", 162, 172], ["hemoptysis", "OBSERVATION", 216, 226], ["anemia", "OBSERVATION", 228, 234], ["diffuse", "OBSERVATION_MODIFIER", 236, 243], ["radiographic", "OBSERVATION_MODIFIER", 244, 256], ["pulmonary", "ANATOMY", 257, 266], ["infiltrates", "OBSERVATION", 267, 278], ["hypoxemic", "OBSERVATION_MODIFIER", 284, 293], ["respiratory failure", "OBSERVATION", 294, 313]]], ["DAH is characterized by the accumulation of intra-alveolar red blood cells originating from the bronchial vessels, the pulmonary vessels, or the microcirculation [[1], [2], [3]].", [["intra-alveolar red blood cells", "ANATOMY", 44, 74], ["bronchial vessels", "ANATOMY", 96, 113], ["pulmonary vessels", "ANATOMY", 119, 136], ["DAH", "DISEASE", 0, 3], ["intra-alveolar red blood cells", "CELL", 44, 74], ["bronchial vessels", "MULTI-TISSUE_STRUCTURE", 96, 113], ["pulmonary vessels", "MULTI-TISSUE_STRUCTURE", 119, 136], ["[3]", "SIMPLE_CHEMICAL", 173, 176], ["intra-alveolar red blood cells", "CELL_TYPE", 44, 74], ["DAH", "PROBLEM", 0, 3], ["the accumulation of intra-alveolar red blood cells", "PROBLEM", 24, 74], ["accumulation", "OBSERVATION_MODIFIER", 28, 40], ["intra-alveolar red blood cells", "OBSERVATION", 44, 74], ["bronchial vessels", "ANATOMY", 96, 113], ["pulmonary vessels", "ANATOMY", 119, 136]]], ["Bronchoscopy with bronchoalveolar lavage is the gold standard to confirm the diagnosis.", [["bronchoalveolar lavage", "ANATOMY", 18, 40], ["Bronchoscopy", "TEST", 0, 12], ["bronchoalveolar lavage", "TEST", 18, 40], ["bronchoalveolar lavage", "OBSERVATION", 18, 40]]], ["Systemic autoimmune diseases such as anti-neutrophil cytoplasmic antibody-associated vasculitis, anti-glomerular basement membrane disease, and systemic lupus erythematosus, represent the most common cause of capillaritis associated with DAH.", [["anti-glomerular basement membrane", "ANATOMY", 97, 130], ["capillaritis", "ANATOMY", 209, 221], ["autoimmune diseases", "DISEASE", 9, 28], ["vasculitis", "DISEASE", 85, 95], ["anti-glomerular basement membrane disease", "DISEASE", 97, 138], ["systemic lupus erythematosus", "DISEASE", 144, 172], ["capillaritis", "DISEASE", 209, 221], ["DAH", "DISEASE", 238, 241], ["anti-neutrophil cytoplasmic antibody", "GENE_OR_GENE_PRODUCT", 37, 73], ["capillaritis", "CANCER", 209, 221], ["anti-neutrophil cytoplasmic antibody", "PROTEIN", 37, 73], ["Systemic autoimmune diseases", "PROBLEM", 0, 28], ["anti-neutrophil cytoplasmic antibody", "PROBLEM", 37, 73], ["vasculitis", "PROBLEM", 85, 95], ["anti-glomerular basement membrane disease", "PROBLEM", 97, 138], ["systemic lupus erythematosus", "PROBLEM", 144, 172], ["capillaritis", "PROBLEM", 209, 221], ["DAH", "PROBLEM", 238, 241], ["autoimmune", "OBSERVATION", 9, 19], ["anti-neutrophil cytoplasmic antibody", "OBSERVATION", 37, 73], ["vasculitis", "OBSERVATION", 85, 95], ["anti-glomerular basement membrane disease", "OBSERVATION", 97, 138], ["systemic", "OBSERVATION_MODIFIER", 144, 152], ["lupus erythematosus", "OBSERVATION", 153, 172], ["most common", "OBSERVATION_MODIFIER", 188, 199], ["capillaritis", "OBSERVATION", 209, 221], ["DAH", "OBSERVATION", 238, 241]]], ["Although rare in immunocompetent patients, lung infections can also cause alveolar microcirculation injury, secondary to generalized or lung-specific disease, and DAH [2,3].", [["lung", "ANATOMY", 43, 47], ["alveolar", "ANATOMY", 74, 82], ["lung", "ANATOMY", 136, 140], ["lung infections", "DISEASE", 43, 58], ["alveolar microcirculation injury", "DISEASE", 74, 106], ["lung-specific disease", "DISEASE", 136, 157], ["DAH", "DISEASE", 163, 166], ["patients", "ORGANISM", 33, 41], ["lung", "ORGAN", 43, 47], ["alveolar microcirculation", "MULTI-TISSUE_STRUCTURE", 74, 99], ["lung", "ORGAN", 136, 140], ["patients", "SPECIES", 33, 41], ["lung infections", "PROBLEM", 43, 58], ["alveolar microcirculation injury", "PROBLEM", 74, 106], ["generalized or lung-specific disease", "PROBLEM", 121, 157], ["DAH", "PROBLEM", 163, 166], ["rare", "OBSERVATION_MODIFIER", 9, 13], ["immunocompetent", "OBSERVATION_MODIFIER", 17, 32], ["lung", "ANATOMY", 43, 47], ["infections", "OBSERVATION", 48, 58], ["alveolar", "ANATOMY_MODIFIER", 74, 82], ["microcirculation injury", "OBSERVATION", 83, 106], ["generalized", "OBSERVATION_MODIFIER", 121, 132], ["lung", "ANATOMY", 136, 140], ["specific", "OBSERVATION_MODIFIER", 141, 149], ["disease", "OBSERVATION", 150, 157]]], ["In our patient, likely the presence of chronic alcoholism, unmanaged end-stage liver disease, decompensated liver cirrhosis, and hence baseline predisposition for bleeding diastasis played an essential role in the development of infectious DAH.DiscussionHuman metapneumovirus is an enveloped, non-segmented, negative-sense, single-stranded RNA virus [7].", [["liver", "ANATOMY", 79, 84], ["liver", "ANATOMY", 108, 113], ["alcoholism", "DISEASE", 47, 57], ["end-stage liver disease", "DISEASE", 69, 92], ["decompensated liver cirrhosis", "DISEASE", 94, 123], ["bleeding", "DISEASE", 163, 171], ["diastasis", "DISEASE", 172, 181], ["DAH", "DISEASE", 240, 243], ["DiscussionHuman metapneumovirus", "DISEASE", 244, 275], ["patient", "ORGANISM", 7, 14], ["liver", "ORGAN", 79, 84], ["liver", "ORGAN", 108, 113], ["DiscussionHuman metapneumovirus", "ORGANISM", 244, 275], ["patient", "SPECIES", 7, 14], ["DiscussionHuman metapneumovirus", "SPECIES", 244, 275], ["chronic alcoholism", "PROBLEM", 39, 57], ["unmanaged end-stage liver disease", "PROBLEM", 59, 92], ["decompensated liver cirrhosis", "PROBLEM", 94, 123], ["bleeding diastasis", "PROBLEM", 163, 181], ["infectious DAH", "PROBLEM", 229, 243], ["DiscussionHuman metapneumovirus", "PROBLEM", 244, 275], ["single-stranded RNA virus", "PROBLEM", 324, 349], ["chronic", "OBSERVATION_MODIFIER", 39, 46], ["alcoholism", "OBSERVATION", 47, 57], ["unmanaged", "OBSERVATION_MODIFIER", 59, 68], ["end", "OBSERVATION_MODIFIER", 69, 72], ["-stage", "OBSERVATION_MODIFIER", 72, 78], ["liver", "ANATOMY", 79, 84], ["disease", "OBSERVATION", 85, 92], ["decompensated", "OBSERVATION_MODIFIER", 94, 107], ["liver", "ANATOMY", 108, 113], ["cirrhosis", "OBSERVATION", 114, 123], ["bleeding", "OBSERVATION_MODIFIER", 163, 171], ["diastasis", "OBSERVATION", 172, 181], ["infectious", "OBSERVATION_MODIFIER", 229, 239], ["DAH", "OBSERVATION", 240, 243]]], ["It belongs to the order Mononegavirales in the family Paramyxoviridae, and it was the first human member of the Metapneumovirus genus in the subfamily Pneumovirinae of the family Paramyxoviridae [7,8].", [["Mononegavirales", "GENE_OR_GENE_PRODUCT", 24, 39], ["Paramyxoviridae", "GENE_OR_GENE_PRODUCT", 54, 69], ["human", "ORGANISM", 92, 97], ["Metapneumovirus genus", "ORGANISM", 112, 133], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 92, 97], ["Paramyxoviridae", "TREATMENT", 54, 69], ["Metapneumovirus", "OBSERVATION", 112, 127]]], ["Since its discovery, hMPV has been isolated on all continents and has a seasonal distribution, with outbreaks primarily occurring in the spring and winter months and accounting for up to 11% of respiratory tract infections [4,5].", [["respiratory tract", "ANATOMY", 194, 211], ["respiratory tract infections", "DISEASE", 194, 222], ["hMPV", "ORGANISM", 21, 25], ["tract", "ORGANISM_SUBDIVISION", 206, 211], ["hMPV", "SPECIES", 21, 25], ["hMPV", "PROBLEM", 21, 25], ["respiratory tract infections", "PROBLEM", 194, 222], ["hMPV", "OBSERVATION", 21, 25], ["isolated", "OBSERVATION_MODIFIER", 35, 43], ["seasonal", "OBSERVATION_MODIFIER", 72, 80], ["distribution", "OBSERVATION_MODIFIER", 81, 93], ["respiratory tract", "ANATOMY", 194, 211]]], ["It is thought to be transmitted by direct or close contact with contaminated secretions, which may involve saliva, droplets, or large particle aerosols.", [["secretions", "ANATOMY", 77, 87], ["saliva", "ORGANISM_SUBSTANCE", 107, 113], ["contaminated secretions", "PROBLEM", 64, 87], ["thought to be", "UNCERTAINTY", 6, 19], ["large", "OBSERVATION_MODIFIER", 128, 133], ["particle aerosols", "OBSERVATION", 134, 151]]], ["It has an incubation period of 5 to 9 days, with a median of 5 days [9].DiscussionIn general terms, hMPV infection cannot be distinguished from other respiratory viruses, and symptoms include fever, cough, rhinorrhea, and wheezing [5,9].", [["hMPV infection", "DISEASE", 100, 114], ["respiratory viruses", "DISEASE", 150, 169], ["fever", "DISEASE", 192, 197], ["cough", "DISEASE", 199, 204], ["rhinorrhea", "DISEASE", 206, 216], ["wheezing", "DISEASE", 222, 230], ["hMPV", "ORGANISM", 100, 104], ["hMPV", "SPECIES", 100, 104], ["hMPV infection", "PROBLEM", 100, 114], ["other respiratory viruses", "PROBLEM", 144, 169], ["symptoms", "PROBLEM", 175, 183], ["fever", "PROBLEM", 192, 197], ["cough", "PROBLEM", 199, 204], ["rhinorrhea", "PROBLEM", 206, 216], ["wheezing", "PROBLEM", 222, 230], ["incubation", "OBSERVATION_MODIFIER", 10, 20], ["infection", "OBSERVATION", 105, 114], ["respiratory viruses", "OBSERVATION", 150, 169], ["rhinorrhea", "OBSERVATION", 206, 216]]], ["The severity of the illness varies considerably, from asymptomatic carriers to acute respiratory distress syndrome.", [["respiratory", "ANATOMY", 85, 96], ["illness", "DISEASE", 20, 27], ["respiratory distress syndrome", "DISEASE", 85, 114], ["the illness", "PROBLEM", 16, 27], ["acute respiratory distress syndrome", "PROBLEM", 79, 114], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["illness", "OBSERVATION", 20, 27], ["acute", "OBSERVATION_MODIFIER", 79, 84], ["respiratory distress", "OBSERVATION", 85, 105], ["syndrome", "OBSERVATION", 106, 114]]], ["Severe disease has been mainly described in children, elderly and immunocompromised patients with underlying conditions, including asthma, cancer, and COPD [6,8,10].", [["cancer", "ANATOMY", 139, 145], ["asthma", "DISEASE", 131, 137], ["cancer", "DISEASE", 139, 145], ["COPD", "DISEASE", 151, 155], ["children", "ORGANISM", 44, 52], ["patients", "ORGANISM", 84, 92], ["cancer", "CANCER", 139, 145], ["children", "SPECIES", 44, 52], ["patients", "SPECIES", 84, 92], ["Severe disease", "PROBLEM", 0, 14], ["underlying conditions", "PROBLEM", 98, 119], ["asthma", "PROBLEM", 131, 137], ["cancer", "PROBLEM", 139, 145], ["COPD", "PROBLEM", 151, 155], ["disease", "OBSERVATION", 7, 14], ["immunocompromised", "OBSERVATION", 66, 83], ["asthma", "OBSERVATION", 131, 137], ["cancer", "OBSERVATION", 139, 145], ["COPD", "OBSERVATION", 151, 155]]], ["DAH is an uncommon manifestation of severe hMPV infection in otherwise immunocompetent patients, in which the more common pathogens include influenza A (H1N1), dengue, leptospirosis, malaria, and Staphylococcus aureus infection [3].DiscussionhMPV should be considered an emerging respiratory pathogen with a significant burden of disease in adults.", [["respiratory", "ANATOMY", 280, 291], ["DAH", "DISEASE", 0, 3], ["hMPV infection", "DISEASE", 43, 57], ["influenza A (H1N1)", "DISEASE", 140, 158], ["dengue", "DISEASE", 160, 166], ["leptospirosis", "DISEASE", 168, 181], ["malaria", "DISEASE", 183, 190], ["Staphylococcus aureus infection", "DISEASE", 196, 227], ["DiscussionhMPV", "CHEMICAL", 232, 246], ["hMPV", "ORGANISM", 43, 47], ["patients", "ORGANISM", 87, 95], ["influenza A (H1N1)", "ORGANISM", 140, 158], ["Staphylococcus aureus", "ORGANISM", 196, 217], ["patients", "SPECIES", 87, 95], ["influenza A (H1N1", "SPECIES", 140, 157], ["Staphylococcus aureus", "SPECIES", 196, 217], ["hMPV", "SPECIES", 43, 47], ["dengue", "SPECIES", 160, 166], ["Staphylococcus aureus", "SPECIES", 196, 217], ["DAH", "PROBLEM", 0, 3], ["severe hMPV infection", "PROBLEM", 36, 57], ["influenza A (H1N1)", "PROBLEM", 140, 158], ["dengue", "PROBLEM", 160, 166], ["leptospirosis", "PROBLEM", 168, 181], ["malaria", "PROBLEM", 183, 190], ["Staphylococcus aureus infection", "PROBLEM", 196, 227], ["an emerging respiratory pathogen", "PROBLEM", 268, 300], ["disease", "PROBLEM", 330, 337], ["uncommon manifestation of", "UNCERTAINTY", 10, 35], ["severe", "OBSERVATION_MODIFIER", 36, 42], ["hMPV", "OBSERVATION_MODIFIER", 43, 47], ["infection", "OBSERVATION", 48, 57], ["otherwise", "OBSERVATION_MODIFIER", 61, 70], ["immunocompetent", "OBSERVATION", 71, 86], ["influenza", "OBSERVATION", 140, 149], ["Staphylococcus aureus", "OBSERVATION", 196, 217], ["disease", "OBSERVATION", 330, 337]]], ["In a population-based surveillance study in the United States (US) by Jain [11], hMPV was isolated as a single pathogen in 4% of hospitalized adults with community-acquired pneumonia.", [["pneumonia", "DISEASE", 173, 182], ["hMPV", "ORGANISM", 81, 85], ["hMPV", "SPECIES", 81, 85], ["surveillance study", "TEST", 22, 40], ["hMPV", "PROBLEM", 81, 85], ["community-acquired pneumonia", "PROBLEM", 154, 182], ["pneumonia", "OBSERVATION", 173, 182]]], ["In one retrospective study by Hasvold [5], 31% of hospitalized patients with hMPV infection required ICU admission, and 48% of those patients met the criteria for ARDS.", [["hMPV infection", "DISEASE", 77, 91], ["ARDS", "DISEASE", 163, 167], ["patients", "ORGANISM", 63, 71], ["hMPV", "ORGANISM", 77, 81], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 63, 71], ["patients", "SPECIES", 133, 141], ["hMPV", "SPECIES", 77, 81], ["hMPV infection", "PROBLEM", 77, 91], ["ARDS", "PROBLEM", 163, 167], ["infection", "OBSERVATION", 82, 91], ["ARDS", "OBSERVATION", 163, 167]]], ["Furthermore, the latest data available from the CDC WONDER mortality database show that 72.6% of the reported deaths in the US since 2011 from hMPV pneumonia or bronchiolitis (ICD-10 codes J12.3 and J21.1, respectively) occurred from 2016 onwards, the vast majority in patients 65 years old or older (45.3%) [12].DiscussionManagement of hMPV infection is primarily supportive care as there is no standard treatment; however, promising therapy with intravenous (IV) ribavirin and IV immunoglobulin (IVIG) has been reported [13].", [["intravenous", "ANATOMY", 448, 459], ["deaths", "DISEASE", 110, 116], ["hMPV pneumonia", "DISEASE", 143, 157], ["bronchiolitis", "DISEASE", 161, 174], ["hMPV infection", "DISEASE", 337, 351], ["ribavirin", "CHEMICAL", 465, 474], ["IVIG", "CHEMICAL", 498, 502], ["ribavirin", "CHEMICAL", 465, 474], ["hMPV", "ORGANISM", 143, 147], ["patients", "ORGANISM", 269, 277], ["hMPV", "ORGANISM", 337, 341], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 448, 459], ["ribavirin", "SIMPLE_CHEMICAL", 465, 474], ["IV immunoglobulin", "SIMPLE_CHEMICAL", 479, 496], ["IVIG", "SIMPLE_CHEMICAL", 498, 502], ["IV immunoglobulin", "PROTEIN", 479, 496], ["IVIG", "PROTEIN", 498, 502], ["patients", "SPECIES", 269, 277], ["hMPV", "SPECIES", 337, 341], ["the latest data", "TEST", 13, 28], ["mortality database", "TEST", 59, 77], ["the US", "TEST", 120, 126], ["hMPV pneumonia", "PROBLEM", 143, 157], ["bronchiolitis", "PROBLEM", 161, 174], ["ICD", "TEST", 176, 179], ["hMPV infection", "PROBLEM", 337, 351], ["supportive care", "TREATMENT", 365, 380], ["standard treatment", "TREATMENT", 396, 414], ["intravenous (IV) ribavirin", "TREATMENT", 448, 474], ["IV immunoglobulin (IVIG", "TREATMENT", 479, 502], ["hMPV", "OBSERVATION_MODIFIER", 143, 147], ["pneumonia", "OBSERVATION", 148, 157], ["bronchiolitis", "OBSERVATION", 161, 174], ["hMPV infection", "OBSERVATION", 337, 351]]], ["Ribavirin is a nucleoside with activity against RNA viruses that have shown in vitro activity against hMPV and exhibited some efficacy in animal models and case series [8,9,13].", [["Ribavirin", "CHEMICAL", 0, 9], ["nucleoside", "CHEMICAL", 15, 25], ["Ribavirin", "CHEMICAL", 0, 9], ["nucleoside", "CHEMICAL", 15, 25], ["Ribavirin", "SIMPLE_CHEMICAL", 0, 9], ["nucleoside", "SIMPLE_CHEMICAL", 15, 25], ["hMPV", "ORGANISM", 102, 106], ["hMPV", "SPECIES", 102, 106], ["Ribavirin", "TREATMENT", 0, 9], ["a nucleoside", "TREATMENT", 13, 25], ["RNA viruses", "PROBLEM", 48, 59], ["hMPV", "PROBLEM", 102, 106]]], ["Commercial IVIG contains neutralizing action against hMPV that also has demonstrated prophylactic and therapeutic efficacy in animal models and case series [8,13].", [["IVIG", "CHEMICAL", 11, 15], ["IVIG", "SIMPLE_CHEMICAL", 11, 15], ["hMPV", "ORGANISM", 53, 57], ["hMPV", "SPECIES", 53, 57], ["Commercial IVIG", "TREATMENT", 0, 15], ["neutralizing action", "TREATMENT", 25, 44], ["hMPV", "PROBLEM", 53, 57], ["prophylactic", "TREATMENT", 85, 97]]], ["Most important, droplet respiratory precautions must be applied to prevent nosocomial transmission of this pathogen.DiscussionLethal hMPV infections in adults have been classically described in immunosuppressed patients.", [["respiratory", "ANATOMY", 24, 35], ["hMPV infections", "DISEASE", 133, 148], ["hMPV", "ORGANISM", 133, 137], ["adults", "ORGANISM", 152, 158], ["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 211, 219], ["droplet respiratory precautions", "TREATMENT", 16, 47], ["this pathogen", "PROBLEM", 102, 115], ["DiscussionLethal hMPV infections", "PROBLEM", 116, 148], ["infections", "OBSERVATION", 138, 148]]], ["Nevertheless, in recent years this pathogen has emerged as a significant respiratory virus that carries high morbidity and mortality, especially in the elderly population.", [["this pathogen", "PROBLEM", 30, 43], ["a significant respiratory virus", "PROBLEM", 59, 90], ["high morbidity", "PROBLEM", 104, 118], ["significant", "OBSERVATION_MODIFIER", 61, 72], ["respiratory virus", "OBSERVATION", 73, 90], ["high", "OBSERVATION_MODIFIER", 104, 108], ["morbidity", "OBSERVATION", 109, 118]]], ["Lower respiratory tract infections are rarely reported in association with DAH, but they should be considered in the differential diagnosis because of the therapeutic implications.Author contributionAll persons who meet authorship criteria are listed as authors, and all authors certify that they have participated sufficiently in this work to take public responsibility for the content, including participation in the concept, design, analysis, writing, or revision of the manuscript.", [["respiratory tract", "ANATOMY", 6, 23], ["Lower respiratory tract infections", "DISEASE", 0, 34], ["DAH", "DISEASE", 75, 78], ["Lower respiratory tract", "ORGANISM_SUBDIVISION", 0, 23], ["persons", "ORGANISM", 203, 210], ["persons", "SPECIES", 203, 210], ["Lower respiratory tract infections", "PROBLEM", 0, 34], ["DAH", "PROBLEM", 75, 78], ["respiratory tract", "ANATOMY", 6, 23], ["infections", "OBSERVATION", 24, 34], ["DAH", "OBSERVATION", 75, 78]]], ["Furthermore, each author certifies that this material or similar material has not been and will not be submitted to or published in any other publication.Informed consentWritten informed consent was obtained from the patient\u2019s next-of-kin for publication of this case report.", [["patient", "ORGANISM", 217, 224], ["patient", "SPECIES", 217, 224]]]], "PMC5069135": [["IntroductionAntisense antimicrobials are short, single-stranded oligomers that mimic the structure of DNA or RNA, and bind to specific, complementary RNA in a target organism.", [["DNA", "CELLULAR_COMPONENT", 102, 105], ["complementary RNA", "RNA", 136, 153], ["IntroductionAntisense antimicrobials", "TREATMENT", 0, 36], ["single-stranded oligomers", "TREATMENT", 48, 73], ["DNA or RNA", "PROBLEM", 102, 112], ["complementary RNA", "PROBLEM", 136, 153]]], ["In microorganisms, antisense therapeutics bind to complementary mRNA and inhibit translation or promote degradation of the targeted mRNA [1].", [["complementary mRNA", "RNA", 50, 68], ["targeted mRNA", "RNA", 123, 136], ["antisense therapeutics bind", "TREATMENT", 19, 46], ["inhibit translation", "TREATMENT", 73, 92]]], ["Although there are many chemical structures that have been designed for antisense technology, we will focus on four structural types that have recently gained the most attention (Figure 1): phosphorothioates, locked nucleic acids, peptide nucleic acids, and phosphorodiamidate morpholino oligomers, plus a few others with structural modifications of these four.IntroductionPhosphorothioate oligodeoxynucleotides (S-oligos) are analogues of phosphodiester oligonucleotides with a sulfur atom instead of one of the non-bridging oxygen atoms on the phosphate linkage.", [["nucleic acids", "CHEMICAL", 216, 229], ["nucleic acids", "CHEMICAL", 239, 252], ["phosphorodiamidate", "CHEMICAL", 258, 276], ["Phosphorothioate oligodeoxynucleotides", "CHEMICAL", 373, 411], ["S-oligos", "CHEMICAL", 413, 421], ["phosphodiester", "CHEMICAL", 440, 454], ["sulfur", "CHEMICAL", 479, 485], ["oxygen", "CHEMICAL", 526, 532], ["phosphate", "CHEMICAL", 546, 555], ["phosphorothioates", "CHEMICAL", 190, 207], ["phosphorodiamidate", "CHEMICAL", 258, 276], ["Phosphorothioate", "CHEMICAL", 373, 389], ["S-oligos", "CHEMICAL", 413, 421], ["phosphodiester", "CHEMICAL", 440, 454], ["sulfur", "CHEMICAL", 479, 485], ["oxygen", "CHEMICAL", 526, 532], ["phosphate", "CHEMICAL", 546, 555], ["phosphorothioates", "SIMPLE_CHEMICAL", 190, 207], ["nucleic acids", "SIMPLE_CHEMICAL", 216, 229], ["peptide nucleic acids", "SIMPLE_CHEMICAL", 231, 252], ["phosphorodiamidate morpholino oligomers", "SIMPLE_CHEMICAL", 258, 297], ["Phosphorothioate oligodeoxynucleotides", "SIMPLE_CHEMICAL", 373, 411], ["S-oligos", "SIMPLE_CHEMICAL", 413, 421], ["phosphodiester oligonucleotides", "SIMPLE_CHEMICAL", 440, 471], ["sulfur atom", "SIMPLE_CHEMICAL", 479, 490], ["oxygen atoms", "SIMPLE_CHEMICAL", 526, 538], ["phosphate", "SIMPLE_CHEMICAL", 546, 555], ["antisense technology", "TREATMENT", 72, 92], ["phosphorothioates", "TREATMENT", 190, 207], ["locked nucleic acids", "TREATMENT", 209, 229], ["peptide nucleic acids", "TREATMENT", 231, 252], ["phosphorodiamidate morpholino oligomers", "TREATMENT", 258, 297], ["IntroductionPhosphorothioate oligodeoxynucleotides (S-oligos)", "TREATMENT", 361, 422], ["analogues of phosphodiester oligonucleotides", "TREATMENT", 427, 471], ["a sulfur atom", "TREATMENT", 477, 490], ["the non-bridging oxygen atoms", "TREATMENT", 509, 538], ["the phosphate linkage", "TREATMENT", 542, 563], ["many", "OBSERVATION_MODIFIER", 19, 23], ["chemical", "OBSERVATION", 24, 32]]], ["This modification increases the stability of the oligonucleotide to nucleases [2, 3, 4].", [["This modification", "TREATMENT", 0, 17], ["the oligonucleotide to nucleases", "TREATMENT", 45, 77], ["stability", "OBSERVATION_MODIFIER", 32, 41]]], ["S-oligos bind to complementary mRNA and activate RNase H degradation of the targeted mRNA [1] (Figure 2).", [["S-oligos", "GENE_OR_GENE_PRODUCT", 0, 8], ["RNase H", "GENE_OR_GENE_PRODUCT", 49, 56], ["complementary mRNA", "RNA", 17, 35], ["RNase H", "PROTEIN", 49, 56], ["oligos bind", "PROBLEM", 2, 13], ["activate RNase H degradation", "TREATMENT", 40, 68]]], ["An S-oligo, fomivirsen (brand name Vitravene), is the only FDA-approved antisense therapeutic that targets a microorganism.", [["S-oligo", "CHEMICAL", 3, 10], ["fomivirsen", "CHEMICAL", 12, 22], ["Vitravene", "CHEMICAL", 35, 44], ["Vitravene", "CHEMICAL", 35, 44], ["An S-oligo, fomivirsen (brand name Vitravene", "TREATMENT", 0, 44], ["a microorganism", "PROBLEM", 107, 122]]], ["Fomivirsen was approved in 1998 for treatment of cytomegalovirus-induced retinitis [5].IntroductionLocked nucleic acids (LNAs) are oxyphosphorothioate analogues with a 2\u2032-O,4\u2032-C-methylene bridge that locks the ribose ring in the C3\u2032-endo conformation [6].", [["Fomivirsen", "CHEMICAL", 0, 10], ["cytomegalovirus-induced retinitis", "DISEASE", 49, 82], ["nucleic acids", "CHEMICAL", 106, 119], ["oxyphosphorothioate", "CHEMICAL", 131, 150], ["2\u2032-O,4\u2032-C-methylene", "CHEMICAL", 168, 187], ["ribose", "CHEMICAL", 210, 216], ["Fomivirsen", "CHEMICAL", 0, 10], ["oxyphosphorothioate", "CHEMICAL", 131, 150], ["2\u2032-O,4\u2032-C-methylene", "CHEMICAL", 168, 187], ["ribose", "CHEMICAL", 210, 216], ["Fomivirsen", "SIMPLE_CHEMICAL", 0, 10], ["cytomegalovirus", "ORGANISM", 49, 64], ["IntroductionLocked nucleic acids", "SIMPLE_CHEMICAL", 87, 119], ["LNAs", "SIMPLE_CHEMICAL", 121, 125], ["oxyphosphorothioate analogues", "SIMPLE_CHEMICAL", 131, 160], ["2\u2032-O,4\u2032-C-methylene bridge", "SIMPLE_CHEMICAL", 168, 194], ["C3\u2032", "PROTEIN", 229, 232], ["cytomegalovirus", "PROBLEM", 49, 64], ["retinitis", "PROBLEM", 73, 82], ["IntroductionLocked nucleic acids", "TREATMENT", 87, 119], ["oxyphosphorothioate analogues", "TREATMENT", 131, 160], ["C-methylene bridge", "TREATMENT", 176, 194], ["the ribose ring", "TREATMENT", 206, 221], ["cytomegalovirus", "OBSERVATION", 49, 64], ["retinitis", "OBSERVATION", 73, 82], ["ribose ring", "OBSERVATION", 210, 221]]], ["Bridged nucleic acids (BNA) are analogues of LNA, as shown in Figure 1.", [["nucleic acids", "CHEMICAL", 8, 21], ["BNA", "CHEMICAL", 23, 26], ["LNA", "CHEMICAL", 45, 48], ["Bridged nucleic acids", "SIMPLE_CHEMICAL", 0, 21], ["BNA", "SIMPLE_CHEMICAL", 23, 26], ["LNA", "SIMPLE_CHEMICAL", 45, 48], ["Bridged nucleic acids (BNA", "TREATMENT", 0, 26], ["analogues of LNA", "PROBLEM", 32, 48], ["nucleic acids", "OBSERVATION", 8, 21]]], ["LNA and BNA oligomers are stable to nucleases, have very high affinity for DNA and RNA, exhibit low toxicity, and also may act through RNase H degradation of targeted mRNA.IntroductionPeptide nucleic acids (PNAs) are constructed by attaching bases to a modified polyamide backbone [7].", [["LNA", "CHEMICAL", 0, 3], ["toxicity", "DISEASE", 100, 108], ["IntroductionPeptide nucleic acids", "CHEMICAL", 172, 205], ["polyamide", "CHEMICAL", 262, 271], ["LNA", "SIMPLE_CHEMICAL", 0, 3], ["BNA oligomers", "GENE_OR_GENE_PRODUCT", 8, 21], ["DNA", "CELLULAR_COMPONENT", 75, 78], ["RNase H", "GENE_OR_GENE_PRODUCT", 135, 142], ["IntroductionPeptide nucleic acids", "SIMPLE_CHEMICAL", 172, 205], ["nucleases", "PROTEIN", 36, 45], ["RNase H", "PROTEIN", 135, 142], ["targeted mRNA", "RNA", 158, 171], ["LNA", "PROBLEM", 0, 3], ["BNA oligomers", "PROBLEM", 8, 21], ["very high affinity", "PROBLEM", 52, 70], ["DNA and RNA", "PROBLEM", 75, 86], ["low toxicity", "PROBLEM", 96, 108], ["targeted mRNA", "PROBLEM", 158, 171], ["IntroductionPeptide nucleic acids (PNAs)", "TREATMENT", 172, 212], ["a modified polyamide backbone", "TREATMENT", 251, 280], ["stable", "OBSERVATION_MODIFIER", 26, 32], ["high affinity", "OBSERVATION_MODIFIER", 57, 70], ["low toxicity", "OBSERVATION_MODIFIER", 96, 108]]], ["They are resistant to nucleases and proteases, and act by blocking translation [8, 9].", [["nucleases", "PROTEIN", 22, 31], ["proteases", "PROTEIN", 36, 45], ["proteases", "TREATMENT", 36, 45]]], ["PNAs are uncharged, which in part accounts for their high affinity for RNA [8].IntroductionPhosphorodiamidate morpholino-oligomers (PMOs) are comprised of the same 4 bases as DNA, but have a modified linkage between bases.", [["Phosphorodiamidate", "CHEMICAL", 91, 109], ["Phosphorodiamidate", "CHEMICAL", 91, 109], ["Phosphorodiamidate morpholino-oligomers", "SIMPLE_CHEMICAL", 91, 130], ["PMOs", "SIMPLE_CHEMICAL", 132, 136], ["DNA", "CELLULAR_COMPONENT", 175, 178], ["PNAs", "PROBLEM", 0, 4], ["IntroductionPhosphorodiamidate morpholino-oligomers (PMOs", "TREATMENT", 79, 136], ["a modified linkage between bases", "PROBLEM", 189, 221], ["uncharged", "OBSERVATION_MODIFIER", 9, 18], ["bases", "ANATOMY_MODIFIER", 216, 221]]], ["A morpholine ring is substituted for the ribose, and a dimethyl amine is substituted for one of the non-bridging oxygen atoms on the phosphate linkage.", [["morpholine", "CHEMICAL", 2, 12], ["ribose", "CHEMICAL", 41, 47], ["dimethyl amine", "CHEMICAL", 55, 69], ["oxygen", "CHEMICAL", 113, 119], ["phosphate", "CHEMICAL", 133, 142], ["morpholine", "CHEMICAL", 2, 12], ["ribose", "CHEMICAL", 41, 47], ["dimethyl amine", "CHEMICAL", 55, 69], ["oxygen", "CHEMICAL", 113, 119], ["phosphate", "CHEMICAL", 133, 142], ["morpholine ring", "SIMPLE_CHEMICAL", 2, 17], ["ribose", "SIMPLE_CHEMICAL", 41, 47], ["dimethyl amine", "SIMPLE_CHEMICAL", 55, 69], ["non-bridging oxygen atoms", "SIMPLE_CHEMICAL", 100, 125], ["phosphate", "SIMPLE_CHEMICAL", 133, 142], ["A morpholine ring", "TREATMENT", 0, 17], ["the ribose", "TREATMENT", 37, 47], ["a dimethyl amine", "TREATMENT", 53, 69], ["the non-bridging oxygen atoms", "TREATMENT", 96, 125], ["the phosphate linkage", "TREATMENT", 129, 150], ["morpholine ring", "OBSERVATION", 2, 17], ["oxygen atoms", "OBSERVATION", 113, 125]]], ["PMOs are nearly net neutral in charge, water soluble, and resistant to nucleases [10].", [["PMOs", "SIMPLE_CHEMICAL", 0, 4], ["water soluble", "TREATMENT", 39, 52]]], ["PMOs act by sterically blocking initiation of translation and do not activate RNase H degradation [11, 12].", [["PMOs", "SIMPLE_CHEMICAL", 0, 4], ["RNase H", "GENE_OR_GENE_PRODUCT", 78, 85], ["RNase H", "PROTEIN", 78, 85]]], ["PMOplus are analogues of PMO with positive charged piperazinyl phosphorodiamidate linkages.IntroductionThe need for new antimicrobials has never been greater due to a limited selection of available therapeutics and the proliferation of multidrug resistant organisms.", [["PMOplus", "CHEMICAL", 0, 7], ["PMO", "CHEMICAL", 25, 28], ["piperazinyl phosphorodiamidate", "CHEMICAL", 51, 81], ["PMOplus", "CHEMICAL", 0, 7], ["PMO", "CHEMICAL", 25, 28], ["piperazinyl phosphorodiamidate", "CHEMICAL", 51, 81], ["PMOplus", "SIMPLE_CHEMICAL", 0, 7], ["PMO", "SIMPLE_CHEMICAL", 25, 28], ["piperazinyl phosphorodiamidate", "SIMPLE_CHEMICAL", 51, 81], ["analogues of PMO", "TREATMENT", 12, 28], ["positive charged piperazinyl phosphorodiamidate linkages", "TREATMENT", 34, 90], ["new antimicrobials", "TREATMENT", 116, 134], ["available therapeutics", "TREATMENT", 188, 210], ["multidrug resistant organisms", "PROBLEM", 236, 265], ["multidrug resistant", "OBSERVATION", 236, 255]]], ["Recent developments in antisense inhibition of microbial targets has shown great potential for addressing these urgent needs and presents an entirely new and exciting paradigm for drug development.", [["microbial targets", "TREATMENT", 47, 64], ["great potential", "OBSERVATION_MODIFIER", 75, 90]]], ["While antisense technology is used as a molecular tool to selectively silence RNA for identification of gene function [13, 14] or as a substitute for knockout mutations [15], this compilation is focused on antisense technology developed as therapies against microbial infections.", [["microbial infections", "DISEASE", 258, 278], ["gene function", "TEST", 104, 117], ["knockout mutations", "PROBLEM", 150, 168], ["antisense technology", "TREATMENT", 206, 226], ["microbial infections", "PROBLEM", 258, 278]]], ["Here, we will review the most recent uses of antisense technology as antivirals, antiparasitics, and antibacterials, and the future directions of this platform technology.AntiviralsAntisense technology has been used for many years to combat viral infections, including RNA viruses such as influenza virus [16, 17], dengue virus [18], coronavirus [19], and West Nile virus [20], and DNA viruses such as cytomegalovirus [21, 22], and hepatitis C virus [23\u2022\u2022].", [["viral infections", "DISEASE", 241, 257], ["influenza virus", "DISEASE", 289, 304], ["dengue virus", "DISEASE", 315, 327], ["hepatitis C", "DISEASE", 432, 443], ["influenza virus", "ORGANISM", 289, 304], ["dengue virus [18]", "ORGANISM", 315, 332], ["coronavirus [19]", "ORGANISM", 334, 350], ["West Nile virus", "ORGANISM", 356, 371], ["DNA", "CELLULAR_COMPONENT", 382, 385], ["cytomegalovirus", "ORGANISM", 402, 417], ["hepatitis C virus", "ORGANISM", 432, 449], ["influenza virus", "SPECIES", 289, 304], ["dengue virus", "SPECIES", 315, 327], ["coronavirus", "SPECIES", 334, 345], ["West Nile virus", "SPECIES", 356, 371], ["hepatitis C virus", "SPECIES", 432, 449], ["influenza virus", "SPECIES", 289, 304], ["dengue virus", "SPECIES", 315, 327], ["West Nile virus", "SPECIES", 356, 371], ["hepatitis C virus", "SPECIES", 432, 449], ["antisense technology", "TREATMENT", 45, 65], ["antivirals", "TREATMENT", 69, 79], ["antiparasitics", "TREATMENT", 81, 95], ["antibacterials", "TREATMENT", 101, 115], ["this platform technology", "TREATMENT", 146, 170], ["AntiviralsAntisense technology", "TREATMENT", 171, 201], ["viral infections", "PROBLEM", 241, 257], ["RNA viruses", "PROBLEM", 269, 280], ["influenza virus", "PROBLEM", 289, 304], ["dengue virus", "PROBLEM", 315, 327], ["coronavirus", "PROBLEM", 334, 345], ["West Nile virus", "PROBLEM", 356, 371], ["DNA viruses", "PROBLEM", 382, 393], ["cytomegalovirus", "TEST", 402, 417], ["hepatitis C virus", "PROBLEM", 432, 449], ["cytomegalovirus", "OBSERVATION", 402, 417]]], ["Recent results have shown promising efficacy of antisense oligomers against the extremely pathogenic filoviruses, Marburg and Ebola [24, 25].AntiviralsEarly work with antisense therapeutics for Ebola virus (EBOV) showed that therapeutic treatment with a combination of two PMO-based oligomers increased survival up to 90% in infected mice or guinea pigs [26].", [["filoviruses", "DISEASE", 101, 112], ["Ebola", "DISEASE", 126, 131], ["Ebola virus", "DISEASE", 194, 205], ["PMO", "CHEMICAL", 273, 276], ["Ebola", "ORGANISM", 126, 131], ["Ebola virus", "ORGANISM", 194, 205], ["EBOV", "ORGANISM", 207, 211], ["PMO", "SIMPLE_CHEMICAL", 273, 276], ["mice", "ORGANISM", 334, 338], ["guinea pigs", "ORGANISM", 342, 353], ["Ebola virus", "SPECIES", 194, 205], ["mice", "SPECIES", 334, 338], ["guinea pigs", "SPECIES", 342, 353], ["Ebola virus", "SPECIES", 194, 205], ["EBOV", "SPECIES", 207, 211], ["mice", "SPECIES", 334, 338], ["guinea pigs", "SPECIES", 342, 353], ["antisense oligomers", "TREATMENT", 48, 67], ["the extremely pathogenic filoviruses", "PROBLEM", 76, 112], ["Antivirals", "TREATMENT", 141, 151], ["antisense therapeutics", "TREATMENT", 167, 189], ["Ebola virus", "PROBLEM", 194, 205], ["therapeutic treatment", "TREATMENT", 225, 246], ["a combination of two PMO", "TREATMENT", 252, 276], ["based oligomers increased survival", "TREATMENT", 277, 311]]], ["Further tests in a rhesus monkey model of infection showed that antisense therapy increased survival up to 62%, depending on the dose, and reduced viremia, inflammation and liver damage.", [["liver", "ANATOMY", 173, 178], ["infection", "DISEASE", 42, 51], ["viremia", "DISEASE", 147, 154], ["inflammation", "DISEASE", 156, 168], ["liver damage", "DISEASE", 173, 185], ["rhesus", "ORGANISM", 19, 25], ["monkey", "ORGANISM", 26, 32], ["liver", "ORGAN", 173, 178], ["rhesus monkey", "SPECIES", 19, 32], ["rhesus monkey", "SPECIES", 19, 32], ["Further tests", "TEST", 0, 13], ["infection", "PROBLEM", 42, 51], ["antisense therapy", "TREATMENT", 64, 81], ["reduced viremia", "PROBLEM", 139, 154], ["inflammation", "PROBLEM", 156, 168], ["liver damage", "PROBLEM", 173, 185], ["infection", "OBSERVATION", 42, 51], ["viremia", "OBSERVATION", 147, 154], ["inflammation", "OBSERVATION", 156, 168], ["liver", "ANATOMY", 173, 178], ["damage", "OBSERVATION", 179, 185]]], ["More recently, Warren et al. now report that therapeutic treatment with one oligomer alone, targeting the VP24 EBOV protein, protected 75% of rhesus monkeys against a lethal EBOV infection [27\u2022\u2022].", [["EBOV infection", "DISEASE", 174, 188], ["VP24 EBOV", "ORGANISM", 106, 115], ["rhesus", "ORGANISM", 142, 148], ["monkeys", "ORGANISM", 149, 156], ["EBOV", "ORGANISM", 174, 178], ["VP24 EBOV protein", "PROTEIN", 106, 123], ["rhesus monkeys", "SPECIES", 142, 156], ["rhesus monkeys", "SPECIES", 142, 156], ["EBOV", "SPECIES", 174, 178], ["therapeutic treatment", "TREATMENT", 45, 66], ["the VP24 EBOV protein", "TREATMENT", 102, 123], ["a lethal EBOV infection", "PROBLEM", 165, 188]]], ["A particularly interesting development is that these antisense oligomers (called PMOplus [28]) did not require a cationic, membrane-penetrating peptide for efficacy.", [["membrane", "ANATOMY", 123, 131], ["membrane", "CELLULAR_COMPONENT", 123, 131], ["a cationic, membrane", "TREATMENT", 111, 131], ["penetrating peptide", "TREATMENT", 132, 151]]], ["Instead, positive charges are added to the molecular backbone of the molecule.", [["positive charges", "PROBLEM", 9, 25], ["positive charges", "OBSERVATION", 9, 25], ["backbone", "ANATOMY_MODIFIER", 53, 61], ["molecule", "ANATOMY", 69, 77]]], ["Although the mechanism is unknown by which the positive charges on the backbone enable efficacy, it appears that they enable membrane penetration and provide intracellular access to the replicating virus.AntiviralsAnother related, hemorrhagic virus, Marburg virus (MARV), is also susceptible to antisense inhibition.", [["membrane", "ANATOMY", 125, 133], ["intracellular", "ANATOMY", 158, 171], ["hemorrhagic virus", "DISEASE", 231, 248], ["Marburg virus", "DISEASE", 250, 263], ["membrane", "CELLULAR_COMPONENT", 125, 133], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 158, 171], ["hemorrhagic virus", "ORGANISM", 231, 248], ["Marburg virus", "ORGANISM", 250, 263], ["MARV", "ORGANISM", 265, 269], ["Marburg virus", "SPECIES", 250, 263], ["Marburg virus", "SPECIES", 250, 263], ["MARV", "SPECIES", 265, 269], ["membrane penetration", "TREATMENT", 125, 145], ["intracellular access", "TREATMENT", 158, 178], ["Antivirals", "TREATMENT", 204, 214], ["hemorrhagic virus", "PROBLEM", 231, 248], ["Marburg virus", "PROBLEM", 250, 263], ["antisense inhibition", "TREATMENT", 295, 315], ["hemorrhagic", "OBSERVATION_MODIFIER", 231, 242], ["virus", "OBSERVATION", 243, 248]]], ["A PMOplus that targets the MARV nucleoprotein, which is the major nucleoprotein involved in RNA encapsidation and interference with interferon signaling, showed a dose-dependent survival rate up to 100% in a non-human model of infection [29\u2022\u2022].", [["infection", "DISEASE", 227, 236], ["PMOplus", "GENE_OR_GENE_PRODUCT", 2, 9], ["MARV", "ORGANISM", 27, 31], ["interferon", "GENE_OR_GENE_PRODUCT", 132, 142], ["PMOplus", "PROTEIN", 2, 9], ["MARV nucleoprotein", "PROTEIN", 27, 45], ["interferon", "PROTEIN", 132, 142], ["MARV", "SPECIES", 27, 31], ["the MARV nucleoprotein", "PROBLEM", 23, 45], ["RNA encapsidation", "TREATMENT", 92, 109], ["interferon signaling", "TREATMENT", 132, 152], ["survival rate", "TEST", 178, 191], ["infection", "PROBLEM", 227, 236], ["RNA encapsidation", "OBSERVATION", 92, 109], ["infection", "OBSERVATION", 227, 236]]], ["This PMOplus was also tested for safety and pharmacokinetics in humans (intravenous, range of 1\u201316 mg kg\u22121 for 14 days), and the results showed no significant effects in any safety endpoint evaluated, although some non-serious adverse events were reported by the participants.AntiviralsChikungunya virus (CHIKV) is a mosquito-borne, zoonotic RNA virus that has experienced a resurgence in the last decade, with large outbreaks being seen in Africa and areas of southern Asia [30, 31, 32].", [["intravenous", "ANATOMY", 72, 83], ["Chikungunya virus (CHIKV)", "DISEASE", 286, 311], ["zoonotic RNA virus", "DISEASE", 333, 351], ["PMOplus", "SIMPLE_CHEMICAL", 5, 12], ["humans", "ORGANISM", 64, 70], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 72, 83], ["Antivirals", "ORGANISM", 276, 286], ["Chikungunya virus", "ORGANISM", 286, 303], ["CHIKV", "ORGANISM", 305, 310], ["humans", "SPECIES", 64, 70], ["participants", "SPECIES", 263, 275], ["Chikungunya virus", "SPECIES", 286, 303], ["humans", "SPECIES", 64, 70], ["Chikungunya virus", "SPECIES", 286, 303], ["CHIKV", "SPECIES", 305, 310], ["This PMOplus", "TREATMENT", 0, 12], ["pharmacokinetics in humans (intravenous", "TREATMENT", 44, 83], ["significant effects", "PROBLEM", 147, 166], ["some non-serious adverse events", "PROBLEM", 210, 241], ["AntiviralsChikungunya virus (CHIKV", "PROBLEM", 276, 310], ["zoonotic RNA virus", "PROBLEM", 333, 351], ["large outbreaks", "PROBLEM", 411, 426], ["no", "UNCERTAINTY", 144, 146], ["significant", "OBSERVATION_MODIFIER", 147, 158], ["large", "OBSERVATION_MODIFIER", 411, 416], ["outbreaks", "OBSERVATION", 417, 426]]], ["In recent work, two anti-CHIKV phosphorodiamidate morpholino oligomers (CPMOs) were designed to bind to the two open reading frames of the viral genomic RNA [33].", [["phosphorodiamidate", "CHEMICAL", 31, 49], ["CPMOs", "CHEMICAL", 72, 77], ["phosphorodiamidate", "CHEMICAL", 31, 49], ["anti-CHIKV phosphorodiamidate morpholino oligomers", "SIMPLE_CHEMICAL", 20, 70], ["CPMOs", "SIMPLE_CHEMICAL", 72, 77], ["open reading frames", "DNA", 112, 131], ["two anti-CHIKV phosphorodiamidate morpholino oligomers", "TREATMENT", 16, 70], ["viral genomic RNA", "OBSERVATION", 139, 156]]], ["The authors show that CPMO1 (targeted to ORF1) suppressed viral replication in human cells (HeLa), and significantly lowered viral titers in the tissues using a neonatal mouse model of infection.", [["cells", "ANATOMY", 85, 90], ["HeLa", "ANATOMY", 92, 96], ["tissues", "ANATOMY", 145, 152], ["CPMO1", "CHEMICAL", 22, 27], ["infection", "DISEASE", 185, 194], ["CPMO1", "GENE_OR_GENE_PRODUCT", 22, 27], ["ORF1", "GENE_OR_GENE_PRODUCT", 41, 45], ["human", "ORGANISM", 79, 84], ["cells", "CELL", 85, 90], ["HeLa", "CELL", 92, 96], ["tissues", "TISSUE", 145, 152], ["mouse", "ORGANISM", 170, 175], ["CPMO1", "PROTEIN", 22, 27], ["ORF1", "DNA", 41, 45], ["human cells", "CELL_TYPE", 79, 90], ["HeLa", "CELL_LINE", 92, 96], ["human", "SPECIES", 79, 84], ["mouse", "SPECIES", 170, 175], ["human", "SPECIES", 79, 84], ["mouse", "SPECIES", 170, 175], ["CPMO1", "TEST", 22, 27], ["viral replication in human cells", "PROBLEM", 58, 90], ["significantly lowered viral titers in the tissues", "PROBLEM", 103, 152], ["infection", "PROBLEM", 185, 194], ["human cells", "OBSERVATION", 79, 90], ["viral titers", "OBSERVATION", 125, 137], ["tissues", "ANATOMY", 145, 152], ["infection", "OBSERVATION", 185, 194]]], ["Importantly, no cytotoxicity was seen in HeLa cells nor was there any PMO-induced toxicity in the neonatal mice.AntiviralsEnterovirus 71 (EV71) is a main causative pathogen of hand, foot, and mouth disease, the impact of which is felt worldwide but primarily in Asia [34].", [["HeLa cells", "ANATOMY", 41, 51], ["hand", "ANATOMY", 176, 180], ["foot", "ANATOMY", 182, 186], ["mouth", "ANATOMY", 192, 197], ["PMO", "CHEMICAL", 70, 73], ["toxicity", "DISEASE", 82, 90], ["EV71", "DISEASE", 138, 142], ["hand, foot, and mouth disease", "DISEASE", 176, 205], ["PMO", "CHEMICAL", 70, 73], ["HeLa cells", "CELL", 41, 51], ["PMO", "SIMPLE_CHEMICAL", 70, 73], ["mice", "ORGANISM", 107, 111], ["Antivirals", "ORGANISM", 112, 122], ["Enterovirus 71", "ORGANISM", 122, 136], ["EV71", "ORGANISM", 138, 142], ["hand", "ORGANISM_SUBDIVISION", 176, 180], ["foot", "ORGANISM_SUBDIVISION", 182, 186], ["mouth", "ORGAN", 192, 197], ["HeLa cells", "CELL_LINE", 41, 51], ["mice", "SPECIES", 107, 111], ["mice", "SPECIES", 107, 111], ["Enterovirus 71", "SPECIES", 122, 136], ["EV71", "SPECIES", 138, 142], ["cytotoxicity", "PROBLEM", 16, 28], ["HeLa cells", "PROBLEM", 41, 51], ["any PMO", "PROBLEM", 66, 73], ["AntiviralsEnterovirus", "TREATMENT", 112, 133], ["mouth disease", "PROBLEM", 192, 205], ["no", "UNCERTAINTY", 13, 15], ["cytotoxicity", "OBSERVATION", 16, 28], ["pathogen", "OBSERVATION", 164, 172], ["hand", "ANATOMY", 176, 180], ["foot", "ANATOMY", 182, 186], ["mouth", "ANATOMY", 192, 197], ["disease", "OBSERVATION", 198, 205]]], ["Recent work describes EV5, an antisense phosphorothioate oligonucleotide which shows a protective effect both in vitro and in vivo [35].", [["phosphorothioate", "CHEMICAL", 40, 56], ["phosphorothioate", "CHEMICAL", 40, 56], ["EV5", "GENE_OR_GENE_PRODUCT", 22, 25], ["EV5", "DNA", 22, 25], ["an antisense phosphorothioate oligonucleotide", "TREATMENT", 27, 72], ["protective effect", "OBSERVATION_MODIFIER", 87, 104]]], ["Treatment of infected tissue culture cells with EV5 reduced viral replication, viral VP1 protein expression, and cell death.", [["tissue culture cells", "ANATOMY", 22, 42], ["cell", "ANATOMY", 113, 117], ["EV5", "CHEMICAL", 48, 51], ["death", "DISEASE", 118, 123], ["tissue culture cells", "CELL", 22, 42], ["EV5", "SIMPLE_CHEMICAL", 48, 51], ["VP1", "GENE_OR_GENE_PRODUCT", 85, 88], ["cell", "CELL", 113, 117], ["infected tissue culture cells", "CELL_LINE", 13, 42], ["viral VP1 protein", "PROTEIN", 79, 96], ["infected tissue culture cells", "PROBLEM", 13, 42], ["EV5 reduced viral replication", "PROBLEM", 48, 77], ["viral VP1 protein expression", "PROBLEM", 79, 107], ["cell death", "PROBLEM", 113, 123], ["infected tissue", "OBSERVATION", 13, 28], ["culture cells", "OBSERVATION", 29, 42], ["viral replication", "OBSERVATION", 60, 77], ["viral VP1 protein expression", "OBSERVATION", 79, 107], ["cell death", "OBSERVATION", 113, 123]]], ["When administered in vivo using a mouse model of EV71 infection, EV5 protected 70\u201390% of mice and reduced viral replication in selected organs.AntiviralsHepatitis B virus (HBV) is carried by approximately 350 million people worldwide with 0.5\u20131 million dying annually due to hepatocellular carcinoma or chronic HBV liver failure [36, 37].", [["organs", "ANATOMY", 136, 142], ["hepatocellular carcinoma", "ANATOMY", 275, 299], ["liver", "ANATOMY", 315, 320], ["EV71 infection", "DISEASE", 49, 63], ["EV5", "CHEMICAL", 65, 68], ["Hepatitis B", "DISEASE", 153, 164], ["hepatocellular carcinoma", "DISEASE", 275, 299], ["HBV liver failure", "DISEASE", 311, 328], ["mouse", "ORGANISM", 34, 39], ["EV71", "ORGANISM", 49, 53], ["EV5", "GENE_OR_GENE_PRODUCT", 65, 68], ["mice", "ORGANISM", 89, 93], ["organs", "ORGAN", 136, 142], ["Antivirals", "ORGANISM", 143, 153], ["Hepatitis B virus", "ORGANISM", 153, 170], ["HBV", "ORGANISM", 172, 175], ["people", "ORGANISM", 217, 223], ["hepatocellular carcinoma", "CANCER", 275, 299], ["liver", "ORGAN", 315, 320], ["mouse", "SPECIES", 34, 39], ["mice", "SPECIES", 89, 93], ["Hepatitis B virus", "SPECIES", 153, 170], ["people", "SPECIES", 217, 223], ["mouse", "SPECIES", 34, 39], ["EV71", "SPECIES", 49, 53], ["EV5", "SPECIES", 65, 68], ["mice", "SPECIES", 89, 93], ["Hepatitis B virus", "SPECIES", 153, 170], ["HBV", "SPECIES", 172, 175], ["HBV", "SPECIES", 311, 314], ["EV71 infection", "PROBLEM", 49, 63], ["EV5", "TEST", 65, 68], ["reduced viral replication in selected organs", "PROBLEM", 98, 142], ["Antivirals", "TREATMENT", 143, 153], ["Hepatitis B virus (HBV", "PROBLEM", 153, 175], ["hepatocellular carcinoma", "PROBLEM", 275, 299], ["chronic HBV liver failure", "PROBLEM", 303, 328], ["viral replication", "OBSERVATION", 106, 123], ["hepatocellular", "ANATOMY", 275, 289], ["carcinoma", "OBSERVATION", 290, 299], ["chronic", "OBSERVATION_MODIFIER", 303, 310], ["HBV", "OBSERVATION", 311, 314], ["liver", "ANATOMY", 315, 320], ["failure", "OBSERVATION", 321, 328]]], ["The HBV S gene encodes the three envelope proteins which comprise the Hepatitis B surface antigens (HBsAg) [38].", [["HBsAg", "CHEMICAL", 100, 105], ["HBV S", "GENE_OR_GENE_PRODUCT", 4, 9], ["Hepatitis B surface antigens", "GENE_OR_GENE_PRODUCT", 70, 98], ["HBsAg", "GENE_OR_GENE_PRODUCT", 100, 105], ["HBV S gene", "DNA", 4, 14], ["envelope proteins", "PROTEIN", 33, 50], ["Hepatitis B surface antigens", "PROTEIN", 70, 98], ["HBsAg", "PROTEIN", 100, 105], ["HBV", "SPECIES", 4, 7], ["Hepatitis B", "SPECIES", 70, 81], ["The HBV S gene", "TEST", 0, 14], ["the three envelope proteins", "PROBLEM", 23, 50], ["the Hepatitis B surface antigens", "TEST", 66, 98], ["HBsAg", "TEST", 100, 105], ["HBV", "OBSERVATION", 4, 7], ["Hepatitis", "OBSERVATION", 70, 79]]], ["The HBcAg, encoded by the C gene, is found in the core of the nucleocapsid and is a precursor to the secretion of HBeAg [39].", [["HBeAg", "CHEMICAL", 114, 119], ["HBcAg", "GENE_OR_GENE_PRODUCT", 4, 9], ["C", "GENE_OR_GENE_PRODUCT", 26, 27], ["nucleocapsid", "CELLULAR_COMPONENT", 62, 74], ["HBeAg", "GENE_OR_GENE_PRODUCT", 114, 119], ["HBcAg", "PROTEIN", 4, 9], ["C gene", "DNA", 26, 32], ["The HBcAg", "TEST", 0, 9], ["HBeAg", "TEST", 114, 119], ["nucleocapsid", "OBSERVATION", 62, 74]]], ["Deng et al. synthesized 3 locked nucleic acids targeted to either the HBV S gene, C gene, or the S/C double gene, encapsulated each in liposomes, and treated HBV transgenic mice [40].", [["nucleic acids", "CHEMICAL", 33, 46], ["HBV S gene", "GENE_OR_GENE_PRODUCT", 70, 80], ["C", "GENE_OR_GENE_PRODUCT", 82, 83], ["S/C", "GENE_OR_GENE_PRODUCT", 97, 100], ["liposomes", "SIMPLE_CHEMICAL", 135, 144], ["HBV", "ORGANISM", 158, 161], ["mice", "ORGANISM", 173, 177], ["HBV S gene", "DNA", 70, 80], ["C gene", "DNA", 82, 88], ["S/C double gene", "DNA", 97, 112], ["mice", "SPECIES", 173, 177], ["HBV", "SPECIES", 70, 73], ["HBV", "SPECIES", 158, 161], ["mice", "SPECIES", 173, 177], ["synthesized 3 locked nucleic acids", "TREATMENT", 12, 46], ["the S/C double gene, encapsulated each in liposomes", "TREATMENT", 93, 144]]], ["The results show that all three treatments decreased HBV DNA replication, but the dual-target S/C LNA showed the greatest reduction.", [["LNA", "CHEMICAL", 98, 101], ["HBV", "ORGANISM", 53, 56], ["DNA", "CELLULAR_COMPONENT", 57, 60], ["HBV", "SPECIES", 53, 56], ["all three treatments", "TREATMENT", 22, 42], ["HBV DNA replication", "TREATMENT", 53, 72], ["the dual-target S/C LNA", "TEST", 78, 101], ["the greatest reduction", "TREATMENT", 109, 131], ["greatest", "OBSERVATION_MODIFIER", 113, 121], ["reduction", "OBSERVATION_MODIFIER", 122, 131]]], ["Furthermore, each of the three HBV LNAs reduced the number of HBsAg-positive or HBcAg-positive liver cells as measured by immunohistochemistry.", [["liver cells", "ANATOMY", 95, 106], ["HBsAg", "CHEMICAL", 62, 67], ["HBV", "ORGANISM", 31, 34], ["LNAs", "GENE_OR_GENE_PRODUCT", 35, 39], ["HBsAg", "GENE_OR_GENE_PRODUCT", 62, 67], ["HBcAg", "GENE_OR_GENE_PRODUCT", 80, 85], ["HBsAg", "PROTEIN", 62, 67], ["HBcAg", "PROTEIN", 80, 85], ["positive liver cells", "CELL_TYPE", 86, 106], ["HBV", "SPECIES", 31, 34], ["the three HBV LNAs", "TEST", 21, 39], ["HBsAg", "TEST", 62, 67], ["HBcAg", "TEST", 80, 85], ["positive liver cells", "PROBLEM", 86, 106], ["immunohistochemistry", "TEST", 122, 142], ["liver", "ANATOMY", 95, 100], ["cells", "OBSERVATION", 101, 106]]], ["These results, taken with the findings that there was no obvious toxicity, suggest that these LNAs warrant further consideration as therapies against HBV.AntiviralsWork by Billioud et al. also targeted HBsAg production, but used a 2\u2032-O-methoxyethyl-modified phosphorothioate to enhance potency and stability [41\u2022].", [["toxicity", "DISEASE", 65, 73], ["HBsAg", "CHEMICAL", 202, 207], ["2\u2032-O-methoxyethyl", "CHEMICAL", 231, 248], ["phosphorothioate", "CHEMICAL", 258, 274], ["2\u2032-O-methoxyethyl", "CHEMICAL", 231, 248], ["phosphorothioate", "CHEMICAL", 258, 274], ["LNAs", "GENE_OR_GENE_PRODUCT", 94, 98], ["HBV", "ORGANISM", 150, 153], ["HBsAg", "GENE_OR_GENE_PRODUCT", 202, 207], ["2\u2032-O-methoxyethyl-modified phosphorothioate", "SIMPLE_CHEMICAL", 231, 274], ["HBsAg", "PROTEIN", 202, 207], ["HBV", "SPECIES", 150, 153], ["obvious toxicity", "PROBLEM", 57, 73], ["these LNAs", "PROBLEM", 88, 98], ["therapies", "TREATMENT", 132, 141], ["HBV", "PROBLEM", 150, 153], ["AntiviralsWork", "TREATMENT", 154, 168], ["targeted HBsAg production", "PROBLEM", 193, 218], ["methoxyethyl", "TREATMENT", 236, 248], ["modified phosphorothioate", "TREATMENT", 249, 274], ["no obvious", "UNCERTAINTY", 54, 64], ["HBsAg", "OBSERVATION", 202, 207]]], ["In a hepatoma culture, the HBsAg oligomer reduced HBV RNA and DNA, as well as HBsAg and HBeAg proteins.", [["hepatoma culture", "ANATOMY", 5, 21], ["HBsAg", "CHEMICAL", 27, 32], ["HBsAg", "CHEMICAL", 78, 83], ["HBeAg", "CHEMICAL", 88, 93], ["hepatoma culture", "CELL", 5, 21], ["HBsAg", "GENE_OR_GENE_PRODUCT", 27, 32], ["HBV", "ORGANISM", 50, 53], ["DNA", "CELLULAR_COMPONENT", 62, 65], ["HBsAg", "GENE_OR_GENE_PRODUCT", 78, 83], ["HBeAg", "GENE_OR_GENE_PRODUCT", 88, 93], ["HBsAg oligomer", "RNA", 27, 41], ["HBV RNA", "RNA", 50, 57], ["HBsAg", "PROTEIN", 78, 83], ["HBeAg proteins", "PROTEIN", 88, 102], ["HBV", "SPECIES", 50, 53], ["a hepatoma culture", "TEST", 3, 21], ["the HBsAg oligomer", "TEST", 23, 41], ["HBV RNA", "PROBLEM", 50, 57], ["DNA", "TEST", 62, 65], ["HBsAg", "TEST", 78, 83], ["HBeAg proteins", "TEST", 88, 102], ["hepatoma", "ANATOMY", 5, 13]]], ["When administered to HBV transgenic mice, the HBsAg oligomer decreased HBsAg and HBeAg serum levels within the first days of treatment, which then remained below the original levels for three weeks.AntiviralsHepatitis C virus (HCV) affects 170 million people and is a major causative agent of chronic liver diseases such as cirrhosis and hepatocellular carcinoma [42].", [["serum", "ANATOMY", 87, 92], ["liver", "ANATOMY", 301, 306], ["hepatocellular carcinoma", "ANATOMY", 338, 362], ["HBsAg", "CHEMICAL", 46, 51], ["HBsAg", "CHEMICAL", 71, 76], ["HBeAg", "CHEMICAL", 81, 86], ["Hepatitis C", "DISEASE", 208, 219], ["chronic liver diseases", "DISEASE", 293, 315], ["cirrhosis", "DISEASE", 324, 333], ["hepatocellular carcinoma", "DISEASE", 338, 362], ["HBV transgenic mice", "ORGANISM", 21, 40], ["HBsAg", "GENE_OR_GENE_PRODUCT", 46, 51], ["HBsAg", "GENE_OR_GENE_PRODUCT", 71, 76], ["HBeAg", "GENE_OR_GENE_PRODUCT", 81, 86], ["serum", "ORGANISM_SUBSTANCE", 87, 92], ["Antivirals", "ORGANISM", 198, 208], ["Hepatitis C virus", "ORGANISM", 208, 225], ["HCV", "ORGANISM", 227, 230], ["people", "ORGANISM", 252, 258], ["liver", "ORGAN", 301, 306], ["hepatocellular carcinoma", "CANCER", 338, 362], ["HBsAg", "PROTEIN", 71, 76], ["mice", "SPECIES", 36, 40], ["Hepatitis C virus", "SPECIES", 208, 225], ["people", "SPECIES", 252, 258], ["HBV", "SPECIES", 21, 24], ["mice", "SPECIES", 36, 40], ["Hepatitis C virus", "SPECIES", 208, 225], ["HCV", "SPECIES", 227, 230], ["HBV transgenic mice", "TREATMENT", 21, 40], ["the HBsAg oligomer", "TEST", 42, 60], ["HBsAg", "TEST", 71, 76], ["HBeAg serum levels", "TEST", 81, 99], ["treatment", "TREATMENT", 125, 134], ["AntiviralsHepatitis C virus (HCV)", "PROBLEM", 198, 231], ["chronic liver diseases", "PROBLEM", 293, 315], ["cirrhosis", "PROBLEM", 324, 333], ["hepatocellular carcinoma", "PROBLEM", 338, 362], ["chronic", "OBSERVATION_MODIFIER", 293, 300], ["liver", "ANATOMY", 301, 306], ["diseases", "OBSERVATION", 307, 315], ["cirrhosis", "OBSERVATION", 324, 333], ["hepatocellular", "ANATOMY", 338, 352], ["carcinoma", "OBSERVATION", 353, 362]]], ["Miravirsen is a 15-base \u03b2-d-oxy-LNA-modified phosphorothioate antisense oligonucleotide complementary to part of miR-122, a liver-specific miRNA expressed in hepatocytes and important factor for HCV virus replication [43, 44].", [["liver", "ANATOMY", 124, 129], ["hepatocytes", "ANATOMY", 158, 169], ["Miravirsen", "CHEMICAL", 0, 10], ["LNA", "CHEMICAL", 32, 35], ["phosphorothioate", "CHEMICAL", 45, 61], ["Miravirsen", "CHEMICAL", 0, 10], ["\u03b2-d-oxy-LNA", "CHEMICAL", 24, 35], ["phosphorothioate", "CHEMICAL", 45, 61], ["Miravirsen", "SIMPLE_CHEMICAL", 0, 10], ["\u03b2-d-oxy-LNA", "SIMPLE_CHEMICAL", 24, 35], ["miR-122", "GENE_OR_GENE_PRODUCT", 113, 120], ["liver", "ORGAN", 124, 129], ["hepatocytes", "CELL", 158, 169], ["HCV virus", "ORGANISM", 195, 204], ["miR-122", "DNA", 113, 120], ["hepatocytes", "CELL_TYPE", 158, 169], ["HCV virus", "SPECIES", 195, 204], ["d-oxy", "TREATMENT", 26, 31], ["LNA", "TREATMENT", 32, 35], ["modified phosphorothioate antisense oligonucleotide complementary", "TREATMENT", 36, 101], ["HCV virus replication", "TREATMENT", 195, 216], ["liver", "ANATOMY", 124, 129], ["hepatocytes", "ANATOMY", 158, 169]]], ["Recently, Ottosen et al. showed that treatment with miravirsen has an additive antiviral effect when used in conjunction with inhibitors of nonstructural HCV proteins [23\u2022\u2022].", [["miravirsen", "CHEMICAL", 52, 62], ["miravirsen", "CHEMICAL", 52, 62], ["miravirsen", "SIMPLE_CHEMICAL", 52, 62], ["nonstructural HCV proteins", "PROTEIN", 140, 166], ["HCV", "SPECIES", 154, 157], ["treatment", "TREATMENT", 37, 46], ["miravirsen", "TREATMENT", 52, 62], ["an additive antiviral effect", "TREATMENT", 67, 95], ["inhibitors", "TREATMENT", 126, 136], ["nonstructural HCV proteins", "PROBLEM", 140, 166]]], ["Importantly, miravirsen alone is active against HCV replicons resistant to these inhibitors.", [["miravirsen", "CHEMICAL", 13, 23], ["miravirsen", "CHEMICAL", 13, 23], ["miravirsen", "SIMPLE_CHEMICAL", 13, 23], ["HCV", "ORGANISM", 48, 51], ["HCV", "SPECIES", 48, 51], ["miravirsen", "TREATMENT", 13, 23], ["HCV replicons", "TREATMENT", 48, 61], ["these inhibitors", "TREATMENT", 75, 91]]], ["Currently, humans who have received miravirsen in Phase 2 clinical trials exhibit a prolonged decrease in plasma miR-122 levels [45].", [["plasma", "ANATOMY", 106, 112], ["miravirsen", "CHEMICAL", 36, 46], ["miR-122", "CHEMICAL", 113, 120], ["miravirsen", "CHEMICAL", 36, 46], ["humans", "ORGANISM", 11, 17], ["plasma", "ORGANISM_SUBSTANCE", 106, 112], ["miR-122", "GENE_OR_GENE_PRODUCT", 113, 120], ["humans", "SPECIES", 11, 17], ["humans", "SPECIES", 11, 17], ["miravirsen in Phase", "TREATMENT", 36, 55], ["a prolonged decrease", "PROBLEM", 82, 102], ["plasma miR", "TEST", 106, 116]]], ["Although miravirsen appears effective in clinical trials, its commercial fate is unknown, particularly since the introduction of effective small molecule inhibitors of HCV, Sovaldi and Harvoni [46].AntiparasiticsWhile parasitic diseases continue to affect hundreds of millions of people worldwide, most current therapies are outdated and have deleterious side effects [47].", [["miravirsen", "CHEMICAL", 9, 19], ["parasitic diseases", "DISEASE", 218, 236], ["miravirsen", "CHEMICAL", 9, 19], ["miravirsen", "SIMPLE_CHEMICAL", 9, 19], ["HCV", "ORGANISM", 168, 171], ["Sovaldi", "SIMPLE_CHEMICAL", 173, 180], ["people", "ORGANISM", 280, 286], ["people", "SPECIES", 280, 286], ["HCV", "SPECIES", 168, 171], ["miravirsen", "PROBLEM", 9, 19], ["effective small molecule inhibitors", "TREATMENT", 129, 164], ["HCV", "TREATMENT", 168, 171], ["Sovaldi", "TREATMENT", 173, 180], ["Harvoni", "TREATMENT", 185, 192], ["Antiparasitics", "TREATMENT", 198, 212], ["parasitic diseases", "PROBLEM", 218, 236], ["deleterious side effects", "PROBLEM", 343, 367], ["effective", "OBSERVATION_MODIFIER", 28, 37], ["parasitic diseases", "OBSERVATION", 218, 236]]], ["Anti-parasitic drug discovery is fraught with difficulties, mainly because of the biological complexity of parasites associated with the physiologic changes during parasitic life cycles.", [["parasites", "PROBLEM", 107, 116], ["the physiologic changes", "PROBLEM", 133, 156], ["parasitic life cycles", "TREATMENT", 164, 185], ["parasites", "OBSERVATION", 107, 116]]], ["These recent studies with gene-specific antisense therapeutics against parasite infections pave the way for further development.AntiparasiticsThe malaria-causing parasite Plasmodium falciparum replicates inside red blood cells and infects an estimated 350\u2013600 million people per year [50].", [["red blood cells", "ANATOMY", 211, 226], ["parasite infections", "DISEASE", 71, 90], ["malaria", "DISEASE", 146, 153], ["Plasmodium falciparum", "DISEASE", 171, 192], ["Plasmodium", "ORGANISM", 171, 181], ["falciparum", "ORGANISM", 182, 192], ["red blood cells", "CELL", 211, 226], ["red blood cells", "CELL_TYPE", 211, 226], ["Plasmodium falciparum", "SPECIES", 171, 192], ["people", "SPECIES", 268, 274], ["Plasmodium falciparum", "SPECIES", 171, 192], ["These recent studies", "TEST", 0, 20], ["specific antisense therapeutics", "TREATMENT", 31, 62], ["parasite infections", "PROBLEM", 71, 90], ["The malaria", "PROBLEM", 142, 153], ["parasite Plasmodium falciparum", "PROBLEM", 162, 192], ["red blood cells", "TEST", 211, 226], ["malaria", "OBSERVATION", 146, 153], ["parasite", "OBSERVATION_MODIFIER", 162, 170], ["Plasmodium falciparum", "OBSERVATION", 171, 192], ["blood cells", "ANATOMY", 215, 226]]], ["A unique feature of P. falciparum is a genome comprised of 80% AT base pairs [51].", [["P. falciparum", "DISEASE", 20, 33], ["P. falciparum", "ORGANISM", 20, 33], ["P. falciparum", "SPECIES", 20, 33], ["P. falciparum", "SPECIES", 20, 33], ["P. falciparum", "PROBLEM", 20, 33], ["P. falciparum", "OBSERVATION", 20, 33]]], ["This distinction from the human genome makes the P. falciparum genome a great candidate for targeting by sequence-specific inhibitors.", [["human", "ORGANISM", 26, 31], ["P. falciparum", "ORGANISM", 49, 62], ["human genome", "DNA", 26, 38], ["P. falciparum genome", "DNA", 49, 69], ["human", "SPECIES", 26, 31], ["P. falciparum", "SPECIES", 49, 62], ["human", "SPECIES", 26, 31], ["P. falciparum", "SPECIES", 49, 62], ["the P. falciparum genome", "PROBLEM", 45, 69], ["specific inhibitors", "TREATMENT", 114, 133], ["human genome", "OBSERVATION", 26, 38]]], ["Kolevzon et al. utilized a PNA to alter gene expression in P. falciparum [52\u2022\u2022].", [["P. falciparum", "DISEASE", 59, 72], ["PNA", "SIMPLE_CHEMICAL", 27, 30], ["P. falciparum", "ORGANISM", 59, 72], ["P. falciparum", "SPECIES", 59, 72], ["P. falciparum", "SPECIES", 59, 72], ["a PNA", "PROBLEM", 25, 30], ["PNA", "OBSERVATION", 27, 30]]], ["The PNA targeted PfSec13, which is an ortholog of Sec13, a conserved nucleoporin that is essential for viability in P. falciparum [53].", [["P. falciparum", "DISEASE", 116, 129], ["PNA", "SIMPLE_CHEMICAL", 4, 7], ["PfSec13", "GENE_OR_GENE_PRODUCT", 17, 24], ["Sec13", "GENE_OR_GENE_PRODUCT", 50, 55], ["nucleoporin", "GENE_OR_GENE_PRODUCT", 69, 80], ["P. falciparum", "ORGANISM", 116, 129], ["PfSec13", "PROTEIN", 17, 24], ["Sec13", "PROTEIN", 50, 55], ["nucleoporin", "PROTEIN", 69, 80], ["P. falciparum", "SPECIES", 116, 129], ["P. falciparum", "SPECIES", 116, 129], ["The PNA", "TEST", 0, 7], ["a conserved nucleoporin", "TREATMENT", 57, 80], ["PNA", "OBSERVATION", 4, 7]]], ["As a means to facilitate solubility and permeability through the cell membranes, the PNA was conjugated to a poly-d-lysine.", [["cell membranes", "ANATOMY", 65, 79], ["poly-d-lysine", "CHEMICAL", 109, 122], ["poly-d-lysine", "CHEMICAL", 109, 122], ["cell membranes", "CELLULAR_COMPONENT", 65, 79], ["PNA", "SIMPLE_CHEMICAL", 85, 88], ["poly-d-lysine", "SIMPLE_CHEMICAL", 109, 122], ["the cell membranes", "TREATMENT", 61, 79], ["the PNA", "PROBLEM", 81, 88], ["a poly-d-lysine", "TREATMENT", 107, 122], ["cell membranes", "OBSERVATION", 65, 79], ["PNA", "OBSERVATION", 85, 88]]], ["The results show that the Sec13 PNA reached the nucleus, downregulated PfSec13 expression, and decreased viability of the parasite in culture.AntiparasiticsA different group targeted essential genes of P. falciparum, involved in apicoplast biogenesis (PfDXR), membrane biosynthesis (PfPMT), and drug/metabolite transport (PfCRT) [54].", [["nucleus", "ANATOMY", 48, 55], ["apicoplast", "ANATOMY", 229, 239], ["membrane", "ANATOMY", 260, 268], ["AntiparasiticsA", "CHEMICAL", 142, 157], ["P. falciparum", "DISEASE", 202, 215], ["Sec13 PNA", "GENE_OR_GENE_PRODUCT", 26, 35], ["nucleus", "CELLULAR_COMPONENT", 48, 55], ["PfSec13", "GENE_OR_GENE_PRODUCT", 71, 78], ["P. falciparum", "ORGANISM", 202, 215], ["apicoplast", "CELLULAR_COMPONENT", 229, 239], ["PfDXR", "GENE_OR_GENE_PRODUCT", 252, 257], ["membrane", "CELLULAR_COMPONENT", 260, 268], ["Sec13 PNA", "PROTEIN", 26, 35], ["PfSec13", "PROTEIN", 71, 78], ["essential genes", "DNA", 183, 198], ["PfDXR", "PROTEIN", 252, 257], ["P. falciparum", "SPECIES", 202, 215], ["P. falciparum", "SPECIES", 202, 215], ["the Sec13 PNA", "PROBLEM", 22, 35], ["decreased viability of the parasite in culture", "PROBLEM", 95, 141], ["AntiparasiticsA", "TREATMENT", 142, 157], ["P. falciparum", "PROBLEM", 202, 215], ["membrane biosynthesis (PfPMT)", "TREATMENT", 260, 289], ["PNA", "OBSERVATION", 32, 35], ["nucleus", "ANATOMY", 48, 55], ["downregulated", "OBSERVATION_MODIFIER", 57, 70], ["PfSec13 expression", "OBSERVATION", 71, 89], ["decreased", "OBSERVATION_MODIFIER", 95, 104], ["viability", "OBSERVATION_MODIFIER", 105, 114], ["parasite", "OBSERVATION_MODIFIER", 122, 130]]], ["Peptide-conjugated PMOs (PPMOs) and octa-guanidinium-conjugated PMOs (VMOs) [55] were constructed and tested in culture.", [["PMOs", "CHEMICAL", 19, 23], ["PPMOs", "CHEMICAL", 25, 30], ["octa-guanidinium", "CHEMICAL", 36, 52], ["PMOs", "CHEMICAL", 19, 23], ["PPMOs", "CHEMICAL", 25, 30], ["octa-guanidinium", "CHEMICAL", 36, 52], ["PMOs", "CHEMICAL", 64, 68], ["VMOs", "CHEMICAL", 70, 74], ["Peptide-conjugated PMOs", "SIMPLE_CHEMICAL", 0, 23], ["PPMOs", "SIMPLE_CHEMICAL", 25, 30], ["octa-guanidinium-conjugated PMOs", "SIMPLE_CHEMICAL", 36, 68], ["VMOs", "SIMPLE_CHEMICAL", 70, 74], ["PPMOs", "PROTEIN", 25, 30], ["VMOs", "PROTEIN", 70, 74], ["Peptide-conjugated PMOs", "TREATMENT", 0, 23], ["PPMOs", "TEST", 25, 30], ["octa-guanidinium", "TEST", 36, 52], ["culture", "TEST", 112, 119]]], ["Exposure of the parasite to the conjugates decreased target RNA expression and inhibited parasite viability inside red blood cells.", [["red blood cells", "ANATOMY", 115, 130], ["red blood cells", "CELL", 115, 130], ["red blood cells", "CELL_TYPE", 115, 130], ["parasite viability", "TEST", 89, 107], ["red blood cells", "TEST", 115, 130], ["parasite", "OBSERVATION", 16, 24], ["RNA expression", "OBSERVATION", 60, 74], ["parasite", "OBSERVATION_MODIFIER", 89, 97], ["viability", "OBSERVATION_MODIFIER", 98, 107], ["blood cells", "OBSERVATION", 119, 130]]], ["Notably, the authors are able to restore chloroquine sensitivity to a resistant strain of P. falciparum by treating it with PfCRT-VMO.AntiparasiticsChagas\u2019 disease is caused by the parasite Trypanosoma cruzi and is historically found in rural Latin America [56].", [["chloroquine", "CHEMICAL", 41, 52], ["P. falciparum", "DISEASE", 90, 103], ["PfCRT", "CHEMICAL", 124, 129], ["Chagas\u2019 disease", "DISEASE", 148, 163], ["Trypanosoma cruzi", "DISEASE", 190, 207], ["chloroquine", "CHEMICAL", 41, 52], ["chloroquine", "SIMPLE_CHEMICAL", 41, 52], ["P. falciparum", "ORGANISM", 90, 103], ["PfCRT-VMO", "SIMPLE_CHEMICAL", 124, 133], ["Trypanosoma cruzi", "ORGANISM", 190, 207], ["P. falciparum", "SPECIES", 90, 103], ["Trypanosoma cruzi", "SPECIES", 190, 207], ["P. falciparum", "SPECIES", 90, 103], ["Trypanosoma cruzi", "SPECIES", 190, 207], ["chloroquine sensitivity", "TREATMENT", 41, 64], ["P. falciparum", "TREATMENT", 90, 103], ["AntiparasiticsChagas\u2019 disease", "PROBLEM", 134, 163], ["the parasite Trypanosoma cruzi", "PROBLEM", 177, 207], ["parasite", "OBSERVATION_MODIFIER", 181, 189], ["Trypanosoma cruzi", "OBSERVATION", 190, 207]]], ["The disease affects approximately eight million people, and 25\u201335% of those infected will develop cardiomyopathy [57, 58].", [["cardiomyopathy", "DISEASE", 98, 112], ["people", "ORGANISM", 48, 54], ["people", "SPECIES", 48, 54], ["The disease", "PROBLEM", 0, 11], ["cardiomyopathy", "PROBLEM", 98, 112], ["disease", "OBSERVATION", 4, 11], ["approximately", "OBSERVATION_MODIFIER", 20, 33], ["eight", "OBSERVATION_MODIFIER", 34, 39]]], ["Hashimoto et al. utilized phosphorothioate antisense oligos (S-oligos) targeted to T. cruzi inositol 1,4,5-triphosphate receptor (TcIP3R) mRNA [59].", [["phosphorothioate", "CHEMICAL", 26, 42], ["S-oligos", "CHEMICAL", 61, 69], ["inositol 1,4,5-triphosphate", "CHEMICAL", 92, 119], ["phosphorothioate", "CHEMICAL", 26, 42], ["inositol 1,4,5-triphosphate", "CHEMICAL", 92, 119], ["phosphorothioate", "SIMPLE_CHEMICAL", 26, 42], ["S-oligos", "SIMPLE_CHEMICAL", 61, 69], ["T. cruzi inositol 1,4,5-triphosphate receptor", "GENE_OR_GENE_PRODUCT", 83, 128], ["TcIP3R", "GENE_OR_GENE_PRODUCT", 130, 136], ["T. cruzi inositol 1,4,5-triphosphate receptor (TcIP3R) mRNA", "RNA", 83, 142], ["T. cruzi", "SPECIES", 83, 91], ["T. cruzi", "SPECIES", 83, 91], ["phosphorothioate antisense oligos (S-oligos)", "TREATMENT", 26, 70], ["T. cruzi inositol", "TEST", 83, 100], ["triphosphate receptor (TcIP3R)", "TREATMENT", 107, 137]]], ["TcIP3R is an essential protein required for the parasitic invasion into host cells [60].", [["cells", "ANATOMY", 77, 82], ["TcIP3R", "GENE_OR_GENE_PRODUCT", 0, 6], ["host cells", "CELL", 72, 82], ["TcIP3R", "PROTEIN", 0, 6], ["host cells", "CELL_TYPE", 72, 82], ["an essential protein", "PROBLEM", 10, 30], ["the parasitic invasion into host cells", "PROBLEM", 44, 82], ["parasitic", "OBSERVATION_MODIFIER", 48, 57], ["invasion", "OBSERVATION", 58, 66]]], ["The results show that the antisense oligomer (antisense 5995) decreased the level of the TcIP3R in T. cruzi trypomastigotes.", [["trypomastigotes", "ANATOMY", 108, 123], ["antisense 5995", "CHEMICAL", 46, 60], ["TcIP3R", "GENE_OR_GENE_PRODUCT", 89, 95], ["T. cruzi trypomastigotes", "ORGANISM", 99, 123], ["TcIP3R", "PROTEIN", 89, 95], ["T. cruzi", "SPECIES", 99, 107], ["T. cruzi", "SPECIES", 99, 107], ["the antisense oligomer (antisense", "TREATMENT", 22, 55], ["cruzi trypomastigotes", "OBSERVATION", 102, 123]]], ["Moreover, this decrease of TcIP3R corresponded with an inhibition of invasion of T. cruzi into 3T3-Swiss albino cells and HeLa cells.", [["3T3-Swiss albino cells", "ANATOMY", 95, 117], ["HeLa cells", "ANATOMY", 122, 132], ["TcIP3R", "GENE_OR_GENE_PRODUCT", 27, 33], ["T. cruzi", "ORGANISM", 81, 89], ["3T3-Swiss albino cells", "CELL", 95, 117], ["HeLa cells", "CELL", 122, 132], ["TcIP3R", "PROTEIN", 27, 33], ["3T3-Swiss albino cells", "CELL_LINE", 95, 117], ["HeLa cells", "CELL_LINE", 122, 132], ["T. cruzi", "SPECIES", 81, 89], ["T. cruzi", "SPECIES", 81, 89], ["this decrease of TcIP3R", "PROBLEM", 10, 33], ["T. cruzi", "TEST", 81, 89], ["HeLa cells", "PROBLEM", 122, 132], ["HeLa cells", "OBSERVATION", 122, 132]]], ["Hashimoto et al. has also tested a morpholino oligomer targeted to a splicing site of pre-TcIP3R mRNA [61].", [["pre-TcIP3R", "GENE_OR_GENE_PRODUCT", 86, 96], ["splicing site", "DNA", 69, 82], ["pre-TcIP3R mRNA", "RNA", 86, 101], ["a morpholino oligomer", "TREATMENT", 33, 54]]], ["This oligomer (MAO-1) bound to the spliced leader acceptor region and inhibited the maturation of the target mRNA.", [["MAO-1", "CHEMICAL", 15, 20], ["MAO-1", "GENE_OR_GENE_PRODUCT", 15, 20], ["spliced leader acceptor region", "DNA", 35, 65], ["target mRNA", "RNA", 102, 113], ["This oligomer (MAO", "TEST", 0, 18], ["target mRNA", "OBSERVATION", 102, 113]]], ["Exposure of the parasites to the MAO-1 impaired growth in culture and decreased invasion into host cells.", [["cells", "ANATOMY", 99, 104], ["MAO-1", "CHEMICAL", 33, 38], ["MAO-1", "GENE_OR_GENE_PRODUCT", 33, 38], ["host cells", "CELL", 94, 104], ["MAO-1", "PROTEIN", 33, 38], ["host cells", "CELL_TYPE", 94, 104], ["the parasites", "PROBLEM", 12, 25], ["the MAO", "TEST", 29, 36], ["impaired growth in culture", "PROBLEM", 39, 65], ["decreased invasion into host cells", "PROBLEM", 70, 104], ["parasites", "OBSERVATION", 16, 25], ["impaired", "OBSERVATION_MODIFIER", 39, 47], ["growth", "OBSERVATION_MODIFIER", 48, 54], ["decreased", "OBSERVATION_MODIFIER", 70, 79], ["invasion", "OBSERVATION", 80, 88], ["host cells", "OBSERVATION", 94, 104]]], ["The mechanism of action of the MAO-1 was confirmed to be the inhibition of trans-splicing using real-time RT-PCR.Antiparasitics", [["MAO-1", "GENE_OR_GENE_PRODUCT", 31, 36], ["MAO-1", "PROTEIN", 31, 36], ["the MAO", "TEST", 27, 34], ["Antiparasitics", "TREATMENT", 113, 127]]]]}